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3. Abstract 
3.1. English 
Chemoselective transformations constitute a particularly powerful class of chemical reactions, when 
applied to both: Classical organic synthesis as well as modern bioconjugation reactions. A 
chemoselective reaction allows on the one hand a facile transformation of functional organic 
compounds without the need of tedious protecting group manipulations and facilitates on the other 
hand the attachment of modifications to a distinct site of a biomolecule. While the former can 
significantly decrease the number of synthetic steps that are necessary to obtain a desired product, 
the latter is essential for a plethora of applications in the life sciences, in particular for the investigation 
of biological processes and the development of targeted therapeutics.  
The present work introduces a novel modular reaction sequence of two chemoselective manipulations 
in a row. It is shown that vinyl- and ethynylphosphonamidates react selectively with cysteine residues 
on biomolecules such as proteins and antibodies. Most importantly, it is demonstrated that those 
electrophilic phosphonamidates can be incorporated into a given molecule in another preceding 
chemoselective Staudinger-phosphonite reaction (SPhR) from unsaturated phosphonites and azides. 
During this reaction, an electron-rich phosphonite is transformed into an electron-deficient 
phosphonamidate that is thereby activated for the subsequent thiol addition. The described technique 
thereby extends the existing repertoire of bioconjugations by introducing a new concept in protein 
synthesis: A chemoselective reaction that induces reactivity for a subsequent bioconjugation. The SPhR 
enables the synthesis of various functional electrophilic phosphonamidates, including biotin 
derivatives, fluorescent dyes, functional peptides and pharmaceutically active drugs. Together with 
the subsequent attachment to cysteine residues, the method facilitates the generation of highly 
functional protein and antibody conjugates in only two chemical steps. The thiol addition is reasonably 
fast with second order rate constants of up to 0.62 M-1s-1 and highly selective for the addition to 
cysteine over all other proteinogenic amino acids when ethynylphosphonamidates are used. 
Vinylphosphonamidates on the other hand are slower in the reaction with cysteine and less selective 
but can be tuned in cysteine reactivity by the attachment of electron withdrawing substituents to the 
phosphonamidate ester residue. Since retro-thiol addition is not observed, phosphonamidate-adducts 
hold an excellent conjugate stability in the presence of human serum, cell lysate and other thiols in 
excess.  
Bioconjugations that are used to obtain therapeutic conjugates have to fulfil crucial criteria, including 
high selectivity for a given amino acid, clean reaction products and excellent stability of the protein 
Abstract 
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adducts in biological environments. Those properties drastically influence the performance and safety 
profile of a medication. Since phosphonamidate conjugations to cysteine hold all these features, it is 
described in the second part of the present work how ethynylphosphonamidates can be employed for 
the conjunction of tumor-sensing antibodies and cytotoxic drugs to generate Antibody-Drug-
Conjugates (ADCs). A simple synthetic protocol starting from unengineered antibodies, using only a 
slight excess of the desired drug in a one-pot synthesis protocol is introduced. In a direct comparison 
to the maleimide containing FDA-approved Adcetris®, phosphonamidate linked ADCs show a superior 
behaviour in terms of linkage stability in serum, combined with an increased in vivo efficacy in a tumor 
xenograft mouse model. Taken together, the method described herein combines simple synthetic 
access with high selectivity, superior conjugate stability and the possibility to synthesize highly 
efficacious drug conjugates and is therefore likely to have a great contribution to the field of targeted 
therapeutics.  
3.2. Deutsch 
Chemoselektive Umwandlungen, angewendet auf klassische organische Synthese, wie auch auf 
moderne Biokonjugationsreaktionen stellen eine besonders leistungsstarke Klasse von chemischen 
Reaktionen dar. Eine chemoselektive Reaktion erlaubt einerseits eine mühelose Umwandlung von 
organischen Verbindungen ohne aufwändige Schutzgruppenmanipulationen und ermöglicht 
andererseits die Anbindung einer Modifikation an einer definierten Stelle eines Biomoleküls. Während 
Ersteres die Anzahl von synthetischen Schritten, die benötigt werden um ein gewünschtes Produkt zu 
synthetisieren drastisch reduzieren kann, ist letzteres unerlässlich für eine Vielzahl von Anwendungen 
im Bereich der Lebenswissenschaften, insbesondere bei der Untersuchung von biologischen Prozessen 
und der Entwicklung von zielgerichteten Therapien.  
In der vorliegenden Arbeit wird eine neuartige Reaktionssequenz von zwei aufeinanderfolgenden 
chemoselektiven Umwandlungen vorgestellt: Es wird gezeigt, dass Vinyl- und 
Ethynylphosphonamidate chemoselektiv mit Cysteinen von Biomolekülen, wie Proteinen und 
Antikörpern reagieren. Im Besonderen wird weiterhin aufgezeigt, dass diese elektrophilen 
Phosphonamidate durch eine vorhergehende chemoselektive Staudinger-Phosphonit Reaktion 
zwischen Aziden und ungesättigten Phosphoniten in das gewünschte Molekül eingebaut werden 
können. Hierbei wird ein elektronenreiches Phosphonit in ein elektronenarmes Phosphonamidat 
umgewandelt, welches somit für die nachfolgende Thiol-Addition aktiviert wird. Die beschriebene 
Methode erweitert dadurch das bestehende Repertoire von Biokonjugationen durch die Einführung 
eines neuen Konzepts in der Proteinsynthese: Eine chemoleselektive Reaktion, die Reaktivität für eine 
nachfolgende Biokonjugation induziert. Die Staudinger-Phosphonit-Reaktion ermöglicht die 
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Herstellung von verschiedenen funktionalen elektrophilen Phosphonamidaten, wie zum Beispiel 
Biotinderivaten, fluoreszierenden Farbstoffen, funktionalen Peptiden und Wirkstoffmolekülen mit 
pharmakologischer Aktivität. Mit der nachfolgenden Addition an Cysteine können somit hoch-
funktionale Konjugate von Proteinen und Antikörpern in nur zwei chemischen Schritten hergestellt 
werden. Die Thiol-Addition ist angemessen schnell mit einer Geschwindigkeitskonstante zweiter 
Ordnung von bis zu 0.62 M-1s-1 und hoch-selektiv für die Modifikation von Cystein in Gegenwart von 
allen anderen proteinogenen Aminosäuren, wenn Ethynylphosphonamidate verwendet werden. 
Obwohl Vinylphosphonamidate langsamer in der Reaktion und weniger selektiv für Cysteine sind, kann 
die Reaktivität hier durch die Anbindung von elektronenziehenden Substituenten an den 
Phosphonamidatester-Substituenten justiert werden. Da keine Rückreaktion der Thiol-Addition 
beobachtet wird, weisen Phosphonamidat-Addukte eine herausragende Stabilität in Gegenwart von 
humanem Serum, Zelllysat oder einem Überschuss von anderen Thiolen auf.  
Werden Biokonjugationen verwendet um therapeutische Konjugate herzustellen, müssen 
entscheidende Kriterien erfüllt sein, wie zum Beispiel eine hohe Selektivität für eine bestimmte 
Aminosäure, saubere Reaktionsprodukte und eine hervorragende Stabilität der Protein-Addukte in 
biologischen Umgebungen. Diese Eigenschaften beeinflussen die Leistungsfähigkeit und die Sicherheit 
eines Medikaments maßgeblich. Da Phosphonamidat-Konjugationen an Cysteine all diese 
Eigenschaften mitbringen, wird im zweiten Teil dieser Arbeit beschrieben wie 
Ethynylphosphonamidate für die Anbindung von zytotoxischen Wirkstoffen an tumor-bindende 
Antikörper genutzt werden können um sogenannte Antikörper-Wirkstoff-Konjugate herzustellen. Ein 
einfaches Syntheseprotokoll für die Herstellung, ausgehend von einem nicht gentechnisch 
veränderten Antikörper mit nur geringen Überschüssen des gewünschten Wirkstoffs wird vorgestellt. 
Phosphonamidat-verbundene Antikörper-Wirkstoff-Konjugate zeigen im direkten Vergleichen zum 
zugelassenen, Maleimid-verbundenen Adcetris® überlegende Eigenschaften, wie eine erhöhte 
Stabilität in Serum, kombiniert mit einer erhöhten in vivo Wirksamkeit in einem Tumor Xenograft 
Mausmodel. Zusammenfassend verbindet die hier vorgestellte Methode einen einfachen 
synthetischen Zugang mit hoher Selektivität, überragender Konjugat-Stabilität und der Möglichkeit 
hochwirksame Wirkstoffkonjugate herzustellen und wird daher aller Voraussicht nach einen großen 
Beitrag zum Gebiet der zielgerichteten Therapie leisten.  
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4. Introduction
4.1. Motivation
Despite tremendous research efforts world-wide with breakthroughs in the development of new 
medications for the treatment of neoplastic diseases in the last decades, cancer is still one of the most 
life-threatening diseases with an estimated account for 9.6 million death globally in 2018 according to 
the world health organization.[1] 
Figure 1: Mortality from all cancer types in Germany and the USA. Depicted are numbers of deaths for men (blue) and women (light blue) 
caused by malignant diseases per year. Data originates from the GLOBOCAN 2018 database, part of the international agency for research on 
cancer’s (IARC’s) global cancer observatory. 
The development of novel treatment options for a lot of malignant diseases led to a 25-year decline in 
mortality rate for diagnosed cases.[2] However, due to a steady increase in diagnosed cases, cancer is 
the second leading cause of death and is estimated to surpass cardiovascular disease, expected to 
become the leading cause of death in industrial countries within the next ten years (Figure 1).[3] The 
increasing cancer burden is attributed to several factors such as population growth, ageing and 
changing prevalence of certain causes of cancer linked to social and economic development.[2]  
4.2. Cancer treatment 
The growing number of diagnosed neoplasms have spurred research-efforts to develop novel 
treatment options that prolong life expectancy of patients or even completely cure the disease. Even 
though cytotoxic agents (chemotherapeutics) still remain an important therapy option, recent break-
through in understanding tumor biology have let to the development of more targeted approaches. 
Important novel therapy options include angiogenesis inhibitors, laser therapy, hyperthermia, 
photodynamic therapy, bone marrow and peripheral blood stem cell transplantations. Furthermore, 
biological therapies have been developed, including interferons, interleukins, monoclonal antibodies, 
vaccines and gene therapy.[4]  
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Figure 2: Examples for systemically applied drugs to treat cancer. Schematic representation (body: grey, tumor: red, antibody: blue, cytotoxic 
agent: yellow). Idealized scenario: Targeted drug delivery combines the effectiveness of chemotherapy with tumor specificity of targeted 
therapy.  
This introduction will discuss oncological developments of systemically applied drugs starting from 
early unspecific chemotherapy, going on to more targeted approaches including modern 
immunotherapy, finally leading towards advanced drug delivery approaches. Here, focus will be set on 
directed delivery of highly effective toxins to the site of the tumor with the aid of antibody-drug-
conjugates (ADCs) among others (Figure 2).  
4.2.1. Chemotherapy 
Until the first half of the 20th century surgery and radiotherapy were the only available options for the 
treatment of cancer. With medical oncology as a growing research area from the 1940s onwards, it 
became clear that a chemical treatment in addition to tumor removal is able to enhance the probability 
of patient survival also with advanced cancer types.[5] Chemotherapy was born with the initial 
experiments in treating non-Hodgkin’s lymphoma with nitrogen mustards and the first cure of a solid 
tumor in humans employing the anti-folate drug methotrexate in 1958.[6] From then on, a broad range 
of structurally diverse chemical compound classes have been approved for the treatment of cancer. 
The most prominent classes include nucleobase and nucleoside analogues[7], inorganic platinum based 
compounds[8], various natural products[9] and different combinations of those.[6]  
The majority of these classical cytotoxic chemotherapeutics preferentially damage proliferating 
cells.[10] Since malignant cells are usually rapidly dividing, these agents preferentially kill cancer cells 
while sparing healthy tissue.[11] However, higher levels of proliferation are also common in various 
normal cells such as those of the bone marrow and the gastrointestinal tract. As a consequence, 
chemotherapy has to be administered close to the maximum tolerated dose (MTD) to achieve a 
Introduction 
 
 
24 
 
significant therapeutic effect. Expanding the limited therapeutic window due to systemic toxicity 
remains the biggest challenge in treatment with cytotoxic substances.[12]  
4.2.2. Targeted therapy 
To overcome severe side effects of common unspecific chemotherapy, extensive efforts have been 
undertaken to find drugs with new mechanisms of action exploiting more cancer specific 
characteristics than only enhanced proliferation. Thus, due to deeper understandings of tumor 
signaling pathways, new targets on the surface of malignant cells were identified which are believed 
to play a critical role for cancer growth and survival.[13] Many of those targets represent receptor 
kinases that show characteristic mutations in certain cancer types when compared to healthy cells. 
Targeting those mutant kinases is most promising if tumor proliferation is directly dependent on kinase 
activity.[14] Here, great success has been achieved with the small molecule tyrosine kinase inhibitor 
imatinib (Gleevec®) in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors 
with extraordinary response rates in patients.[15] However, regularly acquired resistance to such 
specific modes of actions[16] and severe off-target toxicity due to insufficient selectivity for a specific 
kinase are well-known issues in the development of novel kinase inhibitors for targeted cancer 
therapeutics.[17]  
As an alternative to such small molecule inhibitors, monoclonal antibodies (mAbs, Figure 3) have 
become more and more important in the field of specific cancer treatment. Highly specific monoclonal 
antibodies can be raised against certain molecular markers on the tumor surface that are important in 
tumor proliferation or progression.[18] In the best case, those markers, or tumor antigens, are 
overexpressed on the malignant cell and less abundant on healthy tissue. Typical antigens are cell-
surface proteins, glycoproteins or carbohydrates.[12] After binding those tumor antigens, the killing of 
a malignant cell can result from different mechanisms of action, such as receptor blockage of growth 
factors, specific effects of an antibody on tumor vasculature and stroma or by immune mediated cell 
killing mechanisms, were the immune system of the patient is stimulated to attack the cancer cell such 
as complement-dependent cytotoxicity (CDC), (ADCC) and regulation of T cell function.[19] More 
recently, monoclonal antibodies were raised against immune checkpoints, regulators of the immune 
system that prevent t-cells from attacking the tumor. The field of immune checkpoint therapy was 
born and honored with the Nobel Prize in medicine for James P Allison and Tasuku Honjo in 2018.[20]  
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Figure 3: Structure of an immunoglobulin G1 (IgG1) antibody. Monoclonal antibodies consist of two heavy chains (dark blue) that are 
composed of the variable (VH) and the constant (CH1-3) region and two light chains (light blue) that are composed of the variable (VL) and 
constant (CL) region, connected via four disulfide bonds. N‑glycosylation site is present at the conserved N297 residue of the Fc region. Two 
epitope binding sites are present in the variable regions. Figure adapted from Chudasama et al.[21]  
Despite the recent success of therapeutical monoclonal antibodies, with increasing counts of FDA 
approvals every year[22], many antibodies still fall short of expectations, since they lack efficacy when 
applied as single agents. To overcome this inefficacy, especially in the treatment of solid tumors, many 
mAbs are only approved in combination with classical chemotherapy. The drawback of those 
combination therapies remains the toxicity of the unspecific chemotherapy which narrows the 
therapeutic window and leads to serious side effects in the patient.[12]  
4.2.3. Targeted drug delivery 
A concept that increases the efficacy of targeted therapy while retaining its high specificity is targeted 
drug delivery. Here, a highly potent cytotoxic molecule gets covalently attached to a targeting unit in 
order to improve selectivity and efficacy as well as avoiding biodistribution issues that are associated 
with chemotherapy and targeted therapy. In addition to side effect reduction, targeted therapy 
facilitates the usage of highly toxic warheads that are not tolerated in their unconjugated form and 
allow the administration of lower doses, since the drug can accumulate specifically in the targeted cell 
without unspecific damage of healthy tissue.[23] This concept of delivering toxic payloads to malignant 
cells using a targeting agent was first described in 1913 by Paul Ehrlich, who predicted a “haptophore” 
that can specifically deliver a “toxophore” selectively to a tumor site.[24] 
A huge variety of different targeting ligands have been applied to specific drug delivery, ranging from 
small molecules of a few hundred Dalton (Da) to full length IgG antibodies with sizes of around 150 
kDa. Small molecule targeting units that are applied to conjugates in recent clinical trials include 
carbohydrates such as β-D-glucose,[25] short peptides like NGR[26] and urea linked dimers of glutamate 
(DUPA).[23, 27] Probably the most prominent example for small molecule targeting is the vitamin folic 
acid that binds to the folate receptor with a very high affinity (KD ∼ 10−10 M). The folate receptor alpha 
Introduction 
 
 
26 
 
is overexpressed in many human tumors, including cancers of the ovary, lung, kidney, endometrium, 
colon, and breast[28] and therefore an interesting target for drug delivery with several cytotoxic and 
diagnostic conjugates in recent clinical trials.[23]  
 
Figure 4: Selection of targeting ligands that have been applied to drug delivery in increasing order of size. Depicted are average molecular 
weights. Figure is adapted from Srinivasarao et al.[23] 
However, besides plenty advantages of small-molecule targeting units in drug delivery such as the 
generation of highly defined products, ease of manufacturing and oral availability for some of the 
constructs, their biggest drawback remains their pharmacokinetics. Molecules with a molecular weight 
of far less than 40 kDa are readily released from circulation in the patient by renal filtration.[29] A 
strategy to improve the pharmacokinetics of small molecule targeting units is to increase their size by 
the attachment of a water-soluble polymer such as polyethylene glycol (PEG).[30] On the other hand, 
polymers itself can function as guiding ligands by selective target binding with molecularly imprinted 
polymers (MIPs)[31] or other mechanisms such as the enhanced permeability and retention (EPR) effect 
that describes the phenomenon that nanoparticles ranging from 10 to 100 nm can accumulate in solid 
tumors.[32]  Other targeting ligands overcome the issue of rapid plasma clearance by relying on larger 
protein and oligonucleotide scaffolds including nucleic acids aptamers[33], full length IgG antibodies[21], 
antibody fragments such as Fab fragments[34], diabodies[35] or single-chain variable fragment (scFv)[36] 
and antibody mimetics such as affibodies[37] or centyrins[38] (Figure 4). 
4.3. Antibody-Drug-Conjugates for cancer treatment 
Among the aforementioned scaffolds, full length IgG-monoclonal antibodies bound to cytotoxic 
warheads have attracted the most attention in the field of targeted drug delivery in recent years.[39] 
These Antibody-Drug-Conjugates (ADCs) combine the antitumor potency of small-molecule drugs with 
the high selectivity, stability and prolonged circulation times of mAbs.[40] Recent success of those ADCs 
in clinical development include the approval of inotuzumab ozogamicin (Besponsa™)[41] and the re-
approval of gemtuzumab ozogamicin (Mylotarg™).[42] Together with brentuximab vedotin (Adcetris®) 
and trastuzumab emtansine (Kadcyla®) (Figure 5), approved in 2010 and 2013, respectively there are 
four ADCs currently on the market and more than 80 candidates in recent clinical trials. [40] This clearly 
underlines the high potential of this compound class. [43] 
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Figure 5: Comparison of two FDA-approved ADCs Adcetris® and Kadcyla®. Toxins are connected to cysteine residues (yellow) in the antibody’s 
Hinge region for Adcetris® and to lysine residues (orange) all over the antibody structure for Kadcyla®. Antibody structure rendered using 
PyMol from structural data of Harris et al.[44] 
Before first approvals were conceivable, a long list of failures had to be overcome in the development 
of ADCs for cancer treatment. First in vitro evaluated ADCs in the 1980s on antigen positive cell lines 
revealed only moderate activity and insufficient selectivity for the targeted cell line.[12] Nevertheless, 
researchers proceeded with first in vivo evaluations with human xenograft models in mice, showing a 
superior efficacy when compared to the unconjugated drug.[45] Encouraged by these results, two Phase 
I studies were initiated to evaluate a methotrexate-antibody conjugate in patients with non-small-cell 
lung cancer.[46] However, all first clinical trials with ADCs were discontinued due to a lack of efficacy 
and severe side effects such as strong immune responses against the murine antibodies that were used 
back then.[47] Afterwards, all parts of the ADC have been careful analyzed, which led to the 
identification of several factors that were improved, before Mylotarg™ was approved by the FDA as 
the first ADC for the treatment of Acute Myeloid Leukemia (AML) in 2000.  
4.3.1. Technological requirements on ADCs 
Learning from these early setbacks in ADC development, recent focus in the improvement of next-
generation ADCs is put on all three parts: the antibody, the cytotoxic payload, and the linker that 
connects the two parts. Here, requirements for a safe and efficacious therapeutic are enormously 
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high.[48] Figure 6 summarizes the most important demands on all three parts of an ADC that will be 
discussed in detail in the following chapters.  
 
Figure 6: Demands on the three parts of an ADC: the antibody, the linker and the drug. Figure depicts are rough overview about what has 
been investigated. Not all requirements are compulsory to ensure a safe medication. Antibody structure rendered from structural data of 
Harris et al.[44] 
4.3.1.1. Monoclonal antibodies  
The selection of a suitable mAb is crucial for the generation of a safe ADC, since it has to ensure a good 
selectivity for tumor- over non-malignant cells. Therefore selection of a suitable antigen that is 
targeted by the mAb is very important. First of all, the targeted antigen should be homogenously 
expressed on the cell surface of all tumor cells in a high copy number of more than 105/cell with a 
significantly higher expression level compared to normal cells. In addition, receptor internalization 
upon binding is beneficial to ensure an intracellular delivery of the cytotoxic molecule to its side of 
action.[12] However, recent studies also include non-internalizing targets, which necessitates an 
extracellular release of the drug followed by diffusion in the cytosol.[49]  
Furthermore, the mAb itself should bind the targeted receptor with a good affinity, typically in the 
range of 0.1-1.0 nM.[48] It has been shown that high affinities can hamper deep tumor penetration and 
therefore lower the efficacy in the treatment of solid tumors.[50] Finally, the antibody should be 
chimeric, humanized or most preferably even fully human to prevent an immune response in the 
patient[40] and prolong the circulation half-life in humans.[51] As indicated in Figure 7, in chimeric 
antibodies, the constant region of the originated species is replaced with the human form. In 
humanized antibodies typically everything is replaced, except for the complementarity determining 
regions (CDRs).  
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Figure 7: Monoclonal antibodies with increasing degree of humanization and the assigned suffixes that have been used until 2017.  
The use of the suffixes depicted in Figure 7 have been discontinued for newly introduced monoclonal 
antibodies in 2017 because of increasing complexity in assigning the antibodies origin due to a lot of 
technological production advances.[52] 
4.3.1.2. Cytotoxic payloads 
Apart from choosing a suitable antibody, the choice of an appropriate cytotoxic payload defines the 
efficacy of the final ADC. Many clinical evaluations of ADCs with promising in vitro efficacy, employing 
drugs with a fifty percent growth inhibition concentration (IC50) in the submicromolar range, such as 
doxorubicin[53] failed due to a lack of efficacy in the patient.[54] Further studies in cancer patients have 
revealed that tumor uptake of the ADC is below 0.01% of the injected dose per gram of tumor.[12] This 
data suggested that drugs, applied to ADCs must be highly efficient in cell killing at low intracellular 
concentrations with a low nanomolar to picomolar affinity for its target (IC50).[48] Furthermore, 
commonly applied toxins are usually hydrophobic to enable unimpeded diffusion through cellular 
membranes ensuring endosomal escape and allowing toxin diffusion into neighboring cells, causing 
the so called bystander effect. Since solid tumors often express the target antigen in a heterogeneous 
manner, this bystander effect can enable cell killing also of antigen-negative cancer cells.[49] Finally, the 
chemical structure of the drug must allow the attachment of a linker that enables conjugation to the 
antibody while retaining its potency.[40] The cytotoxic compounds used in most of the marketed ADCs 
and in current clinical development (as of 2019) are either auristatins or maytansinoids, which are 
potent antimitotic microtubule-disrupting agents or derivatives of DNA damaging agents like 
calicheamicin, duocarmycin, indolinobenzodiazepine or pyrrolobenzodiazepine (PBD)-dimers (Figure 
8).[48] Other, less commonly applied drugs used in ADCs include α-amanitin that kills cells by inhibiting 
RNA polymerase II[55] and analogues of the topoisomerase inhibitor camptothecin.[56] 
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Figure 8: Examples for structures of cytotoxic payloads for ADCs in recent clinical trials. Depicted are derivatives of the most important toxin 
classes. Attachment site to the antibody is marked with a waved line. 
Next to the nature of the drug itself, another important parameter for efficacy and stability of an ADC 
is the drug to antibody ratio (DAR). ADCs with a low drug load (i.e. low DAR) do not deliver enough 
cytotoxic payload into the targeted cell and are therefore ineffective. On the other hand it has been 
shown that a high loading of the antibody with hydrophobic drug molecules can increase unspecific 
uptake into non-targeted cells and therefore contribute to off-target toxicity and accelerated plasma 
clearance.[57] Furthermore, high DAR-species can be rapidly recognized by the immune system.[58] 
Hence, the DAR of the majority of ADCs in clinical development is often limited to a maximum of 4.[59] 
 
4.3.1.3. Linker technology 
The third part that allows improvement in ADC synthesis is the applied linker technology to connect 
the already discussed mAb and payload. Requirements on linkage technology are exceptionally high, 
since linkage stability drastically influences the safety profile of the final product. A premature release 
of the highly potent cytotoxin during circulation in the blood stream leads to severe off-target toxicity 
in the patient.[40] Therefore, the linker has to be tightly bound to the antibody as well as to the 
warhead. However, an inherent lability at the site of the warhead that allows a traceless release of the 
drug upon cellular uptake can also be desirable.  
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Figure 9: Mechanism of ADC mediated killing of target-receptor overexpressing cells. After binding to the targeted receptor (1), the ADC gets 
internalized into endosomes (2) that ripen to proteolytically active lysosomes (3). Antibody degradation and optional linker cleavage (4) 
facilitates drug release into the cytoplasm (5). Cleaved and uncleaved drug molecules act at the intracellular target (6). Cleaved drugs may 
freely diffuse into neighboring cells and enable the bystander effect (7). Receptor can be recycled to the cell-surface (8). 
Usually, a linker is considered as cleavable if it facilitates a traceless release of the drug molecule after 
uptake into the targeted cell. Both, cleavable and non-cleavable linker, have been applied to approved 
ADCs and constructs in recent clinical trials.[12] In case of non-cleavable linker systems, the antibody is 
proteolytically degraded after receptor mediated uptake in the lysosomes to release the linker–drug 
moiety attached to one residual amino acid of the antibody (Figure 9).[60] Depending on the structure-
activity relationship of the applied drug, a non-cleavable linker can be applied, if this cellular 
metabolite of the conjugated drug remains active in cell killing. In a recent study it has been shown 
that the auristatin MMAE, the toxin used in Adcetris®, remains active in its uncleaved form, while a 
cleavage is crucial in case of a PBD dimer that is attached via its DNA-binding imine.[61] Non-cleavable 
linker system also impair the aforementioned bystander effect (Figure 9), since the charge from the 
attached amino acid remaining after antibody lysis, reduces membrane permeability of the drug.[62] On 
the other hand, cleavable linkers are inherently labile and have to balance the need for good stability 
in circulation to ensure a safe ADC and efficient cleavage upon delivery into the target cell to preserve 
the payloads potency.[12] Apart from the mechanism of action triggering an intracellular cleavage, the 
drug’s site of attachment is crucial to facilitate a traceless release. Self-immolative linker systems based 
on cyclization or 1,6-elimination mechanisms have been developed to combine various cleavage 
strategies with common functional groups such as primary, secondary and tertary amines, pyridines,[63] 
alcohols and thiols in drug molecules.[23]  
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One strategy to induce intracellular release is to use acid labile chemical moieties between drug and 
antibody. Hydrazones, for example, are stable to the neutral conditions during circulation (pH 7.4) but 
cleave in the acidic endosomal environment (~pH 5) after receptor mediated uptake.[64] Prominent 
examples using hydrazones include the approved ADCs Besponsa™ and Mylotarg™ (Scheme 1).[48] 
However, it has been shown in clinical trials that unspecific release during blood circulation is an issue 
for hydrazone linked ADCs.[65] In fact, Mylotarg’s commonly triggered side effects have been attributed 
to the instability of its hydrazone linker that caused drug release during circulation.[66] 
 
Scheme 1: Acidic release mechanism of the hydrazone linkage in Mylotarg™. 
Other linker systems, applied to ADCs in recent clinical trials, incorporate disulfide bridges that can be 
selectively reduced in the presence of high intracellular concentrations (∼2−10 mM) of glutathione.[23] 
For drugs that do not contain sulfhydryl groups, disulfides can be combined with self-immolative 
structures that release primary, secondary and more recently also tertiary amines after reduction 
(Scheme 2).[23, 63] A premature drug release of this systems, for example by disulfide reduction 
mediated by cysteine containing serum proteins in the bloodstream and interstitial fluids, can be 
prevented with short linker length to protect the disulfide with the protein structure of the antibody[67] 
or by the incorporation of sterically hindered disulfides.[23] In an anti-CD22 antibody based PBD-dimer 
delivery system, it has been shown that the stability of disulfide bridges can be optimized to limit 
premature cleavage by incorporation of various bulky groups such as methyl or cyclobutyl in α-position 
to the disulfide (Scheme 2).[68] However, very sterically hindered disulfides are also known to impair 
efficient intracellular reductive cleavage,[67] therefore careful optimization is required to find a 
structure that balances both needs. 
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Scheme 2: Linker systems based on reductively cleavable disulfides for the traceless release of amino-modified drug molecules. Sterically 
hindered disulfides are less prone to be cleaved during blood circulation. Cyclization to form a thiirane and release of CO2 can be exploited 
to facilitate a traceless release of primary- and secondary amines (left).[23] Additional 1,6-elimination linker enables release of tertary amines 
(right).[63] Attachment site to the antibody is marked with a waved line. R depicts the drug molecule. 
Since the composition of hydrolytic enzymes in the blood stream widely varies from those that are 
intracellularly abundant, cleavable linkers can also be designed from structural motives that are 
selectively recognized and cleaved by intracellular enzymes. Moreover, many hydrolytic enzymes are 
upregulated in malignant cells, whose activities can be exploited to further increase selectivity by an 
increased drug release in the targeted cell.[69] Cleavage motives that are recognized by cathepsins, a 
protein family that is predominantly expressed in acidic lysosomes are often applied to ADCs. Adcetris® 
for example is equipped with a cathepsin B cleavable valine−citrulline linker, which is known to be 
more than 100 times more stable than other commonly used cleavable linkers during blood 
circulation.[70] Coupled to a 4-amino benzyl structure that facilitates a 1,6-elimination cascade, this 
linker enables the traceless release of MMAE after enzyme mediated cleavage (Scheme 3a).[70a] When 
the cleavage side is attached to quarternary ammonium salts via a 1,6-elimination linker, cathepsin B 
cleavage furthermore facilitates the release of drugs containing tertiary amines.[63] Apart from 
cathepsins, the glycosidase β-glucuronidase has also been utilized for the release of various toxins, 
including MMAE, MMAF and doxorubicin (Scheme 3b). As an example, the anti-CD30 antibody, 
equipped with a β-glucuronide linker to release a cytotoxic payload after deglycosylation and 1,6-
elimination displayed pronounced antitumor activity in a subcutaneous lymphoma tumor model in 
mice.[71]  
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Scheme 3: Mechanism of enzyme mediated traceless drug release. a) Valine-citrulline cleavage side for cathepsin B cleavage. b) β-glucuronide 
self-immolative linker for glucuronidase cleavage. 1,6-elimination systems facilitate traceless release. Attachment site to the antibody is 
marked with a waved line. 
In addition to the incorporation of cleavable systems, linker technology can also be optimized to 
increase the overall stability of ADCs. As mentioned in the previous chapter, severe issues can arise 
from the hydrophobic nature of drugs commonly applied to ADCs. In addition to unspecific uptake into 
non-targeted cells, the formation of High Molecular Weight Species (HMWS) or so called aggregates is 
a general issue in the field of antibody based therapeutics.[72] Aggregates impair the pharmacokinetic 
profile and efficacy[73] and can drastically increase the risk of immunogenicity in the patient[74]. To 
overcome problems that are usually associated with HMWS, hydrophilic linker systems, mostly based 
on PEGylation, have been developed that compensate for the hydrophobic nature of the drug.[57, 75] 
However, it has been recently demonstrated that long solubilizing PEG-chains negatively impair the 
pharmacokinetic profile of the final product if installed between the antibody and the drug molecule. 
Long polymeric PEG chains increase the solvent exposure of the drug, causing enhanced exposure to 
proteases and inadvertent hydrophobic interactions.[57, 75] In addition to PEG based systems, 
incorporation of quarternary ammonium salts or glucoronides into the linker has been also shown to 
be beneficial in terms of hydrophilicity.[63] 
 
4.3.1.4. Antibody modification strategies for the construction of ADCs 
Aside from linker polarity and the possibility of a traceless drug release, the mode of linker-drug 
attachment to the antibody fundamentally influences the stability and homogeneity of the ADC and 
therefore determines its therapeutic window and the pharmacokinetics.[21, 39] Since the antibody 
structure itself is proteogenic, a big variety of different chemoselective reactions being developed for 
protein modification, have also been applied to the construction of ADCs. First examples for the 
construction of ADC were based on conjugation to the native occurring lysine residues. However, as 
typical antibodies carry approximately 70 accessible lysine residues that all can be statistically 
modified, lysine conjugation yields in a broad mixture of different antibody species that vary in degree 
and site of modification.[76] Since such heterogeneity can drastically narrow the therapeutic window of 
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an ADC,[77] conjugation techniques allowing a better control of the conjugation side are desirable. To 
overcome this issue, targeting of less abundant amino acids such as methionine[78] and especially 
cysteine has become more and more important for the modification of antibodies.[79] Next to lysine, 
cysteine is one of the most commonly exploited amino acid for antibody conjugation. It has been 
shown that the four interchain disulfide bonds of an IgG antibody can be selectively reduced to yield 
eight free cysteine residues that can subsequently be modified with thiol selective conjugation 
techniques.[70a] It is thought that the antibody stability and structure is not impaired by these 
modifications, since antibody assembly is primarily dependent on non-covalent affinities of the 
antibody subunits to each other.[80] Other approaches for the modification of native antibodies not 
relying on the reactivity of certain amino acids, target the glycan structure at the conserved N297 
residue of the Fc region. Here, modification can either be achieved by a selective transformation of the 
glycan structure into a chemical reporter, as for example an aldehyde that can be subsequently 
modified with hydrazides[81] or by an enzymatic removal of the glycans followed by modification of the 
unique asparagine residue with a transglutaminase.[82] Furthermore, the Z-domain that is derived from 
the immunoglobulin-binding domain of protein A has been used in proximity based labelling 
techniques to specifically modify amino acids in the Fc-part of the antibody.[83]  
 
Figure 10: Typical residues that can be utilized for the modification of antibodies starting from either native (left) or biochemically engineered 
antibodies (right). Figure inspired by Chudasama et al.[21]  
Another way to generate highly homogenous ADCs with defined DARs is to use genetic engineering. 
Amber suppression for instance can be employed to install unnatural amino acids into the primary 
structure of an expressed antibody, carrying bioorthogonal handles that enable site-specific payload 
attachment.[39] On the one hand, this approach is very versatile since it allows a simple prepositioning 
of the desired drug attachment site within the antibody structure. On the other hand amber 
suppression is associated with low expression yields.[84] Alternatively, additional cysteine residues can 
be engineered into the sequence to generate so called Thiomab™ antibodies, which can be selectively 
modified, since all the other cysteines of the antibody are trapped in disulfides.[77] Other strategies that 
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are not impairing the antibodies expression yields are dealing with the incorporation of certain peptide 
tags to the antibody that allow the incorporation of a chemical reporter by an enzyme-directed 
modification.[21] An overview of the most important antibody modification strategies can be found in 
Figure 10. The protein-modification strategies behind those methods are discussed in detail in the next 
chapters. 
4.4. Chemoselective strategies for the modification of native proteins 
The chemical attachment of synthetic molecules at distinct sites of a protein to add a functionality that 
is not defined by the genetic code, represents an essential process not only in the area of targeted 
drug delivery but also in fundamental research of basic biological processes.[85] In principle, protein 
modification can be achieved by two strategies: Incorporation of an unnatural chemoselective handle 
with the aid of unnatural amino acids or chemoenzymatic labelling techniques or by exploiting the 
specific reactivity of native proteinogenic amino acids.[86] Even though the former yields highly 
uniformly proteins, the incorporation of unnatural residues requires tedious biochemical 
manipulations like amber suppression techniques, selective pressure incorporation or site directed 
mutagenesis. Therefore protein modifications targeting natural occurring residues can be more 
straightforward for certain applications. One drawback of those approaches is that there are only 
residue specific, leading to heterogeneous mixtures of proteins with a different degree of modification 
including several regioisomers.[87] However, decent amounts of homogeneity can be achieved by 
targeting low abundant amino acids or the aid of affinity based protein modification techniques.[88]  
4.4.1. Chemical modification of lysine residues and the N-terminus 
The nucleophilicity of the primary amines of lysine and the N-termini of proteins has been exploited 
for a number of successful protein modification reactions. Due to its high natural abundance, targeting 
lysine residues is particularly attractive when selectivity for a distinct site of a protein is dispensable or 
when a high copy number of modifications per proteins is desired.[86a] In fact, three of the four FDA-
approved ADCs are conjugated via lysine residues.[48] 
Active esters of carboxylic acids have been applied in various examples to form amide bonds with 
primary amines irreversibly in slightly basic aqueous systems. The most prominent examples for such 
activated acids are N-hydroxysuccinimide esters (NHS). Several NHS derivatives of commonly used 
protein labels such as fluorescent dyes, biotin probes or crosslinking agents are commercially available. 
Selectivity for the N-terminus over the modification of lysine can be achieved with careful control of 
the pH,[89] or if the N-terminal amino acid is cysteine, by prior incubation with MESNA.[90] Furthermore, 
sulfonic acid modified NHS-derivatives have been applied for increased water solubility.[87b] NHS esters 
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have been applied for the modification of trastuzumab’s lysine residues and subsequent attachment 
of DM1 to produce the FDA approved ADC Kadcyla®.[91] Selectivity for the amine group over the more 
nucleophilic sulfhydryl group of cysteine is attributed to NHS-ester being a harder electrophile and 
therefore preferably react with the harder amine of lysine.[86a] The same is true for isocyanates and 
isothiocyanantes that readily react with amines to form urea or thiourea, respectively,[92] even though 
more basic conditions are required when compared to NHS esters.[93] An alternative, well-established 
modification utilizes a reductive amination reaction. Here aldehydes react with primary amines of 
proteins to imines that can be subsequently reduced to secondary amines in the presence of a 
reduction agent that is stable under aqueous conditions such as sodium cyanoborohydride (Scheme 
4).[94]  
 
Scheme 4: Overview of different chemical protein modifications selective for amino residues. Iso-(thio)cyanates: left; NHS-esters right and 
reductive amination strategies: bottom. 
Other reagents for the modification of amines that have been developed more recently are based on 
a 6π-aza-electrocyclization reaction and show selectivity of accessible lysine residues over the N-
terminus. Here an unsaturated E-ester aldehyde reacts with primary amines to yield 1,2‐
dihydropyridines in an irreversible reaction.[95] In a very recent study, Bernardes and coworkers claim 
that a modification of a single lysine residue on native proteins can be achieved with sulfonyl acrylate 
reagents.[96] Another method that has been extensively used in the modification of the N-terminus is 
native chemical ligation (NCL).[97] In NCL, an N-terminal cysteine reacts with a thioester followed by an 
intramolecular S- to N-acyl shift to form a native peptide bond. NCL is one of the most important 
methods for the construction of synthetic proteins from either expressed N-terminal cysteine 
containing proteins or from expressed protein thioesters than termed expressed protein ligation 
(EPL).[98] In a similar manner, N-terminal serine or threonine residues can form native peptide bonds 
with C-terminal salicylaldehyde ester, which is known as the serine/threonine ligation.[99] Other 
strategies rely on the incorporation of an aldehyde or ketone to the N-terminus that can be selectively 
modified in a subsequent reaction step. This has been achieved by oxidation of N-terminal serine or 
threonine residues with sodium periodate[100] or by treatment of the native protein with pyridoxal‐5‐
phosphate under slightly acidic conditions.[101]  
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4.4.2. Chemical modification of cysteine 
In contrast to most of the other amino acids, cysteine is relatively low abundant with only 2.26% over 
all other amino acids in mammals.[102] Chemical protein modification via cysteine is therefore a 
promising strategy for a lot of biochemical applications, since it can allow functionalization of a distinct 
site of a protein (Figure 11). The unique nucleophilic properties of its sulfhydryl group has been utilized 
in the development of several cysteine selective modification techniques. Since the pKa of cysteine is 
ranging from 7.4 to 9.1 under physiological conditions,[103] depending on the protein conformation and 
its microenvironment, the highly reactive thiolate anion can be modified already under slightly basic 
conditions.[104]  
 
Figure 11: Selective chemical protein modification through cysteine next to all other naturally occurring nucleophilic functional groups and 
disulfides. X depicts the chemical warhead that facilitates the reaction. Figure adapted from Gunnoo et al.[104b] 
Another unique characteristic of cysteines is that two cysteine residues within a protein structure can 
oxidize to either form an intramolecular disulfide bond or ensure a covalent intermolecular fusion of 
two protein fragments. This post-translational modification (PTM) occurs in the vast majority of 
proteins and plays key roles in protein folding and structural integrity since it stabilizes its tertiary and 
quarternary structure.[105] Furthermore, the ability to form disulfide bonds has been exploited in 
protein synthesis. On the one hand disulfides protect cysteine residues from reactions with 
electrophiles, thereby allowing the modification of a certain cysteine residue next to others that are 
trapped in disulfides.[106] On the other hand selective reduction of disulfides and subsequent 
modification with electrophiles can also be employed for conjugation. This concept has been applied 
for the construction of ADCs, with the FDA approved Adcetris® as its most prominent example.[70b] 
Here, a partial reduction strategy was applied that reduces only two of four native interchain disulfide 
bonds to generate four cysteine residues that can be subsequently modified with maleimides to 
synthesize an ADC with an average DAR of 4.[107]  
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4.4.2.1. Maleimides and related compounds 
Within the variety of different compound classes that have been employed for the purpose of cysteine 
selective modification reactions, maleimides are by far the most used ones.[104b] The reaction with 
sulfhydryl groups proceeds via a conjugate addition of the thiolate anion to the double bond that is 
electrophillically activated by two neighboring carbonyls. Such conjugate additions of nucleophiles to 
activated olefins and alkynes has been first described by Michael in 1887 and ever since exploited in a 
plethora of different reactions in organic chemistry.[108] In maleimides, the release of ring-strain upon 
product formation provides an additional driving force towards product formation and makes the thiol-
maleimide reaction one of the most efficient Michael-type additions,[109] with second order rate 
constants of more than 700 M-1s-1.[110] After the first reactions have been described in the 1950s[111], 
maleimides have become enormously popular in selective protein modification via cysteine. 
Maleimide-linkage has been employed for the synthesis of FDA approved therapeutics such as the two 
ADCs Kadcyla® and Adcetris®[40] and for the PEGylation of an anti-TNF construct for the treatment of 
Crohn’s disease and arthritis.[112] Other than that, fluorescently labelled maleimides have been used 
for analytical purposes such as mapping of cysteine[113] and proteomic analyses with small reagents 
such as N-Ethyl maleimide.[114] Despite the huge success that is also reflected in the great variety of 
maleimide reagents that are commercially available, there are also drawbacks of this technology that 
have been described. One issue that is scarcely discussed in the literature constitutes side-reactions of 
maleimides with other nucleophilic amino acids than cysteine such as lysine and histidine.[115] In some 
applications this might be negligible, since the reaction of maleimide reagents with sulfhydryl groups 
is rapid and allows the addition of almost stoichiometric amounts of labelling reagent to the protein. 
However, it has been shown recently that the issue of unselective labelling can limit the applicability 
of maleimide labelling in certain applications. This was demonstrated by a loss of activity of the retro-
aldolase RA-CM after maleimide labelling due to unspecific modification of a catalytically active lysine 
residue.[116] Another problem that is discussed more often in the context of maleimide labelling is the 
stability of the thio-succinimide bond that is formed upon thiol addition. It is known, that a retro-
Michael reaction in solution can reform the unconjugated maleimide (Scheme 5).[117] Since the 
equilibrium of this reaction is far on the side of the Michael-adduct, this might be less problematic for 
most in vitro applications. However, it can be a drastic issue when the conjugate is exposed to other 
external thiols in solution that can reattach to the released maleimide. This thiol exchange reaction is 
particularly problematic in the context of targeted therapeutics, since the conjugates are exposed to 
cysteine containing proteins like albumin during circulation in the blood stream.[118] Here, a retro-
Michael addition can lead to drugs conjugated to endogenous proteins as well as free drug molecules 
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and can therefore cause severe side effects and narrow the therapeutic window of the therapeutic 
conjugate.[119]  
 
Scheme 5: Structures and chemistry of thiol-reactive maleimides. Reversible thiol-maleimide conjugation reaction (retro-Michael) can cause 
maleimide transfer to external thiols such as albumin’s cysteine in serum. Retro-Michael can be avoided by succinimide hydrolysis. Self-
hydrolyzing maleimides have an increased hydrolysis rate. Stars indicate stereo centers (usually racemic).  
During optimization of the maleimide linkage, it has been shown that retro-Michael reaction does not 
occur in the hydrolyzed ring-opened form of the thio-succinimide adduct.[120] This phenomenon has 
been exploited in the construction of maleimide linked ADCs that are stable to thiol exchange, either 
by forcing the hydrolysis under slightly basic conditions at elevated temperature[121] or by the 
development of so called self-hydrolyzing maleimides. Here, a basic amino-group in close proximity to 
the thio-succinimide ring induces its hydrolysis after thiol-addition even at neutral pH and room 
temperature by intramolecular catalysis (Scheme 5).[122] It should be noted that several different regio- 
and stereoisomers are being formed after hydrolysis, which increases the heterogeneity of the final 
conjugates.[123] Other structurally refined Michael systems that were developed based on maleimide 
chemistry to form stable thiol adducts include exocyclic maleimides that are readily available by a 
solvent-free Wittig transformation (Scheme 6).[124]  
 
Scheme 6: Exocyclic maleimides form thiol adducts irreversibly.  
Furthermore, maleimides that carry one or two additional leaving groups at the double-bond, so called 
next-generation maleimides (NGMs) have been designed within the last ten years. Here, cysteine 
modification occurs via an addition elimination mechanism forming a thio-maleimide bond. Mono-
bromomaleimides for example have been shown to rapidly react selectively with cysteine residues.[125] 
Phenol substituted maleimides show a comparable reactivity with only slightly decreased kinetics.[126] 
The resulting thio-maleimide adducts are even more unstable than their saturated counterparts and 
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can be employed to either reform the unmodified cysteine by incubation with TCEP or treated with a 
base to form dehydroalanine.[125] The double bond of the thio-maleimide that is formed after the first 
addition can undergo a subsequent thiol addition, which makes these reagents suitable for disulfide 
rebridging. However it should be noted that the second addition is reversible and can eliminate one or 
the other thiol (Scheme 7).[126]  
 
Scheme 7: Monosubstituted maleimides with leaving groups form thio-maleimide with cysteine residues. Reaction is reversible by the 
reaction with TCEP, Retro-addition is caused by addition of a second thiol. Thio-maleimide adducts that can be eliminated to form 
dehydroalanine under strongly basic conditions. 
Another class of maleimides allowing disulfide rebridging are disubstituted maleimides. Disulfide 
rebridging involves the reduction of native occurring disulfide bonds in peptides and proteins followed 
by the attachment of a covalent junction to generate a structural mimic that is less prone to reduction 
and therefore increases protein stability. A functional rebridging agent additionally offers the 
possibility to add a modification to the stabilized disulfide such as a PEG- or a fluorescent tag.[104b] A 
broad variety of different leaving groups have been tested in the reaction of disubstituted maleimides 
with reduced disulfides. There, the leaving-group ability is determining the rate of the reaction with 
diodo- ˃dibromo- ˃ dichloromaleimides. Dithiophenylmaleimides are advantageous since they tolerate 
the addition of TCEP to the reaction mixture, leading to a higher disulfide conversion due to prevention 
of reoxidation.[127] The addition of cysteine to disubstituted maleimides is generally reversible in the 
presence of external thiols allowing the intracellular release of a cargo that is connected via a 
disubstituted maleimide. This has been demonstrated with rhodamine–GFP conjugates by monitoring 
FRET intensities after cellular uptake.[128] 
 
Scheme 8: Disulfide rebridging with disubstituted maleimides. Conjugates can be stabilized by ring hydrolysis.  
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The instability of NGMs due to retro-Michael reaction can be circumvented by hydrolysis of the 
maleimide to the open-ring form, analogously to simple maleimides (Scheme 8).[129] Even though two 
different regioisomers can be formed during hydrolysis, the generation of different diastereomers is 
not an issue in this case. NGMs have been applied to broad variety of applications,[104b] including 
rebridged ADCs from native trastuzumab and doxorubicin with control over the drug loading in a range 
between 0 and 4.[129a] Furthermore, near homogenous ADCs have been synthesized from an antibody 
containing an additional cysteine residue (THIOMAB™) in combination with NGMs.[130]  
Another compound class inspired by dibromomaleimides are dibromopyridazinediones that are readily 
available by treating certain dibromomaleimides with hydrazine.[131] Dibromopyridazinediones react 
analogously to disubstituted maleimides with reduced disulfides (Scheme 9) and have been applied to 
the construction of various ADCs with DARs.[132] Since both nitrogen atoms of the pyridazinedione core 
have to be alkylated to be cysteine reactive, dibromopyridazinediones offer the possibility of the 
introduction of either one or two different modifications to a reduced disulfide on a protein or 
antibody.[132a] In accordance to dibromomaleimide adducts, dibromopyridazinediones conjugates are 
also prone to be cleaved in the presence of other thiols in solution. Inspired by the observation that 
both nitrogen atoms have to be alkylated to be reactive for cysteine, dibromopyridazinediones have 
been developed that allow a selective TCEP mediated cleavage of one of the substituents after the 
conjugation to the protein. The resulting N-monosubstituted dibromopyridazinediones proofed stable 
to thiol exchange.[133]  
 
Scheme 9: Dibromopyridazinediones for disulfide rebridging. Conjugates can be stabilized by the selective removal of one N-substituent, as 
demonstrated for a 4-azido benzyl substituent that can be cleaved after cysteine rebridging by azide reduction and subsequent 1,6-
elimination. 
4.4.2.2. α,β-unsaturated carbonyl reagents 
Due to the high reactivity of α,β-unsaturated carbonyl compounds towards thiols in a Michael addition 
reaction, a great variety of these compound classes have been employed for cysteine selective 
conjugation reactions on peptides and proteins. While derivatives of acrylic acid esters are more often 
applied in the field of polymer modification in material sciences,[134] early examples of protein 
modification include unsubstituted acrylamide that has been utilized to cap cysteine residues before 
protein sequencing in the Edman-degradation.[135] Structurally more refined α,β-unsaturated carbonyl 
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compounds have been developed by Bernardes and coworkers. To circumvent the reversibility of thiol 
additions to maleimides the group developed carbonylacrylic reagents that retain the high reactivity 
of maleimides while exhibiting a good stability when exposed to external thiols (Scheme 10). Both, 
carbonylacrylic -acids and -amides react rapidly with small molecule cysteine derivatives. The reaction 
is considered to be stoichiometric, since it proceeds with a high degree of cysteine labelling using 
equimolar amounts of reagent to protein. It has been successfully applied to the modification of a 
Thiomab™ variant of Trastuzumab that retained its function upon modification.[136] However, it should 
be mentioned that a stereocenter is formed upon conjugation which might impair the practicability 
for certain applications.  
 
Scheme 10: Carbonylacrylic reagents form stable adducts with cysteine residues.  
Other than that, α,β-unsaturated aryl ketones that carry an additional β-aryl sulfone have been used 
for disulfide rebridging reactions. Here, the conjugated double bond gets attacked by a cysteine 
residue, which initiates an elimination of sulfinic acid, reforming a conjugated double bond that can 
subsequently be attacked by a second cysteine (Scheme 11). This reaction can form a three-carbon 
bridge between the two sulfur atoms of a disulfide after reduction and has been applied successfully 
to PEGylation of therapeutically relevant proteins with retained activity.[137] Based on those findings, 
latent α,β-unsaturated bis-sulfone reagents have been developed, in which elimination of a first 
sulfinic acid occurs that generates the previously described unsaturated mono aryl sulfone reagent in 
situ (Scheme 11).[138] 
 
Scheme 11: Disulfide rebridging with α,β-unsaturated carbonyl reagents carrying an additional β-sulfonyl group that is susceptible to 
elimination. Reagents can also be generated in situ from bis-sulfones. 
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Next to alkenes, electron-deficient alkynes have also been introduced as reagents for chemoselective 
cysteine modification. Alkynoic amides, esters and alkynones have been shown to selectively modify 
cysteine residues in peptides under slightly basic aqueous conditions. A second thiol can be added to 
the generated vinyl sulfide linkage to give a dithioacetal, which is prone to eliminate one or the other 
thiol spontaneously (Scheme 12). Due to this, the addition is highly reversible in solution in the 
presence of other thiols. This has been exploited in the development of a biotinylated probe that 
allows for the enrichment of cysteine containing peptides from a peptide mixture followed by a mild 
thiol mediated elution with a high recovery.[139] 
 
Scheme 12: Electron-deficient alkynes for reversible cysteine modifications. 
Aside from classical carbonyl based Michael-acceptors, α,β-unsaturated sulfone reagents have been 
developed, were the carbonyl moiety is exchanged with an electron-withdrawing sulfone.[140] 
Vinylsulfone reagents have been shown to selectively modify cysteine residues in an almost 
quantitative manner and form a chemically stable thioether bond upon conjugation. Even though 
cross-reactivity with lysine and histidine was observed with these reagents under more basic 
conditions[140] they still comprise an interesting compound class, since no additional stereocenter is 
formed upon conjugation. This makes the technology attractive for certain applications such as 18F-
labelling.[141]  
4.4.2.3. Unsaturated Phosphorus (V) reagents  
Due to the electron withdrawing nature of phosphorus(V) substituents[142] it could be assumed that 
α,β-unsaturated compounds such as P-vinyl and P-ethynyl phosphorus(V) reagents can react with 
sulfhydryl groups in a conjugate addition reaction. However, despite from the work that is described 
in this thesis, there is only one literature example describing a conjugate thiol addition to α,β-
unsaturated phosphorus(V) reagents. Gao et al. have synthesized P-vinylphosphonates and 
phosphonamidates from aminoglycosides and tested their reactivity towards an addition of sulfhydryl 
containing coenzyme A in order to design potent inhibitors for the enzyme aminoglycoside N-6’-
acetyltransferase which is one of the key players in antibiotic resistance. However, it was reported that 
none of the tested conditions for the addition of CoA was successful in the addition to a 
vinylphosphonamidate. Switching to a vinylphosphonate for the conjugate addition was successful and 
provided the desired product in moderate yield (Scheme 13).[143] 
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Scheme 13: Observations by Gao et al.: Vinylphosphonamidates are unreactive towards a conjugated thiol addition, whereas 
Vinylphosphonates do react. [143] 
4.4.2.4. Alkylation with haloalkyl reagents 
Alkylation with α-halo carbonyls with its most prominent example of iodoacetamides was first 
mentioned in 1935 and belongs to one of the earliest methods that have been developed for cysteine 
selective modifications.[144] Due to the ease of applicability conjugation of iodo-, bromo-, and 
chloroacetamides have been widely applied to cysteine modification (Scheme 14a). Iodoacetamide still 
is the reagent of choice to cap cysteine residues prior to proteomic analyses.[145] However, side-
reactions with other nucleophilic side chains such as lysine and histidine have been reported and can 
lead to misinterpretation of MS-based proteomic analyses due to mass artifacts.[146] This issue can be 
solved by using less reactive chloroacetamide.[147] Due to the decreased electrophilicity of 
chloroacetamide, compared to their corresponding iodo counterparts, chloroacetamides have been 
used in proximity based protein labelling techniques.[148] The use of bromoacetamides for cysteine 
modification can constitute a compromise between sufficient reactivity and selectivity.  
 
Scheme 14: Selective cysteine alkylation with haloalkyl compounds. a) Iodo- bromo- and chloroacetamides. b) 4-Iodobenzyl bromide. 
Bromoacetamides have also been applied to therapeutic protein conjugates, for example to connect a 
folate moiety to a single cysteine-containing cytotoxic protein.[149] Due to the high stability of the 
thioether-bond, bromoacetamides have been also applied to the synthesis of ADCs with increased 
serum stability. Efficacy, potency and toxicity characteristics were however not distinguishable from 
maleimide linked ADC isotypes.[118] Other than acetamides, benzyl halides can also be applied for the 
modification of cysteine, as demonstrated by Chalker et al. (Scheme 14b).[150] 
4.4.2.5. Metal catalyzed arylation 
Most of the methods that are described above yield in alkylated or vinylated cysteine residues. In 
contrast to this, methods for arylation of sulfhydryl-groups in aqueous systems are relatively rare. Most 
prominently, Vinogradova et al. have described Pd(II)-complexes that allow a rapid selective arylation 
of cysteine residues in peptides and proteins (Scheme 15), tolerating a broad pH-range, with high 
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stability of the formed products towards acids, bases, oxidants and excess of external thiols. The 
reactivity, selectivity and stability of the palladium complex is determined by the carefully chosen 
RuPhos ligand that facilitates a specific electronic environment to prevent cross-reactivity with other 
nucleophilic residues like tyrosine for instance. The method has been successfully applied to peptide 
stapling and the synthesis of a linker-free ADC by direct attachment of an aromatic drug to 
trastuzumab’s interchain forming cysteine residues.[151]  
 
Scheme 15: Arylation of cysteine residues with Pd(II) reagents.  
Other metal based reagents for cysteine modification include gold(III) complexes that yield arylated 
cysteine residues[152] and rhodium complexes that catalyze the alkylation of cysteine with diazo 
compounds.[153] Both methods yield in stable bonds and the applicability for protein modification has 
been demonstrated. Challenges however remain since selectivity is often an issue and purification of 
the final conjugates from remaining metal ions, which is crucial for therapeutic applications, can be 
tedious.[104b]  
Very recently, conjugation to antibodies-cysteine residues based on Pt(II)-reagents has been 
introduced. Since it is well-known that chloro complexes of platinum (II) form stable complexes with 
thiols under physiological conditions, diamino-chloro platinum(II) complexes have been employed for 
the linkage of cytotoxic drugs to antibodies by disulfide rebridging (Scheme 16).[154]  
 
Scheme 16: Diamino-chloro platinum(II) complexes rebridging of antibody’s interchain disulfides. For demonstrative reasons, modification 
of only one disulfide is depicted in the scheme; however, all four disulfides do react. 
This linkage technology delivered efficacious ADCs that proofed to be efficient in vivo and less 
susceptible to thiol exchange than maleimide conjugation.  
4.4.2.6. Perfluoroarylation 
Based on the finding that sulfhydryl groups react with perfluoroaryl compounds in a nucleophilic 
aromatic substitution (SNAr), Pentelute and coworkers developed a cysteine-selective modification 
reaction with hexafluorobenzene and decafluorobiphenyl. In their study they showed that the first 
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thiol-substitution to the aromatic systems favors a subsequent substitution in para position and 
therefore avoids mono-substitution of the perfluoroaromatic systems. Consequently, the method was 
applied to peptide cyclization of sequences containing two cysteine residues (Scheme 17).[155] 
Macrocyclication is a useful tool in peptide synthesis, since cyclized peptidic structures show enhanced 
biophysically properties, such as increased stability towards proteases[156] and restricted 
conformational flexibility.[157] Derda and coworkers refined the system of Pentelute by using decafluor-
diphenylsulfone reagents, which are also capable of cyclizing peptides containing two cysteines 
(Scheme 17). These compounds modify cysteine residues with an unusual high reaction rate of up to 
180 M-1s-1, making this reaction to one of the fastest cysteine modifications known in the literature to 
date.[158] 
 
Scheme 17: Hexafluorobenzene (left) and decafluora-diphenylsulfon (right) for macrocyclization of peptides containing two cysteines.  
Based on the findings that glutathione S‐transferase catalyzes the reaction of the sulfhydryl-group of 
glutathione to various electrophiles, it was found out that this enzyme can be repurposed to transfer 
perfluoroaromatic structures to glutathione and also to glutathione-tagged polypeptides. Exploiting 
this concept, it has been shown that it is possible to modify the cysteine in the GSH-tag selectively next 
to other cysteine residues in the polypeptide that remained unmodified.[159] Even though site specific 
modification of cysteine residues is very desirable, this method is limited by the isopeptide bond of the 
GSH-tag, which hampers a general applicability to commonly expressed proteins. This issue has been 
solved by the development of a short genetically encodable peptide tag (Phe-Cys-Pro-Phe) which 
promotes the reaction with perfluoroaromatic probes in aqueous systems (Scheme 18). Zhang et al. 
demonstrated that this π-Clamp motif facilitates the modification of one cysteine site in proteins 
containing other endogenous cysteine residues.[160] 
 
Scheme 18: π-Clamp-mediated site-selective cysteine conjugation to the Phe-Cys-Pro-Phe-motif. 
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4.4.2.7. Modification with hypervalent iodine species 
Based on findings from Waser and coworkers that ethynyl benziodoxolone (EBX) hypervalent iodine 
reagents selectively alkynylate thiols in the presence of various functional groups,[161] those reagents 
have also been applied to selective cysteine alkynylation on proteins (Scheme 19).[162] In a proteome 
wide cysteine modification it could be shown that EBX reagents can incorporate an azide handle 
selectively on cysteine residues within living cells. A significantly higher cysteine selectivity has been 
described in a direct comparison experiment with iodoacetamides.  
 
Scheme 19: Selective modification of cysteine with hypervalent iodine species. Tetrafluoroethyl-substituted hypervalent iodine (left) and 
ethynyl benziodoxolone (EBX) (right). 
Fluoroalkyl derivatives of hypervalent iodine species are known to transfer the trifluoromethyl group 
and other fluoroalkyl-species to various nucleophiles including S-, P-, O-, N- and C-functionalities.[163] 
Inspired by this, Togni and coworkers developed tetrafluoroethylated hypervalent iodine reagents for 
selective cysteine modification (Scheme 19).[116] Superior selectivity was proven by labelling of a retro-
aldolase that carries a hyper-reactive lysine residue in the active pocket. The enzyme activity remained 
intact upon cysteine labelling using fluoroalkylation reagents and dropped due to unspecific lysine 
modification with maleimide and iodoacetamide reagents.  
4.4.2.8. Protein modification via disulfides 
Since disulfides are readily cleaved in the reductive environment of the cytosol, attachment of 
functional moieties to proteins can be useful if an intracellular release of the cargo from the protein is 
desired.[164] To this end, several methods have been developed to selectively form a disulfide bond 
between a protein cysteine and a thiol containing modifier.  
The simplest way to promote the formation of a disulfide bond between a cysteine residue and another 
sulfhydryl group is coincubation of the two thiols followed by oxidation. Even though this can be very 
convenient since air can serve as an oxidant and no additional reagents are required for the reaction, 
long reaction times and homodimer formation of either the protein or the modifier can be 
problematic.[104a] To circumvent undesired dimerization, specific disulfide formation can be achieved 
by directed disulfide exchange. Here, one reaction partner can be activated as an electrophilic disulfide 
preventing the formation of homodimers. After removal of the activation agent, the sulfhydryl group 
of the second reaction partner can attack the activated disulfide to form the desired disulfide bond 
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(Scheme 20). Electron-deficient aromatic disulfides, such as 5,5’-dithiobis(2-nitrobenzoic acid) known 
as Ellman’s reagent,[165] that has been primary developed for quantification of free sulfhydryl groups 
or 2,2’-dithiobis(5-nitropyridine) (DTNP)[166] can serve as activation reagents.  
 
Scheme 20: Disulfide formation on proteins using Ellman’s reagent. Either the protein or the modifier can be activated. 
Exploiting this approach, several reductively cleavable protein constructs have been developed, 
including protein-protein[166] and protein-peptide conjugates[167] as well as several examples of 
ADCs.[168] Apart from forming disulfides with other cysteine residues, the activated electrophilic 
disulfide can also react with phosphites to install phosphocysteine residues site specifically.[169] 
Due to possible intracellular release triggered by high amounts of glutathione in the cytoplasm 
(typically 1 to 11 mM), the application of disulfide linkages to drug delivery is of particular interest. 
However, even though the blood plasma is generally expected to be an environment in which disulfide 
exchange reactions are minimal, undesired cleavage during blood circulation can still occur due to 
reactive cysteine residues of blood proteins such as Cys34 of albumin.[164] To circumvent the problem 
of premature disulfide release during circulation, steric interference next to the disulfide bond in form 
of methyl groups for instance can be introduced.[23] In another example Pillow et al. have shown that 
a site-specific disulfide formation at certain sites of a Thiomab™ antibody can yield ADCs that are stable 
during blood circulation. In this case the protein structure in the surrounding of the conjugation site 
prevents premature disulfide reduction.[67]  
4.4.2.9. Transformation of cysteine residues to dehydroalanine  
The conversion of nucleophilic cysteine residues to electrophilic dehydroalanine that can be further 
derivatized by several modifiers, has been studied extensively by the Davis group.[104a] Next to methods 
that require organic solvents, elevated temperatures and/or strong basic conditions for the conversion 
and are therefore incompatible with many proteins, a bis-alkylation-elimination sequence turned out 
to be ideal for the generation of dehydroalanine residues in proteins.[170] 2,5-Dibromohexanediamide 
was identified as the most suitable reagent for the alkylation or dialkylation of cysteine residues 
followed by the elimination to dehydroanaline under slightly elevated temperatures (Scheme 21a). 
The generated Michael-system of dehydroanaline has been exploited extensively for the attachment 
of various functional moieties to different proteins. Several PTMs were incorporated for instance to 
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yield mimics of methylated and acylated lysine residues as well as phosphorylated and glycosylated 
serine mimics.[171] Brik and coworkers have applied the method to the synthesis of electrophilic 
diubiquitin activity probes for the characterization of several deubiquitinating enzymes.[172] More 
recently, dehydroanaline served also as a precursor for radical mediated modifications. Since this 
allows for the incorporation of C-C-bonds that depict native bonds in a great variety of natural 
occurring amino acid residues and PTM carrying amino acids, this method allows for the chemical 
transformation of dehydroalanine to other natural- and non-natural occurring amino acid residues 
(Scheme 21b).[173]  
 
Scheme 21: Modification of cysteine residues via dehydroanaline formation. a) 2,5-Dibromohexanediamide for selective reaction of cysteine 
residues to yield dehydroanaline. b) Subsequent thiol addition or radical mediated C-C-bond formation. 
One disadvantage of protein modification via dehydroanaline is the loss of cysteines chiral center after 
the formation of a sp2-hybridized carbon. After subsequent modification of the double bond, the 
absolute configuration is depending on the tertiary structure of the protein and is therefore hard to 
predict.[174] It has been shown that the two diastereoisomers that arise after thiol addition to the 
dehydroanaline can be separated by HPLC.[175]  
4.4.2.10. The thiol-ene reaction 
The previous methods described above rely on the principle that an electrophilic reagent is attacked 
by the nucleophilic sulfhydryl group of cysteine to form a covalent bond. However, since sulfhydryl 
groups tend to generate thiyl radicals under photoirradiation conditions, selective conversion of 
cysteine residues can also be achieved by radical transformations.[176] In contrast to thiolates, thiyl 
radicals can also react with electron-rich alkenes and alkynes in a chain reaction. Propagation of these 
chain reactions proceeds via hydrogen abstraction by the carbon radical from another sulfhydryl group 
which leads to the formation of a new thiyl radical. The process is terminated by disulfide formation 
between two thiyl radicals (Scheme 22a).[177] Although requirements for protein modifications such as 
rapid kinetics, orthogonality to a lot of functional groups and reactivity in aqueous systems, are 
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fulfilled,[178] it has been mostly applied in the field of polymer chemistry. Described reactions on 
proteins mostly use alkene modified structures like homoallylglycine modified-[179] or farnesylated 
proteins.[180] However, several examples exploit the thiol-ene reaction also for the modification of 
protein cysteines with electron-rich alkenes. Strieter and coworkers successfully synthesized ubiquitin 
trimers from an ubiquitin mutant carrying two cysteine residues and allyl amide modified variants to 
yield unnatural isopeptide bonds that were recognized by deubiquitinating enzymes.[181] In another 
example radical addition of cysteine to N‐vinylacetamide gave acetyl‐thialysine which served as a 
mimic of acetyl‐lysine (Scheme 22b).[182] 
 
Scheme 22: Thiol-ene reaction for cysteine selective modifications. a) Mechanism of the thiol-ene reaction. b) Application to generate an 
acetyl-lysine mimic. 
4.4.3. Selective modification of amino acids other than lysine and cysteine  
In the previous chapters, the focus was set on protein modification reactions suitable for the selective 
targeting of the most commonly used amino acid residues lysine and cysteine. However, amino acid 
residues that are weakly nucleophilic under ambient conditions such as serine or threonine can also 
be selectively modified even though applied reaction conditions are often incompatible with the 
tertiary structure of most proteins.[123] Thus, the following chapter will focus on modification reactions 
that can be applied under conditions that are tolerated by most proteins.  
Following cysteine, tryptophan is the second lowest abundant amino acid with only about 1% 
occurrence. However, about 90% of the endogenous proteins contain at least one tryptophan, making 
this residue very attractive for the development of a residue specific labelling.[123] Antos et al. 
developed a method for a selective tryptophan labelling with metallocarbenoids. They showed that 
metallocarbenoids, derived from stabilized vinyl diazo compounds, and a rhodium source selectively 
modify tryptophan residues on myoglobin without any cross-reactivity with other amino acid residues. 
In this reaction, two isomers, a 2-alkylated and a N-alkylated indole are formed upon conjugation 
(Scheme 23).[183] Rate acceleration was achieved by addition of hydroxylamine hydrochloride to the 
conjugation reaction, which is assumed to stabilize highly reactive metal intermediates.  
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Scheme 23: Selective tryptophan labelling with rhodium metallocarbenoids. 
Further additive screening led to the discovery of N-tert-butylhydroxylamine, which was able to 
promote the formation of rhodium carbenoids under mild aqueous conditions of pH 6.[184] A transition 
metal-free method for tryptophan-selective labelling based on organoradicals was developed by Kanai 
and coworkers. It was shown that the stable radical 9-azabicyclo[3.3.1]nonane-3-one-N-oxyl reacts 
selectively with tryptophan at ambient temperature and near neutral pH.[185] 
Another residue that is particularly attractive for modification reactions is the tyrosine residue. The 
phenolic moiety of tyrosine constitutes a unique reactivity that is mostly orthogonal to that of cysteine, 
lysine and carboxylate-containing residues. Moreover, because of its amphiphilic nature, tyrosine 
residues are often less abundant on the protein surface and are therefore suitable for the attachment 
of only few modifications to a protein.[186] Francis and coworkers have developed a three-component 
Mannich-type reaction that uses in situ formed imines from formaldehyde and electron-rich anilines 
to modify tyrosine following an electrophilic aromatic substitution pathway. The reaction proceeds 
under mild pH and room-temperature at micromolar concentrations and represents one of the first 
carbon-carbon bond forming reactions on proteins.[186] The same group also developed a tyrosine O-
allylation protocol based on π-allyl intermediates derived from allylic acetate and carbamate 
precursors.[187] Another method with increased kinetics relies on an oxidative coupling of dialkyl 
anilines mediated by cerium(IV) ammonium nitrate. However, it should be noted that tryptophan 
residues do also react.[188] 
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Scheme 24: Overview for different protein modification strategies through tyrosine. 
Other strategies for tyrosine modification include diazodicarboxamide reagents that react with 
phenolic residues on proteins through an aqueous ene-type reaction in a broad pH range.[189] A bench 
stable diazonium hexafluorophosphate reagent has been employed to selectively attach an aldehyde 
to a proteins tyrosine residue which can be further modified with oxime ligation strategies.[190] An 
overview of the most important tyrosine modification strategies is depicted in Scheme 24. 
Furthermore, enzymatic oxidation of tyrosine residues to 1,2-quinones with the aid of mushroom 
tyrosinase has been applied for selective modification. Subsequent modification of the 1,2-quinone 
residue by strain-promoted quinone−alkyne cycloaddition has also been applied to the synthesis of 
ADCs.[191] 
Histidine is the only amino acid with a pKa in the physiological range and is therefore often crucial for 
protein function, taking part in many mechanisms were abstraction or donation of a proton is 
necessary.[192] Therefore, one has to take into account that histidine modification might impair the 
protein function. Epoxides have been described to selectively react with the imidazole side chain of 
histidine, even though high pH and elevated temperature are necessary to achieve sufficient 
labelling.[193] Adusumalli et al. recently introduced a method using an epoxide attached to an aldehyde 
via linker of variable length that reacts intramolecularly with histidine in a proximity induced manner 
after being trapped by reversible intermolecular imine forming reaction with nearby lysine residues. 
The authors claim specific modification in dependence of the linker length on one particular protein 
histidine site.[194] 
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Since methionine is the second rarest amino acid in vertebrates, with a low level of surface exposure 
and a unique thioether functional group, selective modification of this residue offers a valuable 
strategy for selective protein modification of native proteins. However, only a limited set of selective 
modification strategies is available so far. Selective alkylation of methionine to sulfonium salts has only 
been achieved with highly electrophilic reagents at low pH, which limited the applicability as a general 
tool for protein modification.[195] Very recently, a redox-based modification strategy, named ReACT, 
developed by Lin et al. was introduced that allows a highly specific modification of methionine under 
neutral aqueous conditions. Here, an oxaziridine reagent reacts with the thioether bond of methionine 
to form a sulfimide (Scheme 25).[78]  
 
Scheme 25: The ReACT strategy for chemoselective methionine bioconjugation. 
The method was successfully applied to the attachment of azide and alkyne handles to different 
proteins, including BSA, calmodulin as well as GFP- and HER2-binding Fab fragments with and without 
engineered methionine residues that were further derivatized via CuAAC. An ADC, consisting of an α-
Her2 Fab linked to MMAE exhibited increased cytotoxicity to an Her2 expressing cell line.[78] In another 
very recent report, Taylor et al. introduced hypervalent iodonium salts that selectively alkylate the 
thioether of methionine to sulfonium salts. The reaction proceeds fast in water in micromolar 
concentrations and additionally enables the incorporation of a protein modifier, together with a diazo-
group that can be subsequently modified. [196] 
Addressing the carboxylic acid groups of glutamic and aspartic acids as well as the C-terminus has been 
rarely used for protein bioconjugations. Most probably due to the relatively high abundance and their 
low reactivity in aqueous systems. Carboxylic acid functions, activated with water-soluble diimides 
such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), can be reacted with amines to form 
stable amide bonds. To prevent protein cross-linking with lysine residues, it is important to use amines 
with a low pKa that follow modification pH 8.0.[197] More recently, Raines and coworkers introduced 
diazo reagents for a selective modification of carboxylic acid residues in proteins. Since this 
modification turns negatively charged carboxylic acids into uncharged ester residues, this concept is 
particularly interesting for the purpose of intracellular protein delivery. Inside the cell, the introduced 
esters can be selectively hydrolyzed by intracellular esterases, thus reforming the native protein.[198]  
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4.4.4. Affinity-based protein modifications 
In addition to the principles, discussed in the last chapters that achieve selectivity for a certain amino 
acid residue by relying on different reactivities of functional groups, proteins can also be selectively 
modified in a specific spatial region with the aid of the proximity effect. Here, latent electrophiles are 
guided to the protein of interest by an affinity ligand where different nucleophilic amino acid side 
chains in the area of the ligand’s binding side can react to form a covalent bond.[88]   
 
Scheme 26: Principle of the protein modification based on affinity probes. The ligand binds to the protein of interest to bring a reactive 
electrophile x in close proximity to the protein. Nucleophilic amino acids (Nu) react to form a covalent bond to attach the modification. Figure 
adapted from Sakamoto et al.[88]  
Electrophilic warheads that have been employed for this strategy include tosyl groups,[199] acyl 
imidazoles[200] and phenyl esters.[201] In addition to those, several structurally refined electrophiles 
have been developed in the last decades that vary in reactivity and selectivity for the targeted 
nucleophilic amino acid.[88] The concept has been further expanded by Hamachi and coworkers that 
attached DMAP as a nucleophilic catalyst to the guiding ligand that promotes an acyl transfer from an 
electrophilic modifier to the protein. This circumvents the problem of intramolecular decomposition 
in cases where the ligand carries nucleophilic residues by itself.[202] Even though this concept enables 
a region specific modification of native proteins, it’s limited to proteins with an identified ligand and 
the exact amino acid side that is modified is often hard to predict.      
4.5. Modification of engineered proteins 
Even though a lot of effort has been made to develop a plethora of useful methods that allows a 
specific modification of certain amino acid side chains, all these approaches are only residue specific 
and will always lead to multiple modification sides in proteins when more than one surface exposed 
targeted side chain is present. Truly site-specific modification is only possible by the incorporation of 
bioorthogonal functional groups or chemical reporters, carrying a unique reactivity over all other 
natural occurring functionalities (Scheme 27).[85b]  
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Scheme 27: Selective chemical protein modification of unnatural functionalities. 
There are several biochemical methods available that allow the incorporation of very different non-
natural functional groups into proteins and a multitude of chemoselective reactions have been 
developed in the last decades to specifically modify these residues.[92] 
4.5.1. Incorporation of unnatural chemoselective handles into proteins  
A very straightforward way to incorporate a non-canonical amino acid into a protein is to subject the 
expressing cells to media containing an unnatural amino acid with structural similarity to a canonical 
amino acid that tolerated by the translational machinery.[85b] The promiscuous activity of methionyl‐
tRNA synthetase has been widely exploited for the incorporation of a variety of methionine analogues. 
Protein expression yields are increased when the used E. coli strain is auxotrophic, meaning it is unable 
to synthesize methionine by itself.[203] At first demonstrated for selenomethionine, which can almost 
quantitatively replace methionine in protein synthesis,[204] the method has been exploited for the 
incorporation of a variety of bioorthogonal functional groups. Most prominent examples for 
methionine surrogates include homopropargylglycine, homoallylglycine[205] and azidohomoalanine.[206] 
Even though auxotrophic expression is generally associated with high protein expression yields, 
remaining drawbacks include amino acid scope and lack of site-specificity. Since all of the natural 
occurring methionine sites are exchanged by their non-canonical counterpart, the method is only 
residue specific.[85b] 
More structural diversity of the unnatural amino acid and true site specificity can be achieved by 
genetic code expansion and reprogramming techniques that facilitate incorporation of unnatural 
amino acids into proteins beyond the canonical 20 amino acids. Genetic code expansion utilizes an 
aminoacyl–tRNA synthetase/tRNA pair that is orthogonal to natural occurring pairs. A promiscuous 
synthetase specifically transfers the non-canonical amino acids onto a tRNA that is complementary to 
a blank codon.[207] In case of the widely used amber suppression technique, the stop codon UAG gets 
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repurposed for the incorporation of the unnatural amino acid.[208] The method has been applied in 
bacteria and mammalian cells as well as in vivo in Drosphila melanogaster.[209] Several different amino 
acids, carrying various functionalities have been incorporated site-specifically into proteins by means 
of genetic code expansion.[210] Important examples that can be employed for subsequent protein 
modification include ketones, azides, terminal alkynes, strained alkynes, alkenes, strained alkenes and 
tetrazines.[87a] Aside from its excellent site-specificity, a major drawback of amber suppression is the 
competition with the termination of the protein, which is the natural function of the Stop codon. This 
leads to truncated proteins at the modification side and usually limits the number of incorporated 
unnatural amino acids to one per protein. [211] 
To overcome the low expression yields in genetic code expansion approaches, site-specific 
modification can be also achieved with peptide tags consisting of canonical amino acids that are 
recognized by certain enzymes for a specific chemoenzymatic incorporation of the chemical 
reporter.[212] Here, the promiscuity of natural occurring enzymes that catalyze the covalent 
modification of proteins with small-molecule cofactors is exploited. Short peptide sequences, derived 
from the natural protein substrate are often sufficient for recognition by the enzyme and can be 
conveniently fused to the protein of interest. Small structural variations of the cofactors are often 
accepted by the enzyme and therefore allow incorporation of non-natural chemical reporters for 
subsequent labelling. Prominent examples include the formylglycine generating enzyme that 
transforms a cysteine residue in the CXPXR motive into an aldehyde,[213] Sortase A, recognizing the 
pentapeptide LPXTG to fuse an oligoglycine motive that can carry different modifications[214] or 
transglutaminases that are able to transfer a wide variety of unbranched primary amines to the 
carboxamide residue of glutamine to generate an isopeptide bond.[215] More recently, Schumacher et 
al. have introduced the Tub-Tag, a fourteen amino acid peptide sequence that gets recognized by the 
tubulin tyrosine ligase to transfer unnatural tyrosine substrates that can carry various chemical 
reporters such as azides or aldehydes.[216] These chemoenzymatic approaches are attractive due to 
high yielding protein expressions and often rapid labelling reactions, however applications are often 
limited since tags have to be fused to specific parts of the proteins such as either the C- or the N-
terminus.[212] 
4.5.2. Chemoselective reactions for site-specific protein modifications 
The above mentioned techniques are often used to introduce unnatural functionalities into a given 
protein of interest that can subsequently be addressed wit chemoselective reagents. These 
chemoselective reagents have been incorporated in proteins have to fulfill several important criteria 
to ensure site specific labelling. First of all, they should not interfere with any other functional group 
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that is present in native proteins and yield in stable covalent linkages. Furthermore, to preserve the 
structural integrity of the modified protein, the reaction must proceed under physiological conditions 
such as ambient temperature, nearly neutral pH and aqueous conditions.[217] A chemoselective 
reaction is termed bioorthogonal if the reactants are non-toxic and do not interfere with any other in-
vivo process.[218] Several reactions based on very different chemical principles that fulfill those criteria 
have been developed in the last decades. An overview of the most important bioorthogonal reactions 
is given in the next chapters. 
4.5.2.1. Aldehyde and ketone condensations 
One of the first chemical reporters that have been explored for site specific protein modification is the 
carbonyl functionality.[219] Aldehydes and ketones can be selectively reacted with nucleophiles that 
hold a strong α-effect such as alkoxyamines[220], hydrazines[221] or hydrazides[222] (Scheme 28). The 
reaction proceeds under slightly acidic conditions (usually pH 4-6) and is irreversible under 
physiological pH for most examples.[222] Rather slow reaction kinetics with second-order rate constants 
of 10-4 to 10-3 M-1s-1 require often high concentrations or huge excess of one or the other reaction 
partner to achieve sufficient labelling yields.[218] Rate enhancement for the reaction of hydroxylamines 
with aldehydes to form oximes can be achieved by the addition of aniline.[223] Reactions in a cellular 
context are often limited to the cell surface due to the necessity of acidic conditions and interference 
with intracellular aldehyde- and ketone- bearing metabolites.[224]  
 
Scheme 28: Modification of carbonyl-modified proteins with hydrazines (left) and hydroxylamines (right). p-Acetylphenylanalin can be 
incorporated by selective pressure incorporation and genetic code expansion techniques.[87a] 
4.5.2.2. Inverse-electron demand Diels-Alder reactions 
One on of the biggest limitation of bioorthogonal reactions when performed in complex environments 
such as living animals is the reaction rate.[218] Since most of the known protein conjugation reactions 
follow second order kinetics, reactions with inherently slow reaction kinetics require high 
concentrations, that are not feasible to achieve sufficient labelling in vivo. The fastest bioorthogonal 
reaction known is based on the reaction between 1,2,4,5-tetrazines and strained alkenes and alkynes 
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that react in an inverse-electron demand Diels−Alder reaction (IEDDA) to yield dihydropyridazines and 
pyridazines. The release of gaseous nitrogen as the only byproduct, which is the driving force of the 
reaction and precludes reversibility.[225] Based on earlier observations of such reactions[226], the groups 
of Fox and Hilderbrand simultaneously reported on its applicability as a bioorthogonal reaction with 
unprecedented fast kinetics in 2008.[227] The rate constant of the IEDDA can be tuned by either 
increasing the electron density, introducing ring strain to the dienophile or by changing the electron 
deficiency of the tetrazine. Most of the reports from the last decade focus on manipulating the reaction 
rate by expanding the scope of dienophiles. Fox and coworkers at first reported trans-cyclooctene 
(TCO) (Scheme 29a) whereas Hilderbrand’s concept focuses on norbornenes as dienophiles (Scheme 
29b). Both of which exhibit second order rate constants in the range of 103 M-1s-1. The reaction 
proceeds through a Diels-Alder- followed by a retro-Diels-Alder pathway with the release of nitrogen 
as a driving force (Scheme 29c).[225] Other dienophiles that have been applied include simple terminal 
alkenes,[228] bicyclooctynes (BCN),[229] cyclopropenes[230] and vinylboronic acids[231], all exhibiting 
different reactivities towards tetrazines. The applicability of highly reactive dienophiles can be limited 
by decreased stability in the presence of thiols or simply prolonged storage, especially in aqueous 
buffers. Robillard et al. showed that TCO isomerizes in mouse serum to form the unreactive cis-isomer 
at 37°C with a half-life of 3.26 hours.[232]  
 
Scheme 29: Chemical protein modification with tetrazines. a) trans-Cyclooctene modified protein in the reaction with a dipyridyltetrtazine. 
b) Norbornene modified protein in the reaction with a phenyltetrazine. c) Mechanism of the IEDDA. Mechanism adapted from Oliveira et 
al.[225] 
Similar to the developments that led to cyclooctynes with improved reactivity in SPAAC, further 
structural refinements of the TCO by introducing ring strain also yielded dienophiles that are even 
more rapid in IEDDA. Taylor et al. demonstrated that fusion of a cis- cyclopropane to the TCO increases 
the reaction rate with a tetrazine 20-fold.[233] Computational analysis led to the discovery of dioxolane-
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fused d-TCO-derivatives that react with a second order rate constant of more than 300 000 M-1s-1 in 
pure water.[234] Stability studies revealed that d-TCOs display enhanced stability towards isomerization 
and are more easily prepared than other strained alkenes.  
 
Figure 12: Selection of unnatural amino acids that can be genetically incorporated into proteins via genetic code expansion for IEDDA. 
Most importantly, several unnatural amino acids allow for the incorporation of several dienophiles as 
well as tetrazines into proteins via genetic code expansion (Figure 12). Rapid reaction kinetics and high 
selectivity together with a feasible site-specific incorporation of one or the other reaction partner into 
proteins have turned IEDDA into the most promising method for protein modification in biological 
media with a myriad of applications.[225] Prominent examples include tracking and imaging of fast 
biological processes,[235] fluorescent tagging of low abundant proteins in living cells[236] and protein 
profiling in vivo. [237] Due to the absorption in the visible-light range, tetrazines also act as quenchers 
towards a series of fluorophores. A unique absorption change upon IEDDA reaction facilitates a turn-
on in fluorescence of a conjugated dye upon conjugation with the biomolecule. This can results in a 
strong signal and minimizes background fluorescence.[238]  
4.5.2.3. 1,3-dipolar cycloaddition reactions for site-specific protein modification 
In contrast to carbonyl compounds, azides are nearly absent from biological systems and are therefore 
very attractive chemical reporters for the development of bioorthogonal reactions.[218] The first 
description of an azido modified compound tracks back to the middle of the 19th century when Griess 
was the first one to describe the synthesis of phenyl azide.[239] Since then, the unique reactivity of this 
functionality has been further explored and exploited in the development of several groundbreaking 
reactions in organic chemistry and chemical biology. Azides do not hydrolyze under ambient 
conditions, are resistant towards oxidation and only slightly prone to reduction in the presence of high 
intracellular thiol concentrations. In contrast to sodium azide that is a well-known cytotoxin, organic 
azide are usually considered as non-toxic.[240] Decomposition by light irradiation is only known for 
phenyl azides, which have been therefore employed as photo-crosslinking reagents.[241] The most 
important chemical property probably is the irreversible formation of gaseous dinitrogen upon 
chemical reaction, which acts as a powerful driving force. This unique feature enables the reaction with 
electrophiles, soft nucleophiles and radicals.[242]  
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In addition, azides are also 1,3-dipoles that can undergo [3+2] cycloaddition reactions with 
dipolarophiles such as alkynes.[224] This reaction is known since the late 19th century,[243] but was 
significantly refined by Huisgen more than five decades ago.[244] The reaction yields stable triazole 
adducts which are chemically stable towards oxidation, reduction as well as hydrolysis under acidic 
and basic conditions.[245] Thus triazoles are desirable linker systems for protein modifications. Even 
though thermodynamically favored, organic azides react with unactivated alkynes without the addition 
of a catalyst only under elevated temperature or high pressure. To overcome this issue, the groups of 
Sharpless and Meldal almost simultaneously reported that reaction rates can be significantly increased 
by copper(I)-catalysis.[246] The catalyzed reaction proceeds at room temperature without the need of 
oxygen exclusion when adding a source of Cu(I) or Cu(II) with a reduction agent such as sodium 
ascorbate. It should be noted that the 1,4-tetrazole regioisomer is almost exclusively formed under 
copper catalysis, whereas a 1:1 mixture of the two possible 1,4- and 1,5-regioisomers are produced in 
the thermal reaction (Scheme 30a). The reaction mechanism includes several different reactive copper 
complexes as intermediates. Recently, Jin et al. reported that dinuclear copper complexes are more 
pronounced during the reaction. However mononuclear complexes were also identified, suggesting 
that two different catalytic cycles are involved (Scheme 30b). A high functional group tolerance was 
already observed in the first reports of the copper catalyzed azide-alkyne cycloaddition (CuAAC). 
Together with high yields, broad scope, insensitivity towards oxygen and water as well as simple 
reaction workup, the CuAAC fulfills all requirements for a “Click”-reaction[247] and has therefore been 
successfully applied for the modification of azide and alkyne modified proteins for the first time by 
Wang et al.[248] Until today, CuAAC is one of the most important techniques for the chemoselective 
modification of macromolecules with applications in protein-,[249] nucleic acid-,[250] dendrimer-, and 
polymer synthesis.[251] Further improvements have been achieved by the development of new ligands 
that allow a reduced copper content in the ligation reaction.[252] Recently, a new 
tris(triazolylmethyl)amine ligand has been developed that even allows CuAAC modification within E. 
Coli and mammalian cells.[253] 
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Scheme 30: Copper-mediated azide-alkyne cycloaddition (CuAAC). a) Regioisomer-differences between temperature-mediated Huisgen 
cycloaddition and CuAAC. b) Mechanism adapted from Jin et al.[254]  
Even though novel ligands enable the use of significantly reduced amounts of copper in the ligation 
reactions, the primary disadvantage of the CuAAC remains coppers cytotoxicity[255], which limits the 
applicability to living cells and in-vivo ligations. A concept to improve the reaction kinetics in absence 
of a copper catalyst involves activation of the alkyne for the reaction. One possible modification of the 
alkyne is based on the attachment of electron-withdrawing groups such as esters.[256] However, the 
resulting α,β-unsaturated carbonyl compounds are also reactive towards thiols in a Michael-type 
addition and therefore limit the applicability in the presence of other thiols in vivo.[224] Based on early 
observations from Wittig and Krebs who described an explosive reaction between strained alkynes 
such as cyclooctyne with phenyl azide to form a triazole,[257] Agard et al. developed the Strain-
promoted azide-alkyne cycloaddition (SPAAC) that proceeds under physiological conditions without 
the need of copper addition.[258] In the initial study, a biotinylated cyclooctyne (OCT) was synthesized 
and selective labelling of an N-azidoacetyl sialic acid containing glycoprotein was demonstrated in 
absence of copper. Driving force of the reaction is the release of ring strain that accounts for 
approximately 18 kcal/mol. In contrast to acyclic alkynes, substantial bond angle distortion destabilizes 
the ground state of cyclooctynes, which leads to a lower activation energy for the cycloaddition 
reaction.[259]  
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Scheme 31: SPAAC with cyclooctyne (OCT) and improved cyclooctyne derivatives with increased reactivity and water-solubility. 
However, the rather slow kinetics in the reaction with azides, with a second-order rate constant in the 
range of 10-3 M-1 s-1 was still a drawback of the first cyclooctyne derivatives.[85b] To overcome this issue, 
electron-withdrawing substituents were attached to the strained alkyne to lower the LUMO and 
thereby increasing its interaction energy with the HOMO of the azide.[260] The attachment of fluorine 
atoms to generate mono- and difluorinated cyclooctynes, MOFOs[261] and DIFOs[262] increased the rate 
of the reaction by 4- and 60-fold, respectively. Further developments led to the discovery of benzo-
substituted cyclooctynes such as dibenzo- (DIBOs)[263], difluorobenzo- (DIFBOs)[264], aza-dibenzo- 
cyclooctynes (DIBACs)[265], biarylazacyclooctynones (BARACs)[266] and Bicyclononynes (BCNs)[267] to 
increase the overall ring-strain (Scheme 31). Even though all of these reagents are superior in terms of 
reaction kinetics over unmodified cyclooctynes and have found applications in imaging azide-
containing proteins in complex biological systems such as live cells[268] or C. elegans[269] efficient 
labelling failed to translate to more complex organisms. In mice for instance, it has been shown that 
DIFO derivatives bind to the highly abundant murine serum albumin (MSA) and therefore prevents 
selective target labelling.[270] This result already points to common problems that are associated with 
SPAAC, as for instance hydrophobicity of the cyclooctyne[271] and cross-reactivity with thiols of 
cysteines that are attacking the alkyne in a thiol-yne reaction.[272] To decrease hydrophobicity, Sletten 
et al. attached methoxy groups to the cyclooctyne producing DIMAC with increased water solubility 
but diminished reactivity in the cycloaddition.[273] Sulfation of DIBAC also yielded in S-DIBO 
cyclooctynes with increased water solubility and decreased cell-permeability, which can be 
advantageous in certain applications.[274]  
Other than azides, also nitrones can react in a [3+2] cycloaddition reaction called SPANC (strain 
promoted alkyne- nitrone cycloaddition). Van Delft and coworkers developed a method that applies a 
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three-step one-pot protocol for the transformation of N-terminal serine residues into a nitrone that 
reacts subsequently with a cyclooctyne. Nitrones are up to 30 times faster than azides in the 
cycloaddition reaction.[275]  
4.6. Chemoselective modifications based on Staudinger-type reactions  
4.6.1. Staudinger reduction and related reactions 
Reactions of organic azides with phosphines were first described 100 years ago by Staudinger, who 
observed a vigorous reaction between phenylazide and triphenylphosphine to form a 
iminophosphorane that could be hydrolyzed under acidic conditions to form an amine and phosphine 
oxide.[276] Since then, this reduction of an organic azide to an amine by phosphines is known as the 
Staudinger reaction. The reaction sequence is initiated by a nucleophilic attack of the phosphine to the 
terminal nitrogen atom of the azide to form a phosphazide. The release of gaseous nitrogen from the 
molecule to form the iminophosphorane proceeds via a cyclic four-membered transition state without 
any participation of radicals or nitrenes.[277] The iminophosphorane structure can be also described as 
an aza-ylide with a highly nucleophilic nitrogen that can undergo several transformations with 
electrophiles. Whereas it rapidly hydrolyzes in the presence of water to form the reduced amine, it can 
also be alkylated with alkyl halides to yield secondary amines after hydrolysis.[278] Furthermore, it is 
also known to react with aldehydes, amides and cyanates to form imines, amidines and carbodiimides 
in aza-Wittig-type reactions, respectively (Scheme 32).[279]  
 
Scheme 32: Mechanism of the Staudinger reaction and subsequent reactivity with a plethora of nucleophiles. 
4.6.2. Staudinger ligations 
Due to the clean formation of an iminophosphorane that proceeds rapidly also in aqueous systems 
with high yields, Bertozzi and coworkers aimed at applying this reaction for a chemoselective ligation. 
To circumvent the amine formation by hydrolysis, an electrophilic trap in form of an ester can be 
installed onto the phosphine that facilitates an intramolecular reaction with the iminophosphorane to 
yield a stable amide bond (Scheme 33).[280] The bioorthogonality of this Staudinger ligation has been 
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demonstrated by selective cell-surface labelling of azido containing carbohydrates that have been 
incorporated by metabolic glyco-engineering. Other than this, an auxotrophically expressed 
azidohomoalanine containing protein has been selectively modified in cell lysate utilizing the 
Staudinger ligation.[281] More sophisticated phosphines, carrying an additional coumarin have also 
been synthesized by the Bertozzi group. Since those structures have been shown to become 
fluorescent when transformed from a phosphine to a phosphine oxide, they are utilized as specific 
fluorogenic labels of azido containing proteins.[282] 
 
Scheme 33: Mechanism of the Staudinger ligation. An intramolecular reaction of the imminophosphorane via a five-membered transition 
state is favored over hydrolysis. 
Despite from the high efficiency and selectivity of the Staudinger ligation in the reaction with azides to 
form the ligated product, there remains one drawback, which is the attached unnatural phosphine 
oxide residue. Since the formation of a native amide bond is beneficial in a peptide ligation, efforts 
have been made to develop a method were the phosphine oxide is released from the molecule during 
the reaction. This has been achieved almost simultaneously by the groups of Raines[283] and 
Bertozzi[284], who developed the traceless Staudinger ligation. In this reaction, the phosphine carries 
an acylated leaving group such as a phenol, a thiophenol, or an imidazole. After reaction with the azide 
and liberation of dinitrogen, an acyl transfer to the nucleophilic iminophosphorane takes place, 
followed by liberation of the phosphine oxide upon hydrolysis and generation of a native peptide bond 
(Scheme 34).[285]  
 
Scheme 34: Mechanism of the traceless Staudinger ligation with successfully applied phosphines. 
A phenol group proved to be the most effective aromatic leaving group in the reaction,[284] whereas 
the aliphatic methylene bridged thiol has been shown to be even more efficient in forming the native 
peptide bond.[285] In cases were the azides originate from enantiomeric pure α-azido acids, the 
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stereochemistry is retained after traceless Staudinger ligation.[286] Due to its high efficiency paired with 
an excellent selectivity the traceless Staudinger ligation has found application in many different fields 
such as organic synthesis, peptide cyclization and protein synthesis. David et al. used the technique in 
an intramolecular cyclization reaction to generate medium-sized lactams,[287] whereas Hackenberger 
and coworkers expanded this idea and applied the concept to the synthesis of cyclic peptides.[288] Both 
studies report the utilization of diphenylphosphinomethanethiol which is a highly reactive linker for 
the ligation but also prone to oxidation under ambient conditions. Borane-phosphine Lewis acid-base 
pairs are known to prevent phosphine oxidation in the presence of air,[289] therefore borane adducts 
have been used in these studies to address this issue. Borane removal prior to Staudinger ligation can 
be achieved with bases such as DABCO or in the presence of strong acids such as TFA (Scheme 35).[290]  
 
Scheme 35: Acid and base mediated Borane deprotection of phosphines followed by intramolecular Staudinger ligation on peptides.  
Application of this approach to protein synthesis has been achieved by Nilsson et al. who ligated two 
protected synthetic peptide fragments on resin by traceless Staudinger ligation in high yields, followed 
by NCL of this peptide to a biosynthetically produced protein fragment of RNAse A. The resulting 
protein proved to be fully functional RNAse A.[291] 
4.6.3. Staudinger phosphite and phosphonite reactions 
Analogously to the reaction of phosphines and azides that form iminophosphoranes, other 
phosphorous(III) species such as phosphites, phosphonites or phosphinites can also react with azides 
to yield in products with P-N double bonds after release of dinitrogen (Scheme 36). The first description 
of an imidate formation from phosphites and phosphonites in the reaction with phenyl azide goes back 
to a report from 1956.[292] Afterwards several studies on phosphonimidate formation by Staudinger 
reactions can be found in the literature that describe the influence of the P-(III)-substituent on the rate 
of the Staudinger reaction[293] or employ imidates as amino protecting groups in organic syntheses for 
instance.[294]  
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Scheme 36: Reaction of organic azides with differently substituted P(III)-reagents. 
Even though cleavage of P-C-bonds has been described under harsh reaction conditions,[295] those 
bonds are generally considered as stable under ambient conditions. In contrast to this, P-O-bonds are 
generally considered as more labile.[296] Hence, phosphor- and phosphonimidates can undergo 
different rearrangement and hydrolysis pathways that are not possible with their iminophosphorane 
counterparts. Mapp and coworkers for example described a [3,3]-sigmatropic rearrangement of allylic 
phosphorimidates that were synthesized from azides and phosphites to generate N-N-disubstituted 
phosphoramidates. This strategy provides synthetic access to allylic amines from allylic alcohol- and 
azide precursors after hydrolysis (Scheme 37).[297] Based on findings from Iley and coworkers, who first 
described a possible rearrangement of phosphorimidates to N-N-disubstituted phosphoramidates that 
is not depending on allylic O-substituents,[298] Wilkening et al. found out that this reaction can be 
promoted by Lewis acid catalysis (Scheme 37). Here, a one-pot protocol was developed where the 
phosphorimidate is formed from azides and phosphites with a subsequent addition of boron trifluoride 
to generate the desired N-N-disubstituted phosphoramidates in high yields.[299] In another 
comprehensive synthetic study, this concept was also extended to phosphinimidates that yield N-N-
disubstituted phosphinamidates after rearrangement.[300] Based on earlier observations,[298] it was 
shown that the reaction can also be catalyzed by alkyl halides instead of boron trifluoride.  
 
Scheme 37: Reactivity of phosphonimidates in rearrangement reactions and towards hydrolysis.  
Introduction 
 
 
68 
 
It has been observed that phosphorimidates hydrolyze under aqueous conditions to form 
phosphoramidates.[292, 301] In contrast to the classical Staudinger reaction with phosphines, here the P-
N-bond stays intact and one alcohol substituent is liberated instead of the amine. Based on those 
observations, the Hackenberger group developed the Staudinger-phosphite reaction as a 
chemoselective labelling method for azide containing proteins. It has been shown that azido modified 
small molecules, peptides and proteins react with phosphites under aqueous conditions to form the 
desired phosphoramidates in high yields. The conjugated products proved stable over several days in 
solution at neutral pH.[302] Modification of peptides via Staudinger-phosphite reaction can be either 
performed on resin or in solution after cleavage of the peptide.[303] 
The Staudinger-phosphite reaction has been extensively applied to protein and peptide synthesis for 
the introduction of very different functional moieties. For example, PEG-phosphites have been 
synthesized and site-specifically attached to azido-modified peptides and proteins.[304] The procedure 
allows efficient installation of PEG-phosphoramidates on proteins even in highly complex media such 
as cell lysate.  
Since the cleavage of the phosphoramidate ester residue yields a phosphorylated amino group, the 
Staudinger-phosphonite reaction has also been employed for the site-specific incorporation of post-
translational phosphorylations and their mimics (Scheme 38a). A phosphotyrosine analog was installed 
on a protein starting from a p-azido phenylalanine residue that has been reacted with a photocleavable 
PEG-phosphite, followed by phosphodiester cleavage, using light irradiation.[302] In another study, a 
similar approach was used to chemoselectively install phospholysine on peptides, leading to the 
development of a MS-based proteomic detection method for those rare post-translational 
modifications.[305] Furthermore, phosphoramidate-linked carbohydrates have been attached via the 
Staudinger-phosphonite reaction to access glycosylated peptides (Scheme 38b). In these studies, 
glycosylation has been achieved with phosphitylated peptides and azido modified sugars[306] or vice 
versa with carbohydrate modified phosphites and peptides bearing an azide handle.[307] 
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Scheme 38: Staudinger-phosphonite reaction on peptides and proteins. a) Reaction principle with subsequent phosphoramidate ester 
cleavage. b) Examples for site-specific incorporation of unnatural modifications and PTMs. 
All the examples described so far utilize symmetrical phosphites for the reaction with the azide that 
carry three equal substituents. However, ligation products from those phosphites always yield doubly 
modified molecules, since only one substituent is released from the molecule upon hydrolysis. To 
overcome this issue, protocols based on unsymmetrical phosphites have been developed that facilitate 
the introduction of a single functionality (Scheme 39). In this case, two good leaving groups were 
attached to the phosphonite together with the desired modifier.[308]  
 
Scheme 39: Staudinger-phosphite reaction with unsymmetric phosphites. 
Besides azides that have been extensively explored, other electrophiles are also known to yield 
phosphorus(V) species in the reaction with phosphorus(III) reagents. A famous example that has been 
at first described by Michaelis[309] in the late 19th century and further elaborated by Arbuzov, is the 
reaction of alkyl halides with phosphites to give phosphonates.[310] In a more recent example, Bertran-
Vicente et al. have discovered electrophilic disulfides in the reaction with phosphites to yield 
phosphorothiolates. It could be shown that the reaction with unprotected, activated cysteine peptides 
is chemoselective and can introduce a native phosphocysteine residue after phosphodiester cleavage 
(Scheme 40).[169] 
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Scheme 40: Reaction of phosphites with electrophilic disulfides for the chemoselective installation of phosphocysteine.  
Further developments in the area of chemoselective reactions based on phosphorus(III) reagents led 
to the discovery of the Staudinger-phosphonite reaction (SPhR) that yields phosphonamidates. Mono 
modification of an azide containing molecule is easily achieved when the desired modifier is installed 
on the phosphonite via a non-hydrolyzable P-C-bond. However, reactions with phosphonites in the 
presence of air can be more challenging since auto oxidation of phosphonites is known to be more 
rapid in comparison to other P(III)-species such as phosphites or phosphinites.[311] Because of this, first 
attempts were performed with monosilylated phosphonites since they can be readily synthesized from 
stable phosphinic acid ester precursors. Subsequent azide addition in a one pot procedure yields the 
desired phosphonamidate in very good yields.[299] Moreover, carbon substituents with sp2-
hybridization have been shown to increase phosphonites stability over alkyl substituted derivatives. 
Hence, C-phenyl substituted phosphonites have been used in the first example that was applied on 
proteins (Scheme 41).[312] Further increase of the stability in aqueous buffer was achieved by the 
introduction of small solubilizing ethylene glycol chains. It could be demonstrated that the reaction is 
chemoselective for azide residues and facilitates the modification of p-azidophenylalanine carrying 
proteins.  
 
Scheme 41: Principle of the Staudinger-phosphonite reaction. 
Encouraged by this first successful development of the Staudinger-phosphonite reaction as a 
chemoselective transformation, borane protected ethynylphosphonites have been synthesized that 
facilitate a modular stepwise conjugation of two different azide containing building blocks (Scheme 
42). Here, copper-catalyzed azide-alkyne cycloaddition (CuAAC) was employed to form a triazole from 
the alkyne moiety in the first step. The borane-adduct ensured selectivity by preventing the 
phosphorus from reacting with the azide in the first place and likewise protected the P(III) from 
oxidation by air. Subsequent borane removal from the isolated triazole-phosphonites with DABCO and 
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Staudinger-phosphonite reaction with azides yielded triazole-phosphonamidates as the formal 
coupling product of two azides in high yields.[313]  
 
Scheme 42: Borane protected ethynylphosphonites for the sequential coupling of two azide containing building blocks.  
Again, incorporation of ethylene glycol substituents to the ethynylphosphonites increased the stability 
in aqueous systems and therefore facilitated modification of azide containing proteins in the second 
Staudinger transformation.[314] 
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5. Objectives 
The chemical modification of proteins with functional synthetic molecules constitutes an essential 
process in chemical biology and the life sciences in general. Traceable fluorescence-[315] tags or spin 
probes[315] have been attached to proteins to study their biological role applying methods like 
fluorescence microscopy or NMR. Furthermore, post translational modifications were installed to get 
a deeper insight into their function[316] and reactive crosslinkers and warheads were incorporated to 
synthesize activity based protein-probes that enable investigation of potential interaction partners[317]. 
Also drugs have been ligated to antigen binding proteins[23] and antibodies[48] to achieve a guided 
delivery to the side of action for a new generation of targeted therapeutics. All these applications 
require reliable protein bioconjugation techniques with different demands such as control over the 
attachment site, stability of the linkage, sufficient reaction kinetics, facile applicability in terms of 
reaction conditions and simple synthetic access.[85a, 86a, 318] Requirements on bioconjugation techniques 
for the synthesis of targeted therapeutics such as ADCs are exceptionally high, since the safety profile 
of the final medication is highly depending on the product’s homogeneity as well as on the linkage 
stability between ligand and drug.[39] Despite many advances that have been achieved in recent 
decades there is still a great demand on adding methodologically novel chemical protein modification 
methods to the toolbox that enable a straightforward synthetic access combined with a high selectivity 
for the protein’s modification site and linkage stability that is sufficient for targeted drug delivery 
applications. Consequently, two main goals were defined for this thesis: 
1. Development of a modular cysteine-selective bioconjugation method based on electron-
deficient phosphonamidates that can be chemoselectively incorporated via the Staudinger-
phosphonite reaction. 
2. Evaluation of this bioconjugation technique in the context of targeted drug delivery with a 
general focus on ADCs in terms of applicability, sufficient linkage stability and finally in vitro 
and in vivo efficacy.  
Project 1: Chemoselective synthesis of phosphonamidate electrophiles for cysteine modification 
Due to the relatively low natural abundance and the unique nucleophilic reactivity of its sulfhydryl 
group, protein conjugation via cysteine often constitutes a good compromise between highly site 
specific but cumbersome modification of unnatural residues and straightforward but rather 
unselective targeting of other proteinogenic amino acids. Despite recent developments of novel 
reagent classes for the selective modification of cysteine, remaining challenges include cross-reactivity 
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with other nucleophilic amino acids, integrity of the formed bond, especially in the presence of other 
thiol nucleophiles, and pretentious syntheses of the thiol reactive warhead (See chapter 4.4.2).  
The aim of this research project was the development of a cysteine selective modification technique 
based on unsaturated vinyl- and ethynylphosphonamidate-electrophiles. Most importantly, it was 
envisioned that the Staudinger-phosphonite reaction can be employed to incorporate the desired 
phosphonamidates from vinyl- and ethynylphosphonites in a chemoselective manner into azide-
containing molecules without elaborative protecting group manipulations. Since this process turns the 
electron-rich double or triple bond of the phosphonite into an electron-deficient unsaturated 
phosphonamidate, it was anticipated that the first Staudinger-phosphonite reaction induces reactivity 
for the subsequent thiol addition to cysteine. The overall goal was to evaluate the two synthetic steps 
in terms of feasibility, scope, functional group tolerance, modularity, reaction kinetics, selectivity, 
conjugate stability and finally applicability to protein modifications to establish a new, robust method 
for cysteine selective protein synthesis.  
Project 2: Evaluation of phosphonamidates as part of linker systems for ADCs 
Antibody-drug-conjugates combine the high efficiency of cytotoxic drugs with the tumor selectivity of 
monoclonal antibodies and represent therefore an emerging class of cancer therapeutics. In theory 
they are able to broaden the therapeutic window of commonly applied chemotherapy by specifically 
delivering toxins to the cancer site, while sparing healthy tissue. However, problems arise from 
unspecific uptake of the conjugates into healthy cells, pharmacokinetic issues caused by aggregation 
of the strongly hydrophobic drug molecules and insufficient linkage stability during blood circulation. 
The pharmacological consequences of the latter still needs to be investigated in detail, but a premature 
loss of drug from the antibody is assumed to diminish antitumor activity and cause severe side effects 
(see chapter 4.3). 
Aim of this research project was the synthesis and pharmacological evaluation of phosphonamidate-
linked ADCs, applying the methodology that has been developed in project 1 within this thesis. It was 
envisioned that native antibodies serve as a starting point to attach the cysteine reactive 
phosphonamidate drug molecules after reduction of the inter-chain disulfide bonds, as previously 
described for maleimide reagents, among others. After successful synthesis and characterization, it 
was aimed to evaluate the ADCs in terms of selective in vitro activity in cellular based assays, stability 
of the phosphonamidate linkage during blood circulation and finally in vivo antitumor efficacy in 
xenograft mouse models. The overall goal was to provide sufficient amounts of pharmacological data 
with direct comparisons to commonly applied linker technologies to overcome known limitations of 
current methods in ADC synthesis. 
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6. Results and Discussion  
6.1. Chemoselectively installed ethynylphosphonamidates for modular, cysteine-
selective modifications of proteins 
Selective protein modification exploiting the exceptional nucleophilic properties of the sulfhydryl 
group of cysteine constitutes a highly attractive concept in protein synthesis. Requirements on new 
reagents that are developed for the purpose of cysteine modification are particularly high and include 
decent reactivity under aqueous conditions at close to neutral pH, fast reaction kinetics at ambient 
temperature and a good selectivity in the presence of all other proteinogenic amino acids. In addition 
to that, an excellent linkage stability and straightforward synthetic incorporation of the thiol reactive 
moiety into complex molecules is highly desirable. Even though a plethora of different cysteine 
modification techniques has been developed in recent years (chapter 4.4.2), there is no outstanding 
method that satisfies all criteria equally and surpasses all the others.  
The good functional group tolerance of Staudinger-type transformations between P(III) reagents 
including phosphines, phosphites and phosphonites with azides already lead to the development of 
various chemoselective reactions (chapter 4.6). The aim of the work described in this chapter was to 
pursue with previous achievements on the SPhR and exploit this method for the chemoselective 
synthesis of phosphonamidate electrophiles for the modification of sulfhydryl groups. In particular, 
ethynylphosphonites were used for the synthesis of ethynylphosphonamidates and the potential of 
this compound-class to modify cysteine residues on proteins was evaluated with the following main 
goals: 
a) Development of the SPhR with ethynylphosphonites and various azide-modified building 
blocks to synthesize ethynylphosphonamidates in the presence of different unprotected 
functional groups. 
b) Evaluation of the potential of ethynylphosphonamidates to modify cysteine residues with a 
focus on selectivity, linkage stability, reaction kinetics and applicability to proteins in general 
and antibodies. 
c) Exploration of the unique features of the phosphonamidate linker structure, which includes 
the incorporation of functional handles to the ethynylphosphonamidate ester residue and the 
potential to yield a single diastereoisomer after the conjugation to cysteine residues. 
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6.1.1. Chemoselective synthesis of O-ethyl-ethynylphosphonamidates and subsequent 
Cysteine-selective bioconjugation 
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Figure 13: Principle of the SPhR with ethynylphosphonites to generate ethynylphosphonamidates and subsequent cysteine conjugation with 
proteins and its application to cellular protein uptake and receptor imaging. 
Abstract 
We describe a new technique in protein synthesis that extends the existing repertoire of methods for 
protein modification: A chemoselective reaction that induces reactivity for a subsequent 
bioconjugation. Hereby, an azide building block reacts first with an ethynylphosphonite via the 
Staudinger-phosphonite reaction (SPhR) to an ethynylphosphonamidate. The resulting electron-
deficient triple bond subsequently undergoes a cysteine-selective reaction with proteins or antibodies. 
We demonstrate that ethynylphosphonamidates hold excellent cysteine-selective reactivity combined 
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with a superior stability of the thiol adducts. This turns our technique into a versatile and powerful tool 
for the facile construction of stable, functional protein conjugates. 
Responsibility assignment 
Christian P. R. Hackenberger designed and conceived the project. The author developed the SPhR with 
ethynylphosphonites and the subsequent cysteine modification, synthesized and characterized 
phosphonamidates and azide precursors, conceived and performed stability- and kinetic studies, 
developed the antibody modification with phosphonamidates and synthesized, purified and analyzed 
the antibody conjugates. Maria Glanz developed the SPhR with ethynylphosphonites on peptides, 
synthesized and characterized the cyclic peptides, performed stability studies, developed the 
phosphonamidate addition to proteins, expressed eGFP and performed the cellular imaging studies 
with eGFP. Andreas Stengl expressed and purified trastuzumab and performed cellular imaging with 
AFCs. Martin Penkert and Eberhard Krause conceived and performed two-dimensional MS 
experiments. Simon Klenk performed DFT calculations. Tom Sauer performed initial experiments on 
the SPhR and the subsequent thiol addition. Dominik Schumacher designed and cloned the eGFP 
mutant. Jonas Helma and Heinrich Leonhardt designed the cellular imaging experiments with AFCs. M. 
Cristina Cardoso contributed to the design of the cellular imaging studies with eGFP. The author wrote 
the manuscript and translated it into German supported by Christian P. R. Hackenberger. 
Summary of content 
A method for the chemoselective modification of cysteine residues in proteins and antibodies, making 
use of electrophilic ethynylphosphonamidates, is presented. Most importantly, the cysteine selective 
handle can be installed into azide-containing small molecule building blocks and unprotected peptides 
in a chemoselective manner with a high functional group tolerance, making use of the SPhR with 
electron-rich ethynylphosphonites. The electrophilic reactivity for cysteine is induced by this first step, 
forming the electron-deficient ethynylphosphonamidate. The investigations began with the 
development of a protocol to synthesize ethynylphosphonamidates from commercially available 
phosphorus precursors for the SPhR. A one-pot protocol, starting from diethyl chlorophosphite and 
ethynyl magnesiumchloride followed by azide addition and hydrolysis was developed that produces 
ethynylphosphonamidates in good isolated yields from 44% to 80% for phenyl azides. Functional 
groups such as carboxylic acids, amines and NHS esters were well tolerated and excellent isolated 
yields were reported for the reaction on unprotected peptides. Furthermore, it has been shown that 
amino- and NHS-containing ethynylphosphonamidates can be employed as modular building blocks to 
incorporate the thiol reactive moiety into other functional molecules such as fluorescent dyes in high 
yields avoiding the use of potentially unstable phosphorus (III) reagents that might be deterrent for 
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some laboratories. Next, cysteine addition studies to the ethynylphosphonamidates were performed 
with a glutathione model substrate, revealing decently fast reaction with a second order rate constant 
of 0.62 M-1·s-1. An outstanding selectivity for the Z-addition product of more than 97% in aqueous 
solvent systems was supported by DFT calculations that unveiled a higher activation barrier for the E-
product. To test the feasibility of cysteine modification on proteins, the interchain disulfide bonds of 
the monoclonal antibody trastuzumab were reduced, subsequently alkylated with a biotinyl 
ethynylphosphonamidate and successful conjugation was monitored by anti-biotin western blotting. 
Even though more equivalents had to be applied in comparison to other tested cysteine reactive 
reagents to achieve similar labelling degrees, a superior selectivity for cysteine over all other 
proteinogenic amino acids was solely observed for ethynylphosphonamidates. This was further 
confirmed by tandem-MS experiments after trypsin digestion of the antibodies. A good conjugate 
integrity under physiological conditions could be demonstrated in a FRET based stability study. The 
cysteine adducts proofed stable in PBS, human serum and freshly prepared cellular lysate over several 
days. Only very harsh conditions of pH 0 cleaved the P-N-bond over 24 hours. Since linkage-lability in 
the presence of external thiols is particularly problematic for pharmacological applications, stability 
studies in the presence of excess glutathione and serum proteins was tested and directly compared to 
state-of-the-art maleimide conjugation, revealing a superior integrity of the ethynylphosphonamidate-
thiol adducts. Finally, the method was applied to the synthesis of a two functional conjugates, an 
antibody-fluorophore conjugate and a cyclic cell penetrating peptide eGFP conjugate. Both syntheses 
proceeded smoothly to yield the desired protein conjugates in two straightforward chemical steps and 
the conjugates proofed functional on a cellular level, exemplified by fluorescence microscopy.  
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Abstract:We describe a new technique in protein synthesis that
extends the existing repertoire of methods for protein modifi-
cation: A chemoselective reaction that induces reactivity for
a subsequent bioconjugation. An azide-modified building
block reacts first with an ethynylphosphonite through a Stau-
dinger-phosphonite reaction (SPhR) to give an ethynylphos-
phonamidate. The resulting electron-deficient triple bond
subsequently undergoes a cysteine-selective reaction with
proteins or antibodies. We demonstrate that ethynylphospho-
namidates display excellent cysteine-selective reactivity com-
bined with superior stability of the thiol adducts, when
compared to classical maleimide linkages. This turns our
technique into a versatile and powerful tool for the facile
construction of stable functional protein conjugates.
Chemical attachment of synthetic molecules to a distinct site
of a protein is essential for a plethora of applications in the life
sciences, in particular for the investigation of biological
processes and the development of targeted therapeutics.[1]
Protein modification can in principle be achieved by one of
two strategies: incorporation of unnatural amino acids or
peptide sequences, which possess distinct reactivities to
chemical or enzymatic reactions, or reactions that rely on
specific chemical properties of the side chains of proteino-
genic amino acids.[2] The former requires sometimes tedious
biochemical manipulations such as amber suppression or
additional enzymatic transformations, while the latter is only
residue-specific and can produce protein mixtures with
a different degree of modification and several regioisomers
being formed.[3] Despite recent advancements in the engi-
neering of new residue-specific reactions, including the
modification of tyrosine,[4] tryptophan,[5] and methionine,[6]
the targeting of cysteine (Cys) residues for chemical protein
modification still offers many advantages. Cys residues have
a low natural abundance in a reduced form on accessible
protein surfaces and can be readily incorporated into a given
protein or antibody through facile mutagenesis.[7] Moreover,
the unique nucleophilic properties of its sulfhydryl group
have been exploited in the development of several Cys-
selective modification techniques,[7, 8] including metal-cata-
lyzed reactions[9] and radical transformations.[10] Several
compound classes have been employed, including the prom-
inent electrophilic maleimides[11] and a-halo acetamides,[8] as
well as a recent report on perfluorophenyl reagents.[12]
Among other techniques, maleimides remain the most
widely used method for chemical modification on Cys
residues,[7] mostly due to their rapid kinetics in reactions
with sulfhydryl groups.[13] However, one of the biggest
drawbacks of maleimide conjugates is their instability
caused by a retro-Michael addition in the presence of external
thiols.[14] Recently developed alternatives include self-hydro-
lyzing maleimides,[15] structurally refined Michael-type
acceptors such as carbonyl acrylic derivatives,[16] or exocyclic
maleimides.[17] These Michael-type acceptors yield stable
sulfhydryl adducts; however, challenges remain, since
stereo- or regioisomers are formed[18] and their incorporation
into functional molecules usually requires protecting-group
manipulations.
Previous work from our laboratory has shown that
phosphonamidates can be chemoselectively installed into
a given azide-containing protein with high functional-group
tolerance through a Staudinger-phosphonite reaction
(SPhR).[19] By taking advantage of this, we have used
borane-protected ethynylphosphonites for the sequential
coupling of two azide-containing molecules, including
probes, polymers, or proteins.[20] Based on these findings, we
now report a method that enables the chemoselective
installation of a highly Cys-selective handle into a given
azide-containing molecule through SPhR with unprotected
ethynylphosphonites. Most importantly, the chemoselective
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SPhR turns the electron-rich triple bond of an ethynylphos-
phonite into an electron-poor ethynylphosphonamidate and
thereby induces reactivity for subsequent thiol addition
(Figure 1a). With this unique reaction sequence of two
subsequent chemoselective transformations, we developed
a modular method that simplifies the attachment of functional
molecules to proteins and antibodies with superior stability.
At the outset of our studies, we validated our proposed
concept by reacting readily available diethyl ethynylphos-
phonite with different azides containing various functional
groups. In comparison to other PIII species such as phosphites,
auto-oxidation of phosphonites is more rapid.[21] This issue
was previously addressed by isolating air-stable borane
protected phosphonites that had to be deprotected with
strong bases prior SPhR.[19,20] Now, we developed a one-pot
synthesis starting from commercially available diethyl chlor-
ophosphite and ethynylmagnesium bromide followed by
azide addition and hydrolysis without isolation of the
phosphonite intermediate (Figure 1b. We observed that
polar aprotic solvents generally worked best for the SPhR
as they gave the best yields and ensured solubility of all tested
azides. The desired ethynylphosphonamidates 1–6 were iso-
lated in good overall yields, with a better performance in the
formation of N-phenylphosphonamidates compared to the
alkyl derivative 6. Nucleophilic functional groups such as
amines, alcohols, carboxylic acids, and electrophilic NHS
esters were well tolerated. Even unprotected azide-containing
peptides, including cyclic RGD and cyclic cell-penetrating
peptides (cCPPs) could be converted into the desired
ethynylphosphonamidates 7–9 in very good yields of isolated
product, with HPLC analysis verifying the formation of
a single reaction product.
The purified ethynylphosphonamidates showed excellent
stability in solution at neutral pH over several days (Figure S1
in the Supporting Information) and could be stored at 4 8C for
several months without any observable decomposition. Fur-
thermore, we were able to demonstrate that compounds 3 and
4 can be further used as modular building blocks to attach
ethynylphosphonamidates to other functional modules in
high yields, as exemplified by the synthesis of phosphonami-
Figure 1. a) Principle of chemoselective reactivity induction for Cys. b) Yields of isolated product from one-pot SPhR with different unprotected
azides. Unless stated otherwise 1.2 equiv of phosphonite were used with respect to the azide; reactions were carried out in THF at room
temperature overnight. * 4 equiv phosphonite were used, reactions were carried out in DMSO. c) Modular building blocks (3, 4) to attach
ethynylphosphonamidates to other functional modules via amide bonds.
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date derivatives of the fluorescent dyes EDANS (10) and Cy5
(11) in 70% and 94% yield of isolated product, respectively
(Figure 1c).
Previously, Gao et al. observed that vinylphosphonami-
dates do not undergo thiol addition under their tested
conditions.[22] Since we envisioned ethynylphosphonamidates
to be more reactive, we carried out model reactions with the
N-phenyl derivative 1 and glutathione under varying pH
conditions and monitored the progress by UPLC-UV. It was
observed that the conversion rate increases from pH 7.4 to 9.0
with only a slight increase from pH 8.5 to 9.0 (Figure S2 in the
Supporting Information). Considering decreased protein
stability at higher pH, we decided to continue our studies at
pH 8.5. Full conversion to the desired thiol adduct was
observed at pH 8.5 after 30 minutes at a concentration of
10 mm N-phenyl derivative 1 (Figure 2a and Figure S2 in the
Supporting Information). The second-order rate constant for
the thiol addition reaction was determined by fluorescence
HPLC with the N-phenyl-EDANS-phosphonamidate deriva-
tive 10 at a concentration of 0.1 mm to 0.62: 0.01m@1 s@1
(Figure S3 in the Supporting Information). It should be
noted that the thiol adduct is formed with a high Z selectivity
(> 97%) in aqueous systems, as studied for the addition of
ethanethiol to 1 (Figure S4 in the Supporting Information).
Similar observations for the formation of the Z isomer have
been made for other electron-deficient alkynes earlier.[23]
DFT calculations revealed a higher activation barrier for
the E product and can therefore explain the high Z selectivity
(Figure S5 in the Supporting Information).
To test the applicability of our reaction to the construction
of protein conjugates, we proceeded in a proof-of-principle
study with the Her2-addressing IgG monoclonal antibody
trastuzumab. For antibody modification, we applied a previ-
ously described protocol, which reduces and alkylates inter-
chain disulfide bonds of IgG antibodies.[24] In our studies, we
probed the modification of trastuzumab with different
electrophilic biotin derivatives, including a maleimide, an
iodoacetamide, and the ethynylphopshonamidate 5. All anti-
body modifications were carried out at concentrations
between 3 and 6 mm. Anti-biotin western-blot analysis
revealed labeling of the light and heavy chains with DTT-
reduced trastuzumab for all of the tested biotin derivatives
when using the reported conditions of 1.1 equiv. of labeling
reagent per free Cys.[24] Probably due to slower reaction
kinetics (0.62m@1 s@1 for phosphonamidates vs. 734m@1 s@1 for
maleimides),[25] decreased labelling efficiency was observed
for 5 compared to the maleimide derivative (Figure S6 in the
Supporting Information). Therefore, we screened various
phosphonamidate equivalents and monitored the degree of
modification by intact protein MS. Optimal conditions for the
phosphonamidate labelling were identified with 10 equiv of
phosphonamidate per free Cys, which corresponds to 80 equiv
with respect to the antibody (Figure S7 in the Supporting
Information). Side reactions of other nucleophilic amino acid
residues with common Cys-labeling techniques have been
reported earlier[26] and have been shown to be very problem-
atic in certain applications.[27, 26b] To confirm the chemo-
selectivity of the phosphonamidate labeling technique, reac-
tions were carried out without prior reduction of the antibody
disulfide bonds. Compared to other Cys-conjugation tech-
niques at neutral pH, outstanding selectivity for Cys residues
was observed for the labeling reaction with 1.1 equiv ethy-
nylphosphonamidate per free cysteine residue at pH 8.5 when
carried out without prior reduction of the antibody disulfide
bonds (Figure S6 in the Supporting Information). In contrast
to a maleimide reagent, even a larger excess of 10 equiv
ethynylphosphonamidate per free cysteine did not lead to any
unspecific labeling (Figure 2b). The selectivity was further
confirmed by mass spectrometry (LC-MS/MS) after trypsin
digestion of the modified antibody. Only interchain-disulfide-
forming cysteines were modified after reduction and alkyla-
tion with an excess of 1, and no modification on any amino
acid was found without prior reduction (Figure S8 in the
Supporting Information). Taken together, the intrinsic Cys
selectivity of this reaction allows ethynylphosphonamidates
to be employed in bioconjugation reactions even in larger
Figure 2. a) Reaction of glutathione (GSH) with phosphonamidate 1.
10 mm phosphonamidate were reacted with 20 mm GSH at pH 8.5
(NH4HCO3-buffer). Concentrations of the starting material 1 (cyan)
and product 12 (black) over time are sown as a mean and error from
three independent measurements, as monitored by UPLC-UV. b) Tras-
tuzumab modification with three different Cys-reactive biotin deriva-
tives. Reactions were carried out with 80 equiv biotin derivative.
Western-blot analysis: Lanes 1 and 5: untreated antibody. Lanes 2–4:
prior DTT treatment. Lanes 6–8: Control reactions without prior DTT
treatment. HC=Antibody heavy chain, LC= light chain.
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excess without running into the risk of unselective labeling,
which is advantageous when the exact concentration of the
protein or antibody probe is difficult to determine.
The linkage stability of the Cys conjugates is crucial for
many applications and in particular for drug delivery appli-
cations to prevent hazardous off-target effects, especially
during circulation in the blood stream.[7] To test the stability of
our phosphonamidate–thiol adducts a fluorescence-quench-
ing assay was carried out in which a fluorescent signal was
generated upon cleavage of the conjugates (Figure 3a).
Quenched probes were synthesized through the addition of
a DABCYL-modified peptide to the fluorescent phosphona-
midate 10. The phosphonamidate adducts show a high
stability in PBS buffer, HEK cell lysate, and human serum
over several days. Since P@N bonds are generally susceptible
to hydrolysis under acidic conditions,[28] very harsh conditions
of pH 0 were applied, which led to to cleave the phosphona-
midate adduct within 24 h (Figure 3b). Previously, thiol
adducts of electron-deficient alkynes such as propynamides
were described as susceptible to exchange with other thiols.[23]
However, with the ethynylphosphonamidates, high stability
upon exposure to excess thiols was observed, with a superior
performance in a direct comparison to a maleimide conjugate
(Figure S9 in the Supporting Information). Next, we probed
the stability of phosphonamidite- versus maleimide-labelled
antibodies under physiologically relevant concentrations of
serum proteins. This is of particular importance, since the
transfer of maleimide-modified drugs to serum albumin has
been described before and poses a serious risk for off-target
toxicity when applied to drug delivery.[14, 29] Biotin-modified
antibodies were exposed to bovine serum albumin (BSA) at
37 8C under physiological conditions and the potential trans-
fer to BSAwas monitored by western blotting (Figure 3c and
Figure S10 in the Supporting Information). After several days
of incubation, a significant transfer of the biotin to BSA was
observed for the maleimide linkage whereas the phosphona-
midate linkage was stable under the tested conditions. Taken
together with the previously described stability experiments
with quenched fluorescent probes, these results clearly point
to excellent stability of the phosphonamidate conjugates,
especially when compared to conventional maleimide-linked
conjugates.
Encouraged by the outstanding thiol selectivity and the
high stability of the Cys–phosphonamidate adducts, we
proceeded with the functional evaluation of phosphonami-
dite-based antibody conjugates. We modified trastuzumab, an
anti-Her2 antibody, with the fluorescent Cy5 phosphonami-
date 11 to generate an antibody–fluorophore conjugate
(AFC). Trastuzumab modification was carried out by using
the above-mentioned reduction and alkylation of the inter-
chain disulfide bonds (Figure 4a). Successful modification
was confirmed by in-gel fluorescence measurements of the
antibody heavy and light chains (Figure S11 in the Supporting
Information). Immunostaining experiments with the AFC
constructs show excellent target selectivity for the Her2-
receptor on the outer cell membrane (Figure 4b). This
experiment clearly shows that our modification strategy
does not affect the antibodyQs performance and provides
a simple conjugation approach for diagnostic reagents.
Finally, we applied our strategy to the attachment of
cCPPs to eGFP for functional protein delivery into living
cells, in a manner similar to that previously described.[30] An
eGFP mutant with a single addressable cysteine was obtained
by consecutive point mutation of Cys70 to Met and Ser147 to
Cys, and the mutant protein was almost quantitatively
modified with 20 equiv of the phosphonamidate cTAT or
cR10 peptides 8 and 9 after reaction for three hours at 37 8C in
PBS at a protein concentration of 100 mm (Figure 4c,d). With
the eGFP–cCPP conjugates in hand, we performed cellular
uptake studies monitored by live-cell microscopy in HeLa
cells. Unconjugated eGFP was not taken up, whereas a green
fluorescence signal was detected in the cytosol and the
nucleoli for both eGFP–cCPP conjugates following incuba-
tion with 50 mm of the constructs, which is in accordance with
previous observations using CuAAC conjugation for the
Figure 3. a) Set-up of the fluorescence-quenching assay for stability
measurements of the thiol adducts. b) Fluorescence increase was
monitored over time. Measurements were performed at least in
triplicate. Cyan: PBS, green: pH 0 (1n HCl), brown: cell-lysate,
blue: GSH (1000 equiv of glutathione in PBS), red: human serum.
c) Transfer of the antibody modification to serum proteins. Trastuzu-
mab–biotin conjugates were incubated at a concentration of 3 mm with
500 mm BSA in PBS at 37 8C. Lane 1: Untreated maleimide conjugate.
Lanes 2–5: BSA-exposed maleimide adduct after 0, 1, 2 and 5 days.
Lane 6: Untreated phosphonamidate conjugate. Lanes 7–10: BSA-
exposed phosphonamidate adduct after 0, 1, 2 and 5 days.
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attachment of cTAT (Figure 4e).[30a] With these results, we
demonstrated that our method enables the straightforward
synthesis of functional protein–cCPP conjugates for intra-
cellular protein delivery.
In summary, we present a unique reaction sequence that
first incorporates a thiol-reactive ethynylphosphonamidate
into a given molecule through an initial chemoselective SPhR
and subsequently modifies Cys residues smoothly in aqueous
systems with outstanding selectivity towards sulfhydryl
groups. This approach enables the facile conjugation of
complex molecules to proteins, as exemplified by the
conjugation of biotin, fluorophores, and peptides to anti-
bodies and proteins. In contrast to the widespread maleimide
labeling, our thiol adducts showed excellent stability to thiol
exchange with GSH and albumin in the presence of human
serum and cell lysate. The applicability of our method was
demonstrated by the synthesis of a functional AFC for
selective staining of antigen-presenting cells and eGFP–CPP
conjugates for efficient protein delivery into cells. This
method combines facile synthetic access with high flexibility,
chemoselectivity, and superior linkage stability and is there-
fore a powerful and versatile tool for selective protein
conjugation.
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Figure 4. a) Synthetic scheme for phosphonamidate attachment of the Cy5 fluorophore to trastuzumab (anti-Her2 antibody) to generate an AFC.
b) Immunostaining of fixed cells either over-expressing the cell-surface receptor Her2 (BT474) or exhibiting low Her2 expression levels
(MDAMB468). The merged images show the signal from the DNA stain DAPI in blue and the Cy5 signal in red. Scale bar: 10 mm. c) Synthetic
scheme for the attachment of phosphonamidite-modified cCPPs 8 and 9 to a eGFP mutant with a single addressable cysteine. d) Fluorescence
imaging of HeLa cells after incubation with eGFP alone and eGFP–cTat at 50 mm. Images show the GFP channel in green and the Hoechst 33342
nuclear stain in blue. Scale bar: 20 mm. For further information see the Supporting Information.
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6.1.2. Variation of the ethynylphosphonamidate ester residue for further 
functionalizations 
All the work described in the previous chapter has been performed with O-ethyl substituted 
ethynylphosphonites and -phosphonamidates. One unique advantage of phosphonamidate based 
conjugations over other cysteine conjugation techniques is the possibility of a facile incorporation of a 
third functional O-substituent to the phosphonamidate core structure in a few chemical steps (Scheme 
43).  
 
Scheme 43: Principle of the chemoselective SPhR with differently substituted ethynylphosphonites to convert azide building blocks into thiol 
reactive ethynylphosphonamidates with expanded functionality.  
The development of linker systems which can be selectively cleaved by an external stimulus that is not 
affecting the integrity of an attached biomolecule constitutes an important tool in chemical biology.[319] 
Such controlled release systems can for example facilitate purification or enrichment of biomolecules 
by catch and release strategies[320] or enable a controlled release of drugs from the targeting protein 
after cellular uptake in drug delivery applications.[23] Due to the lability of P-N-bonds towards acidic 
conditions, phosphoramidates have been used before to release primary and secondary amines. 
Careful optimization of the phosphoramidate substituents, for example by the attachement of 
carboxylic acids or pyridinium substituents to the phosphoramidate core, can be used to tune the 
lability towards acidic hydrolysis.[321] Based on this observation with phosphoramidates, Siebertz et al. 
could show that cleavage of phosphonamidate ester residues to form phosphonamidic acids also 
induces lability of the P-N-bond. Therefore, a free amine can be released after a cleavage of the O-
substituent of the phosphonamidate under slightly acidic conditions.[322] In the current chapter, this 
principle was translated to ethynylphosphonamidates to enable a cysteine selective protein 
modification technique that facilitates the release of the attached modification from the protein after 
an external stimulus such as light, reducing agents or even enzymes. For this, the attachment of various 
cleavable residues to the O-substituent of ethynylphosphonamidates was planned as depicted in 
Scheme 44.  
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Scheme 44: Phosphonamidate ester for an induced cleavage of the P-N-bond. a) Cleavage of the phosphonamidate ester facilitates an amine 
release from the phosphonamidate under slightly acidic conditions. b) Various ester residues that can be cleaved under the influence of 
different stimuli. 
In addition to cleavable residues, also other functional substituents were attached to 
ethynylphosphonamidates to expand their functionality. Polar oligo ethylene glycol units to increase 
aqueous solubility or alkynes as chemoselective handles for further chemoselective modifications via 
CuAAC were incorporated.  
Goal of the following research project was the variation of the O-substituent of 
ethynylphosphonamidates via the synthetic route that is depicted in Scheme 43. Since this residue is 
preserved during SPhR with azides, we started our investigations by synthesizing different substituted 
ethynylphosphonites with various handles. Afterwards their reactivity with azides in the SPhR was 
tested. And the phosphonamidates were than probed for subsequent thiol addition and functionality 
of the handles in different model experiments.  
6.1.2.1. Synthesis of O-substituted ethynylphosphonites 
Synthesis of phosphonites is in principle possible via two different routes (Scheme 45). One possibility 
is alkylation of a disubstituted chlorophosphite with an organometallic reagent.[313-314] Disubstituted 
chlorophosphites are usually synthesized by substitution of phosphorus trichloride (1) with two 
equivalents of the desired alcohol in the presence of an amine base. However, mono- and triple 
substituted byproducts are usually formed.[322] Since separation of the desired product from these 
byproducts is often a heavy task, an alternative previously established route has been employed herein 
that starts with alkylation of bis(diisopropylamino)-chlorophosphine (2) to generate the 
phosphonamidite 3 followed by 1H-tetrazole mediated substitution of the diisopropylamino groups 
with the alcohol of choice.[312, 322]  
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Scheme 45: Two different synthetic routes for the synthesis of ethynylphosphonites starting from phosphorus trichloride (left) or 
bis(diisopropylamino)-chlorophosphine (right). 
A big issue in the synthesis of P(III) compounds is product isolation, which often fails due to rapid 
oxidation in the presence of air and hydrolysis of the O-substituents in the presence of water.[323] This 
can be in particular problematic for phosphonites, since their auto-oxidation is even more rapid in 
comparison to other P(III)-species such as phosphites or phosphinites.[311] The problem was addressed 
in chapter 6.1.1 by performing the subsequent SPhR in a one-pot reaction without isolation of the 
phosphonite intermediate. An alternative strategy includes the isolation of air-stable borane adducts 
of the P(III)-species, followed by borane deprotection with strong bases directly before SPhR, which 
has been applied earlier.[312-313] Here, it was found out that ethynylphosphonites with electron-
donating substituents are stable enough to be isolated by column chromatography and stored at 
- 20 °C for several weeks, making any borane-adduct formation unnecessary. This proceeding worked 
for most of the phosphonites that did not carry electron-withdrawing substituents except from diethyl 
ethynylphosphonite that has been used for the SPhR in chapter 6.1.1. Several attempts to isolate this 
compound without borane attachment failed due to decomposition of the desired product.  
 
Scheme 46: Synthesis of differently substituted ethynylphosphonites from bis(diisopropylamino)chlorophosphine. Stated are isolated yields.* 
I) 10 equivalents of the alcohol were used. 
                                                          
* Compound 9 was synthesized and characterized by Brian Rusi as part of an internship in the Hackenberger laboratory under the 
supervision of the author 
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For the synthesis of the phosphonites that are depicted in Scheme 46, 2 was alkylated with 
ethynylmagnesium bromide, directly followed by addition of the alcohol and tetrazole without 
isolation of the phosphonamidite intermediate 3. The desired phosphonites were isolated in excellent 
to moderate yields. It should be noted, that mass analysis of phosphonites failed for all of the tested 
compounds, possibly due to decomposition under ESI-conditions. It’s remarkable that the disulfides in 
compound 4-6 were tolerated during synthesis and isolation without decomposition of the 
phosphonite product. This is surprising, since it is well known that P(III) compounds are able to react 
with disulfide bonds in a reducing manner.[324] Additionally, it was even possible to synthesize the 
highly hydrophilic phosphonite 8 with an unprotected alcohol being present, using an excess of the 
diol to avoid multimer formation or polymerization. An aryl ester- and a diazo functionality were also 
well tolerated in the reaction and yielded the desired phosphonites 10 and 11.  
In contrast to these findings, all attempts to isolate unprotected ethynylphosphonites with electron-
withdrawing substituents failed due to rapid decomposition in the presence of air. To overcome this 
issue, all of the ethynylphosphonites unstable to air were isolated as borane adducts to stabilize the 
P(III)-species.[289, 312] 
 
Scheme 47: One-Pot-Procedure for the synthesis of borane protected ethynylphosphonites from bis(diisopropylamino)chlorophosphine. 
Stated are isolated yields.* 
A one pot procedure has been applied, were the borane was directly added to the reaction mixture of 
the phosphonite synthesis (See Scheme 47). After this, phosphonite borane adducts 12-14 were stable 
enough to be isolated by column chromatography in excellent yields to moderate yields.  
6.1.2.2. Staudinger phosphonite reaction with ethynylphosphonites carrying various O-
substituents 
In the next step, differently substituted unprotected ethynylphosphonites were reacted in a SPhR with 
an azide to generate ethynylphosphonamidates with various O-Substituents. Following the 
observations from chapter 6.1.1 that the NHS-ester building block 15 holds a good reactivity in the 
                                                          
* Compounds 13 and 14 were synthesized and characterized by Arif Celik as part of his bachelor thesis in the Hackenberger laboratory 
under the supervision of the author 
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SPhR, 15 was chosen for the test reactions with different ethynylphosphonites. NHS-modified 
phosphonamidates isolated from this reaction have the additional advantage of a facile subsequent 
modification with functional amines as demonstrated with 5-((2-aminoethyl)amino)naphthalene-1-
sulfonic acid (EDANS, 16), a fluorescent dye carrying a primary amine.  
SPhR with differently substituted phosphonites was carried out with one equivalent of azide 15 in DMF 
overnight without any further additive. The good stability of the electron-rich phosphonites towards 
air made an inert atmosphere for the reaction unnecessary. The desired phosphonamidates could be 
isolated for all of the tested substituents in good to moderate yields (Table 1). To probe the reactivity 
of the NHS-modified phosphonamidates towards amines, the building blocks 16-22 were reacted with 
EDANS in the presence of DIPEA in DMF. Fluorescently modified phosphonamidates 23-29 could be 
isolated from all of the tested NHS building blocks in good yields by preparative HPLC.  
Table 1: SPhR of different ethynylphosphonites with azide 15 and subsequent amide bond modification with EDANS. Stated are isolated 
yields of the NHS- and the EDANS phosphonamidates. 
 
entry R phosphonite 
NHS ester 
phosphonamidate 
yield 
EDANS 
phosphonamidate 
yield 
1 
 
4 16 43% 23 67% 
2 
 
5 17 47% 24 62% 
3 
 
6 18 43% 25 40% 
4  7 19 77% 26 74% 
5  8 20 31% 27 56% 
6 
 
10 21 29% 28 30% 
7 
 
11 22 76% 29 51% 
The phosphonites that were isolated as borane adducts had to be deprotected prior to SPhR in order 
to restore reactivity towards azides. Borane removal is usually carried out with strong bases such as 
DABCO.[312-313] A one-pot protocol has been developed that circumvents the isolation of unstable, 
unprotected ethynylphosphonites by a direct addition of the azide to the deprotection mixture in a 
one-pot manner, as also previously reported.[313]  
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Scheme 48: Reaction of different phosphonites with electron withdrawing substituents after borane deprotection with phenyl azide. Stated 
are isolated yields. 
Since the SPhR with ethynylphosphonites with electron withdrawing substituents proved to be difficult 
from the beginning, reactions were carried out with structurally simple phenyl azide and analyzed by 
31P-NMR and MS. However, no evidence for the formation of the desired phosphonamidate was found 
for the tested electron poor phosphonamidates, even though complete conversion of the 
phosphonites was observed in the NMR.* In contrast to this, the desired product could be isolated with 
diethyl ethynylphosphonite in 20% yield, demonstrating the general applicability of the protocol 
(Scheme 48). The synthesis of the diethyl ethynylphosphonite borane adduct has been described 
earlier.[325] 
These results were surprising since electron-deficient 2-nitrobenzyl phosphonites, substituted with a 
triazole at the C-substituent instead of an alkyne have been employed in the SPhR earlier.[322] 
Therefore, further analyses of the formed side products from the reaction between diphenyl 
ethynylphosphonite (12) and phenyl azide were performed. It was found out that the phenol adduct 
31 of the desired ethynylphosphonamidate 30 is the main reaction product, which could be isolated in 
24% yield. This undesired reaction product probably originates from the addition of the liberated 
phenol during SPhR to the electron-deficient triple bond of the phosphonamidate (Scheme 49). It 
should be noted, that 31 was unreactive to thiols, as even an excess of glutathione added under basic 
conditions did not show any conversion.  
 
Scheme 49: Reaction between phenylazide and diphenyl ethynylphosphonite (12). Liberated phenol attacks the triple bond of the desired 
product 30 to form the phenyl enol ether 31. 
The undesired reattack of the liberated phenol might be explained by the high electrophilic character 
of the phosphonamidate 30. Electron withdrawing substituents further increase the electrophilicity of 
ethynylphosphonamidates whereby reactivity for nucleophiles, other than cysteine increases. This 
leads to problems in the synthesis, as demonstrated with this example and could also promote 
undesired effects on the selectivity of the subsequent cysteine addition with proteins.  
                                                          
* Investigations of the SPhR with phosphonites 13 and 14 were performed by Arif Celik as part of his bachelor thesis in the Hackenberger 
laboratory under the supervision of Marc-André Kasper. 
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Since electron withdrawing substituents diminish the stability of ethynylphosphonites, lead to 
synthetic problems in the SPhR and most probably cause undesired side reactions with amino acid 
residues other than cysteine, electron withdrawing substituents were excluded in further reactions of 
azides with ethynylphosphonamidates.  
6.1.2.3. Functional evaluation of cleavable phosphonamidate ester residues 
After successful incorporation of different cleavable substituents to the ethynylphosphonamidate 
residue as described in the previous chapter, the functionality to release a phosphonamidic acid and 
subsequently a primary amine after cleavage of the P-N-bond was monitored in a HPLC and a FRET-
based assay. Substituents were chosen that can be cleaved by different external stimuli. An overview 
of the different substituents with proposed cleavage mechanisms is depicted in Scheme 50. 
It is known that 2-thiolethyl residues that are attached to good leaving groups such as carbamates 
cyclize spontaneously to release carbamic acids (see chapter 4.3.1.3). From this finding, it was 
anticipated that disulfide modified phosphonamidates such as 23-25 can release a phosphonamidic 
acid after disulfide reduction followed by thiirane formation (Scheme 50a). Disulfide modified 
phosphonamidate ester residues could thereof facilitate an intracellular release of an amine due to 
increased intracellular glutathione concentrations. This is in particular interesting for the traceless 
release of amino modified drugs in drug delivery applications, where the phosphonamidate moiety 
functions as cysteine selective linker and traceless release unit in one. Extracellular stability of those 
linker systems is crucial for drug delivery applications. Since the stability of disulfides is dependent on 
the sterically hindrance (see chapter 4.3.1.3, Scheme 2), disulfides with different methyl substitution 
patterns have been synthesized for this study.  
The conversion of carboxylic acids into esters of pharmacologically active drugs to mask their 
hydrophilicity is a common approach in the development of prodrugs.[326] Lipophilic esters are able to 
pass cellular membranes, where they get hydrolyzed by intracellular esterases to release the active 
drug molecule. Based on this strategy it was envisioned that the benzoyl ester in 28 facilitates an 
intracellular release of a phosphonamidic acid after ester cleavage and 1,6,-elimination as depicted in 
Scheme 50b in a similar manner than previously described for other enzymatic cleavable linker systems 
that have been applied to drug delivery (see chapter 4.3.1.3).  
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Scheme 50: Principles of the cleavage of different phosphonamidate ester substituents to release phosphonamidic acid which is prone to 
hydrolytic release of a primary amine from the P-N-bond.[322] a) Reductively cleavable substituent. b) Esterase-cleavable substituent. c) 
Dithionite-cleavable substituent. 
Cleavable diazobenzene-based linker systems are commonly used as dithionite-cleavable affinity tags 
for enrichment strategies in chemical proteomics.[327] Building up on this, the diazo linkage in 
compound 29 was envisioned to release the desired phosphonamidic acid after selective reduction 
with dithionite, followed by 1,6-elimination (Scheme 50c). This could facilitate the development of 
novel phosphonamidate based selectively cleavable affinity tags for proteomic in vitro analyses.  
To investigate the proposed release principles, a cysteine modified DABCYL-peptide was first added to 
the phosphonamidates 23-25 and 28 to synthesize water soluble EDANS-DABCYL-FRET pairs 32-35 that 
generate a fluorescent signal upon cleavage of the phosphonamidate linkage, as previously described 
in chapter 6.1.1 (Scheme 51). A non-cleavable ethyl-substituted derivative 36 was synthesized for 
control reactions from the EDANS-phosphonamidate, as described in chapter 6.1.1. 
 
Scheme 51: Synthesis of phosphonamidate linked EDANS-DABCYL-FRET-Pairs with different cleavable 32-35 and one non cleavable 
phosphonamidate ester residue 36. Peptide sequence is depicted in the amino acid one letter code. Stated are isolated yields after 
preparative HPLC.  
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In a first proof-of-principle study, peptides 32-34 were incubated with 10 equivalents of TCEP in PBS 
(Figure 14a). After incubation for one hour at 37 °C, the samples were analyzed by UPLC/MS and 
compared to control reactions were the constructs were exposed only to PBS for the same amount of 
time and at the same temperature. It could be observed that all of the disulfide-cleavable constructs 
32-34 were fully consumed when exposed to 10 equivalents of TCEP and two new reaction products 
could be detected. No conversion of the starting material was observed in the control reactions 
without TCEP addition. In addition to that, no reaction at all was observed for the non-cleavable ethyl-
substituted compound 36 (Figure 14b-e). The two peaks that arise for all of the samples under 
reductive conditions in the same ratio were identified by MS as the phosphonamidic acid 37 and the 
P-N-cleavage product, the phosphonic acid 38. Firstly, these results confirm that 2-disulfido ethyl 
substituted phosphonamidates efficiently form the phosphonamidic acid upon disulfide reduction. The 
formation is selective for reducing conditions and does not occur for stably linked O-ethyl-
phosphonamidate adducts. However the acidic UPLC conditions containing 0.1% TFA might promote 
the hydrolysis of the P-N-hydrolysis after the phosphonamidate ester cleavage. It is therefore difficult 
to assess, if the P-N-bond is cleaved during UPLC analysis or before during the reaction. It was 
previously demonstrated for other phosphonamidic acids that harsh acidic conditions need to be 
applied to cleave the P-N-bond.[322]  
 
Figure 14: Exposure of the constructs 22-34 and 36 to 10 eq. of TCEP in PBS at 37 °C and analysis via UPLC/MS. Shown is the reaction-scheme 
with potential products 37 and 38 (a) and the normalized chromatograms of the reaction mixtures after incubation with TCEP in PBS (red) or 
in PBS only (black) for construct 32 (b), 33 (c), 34 (d) and 36 (e). Peaks were identified by MS. Traces in e correspond to the same compound, 
even though slightly shifted.   
In a very similar experiment, peptide 35 was exposed to HeLa-cell-lysate and the reaction was 
monitored accordingly (Figure 15a). Here, cleavage occurred in the same way to form peptides 37 and 
38 in similar ratios selectively for the ester-substituent over the ethyl substituted compound 36 and 
only in the presence of lysate (Figure 15b-c). Even though, this experiment also does not answer the 
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question of P-N-bond cleavage efficiency, it still suggests that the ester substituent of 35 can be cleaved 
intracellularly, while it is stable under PBS conditions.  
 
Figure 15: Exposure of the constructs 35 and 36 to freshly prepared HeLa-cell lysate in PBS at 37 °C and analysis via UPLC/MS. Shown is the 
reaction-scheme with potential products 37 and 38 (a) and the normalized chromatograms of the reaction mixtures after incubation with 
cell lysate (red) or in PBS only (black) for construct 35 (b) and 36 (c). Peaks were identified by MS. Traces in b correspond to the same 
compound, even though slightly shifted.   
To exclude any bias of the acidic HPLC on the P-N-bond stability during the analysis, fluorescence 
measurements with the fluorescence-quencher-pairs 32 and 36 were carried out under neutral 
conditions. Here, the probe is still quenched after cleavage of the phosphonamidate ester substituent 
and a fluorescent signal is generated only after subsequent P-N-bond cleavage (Figure 16a). In a first 
experiment, the reductively cleavable probe 32 and the non-cleavable, ethyl substituted compound 36 
were incubated with 10 eq. of TCEP in PBS at pH 7.4 and the fluorescence was monitored over time 
(Figure 16b). Even though, the previous HPLC based assay demonstrated that these conditions 
successfully cleave the disulfide containing phosphonamidate ester from 32 to liberate the 
phosphonamidic acid 37, no increase in fluorescence was observed in a direct comparison to the non-
cleavable variant 36 even after 24 hours (Figure 16c). In a second experiment, the pH was lowered 
after 4 hours of incubation with TCEP to 5.5. This time, compound 32 showed a steady increase in 
fluorescence, while the non-cleavable control did not increase over time, which suggests that the 
phosphonamidic acid is more prone towards acidic hydrolysis than the phosphonamidate ester (Figure 
16d). Taken together, the fluorescence measurements underline that TCEP incubation of 32 delivers 
the phosphonamidic acid 37. However, cleavage of the P-N-bond necessitates acidic conditions as 
previously reported.[322]  
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Figure 16: Stability measurements of the thiol adducts 32 and 36 after TCEP incubation. a) Set-up of the fluorescence-quenching assay. A 
fluorescent signal is only generated upon P-N-Bond cleavage. b) 32 and 36 were incubated at a concentration of 10 µM with 100 µM TCEP. 
c) EDANS-fluorescence intensity over time at pH 7.4. 32 (blue) and 36 (orange). d) EDANS-fluorescence intensity over time at pH 7.4, lowered 
to pH 5.5 after 4h 32 (blue) and 36 (orange). Excitation: 360 nm, emission: 508 nm, bandwidth: 5nm at 20 °C. 
To sum up, it was demonstrated in this chapter that different phosphonamidate substituents can be 
cleaved by disulfide reduction (32-34) or by intracellular esterases (35) to release phosphonamidic 
acids under conditions were the control O-ethyl phosphonamidate 36 is stable. The P-N-bond of the 
phosphonamidic acid 37 is more prone towards acidic hydrolysis than the phosphonamidate ester in 
compound 32 to 36. Future investigations should include studies that identify the exact pH window 
under which the P-N-cleavage occurs to be able to apply the strategy to intracellular drug release as 
described in chapter 4.3.1.3. Successful cleavage at pH 5.5, as depicted in Figure 16d, already suggest 
the applicability to an intracellular release in endosomes, where the pH can drop to 4.5–5.5 in late 
endosomes and lysosomes.[328] 
6.1.2.4. Ethynylphosphonamidates for triple conjugations 
To further expand the functional possibilities of the phosphonamidate ester residue, the building block 
19 was evaluated for the ability to connect three functional moieties in an orthogonal fashion, as 
depicted in Figure 17a. The phosphonamidate ester residue carries in this case a stably linked terminal 
alkyne that enables a site selective attachment of a third functionality via CuAAC (See chapter 4.5.2.3) 
after cysteine labelling of a protein. In a proof of principle study, the NHS-ester of 19 was first reacted 
with the cyclic cell penetrating peptide (cCPP) cR10 39 that carries an unmodified N-terminus (Figure 
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17b).* The R10 peptide is, like other arginine-rich peptides, able to enhance the transduction of 
functional proteins into living cells when covalently attached to the protein cargo.[167, 329] The 
aforementioned eGFP C70M S147C with a single addressable cysteine residue† was subsequently 
labelled with the phosphonamidate modified peptide 40 and successful conjugation confirmed by ESI-
MS and the observation of an indicative mass-shift in the SDS-PAGE (Figure 17d-e).  
 
Figure 17: Compound 40 can be utilized as a functional building block to conjugate three different functionalities in an orthogonal manner. 
a) Principle of the triple conjugation. b) Functionalization of an amine containing cR10 39 with 19. Stated is the isolated yield after preparative 
HPLC. c) Conjugation of the modified peptide 40 to eGFP C70M S147C. d) Successful conjugation was monitored by an indicative SDS-PAGE 
gel shift. line 1: eGFP starting material. line 2: Reaction mixture after overnight incubation. e) Intact-protein MS analysis before (left) and 
after the reaction (right). A mass shift of 2367 Da is indicative for the desired thiol-addition product. 
After successful conjugation of the cysteine eGFP to the peptide 40, the accessibility of the terminal 
alkyne at the phosphonamidate ester residue was evaluated. For this, an azide containing Cy5 was 
attached, using a standard copper catalyzed cycloaddition protocol.  
Azides are usually attached to the dye core via long alkyl chains[330] that add a lot of additional 
hydrophobicity to the molecule, diminish thereby water solubility and hamper protein conjugations 
                                                          
* cR10 was synthesized and purified by Ines Kretzschmar by standard SPPS 
† eGFP C70M S147C was designed and cloned by Dr. Dominik Schumacher as part of his PhD thesis. Expression was performed by Kristin 
Kemnitz-Hassanin. 
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under aqueous conditions. The azide-modified Cy5 45 with a short ethylene linker, used in this work 
has not been described so far. The synthetic route for 45 that has been applied is depicted in Scheme 
52.*  
 
Scheme 52: Synthesis of Cy5-N3 45. The Cy5 precursor 44 was synthesized according to a previously published procedure.[331] 
The Cy5 dye core was synthesized based on a previously described procedure[331] from the 
intermediate 44 and the azido modified indoline 43 in very high yields. The synthesis of 43 was 
conducted from the commercial available trimethyl indol 41 by alkylation with dibromoethane 
followed by a nucleophilic substitution of the bromide with sodium azide in DMSO.  
Copper-catalyzed cycloaddition of 45 to the modified eGFP proceeded smoothly to give the desired 
product in good conversion. Successful conjugation was proven by in-gel fluorescence after excitation 
of the Cy5 at 635 nm. In addition, intact protein ESI-MS revealed good labelling yields (Figure 18). 
                                                          
* Structure and synthesis of Cy5 azide is inspired by a Cy3 synthesis route, developed by Dr. Felix Hövelmann as part of his PhD thesis. 
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Figure 18: CuAAC of Cy5-N3 45 to eGFP, modified with 40. a) Synthetic scheme. b) Successful conjugation was monitored by in-gel 
fluorescence measurements of an SDS-PAGE gel at 635 nm. line 1: eGFP starting material. line 2: Reaction mixture of the addition of 40 to 
eGFP. line 3: Reaction mixture of the CuAAC, depicted in a. c) Intact-protein MS analysis after CuAAC. A mass shift of 438 Da is indicative for 
the desired triazole product. 
To sum up, it has been demonstrated that the installation of a terminal alkyne to the Phosphonamidate 
ester residue facilitates an additional side-specific attachment via CuAAC after the cysteine 
conjugation of the ethynylphosphonamidate. The functional building block 19 enables a triple 
conjugation of an amine, a protein thiol and an azide in a modular subsequent conjugation strategy. In 
the particular case, a cCPP, a Protein and a fluorescent dye were assembled, facilitating the 
observation of cellular uptake by fluorescence microscopy also of non-fluorescent proteins. Next Steps 
include the functional evaluation of the eGFP-40-Cy5 construct in terms of cell penetration and 
application of the concept to other non-fluorescent proteins.  
6.1.3. Enantiomerically pure ethynylphosphonamidates  
One unique feature of the thiol addition to ethynylphosphonamidates is the high Z-selectivity of the 
reaction in aqueous systems, as described in chapter 6.1.1. Due to this, enantiomerically pure 
ethynylphosphonamidates give rise to highly homogenous protein conjugates via cysteine, yielding a 
single diastereoisomer. This is impossible with other cysteine selective labelling reagents such as 
maleimides, since a stereocenter is formed upon thiol addition to the maleimide (Scheme 53). 
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Scheme 53: enantiomeric pure ethynylphosphonamidates yield a single diastereoisomer after cysteine modification. Maleimides react with 
cysteine to form two diastereoisomers.  
Here, it was tested if the two phosphonamidate enantiomers that originate from the SPhR can be 
separated by chiral HPLC. Baseline separation of the two enantiomers of compound 46 was possible 
after optimization of the HPLC conditions and it was observed that a one to one mixture is produced 
from the SPhR, as expected (Figure 19a). With semi-preparative chiral HPLC it was possible to isolate 
the two enantiomers from each other, as demonstrated by analytical chiral HPLC of the two isolated 
fractions (Figure 19b).* 
 
Figure 19: Phosphonamidate enantiomers can be separated by chiral HPLC. a) Chromatogram of the enantiomeric mixture of 46, synthesized 
via standard conditions for the SPhR, as described in chapter 6.1.1. b) Zoom into the analytical chromatograms of enantiomer A (left) 
enantiomeric mixture (middle) and enantiomer B (right). Enantiomers were isolated by semi-preparative chiral HPLC.  
With the enantiomerically pure building blocks of compound 46, it is now in principle possible to attach 
a functionality to a protein’s cysteine residue, yielding a single diastereoisomer.  
 
 
                                                          
* Semi-preparative and analytical chiral HPLC was performed by Christiane Groneberg in the laboratory of Mathias Christmann 
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6.2. Electrophilic vinylphosphonamidates with tunable reactivity for cysteine-
selective modifications of proteins  
As described in the previous chapter, ethynylphosphonamidates function as cysteine-selective 
electrophiles that can be chemoselectively incorporated starting from ethynylphosphonites by the 
SPhR. In the current chapter, vinylphosphonites are described for the transformation of azides into 
electron-deficient vinylphosphonamidates that subsequently modify cysteine residues in peptides and 
proteins. In contrast to ethynylphosphonamidates, which haven’t been described before, some few 
literature examples that describe the compound class of vinylphosphonamidates can be found. 
Vinylphosphonamidates have been evaluated as monomers for polymerization[332], potential inhibitors 
for a hepatitis C virus polymerase[333], antimicrobials[334] and synthetic precursors[335]. Gao et al. were 
the only ones who reported vinylphosphonamidates as potential thiol acceptors for Coenzyme A. 
However, thiol adducts formation was not observed under their tested conditions (see chapter 0).[143] 
All previous synthetic attempts that have been described so far were based on nucleophilic 
substitution of vinylphosphonochloridate precursors with amines under basic conditions, whereas a 
method based on the SPhR has not been described so far. The aim of the work described in this chapter 
was the evaluation of vinylphosphonites as substrates for the SPhR with azide building blocks to 
synthesize vinylphosphonamidates for subsequent thiol addition to modify cysteine residues on 
biomolecules with the following main goals: 
a) Development of the SPhR with differently substituted vinylphosphonites and various azide-
modified building blocks to synthesize vinylphosphonamidates  
b) Evaluation of the reactivity of vinylphosphonamidates for cysteine residues in dependence of 
the electronic nature of the phosphonamidate ester residue to identify suitable derivatives for 
the modification of proteins and antibodies. 
c) Exploration of the unique features of the phosphonamidate linker structure, which includes 
the incorporation of functional handles to the vinylphosphonamidate ester residue 
 
Results and Discussion 
162 
6.2.1. SPhR with vinylphosphonites to generate vinylphosphonamidates for cysteine 
modifications and chemoselective peptide cyclizations 
This chapter was published in the following journal: 
Marc-André Kasper†, Maria Glanz†, Andreas Oder, Peter Schmieder, Jens P. von Kries and 
Christian P. R. Hackenberger* 
“Vinylphosphonites for Staudinger-induced chemoselective peptide cyclization and functionalization” 
Chem. Sci. 2019, 10, 6322-6329 
Publication date (online):  
The article is available online at: May 16th, 2019 
https://pubs.rsc.org/en/content/articlelanding/2019/sc/c9sc01345h#!divAbstract 
† These authors contributed equally 
*Corresponding author
Figure 20: Vinylphosphonites enable the incorporation of vinylphosphonamidates via SPhR that subsequently modify cysteine residues on 
proteins and facilitate a chemoselective peptide cyclization. Altering the phosphonamidate’s O-substituents allows for tuning the reactivity 
for sulfhydryl groups or promotes an increase in cellular uptake of stapled peptides.  
Abstract: 
In this paper, we introduce vinylphosphonites for chemoselective Staudinger-phosphonite reactions 
(SPhR) with azides to form vinylphosphonamidates for the subsequent modification of cysteine 
residues in peptides and proteins. An electron-rich alkene is turned into an electron-deficient 
vinylphosphonamidate, thereby inducing electrophilic reactivity for a following thiol addition. We 
show that by varying the phosphonamidate ester substituent we can fine-tune the reactivity of the 
thiol addition and even control the functional properties of the final conjugate. Furthermore, we 
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observed a drastic increase in thiol addition efficiency when the SPhR is carried out in the presence of 
the thiol substrate in a one-pot reaction. Hence, we utilize vinylphosphonites for the chemoselective 
intramolecular cyclization of peptides carrying an azide-containing amino acid and a cysteine in high 
yields. Our concept was demonstrated for the stapling of a cell-permeable peptidic inhibitor for 
protein–protein–interaction (PPI) between BCL9 and beta-catenin, which is known to create a 
transcription factor complex acting in embryonic development and cancer origin, and for 
macrocyclizing cell-penetrating peptides (CPPs) to enhance the cellular uptake of proteins. 
Responsibility assignment: 
Christian P. R. Hackenberger designed and conceived the project. The author developed the SPhR and 
the subsequent cysteine modification, synthesized and characterized all isolated phosphonites, the 
non-peptidic phosphonamidates and the azide precursors, conceived and performed stability studies 
and all kinetic studies, developed the antibody modification protocol with vinylphosphonamidates and 
synthesized, purified and analyzed the antibody conjugates. Maria Glanz developed the intramolecular 
peptide cyclization, synthesized and characterized all peptides, performed stability studies, expressed 
all proteins, synthesized the eGFP conjugates and performed all cellular imaging studies. Andreas Oder 
performed the HTRF assay. Peter Schmieder conceived and performed two-dimensional NMR 
experiments and analyzed the spectra. Jens P. von Kries designed and conceived the HTRF assay-
experiments. The author wrote the manuscript supported by Maria Glanz and 
Christian P. R. Hackenberger. 
Summary of content: 
A method for the chemoselective transformation of azides with vinylphosphonites to synthesize 
electrophilic vinylphosphonamidates that are reactive for cysteine residues is presented. The SPhR 
turns an electron-rich phosphonite into an electron-deficient phosphonamidate and thereby induces 
reactivity for subsequent thiol addition. The method facilitates either a two-step approach where the 
cysteine-reactive vinylphosphonamidates is incorporated in the first step followed by protein 
modification or a one-step chemoselective intramolecular cyclization of peptides carrying an azide-
containing amino acid and a cysteine. Described is the synthesis of various vinylphosphonites, carrying 
different O-substituents and subsequent SPhR with an aromatic and an aliphatic model azide. 
Vinylphosphonites were stabilized for isolation by borane adduct formation. Subsequent borane 
removal and SPhR with the azides was carried out applying a one-pot protocol. Different electrophilic 
vinylphosphonamidates with various O-substituents could be isolated applying this protocol and the 
reactivity with glutathione as a model cysteine substrate was tested afterwards. It could be 
Results and Discussion 
164 
demonstrated that vinylphosphonamidates react significantly slower with sulfhydryl groups when 
compared to their ethynyl counterparts, but the reactivity can be increased by the attachment of 
electron withdrawing substituents at the phosphonamidate ester residue. The fastest 
vinylphosphonamidate tested in this study carried an O-trifluoroethyl- and a N-phenyl substituent and 
modified glutathione with a second-order rate constant of 0.021 M-1s-1. It could be shown that the 
phosphonamidate with this substitution pattern is able to modify cysteine residues on proteins, as 
demonstrated by alkylation of the interchain disulfide bonds of the therapeutically relevant antibody 
cetuximab. A good cysteine selectivity, using only slight reagent excess could be observed, whereas 
only small degrees of unselective lysine-labelling was observed with high excess of more than 
100 equivalents with respect to the antibody. Furthermore, an intramolecular version of the 
chemically induced thiol addition for a chemoselective cyclization of peptides, carrying an 
azidohomoalanine and a cysteine residue, is presented. It is shown that the reactivity for the thiol 
addition is increased when the SPhR is carried out in the presence of a thiol. Vinylphosphonites 
facilitate thereby a high yielding chemoselective cyclization of azide functionalized cysteine peptides. 
The method was applied to the synthesis of a stapled peptide that is known to disrupt the protein-
protein interaction between BCL-9 and β-Catenin. The helicity of the peptide is increased by the 
cyclization from 20% to 50%, as investigated by CD-spectroscopy and a homogeneous assay with time 
resolved fluorescence (HTRF) revealed that the PPI can be disrupted with concentrations in the 
submicromolar range. Exchanging the phosphonamidate’s O-substituent from ethyl to a more 
lipophilic benzyl residue furthermore enhances the potential of the cyclized peptides to penetrate into 
cells. In addition to that, the technology was used to cyclize a cell-penetrating CR10 peptide, which was 
afterwards conjugated to eGFP. R10 that was cyclized with a vinylphosphonite sufficiently enhanced 
the uptake of eGFP into HeLa cells in a similar manner than the previously described lactam cyclized 
CR10.  
 Manuscript and supporting information 
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In this paper, we introduce vinylphosphonites for chemoselective Staudinger-phosphonite reactions (SPhR)
with azides to form vinylphosphonamidates for the subsequent modification of cysteine residues
in peptides and proteins. An electron-rich alkene is turned into an electron-deficient
vinylphosphonamidate, thereby inducing electrophilic reactivity for a following thiol addition. We show
that by varying the phosphonamidate ester substituent we can fine-tune the reactivity of the thiol
addition and even control the functional properties of the final conjugate. Furthermore, we observed
a drastic increase in thiol addition efficiency when the SPhR is carried out in the presence of a thiol
substrate in a one-pot reaction. Hence, we utilize vinylphosphonites for the chemoselective
intramolecular cyclization of peptides carrying an azide-containing amino acid and a cysteine in high
yields. Our concept was demonstrated for the stapling of a cell-permeable peptidic inhibitor for protein–
protein interaction (PPI) between BCL9 and beta-catenin, which is known to create a transcription factor
complex playing a role in embryonic development and cancer origin, and for macrocyclization of cell-
penetrating peptides (CPPs) to enhance the cellular uptake of proteins.
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Introduction
Selective chemical modication of the sulydryl group of
cysteine is an important tool in the life sciences.1,2 Cysteine-
selective reactions have been employed to covalently modify
proteins in a residue specic manner for various applications
including drug delivery,3 incorporation of post-translational
modications4 and activity based protein proling.5
A plethora of different techniques have been developed in
the past few decades that allow for selective modication of
cysteine residues on peptides and proteins based on various
reaction mechanisms. Michael additions to a,b-unsaturated
carbonyl compounds in maleimides,6 sulfone reagents7 and
recently developed carbonylacrylic reagents8 are the most
prominent examples. Other methods rely on SN2-reactions of
haloalkyl bonds such as iodoacetamides,9 on alkynylation10 and
uoroalkylation11 with hypervalent iodine reagents, on
nucleophilic aromatic substitution of peruoroaromatic
compounds12 or on Pd-mediated cross-coupling.13 The level of
reactivity for cysteine in these methods is predetermined by the
chemical nature of the reactive group itself. Alteration of this
reactivity is oen difficult and requires tedious chemical
manipulations. However, certain applications such as activity
based protein proling14 or covalent enzyme inhibition15 oen
rely on reduced reactivity that allows for modication of the
active site cysteine while sparing all other free nucleophiles in
the proteome. Such decreased reactivity has for instance been
achieved by substituting the highly reactive iodide in a-hal-
oacetamides with a less reactive chloride.16 Therefore, a cysteine
selective modication method that utilizes easily tunable elec-
trophilic warheads would be highly attractive for addressing
challenges in peptide and protein chemistry.
Aside from protein modication, cysteine selective reac-
tions have also been applied to peptide synthesis. One or two
covalent linkages between cysteine residues in peptides enable
the construction of macro or bicyclized peptides with
enhanced biophysical and pharmacological properties.17 Upon
macrocyclization, peptidic structures can become more stable
against proteases,18 they can be locked in their structural
conformation by covalently linking side chains and therefore
restricting their conformational exibility19,20 or increasing
their function by rigid constraint as shown for various cyclic
bioactive21 or cell penetrating peptides (cCPPs).22 The groups
of Pentelute and Derda introduced peruoroaromatic linkages
Cite this: Chem. Sci., 2019, 10, 6322
All publication charges for this article
have been paid for by the Royal Society
of Chemistry
aLeibniz-Forschungsinstitut fu¨r Molekulare Pharmakologie (FMP), Chemical Biology
Department, Robert-Ro¨ssle-Strasse 10, 13125 Berlin, Germany. E-mail: hackenbe@
fmp-berlin.de
bHumboldt Universita¨t zu Berlin, Department of Chemistry, Brook-Taylor-Str. 2, 12489
Berlin, Germany
† This work is dedicated to Prof. Ron Raines on the occasion of his 60th birthday.
‡ Electronic supplementary information (ESI) available. See DOI:
10.1039/c9sc01345h
§ These authors contributed equally.
6322 | Chem. Sci., 2019, 10, 6322–6329 This journal is © The Royal Society of Chemistry 2019
Chemical
Science
EDGE ARTICLE
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
li
sh
ed
 o
n 
16
 M
ay
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
11
/2
01
9 
9:
22
:4
3 
A
M
. 
 T
hi
s 
ar
ti
cl
e 
is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
tt
ri
bu
ti
on
-N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Online
View Journal  | View Issue
Edge Article
for the cyclization of peptides containing two cysteines.23,24
Tricyclic peptides have also been synthesized by alkylation
with tris-(bromomethyl)benzene25 and very recently by the
incorporation of two chemical bridges with a set of various
dibromoalkyl reagents.26 Such chemoselective modication
strategies are advantageous over common cyclization tech-
niques27 such as lactamization,28 since they can be applied
aer cleavage from the resin and preclude therefore tedious
orthogonal protecting group strategies during SPPS. In addi-
tion, even cysteine containing proteins can be cyclized by
applying chemoselective techniques, as recently demonstrated
with the aid of a trimeric chloroacetamide.29
Based on the Staudinger-phosphonite reaction (SPhR),
developed in our laboratory,30 we recently introduced ethynyl-
phosphonamidates as cysteine-selective electrophiles that can
be chemoselectively incorporated starting from ethynylphos-
phonites.31 In the current paper, we report vinylphosphonites as
a new compound class for the transformation of azides into
electron decient alkenes that selectively modify cysteine resi-
dues in peptides and proteins. We observed that the SPhR with
vinylphosphonites facilitates straightforward access to vinyl-
phosphonamidates carrying different O-substituents. We
discovered that the rate of the subsequent thiol addition can be
drastically inuenced by the electronic properties of these
phosphonamidate ester substituents. In addition, we engi-
neered an intramolecular variant of the chemically induced
thiol addition for a chemoselective cyclization of peptides. We
were able to demonstrate that azido modied cysteine peptides
can be cyclized upon SPhR with vinylphosphonites in high
yields (Scheme 1). In contrast to other chemoselective peptide
cyclizations, which have been mainly used for head-to-tail
cyclizations, including traceless Staudinger ligation,32 a-ketoa-
cid–hydroxylamine amide-ligation33 or serine ligation,34 the
method presented herein can be straightforwardly applied to
side-chain ring closure.
Results and discussion
Previously, Gao et al. have observed that methyl-substituted
vinylphosphonamidates are unreactive in base mediated thiol
additions,35 probably due to decreased electrophilicity,
compared to their ethynyl substituted counterparts.31 We
anticipated that the electrophilic reactivity of the double bond
towards thiol-addition can be increased by attaching different
electron-withdrawing substituents to the phosphonamidate
ester moiety. Since this residue is preserved during SPhR with
azides, we started our investigations by synthesizing different
substituted vinylphosphonites. Here, we followed previously
published procedures starting from either phosphorus tri-
chloride (route I) or bis(diisopropylamino)-chlorophosphine
(route II).36 Several attempts to isolate unprotected vinyl-
phosphonites failed due to product decomposition, hence we
decided to isolate the phosphonites in their borane-protected
form and use them directly as starting materials for the
subsequent SPhR. Vinylphosphonite borane adducts proved to
be stable during column chromatography and we were able to
obtain four vinylphosphonites with ethyl, 1a, phenyl, 1b and
electron withdrawing 2-nitrobenzyl, 1c, and triuoroethyl, 1d,
substituents (Fig. 1a).
With vinylphosphonites 1a–d in hand, we continued our
studies to perform the SPhR with two different model azides 2
and 3 to synthesize both N-phenyl 4a–d and N-alkyl substituted
vinylphosphonamidates 5a–d. Here, we applied previously
published procedures, either diethyl chlorophosphite alkyl-
ation with vinylmagnesium bromide31 (route III) or borane
deprotection with DABCO in toluene37 (route IV), directly fol-
lowed by azide addition and hydrolysis without isolation of the
phosphonite intermediate. The SPhR was always carried out in
dry solvents to prevent hydrolysis of the phosphonites. All of the
tested phosphonites reacted smoothly under the tested condi-
tions and the desired vinylphosphonamidates could be isolated
by column chromatography. Electron withdrawing substituents
were well tolerated in the reaction with the aryl azide 2 and with
the alkyl azide 3 (Fig. 1b).
Next, we probed the reactivity of the synthesized vinyl-
phosphonamidates towards thiol addition in aqueous solution
under slightly basic conditions as previously performed for
ethynylphosphonamidates31 (Fig. 2a). For this, a time course for
the addition of glutathione (GSH) to vinylphosphonamidates
4a–d and 5a–d in ammonium bicarbonate buffer was recorded.
Under the tested conditions (10 mM phosphonamidate and
two equivalents of GSH) the N-phenyl vinylphosphonamidate 4a
showed a good conversion of 80% to the desired thiol adduct
aer 24 h. In contrast to 4a, the comparable N-alkyl derivative 5a
was only converted 20% under the same conditions (Fig. 2b),
which is in accordance with the observations of Gao et al. on the
unreactivity of N-alkyl-O-methyl-vinylphosphonamidate
towards thiols; however, the previously mentioned deal-
kylation of the phosphonamidate ester was not observed under
conditions applied here. Since we assumed that such slow
kinetics would limit the applicability to protein modication,
for example by undesired disulde formation of the peptide or
protein substrate, we also tested compounds with electron-
Scheme 1 Vinylphosphonites for intramolecular peptide cyclization and cysteine selective protein modification.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 6322–6329 | 6323
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results clearly show that the reactivity of vinyl-
phosphonamidates can be tuned by varying the phosphona-
midate ester residue. The corresponding N-alkyl substituted
compounds 5a–d also undergo rate enhancement with more
electron withdrawing O-substituents, with a slower reaction
compared to the N-phenyl substituted compounds 4a–d in
general (ESI Fig. S1‡). Notably, the glutathione adduct was the
only detectable product by UPLC/MS and no other side product
was observed for any of the tested phosphonamidates (ESI
Fig. S2‡). The identity of the thiol-glutathione adducts of 4a (ESI
Fig. S3‡) and 4d was conrmed by NMR characterization aer
isolation by preparative HPLC in 60% and 89% yield,
respectively.
Further kinetic investigations of the thiol addition to 4d,
being the fastest compound tested in this study (ESI Fig. S1‡),
revealed a second-order rate constant of 0.021 M1 s1 (ESI
Fig. S4‡). Even though this is considerably slower than that of
maleimides (734 M1 s1),38 ethynylphosphonamidates (0.62
M1 s1)31 and recently introduced dinitroimidazoles,39 the rate
is still higher or in the range of other protein modication
Fig. 1 (a) Synthesis of substituted vinylphosphonites from phosphorus
trichloride (route I) or bis(diisopropylamino)chlorophosphine (route II).
Stated are isolated yields. (b) One-pot SPhR with vinylphosphonites
and azides. Synthesis from borane protected vinylphosphonites (route
III) or diethyl chlorophosphite (route IV). Stated are isolated yields.
Fig. 2 (a) Reaction of glutathione (GSH) with differently substituted
vinylphosphonamidates. 10 mM vinylphosphonamidates were reacted
with 20 mM GSH at pH 8.5 (NH4HCO3 buffer). Concentration of the
starting materials over time, mean and error from three independent
measurements, monitored by UPLC-UV. (b) N-Phenyl vs. N-alkyl
comparison. (c) Comparison of different O-substituents. Dotted line
depicts 50% conversion.
decient phosphonamidate ester substituents in the addition of
glutathione. A conversion of 50% is reached aer two and a half
hours for 2-nitrobenzyl compound 4b and aer only 30 minutes
for triuoroethyl substituted 4d. The O-phenyl compound 4c
shows an accelerating effect over alkoxy-substituents as well,
reaching 50% conversion in only one hour (Fig. 2c). These
6324 | Chem. Sci., 2019, 10, 6322–6329 This journal is © The Royal Society of Chemistry 2019
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reactions such as oxime, Staudinger or Pictet–Spengler liga-
tions.38 Next to reaction rates, an important aspect for many
applications of cysteine selective protein modication reagents
is susceptibility of the conjugate towards thiol exchange.1 Mal-
eimides are in particular known to undergo retro Michael
addition, followed by transfer of the modication to other
cysteine containing molecules in solution.40 To prove the
stability of the vinylphosphonamidate adducts in the presence
of other thiols, we incubated the glutathione adducts of 4a and
4d with an excess of 100 equivalents of 2-mercaptoethanesul-
fonate. Even aer one week of incubation, no thiol exchange
could be observed for both of the constructs by UPLC/MS (ESI
Fig. S5‡).
Next, we wanted to probe the reactivity of electron-poor
vinylphosphonamidates towards cysteine modication on
antibodies. For this, we synthesized a uorescent EDANS-
modied vinylphosphonamidate 6, analogously to compound
4d, with the N-phenyl-O-triuoroethyl substitution pattern that
has been identied to be superior in thiol addition kinetics.
Based on a previously established protocol31 we reduced the
four interchain disulde bonds of cetuximab to generate 8 free
cysteine residues and probed the reactivity towards 6 (Fig. 3a).
Successful labelling aer reduction and incubation with 20
equivalents of reagent per antibody was conrmed by in-gel
uorescence (Fig. 3b). Intact protein MS revealed a decent
degree of modication of 3.8 uorophore molecules per anti-
body (ESI Fig. S6‡). To probe the cysteine selectivity, a control
experiment without prior antibody reduction was performed
and no modication could be detected aer incubation with 20
equivalents of 6 by in-gel uorescence and MS. Only upon
exposure of the unreduced antibody to high reagent excesses of
more than 50 equivalents per antibody, low degrees of modi-
cation were observed (Fig. 3b). The observation of unspecic
labelling at higher reagent concentrations was further investi-
gated by mass spectrometry (LC-MS/MS) aer trypsin digestion
of the reduced antibody modied with 100 eq. of 4d (ESI
Fig. S7‡). In addition to the inter-chain disulde forming
cysteines, a few lysine residues were also found to be modied.
This cross-reactivity with lysine is also known for other cysteine
labelling reagents such as iodoacetamides41 and maleimides.42
The ndings are nevertheless contrary to our previously re-
ported ethynylphosphonamidate reagents that exhibit excellent
cysteine selectivity even with large reagent excesses.31 To further
broaden the scope of our method, we also synthesized a biotin-
modied 2-nitrobenzyl-phosphonamidate with a structure that
has the same substitution pattern as compound 4b. Successful
antibody labelling was conrmed by anti-biotin Western blot
analysis. Analogously to the triuoroethyl compound, only
prolonged reaction times lead to minor labelling degrees
without prior reduction of the antibody disulde bonds (ESI
Fig. S8‡). Taken together, we were able to show that vinyl-
phosphonamidates can lead to efficient and selective modi-
cation of cysteine residues on proteins using only slight reagent
excesses.
We further anticipated that the SPhR with subsequent thiol
addition could also be applied in an intramolecular reaction.
Therefore we synthesized an azidohomoalanine- and cysteine-
containing peptide, aiming to initiate a covalent cyclization.
As the rst proof of principle study, we chose to macrocyclize
the BCL9 derived peptide 8a, which has been reported to act as
a potent PPI-inhibitor when stapled by ring closing metathesis
(RCM).43 We decided to replace the two olenic amino acids in
the i,i+4 position with azidohomoalanine and cysteine in order
to keep the linker length (10 atoms) similar to that of the
literature-known peptide 7 (Scheme 2). In our initial experi-
ments we aimed to keep a double bond in the linker structure
for more rigidity and hence used an ethyl-substituted ethynyl-
phosphonite in the reaction with peptide 8a in dry DMSO based
on our previously published conditions.31 However, we found
that in order to promote the initial SPhR with the alkylazide of
azidohomoalanine the reaction temperature had to be raised to
50 C, upon which the macrocyclized product formed only in
low amounts. A major side product observed by UPLC-UV/MS
was a peptide with an additional 28 Da, which we attribute to
the alkylation of the nitrogen of the phosphonamidate. Similar
N-alkylated phosphoramidates were reported previously by us
aer the rearrangement of phosphorimidates under elevated
temperatures.44 We hypothesized that raising the reactivity of
the phosphonite by using a more nucleophilic vinyl- as opposed
to the ethynyl-phosphonite in the SPhR enables the use of lower
reaction temperature and would thereby prevent the rear-
rangement to the alkylated byproduct. Therefore puried
Fig. 3 Cetuximab modification with 6. (a) Reduction and alkylation
principles and structure of 6. (b) Gel analysis: reactions were carried
out with varying equivalents of 6: Lane 1: untreated antibody. Lane 2–
4: control reactions without prior DTT treatment. Lane 5–7: prior DTT
treatment. HC: antibodies' heavy chain, LC: light chain.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 6322–6329 | 6325
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(1.65 mM) in DMSO for 24 hours. Under these conditions, no
product formation could be observed by MS analysis (ESI
Fig. S10‡). This experiment again points towards the decreased
reactivity of ethyl-substituted vinylphosphonamidates in inter-
molecular reactions with thiol substrates (see Fig. 2a and ref.
35), and furthermore implies that the in situ process benets
from the reaction of thiols with a more reactive SPhR
intermediate.
With the phosphonamidate-cyclized BCL9 peptide 9a in
hand we set out to investigate its stability and helicity. At rst,
9a was incubated at different pH values over several days and
the stability monitored by UPLC. Under acidic conditions
below pH 2 the P–N-bond gets cleaved within 24 hours, which
is in accordance with our previous observations.31 At neutral
and basic pH, the phosphonamidate moiety proved to be
stable over several days without any observable decomposition
(Fig. 4a and b). Next, we evaluated the peptides' helical
propensities by CD spectroscopy and could show a drastic
increase in helicity upon cyclization from 20% to around 50%
(Fig. 4d). To verify the ability to disrupt the PPI between
puried BCL9 and b-catenin we used a homogeneous assay
with time resolved uorescence (HTRF), in which both inter-
acting proteins were recognized by distinct antibodies via
orthogonal tags and conjugated uorophores suitable for
energy transfer.45 Disturbance of the protein–protein interac-
tion causes a decreased FRET signal (ESI Fig. S11‡). Using this
assay, we could show that the phosphonamidate cyclized
peptides can disrupt the PPI at concentrations in the nM range
(Fig. 4e). The IC50 values are almost identical to those reported
for the RCM stapled BCL9 peptide.43 Furthermore, we
observed that the stereochemistry at cysteine seems to have an
inuence on the disruption behavior, with a superior inhibi-
tion constant observed for the D-enantiomer 9b compared to
that of the L-enantiomer 9a.
Since peptide stapling is known to improve cellular uptake
through endocytic vesicle trafficking46 and the BCL-9 and b-
catenin interaction takes place intracellularly in the cytoplasm
and the nucleus,45 we also tested the peptides' ability to
penetrate cells. By treating HeLa cells with 10 mM mixture of
10% uorescein labelled and 90% non-labelled peptides for
three hours, we observed that peptide 9b shows almost no
uptake, whereas the RCM stapled peptide 7 is taken up readily.
We attributed this to a recent observation from the Futaki lab,
in which they show the importance of net hydrophobicity for
the cellular uptake of stapled peptides.47 In order to increase
the hydrophobicity of our linkage, we synthesized peptide 13
with a more lipophilic O-benzyl-substituent at the phospho-
namidate. For this, the SPhR of the azido peptide 8b with
a benzyl phosphonite was carried out at slightly elevated
temperatures to ensure high conversions. The peptide was
only synthesized in the D-cysteine variant due to the afore-
mentioned improved disruption behavior towards the BCL-9
and b-catenin interaction. Isolated 13 showed comparable
helicity to the ethyl substituted 9b (Fig. 4d) and the benzyl-
substituent did not hamper the peptides' ability to disrupt
the PPI (Fig. 4e). In addition, we observed increased cellular
uptake of benzyl substituted 13, compared to 9b, which nicely
Scheme 2 Principle of the intramolecular peptide cyclization of an
azido containing cysteine-BCL-9 derived peptide. Investigations with
a capped cysteine peptide (9) revealed an accelerated thiol addition
when SPhR is performed in the presence of thiols. SPhR on peptides is
always carried out with the crude diethyl phosphonite, synthesized
from diethyl chlorophosphite (route III).
peptide 8a was reacted with crude diethyl vinylphosphonite
(route III) aer SPPS in an over-night reaction in DMSO. To our
delight, we isolated the desired cyclized peptide 9a aer
preparative HPLC as the main product in a very good yield of
45%. This result is particularly remarkable in light of the slow
intermolecular thiol addition to O-ethyl-N-alkyl-
vinylphosphonamidates such as 5a as shown before (Fig. 2b).
UPLC/MS showed a clean conversion towards the desired
product without signicant amounts of the side product (ESI
Fig. S9‡).
To gain more insight into the in situ intramolecular cycliza-
tion, we capped the cysteine of peptide 8a with iodoacetamide
to form peptide 10. This peptide was reacted with glutathione
under two different reaction conditions (Scheme 2). First,
glutathione was added in a one-pot reaction with peptide 10
(1.65 mM) and 5 eq. diethyl vinylphosphonite. Here, the thiol
addition product 12 could be observed by LC-MS as the major
product (ESI Fig. S10‡). In the second experiment, we reacted
peptide 10 with 5 eq. vinyl phosphonite to form the phospho-
namidate 11 aer hydrolysis, as observed by LC-MS. Aer
lyophilization peptide 11 was incubated with 1 eq. glutathione
6326 | Chem. Sci., 2019, 10, 6322–6329 This journal is © The Royal Society of Chemistry 2019
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cyclization technique. The linear unprotected peptide was reac-
ted with the crude diethylvinylphosphonite (route III) in dry
DMSO overnight to yield 48% of the in situmacrocyclized peptide
16 aer purication. For conjugation of 16 to a protein cargo,
the N-terminus of the peptide was capped with an
ethynylphosphonamidate-NHS building block 17 31 to yield 18
(Fig. 5a) for Cys-selective labeling reactions. Conjugation to eGFP
that carries a single addressable cysteine proceeded quantita-
tively according to MALDI-TOF-MS (Fig. 5b). Cellular uptake of
the protein was demonstrated by confocal uorescence imaging
aer incubation of HeLa-cells with 30 mM conjugate for one hour
at 37 C in HEPES buffer and was compared to that of the
standard lactam cyclized cR10-eGFP conjugate. Cytosolic and
nucleolar GFP uorescence was observed and both protein–
peptide-conjugates showed the same amount of transduced
cells, indicating the feasibility of using our novel cyclization
method as a macrocyclization technique (Fig. 5c).
Fig. 4 (a) Stability of 9a at different pH values. Shown are mean and error from three independent measurements, monitored by UPLC-UV. (b)
UPLC-UV spectra of 9a upon incubation at pH 3.1 over several days. *P–N-bond cleavage is the only degradation product observed. (c)
Structures of differently cyclized BCL-9 peptides. Stated are isolated yields from the cyclization reaction. (d) CD-measurement of peptides. (e)
HTRF assay shows disruption of PPI by peptidic inhibitors. (f) Cellular uptake studies of 10 mM mixture of 10% carboxy-fluorescein (CF)-labelled
and 90% non-labelled peptides in HeLa cells. Confocal images with scale bar ¼ 20 mm. Depicted is the overlay of fluorescein-fluorescence and
Hoechst nucleus stain at different time points of laser (405/488 nm) irradiation.
illustrates the modularity of our method that allows a facile
exchange of the O-substituent of phosphonamidates to
modulate the functional properties of the peptide ligation
products.
In addition to the side-chain-stapled peptides, we further
expanded our novel cyclization method to a more general mac-
rocyclization technique for enhancing the cellular uptake prop-
erties of protein conjugates. Therefore, we aimed for the
cyclization of an R10 peptide, which is, like other arginine-rich
peptides, able to enhance the transduction of functional
proteins into living cells when covalently attached to the protein
cargo.48 We and others observed that the cellular transduction
behavior is signicantly improved for the cyclic version of cR10
when compared to its linear counterpart.22,49,50 As an alternative
to the previously applied cyclized R10-CPP 14, we synthesized
peptide 15 containing a cysteine and an azidohomoalanine
residue to replace the former lactam bridge aer our novel
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 6322–6329 | 6327
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51. Supplementary Figures
1.1. Figure S1
Glutathione addition to vinylphosphonamidates. (see chapter 3.1 for details) a) Concentration of 
starting materials 4b, 4d, 5b and 5d over time monitored by UPLC/MS (pH 8.5, 50 mM NH4HCO3, 1 mM 
EDTA). Values were calculated by integration of the peaks in relation to an internal standard (inosin). 
Sample were drawn from the reaction mixture and immediately diluted into 50 mM NaOAc buffer at 
pH 3.5 to stop the reaction and subjected to UPLC analysis. Peaks were assigned by MS. Shown are 
mean and error of three independent measurements (n=3). Solid line: N-phenyl substituents, dotted 
line: N-alkyl-substituents. b) Overview for all vinylphosphonamidates tested in this study in GSH 
addition under the same conditions. Stated is the time until 50% conversion is reached.
61.2. Figure S2
UPLC traces of the reaction of compounds 4a, 4b, 4c, 4d, 5a, 5b and 5d before (red) and after the 
reaction (black) with two equivalents of glutathione, as stated in chapter 3.1. Shown are the traces of 
t=0 and the last time point of the measurements that have been performed for the time-course curves 
in Fig. 2 and S1. The appearance of a single product-peak for each of the compounds suggests a clean 
conversion to the desired cysteine adduct without side reactions. Peaks were assigned by MS. 
7
81.3. Figure S3
Full assignment of the NMR-shifts of the gluthatione adduct to 4a by two dimensional experiments. a) 
1H-1H-COSY-spectrum with important highlighted correlations that underline the assignments of the 
1H-NMR-shifts. b) 1H-13C-HSQC-spectrum and assignment of the measured 13C-NMR-shifts. c) 1H-13C-
HMBC-spectrum. Three highlighted correlations demonstrate successful conjugation to the cysteine’s 
sulfhydryl-group. d) 1H-31P-HMBC-spectrum. Four highlighted correlations underline that all three 
phosphorus substituents (EtO-, RCH2- and PhNH-) are attached to the phosphorus core structure. 
9
10
1.4. Figure S4
Determination of the second-order rate constant of the reaction between glutathione and 4d. a) 
Reaction conditions. Reactions were performed as described in chapter 3.1 in a volume of 0.2 ml, as 
stated in chapter 3.1. The first sample (t=0) was drawn before the addition of glutathione. Samples 
were taken after 5, 15, 30, 60, and 120 min. Samples were drawn in a volume of 20 µl and immediately 
diluted into 80 µl of 50 mM NaOAc buffer at pH 3.6 to stop the reaction. b) Mathematic consideration 
for the determination of a second order rate constant with equal concentrations of the two reactants. 
c) Concentration of starting material over time. Calculated by integration of the peaks in relation to 
the internal standard (inosine). Shown are mean and error of three independent measurements. (n=3) 
d) Graph: 1/c over time and linear plot. Slope is the second order rate constant. Shown are mean and 
error of three independent measurements. 
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1.5. Figure S5
Incubation of the glutathione adducts of 4a and 4d with an excess of mesna to demonstrate stability 
towards thiol exchange. a) Conjugates were incubated at a concentration of 50 µM for 7 days at room 
temperature with 5 mM of mesna in PBS (100 eq.) and analyzed by UPLC/MS. Samples of 10 µl were 
analyzed after day 0, 2 and 7. No Signal was detected by MS over the whole chromatogramm for the 
4a and 4d- Mesna adduct even after 7 days of incubation. b) Overlay of an isolated Mesna adduct to 
4d (black) and 4d-GSH incubated with Mesna for 7 days. The difference in retention time underlines 
that the Mesna adduct is not formed by thiol exchange of 4d-GSH. 
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1.6. Figure S6
Modification of cetuximab with 6 and analysis with intact protein MS (See chapter 3.2 for synthesis 
details). Interchain reduction generates one free cysteine on the light chain and three on the heavy 
chain. MS-spectrum of cetuximab’s heavy and light chain after deglycosylation with PNGase F and 
reduction with DTT as described in chapter 3.3. Shown are crude spectra before the deconvolution and 
Deconvoluted between 20000 and 60000 Da. Calculated delta mass for 6: 557 Da. a) Unmodified 
cetuximab. b) cetuximab, incubated with 20 eq. 6 without prior reduction. No modification detected 
for heavy and light chain. c) cetuximab, incubated with 20 eq. 6 with prior reduction. Modification ratio 
calculated to 3.8 from the MS intensities as stated in chapter 3.3. HC: heavy chain, LC: light chain. 
13
1.7. Figure S7
MS/MS experiments of cetuximab, modified with 100 eq. 4d with prior reduction of the antibody as 
described in chapter 3.2. a) MS-spectrum of cetuximab’s heavy and light chain after deglycosylation 
with PNGase F and reduction with DTT as described in chapter 3.3 to proof successful antibody 
modification. b) SDS Page analysis of the modified antibody. In-gel digestion for tandem-MS has been 
executed as described earlier.1 Bands for HC and LC were excised and digested together. c) MS/MS 
results. Sequence coverage was determined using MASCOT. The phosphonamidate (delta-mass of 4d) 
was searched on Y, S, T, C, K, H & R as variable modifications using maxquant. Aminoacids with a 
Probability of more than 0.7 are highlighted with a red M. (See chapter 2.9 for MS/MS details).
14
1.8. Figure S8
Antibody modifications with vinylphosphonamidates by reduction and alkylation of interchain disulfide 
bonds as described in chapter 3.4. a) Synthesis of a biotin modified O-2-nitrobenzyl 
vinylphophonamidate that can be detected by western blotting. b) Principle of the antibody 
modification procedure. Reaction was carried out either with or without prior disulfide reduction as 
previously described.2 c) Western blot analysis: Lane 1 and 6: untreated antibody. Lane 2-5: prior DTT 
treatment. Lane 7-10: Control reactions without prior DTT treatment. 
15
1.9. Figure S9
Reaction of azide and cysteine containing BCL-9 with a vinylphosphonite yields the cyclized product 
9a. a) Reaction scheme. b) UPLC-chromatogramm of the crude reaction mixture shows a clean 
conversion to two diastereoisomers (*racemic stereocenter at phosphorus). The mass fits the desired 
product. C) HMBC correlating 31P-NMR and 1H-NMR for the isolated product of the reaction. 31P-shift 
matches the thiol addition product. In addition, 31P-Correlations were assigned to the adjacent O-CH2 
and two CH2 groups, which can only be present after thiol addition to the double bond of the 
vinylphosphonamidate. The correlation pattern matches the fully characterized and assigned NMR-
Spectra of the GSH-thiol adduct to 4a (See Figure S1).
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1.10. Figure S10
Thiol addition of unactivated vinylphosphonamidates proceeds with an intermediate of the SPhR. 
Depicted are mass-spectra after the respective reaction sequences. a) In situ addition of glutathione 
to the SPhR. b) Incubation of isolated phosphonamidate 11 with glutathione. c) Mechanistic 
assumption: Accelerated thiol addition to an intermediated of the SPhR such as the phosphonimidate. 
Mechanism adapted from Vallee et al.3
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1.11. Figure S11
Principle of the HTRF assay. A FRET system is created between two fluorescently labeled antibodies 
recognizing a GST-tag on the β-Catenin and a His-tag on the BCL9 protein. If the proteins interact a 
FRET signal is generated upon antibody incubation that vanishes in case of disturbed interaction by a 
BCL-9 stapled peptide for instance. Protein expression and purification was performed as described in 
chapter 3.2 and 3.3. HTRF assay was performed as described in chapter 3.4.
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2. General Information 
2.1. Chemicals and solvents
Chemicals and solvents were purchased from Merck (Merck group, Germany), TCI (Tokyo chemical 
industry CO., LTD., Japan) and Acros Organics (Thermo Fisher scientific, USA) and used without further 
purification. Dry solvents were purchased from Acros Organics (Thermo Fisher scientific, USA). Amino 
acids and resins for SPPS were purchased from Novabiochem (Merck, USA) or Iris Biotech GmbH 
(Germany).
2.2. Flash- and thin layer chromatography 
Flash column chromatography was performed, using NORMASIL 60® silica gel 40-63 µm (VWR 
international, USA). Glass TLC plates, silica gel 60 W coated with fluorescent indicator F254s were 
purchased from Merck (Merck Group, Germany). Spots were visualized by fluorescence depletion with 
a 254 nm lamp or manganese staining (10 g K2CO3, 1.5 g KMnO4, 0.1 g NaOH in 200 ml H2O), followed 
by heating.
2.3. Preparative HPLC
Preparative HPLC was performed on a Gilson PLC 2020 system (Gilson Inc, WI, Middleton, USA) using 
a VP 250/32 Macherey-Nagel Nucleodur C18 HTec Spum column (Macherey-Nagel GmbH & Co. Kg, 
Germany). The following gradient was used: A = H2O + 0.1% TFA (trifluoroacetic acid), B = MeCN 
(acetonitrile) + 0.1% TFA, flow rate 30 ml/min, 5% B 0-5 min, 5-90% B 5-60 min, 90% B 60-65 min
2.4. NMR
NMR spectra were recorded with a Bruker Ultrashield 300 MHz spectrometer and a Bruker Avance III 
600 MHz spectrometer (Bruker Corp., USA) at ambient temperature. Chemical shifts δ are reported in 
ppm relative to residual solvent peak (CDCl3: 7.26 [ppm]; DMSO-d6: 2.50 [ppm]; acetone-d6: 2.05 
[ppm]; CD3CN 1.94 [ppm]; 4.79 D2O [ppm] for 1H-spectra and CDCl3: 77.16 [ppm]; DMSO-d6: 39.52 
18
[ppm]; acetone-d6: 29.84 [ppm]; CD3CN 1.32 [ppm]; for 13C-spectra . Coupling constants J are stated 
in Hz. Signal multiplicities are abbreviated as follows: s: singlet; d: doublet; t: triplet; q: quartet; m: 
multiplet. 
2.5. UPLC-UV/MS
UPLC-UV/MS traces were recorded on a Waters H-class instrument equipped with a quaternary solvent 
manager, a Waters autosampler, a Waters TUV detector and a Waters Acquity QDa detector with an 
Acquity UPLC BEH C18 1.7 μm, 2.1 x 50 mm RP column with a flow rate of 0.6 mL/min (Waters Corp., 
USA). The following gradient was used: A: 0.1% TFA in H2O; B: 0.1% TFA in MeCN. 5% B 0 - 0.5 min, 5-
95% B 0.5-3 min, 95% B 3-3.9 min, 5% B 3.9-5 min.
2.6. SPPS
SPPS was carried out manually or on a Tribute-UV peptide synthesizer (Protein technologies, USA) via 
standard Fmoc-based protocols.
2.7. HR-MS
High resolution ESI-MS spectra were recorded on a Waters H-class instrument equipped with a 
quaternary solvent manager, a Waters sample manager-FTN, a Waters PDA detector and a Waters 
column manager with an Acquity UPLC protein BEH C18 column (1.7 µm, 2.1 mm x 50 mm). Samples 
were eluted with a flow rate of 0.3 mL/min. The following gradient was used: A: 0.01% FA in H2O; B: 
0.01% FA in MeCN. 5% B: 0-1 min; 5 to 95% B: 1-7min; 95% B: 7 to 8.5 min. Mass analysis was 
conducted with a Waters XEVO G2-XS QTof analyzer.
2.8. Intact protein MS
Intact proteins were analyzed using a Waters H-class instrument equipped with a quaternary solvent 
manager, a Waters sample manager-FTN, a Waters PDA detector and a Waters column manager with 
an Acquity UPLC protein BEH C4 column (300 Å, 1.7 µm, 2.1 mm x 50 mm). Proteins were eluted with 
a flow rate of 0.3 mL/min. The following gradient was used: A: 0.01% FA in H2O; B: 0.01% FA in MeCN. 
5-95% B 0-6 min. Mass analysis was conducted with a Waters XEVO G2-XS QTof analyzer. Proteins 
were ionized in positive ion mode applying a cone voltage of 40 kV. Raw data was analyzed with 
MaxEnt 1.
2.9. Analytical HPLC-MS/MS
After in-gel digestion peptides were dissolved in water and analyzed by a reversed-phase capillary 
liquid chromatography system (Dionex Ultimate 3000 NCS-3500RS Nano, Thermo Scientific) connected 
to an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, Germany). LC separations were 
performed with an in-house packed C18 column for reversed phase separation (column material: 
Poroshell 120 EC-C18, 2.7 μm (Agilent Technologies, USA) at an eluent flow rate of 300 µL/min using a 
gradient of 2-40% B in 38 min. Mobile phase A contained 0.1% formic acid in water, and mobile phase 
B 0.1% formic acid in acetonitrile. FT survey scans were acquired in a range of 350 to 1500 m/z with a 
resolution of 60000 (FMHM) and an AGC target value of 4e5. Precursor ions with charge states 2-4 
were isolated with a mass selecting quadrupole (isolation window m/z 1.6). Precursor ions were 
fragmented in alternating mode using EThcD and HCD. HCD MS/MS spectra were acquired with 30% 
NCE. EThcD fragmentation was performed using charge dependent ETD parameters and the 
supplemental activation (sa) was set to 30%. For both fragmentation types the maximum injection 
time was set to 500 ms to collect 5e4 precursor ions. Fragment ion spectra were acquired with a 
resolution of 15000 (FWHM).
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2.10. MALDI-TOF-MS
Spectra were measured on a Bruker LT microflex using a 2,5-DHAP matrix. Proteins were precipitated 
in cold acetone and resolved in 10 mM Ammoniumbicarbonate buffer at pH 7.4. Protein sample (0.8 
µl) was mixed with 2% TFA in water (0.8 µl) and matrix (0.8 µl). After addition of matrix the solution 
was transferred a MSP 96 target (polished steel BC).
2.11. Protein concentration determination
Protein concentrations were determined by absorption spectroscopy measurements at 280 nm using 
the extinction coefficient and molecular weight of the protein on a NanoDrop ND-1000. In addition 
or as alternative concentrations were determined by BCA assay (Thermo Fisher Scientific, USA) 
according to the manufacturers protocol. 
2.12. Protein purification 
Protein purification was accomplished either with an ÄKTA FPLC or a BioRad NGC system as stated 
below.
2.13. CD-spectroscopy 
CD-spectroscopy was measured on a Jasco J-720 spectropolarimeter at 20°C and parameters set to: 
measured wavelength range 190 – 260 nm; data pitch of 0.1 nm; continuous scanning mode; 100 
nm/min scanning speed; 1sec. response; 1.0 nm band width; 0.1 cm cell length; 5 accumulations.
3. Experimental procedures
3.1. Glutathione addition to differently substituted vinylphosphonamidates and analysis by 
UPLC/MS
Reaction buffer: 50 mM NH4HCO3, 1 mM EDTA pH 8.5. In an Eppendorf tube, 11 µl of a 200 mM 
phosphonamidate solution in DMF was mixed with 143 µl reaction buffer and 22 µl of a 10 mM solution 
of Inosin in a mixture of DMF and reaction buffer (1:1). A 16 µl sample was drawn for t=0. 40 µl of a 
solution containing 100 mM glutathione in reaction buffer (50 mM for rate constant determination), 
adjusted to pH 8.5 was added to the mixture to start the reaction. Sample were drawn from the 
reaction mixture after distinct time points and immediately diluted into 180 µl of a 50 mM NaOAc 
buffer at pH 3.5 to stop the reaction and subjected to UPLC analysis (10 µl per injection). Conversions 
were calculated by integration of the Peaks in relation to an internal standard (inosin). Peaks were 
assigned by MS. Exemplaric chromatograms of the reaction of glutathione with O-Phenyl-N-phenyl-P-
vinyl-phosphonamidate (4c) after 0, 15, 30, 60, 120, 240 and 480 minutes are shown below.
3.2. Cetuximab modification with 4d or 6
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5 μl of a 70 mM solution of DTT in 50 mM sodium borate in PBS (pH 8.0) was added to 50 μl of a 
cetuximan solution of 5.0 mg/ml in 50 mM sodium borate in PBS (pH 8.0) and the mixture was 
incubated at 37 °C for 40 min. Excess DTT removal and exchange to the conjugation buffer (50 mM 
Tris, 1 mM EDTA, 100 mM NaCl, pH 8.5 at 14°C) was conducted afterwards using 0.5 mL Zeba™ Spin 
Desalting Columns with 7K MWCO (Thermo Fisher Scientific, USA). 50 μl of the reduced antibody 
solution (4.55 mg/ml, 30.30 μM antibody) were mixed quickly afterwards with desired amount of 4d 
or 6 dissolved in DMSO to give a final amount of 5% DMSO. The mixture was shaken at 850 rpm and 
25 °C for 16 hours.
The crude antibody modification mixtures were purified by size-exclusion chromatography with a 5 ml 
HiTrap® desalting column and a flow of 1.5 ml/min eluting with PBS over four column volumes. The 
antibody containing fractions were pooled and concentrated to 50 µl by spin-filtration to 40 µl (MWCO: 
10 kDa, 0.5 ml, Sartorius, Germany). 
3.3. Antibody analyses
2 µl of the samples, that were prepared as described in 3.2 were subjected to SDS-PAGE analysis. 
For MS analysis, 5 µl of the samples were diluted with 15 µl PBS and 1 μl PNGase-F solution (Pomega, 
Germany, Recombinant, cloned from Elizabethkingia miricola 10 u/μl) was added and the solution was 
incubated at 37 °C for at least 2 hours. Disulfide bridges were reduced by addition of 2 μl DTT solution 
(70 mM in H2O) and incubation at 37°C for 30 min. 10 µl of the samples were diluted with 190 µl of 
pure water and subjected to intact protein MS (see chapter 2.8), injecting 3 µl for each sample.
3.4. Cetuximab modification with biotin
Cetuximab modification was carried out by incubating the antibody (typical concentration 
c = 1.5 mg/ml, 10 µM) in a buffer containing 50 mM sodium borate and 10 mM DTT in PBS (pH 8.0) 
with a total volume of 80 μl at 37 °C for 30 min. Control reactions were carried out without DTT. Excess 
DTT removal and buffer exchange to a solution containing 50 mM NH4HCO3 and 1mM EDTA (pH 8.5) 
was conducted afterwards using 0.5 mL Zeba™ Spin Desalting Columns with 7K MWCO (Thermo Fisher 
Scientific, USA). 1.0 μl of a solution containing 20 mM vinyl phosphonamidate (40eq.) in DMSO was 
added quickly to 50 μl of the reduced antibody solution. 10 μl samples were drawn and deep frozen in 
liquid nitrogen to stop the reaction after 10 minutes, 1, 4 and 20 hours. 1.0 μl of the samples were 
subjected to SDS/PAGE and subsequent western-blot analysis.
3.5. Protein expression β-Catenin-GST
β-Catenin-GST (pGEX-Bcatfl was a gift from David Rimm (Addgene plasmid #24193)) was expressed in 
E.coli BL21 (DE3) with LB medium including 100 µg/ml Ampillicin. Cells were grown at 37°C at 180 rpm 
until OD600 reached 0.73 followed by induction with 0.2 mM IPTG and expression at 18°C at 180 rpm 
for 16 hours.
The cells were harvested by centrifugation at 4000 g for 15 minutes at 4°C. Cell lysis was carried out in 
Dulbecco’s PBS with a sonicator at 30% for six minutes. Finally debris was centrifugation at 27000 g for 
20 minutes. β-Catenin-GST was purified with a BioscaleTM Mini ProfinityTM GST cartridge (5 ml) on a 
BioRad NGC system (Binding/Wash buffer: 50 mM Tris HCl pH 8.0/ 150 mM NaCl/ 0.1 mM EDTA; elution 
buffer: 50 mM Tris HCl pH 8.0/ 150 mM NaCl/ 0.1 mM EDTA/ 10 mM reduced glutathione). After 
elution the peak fractions were combined and dialyzed to Dulbecco’s PBS. The protein was aliquoted 
at a concentration of 0.87 mg/ml, shock frozen and stored at -80°C. a) Purification of GST- β-Catenin. 
b) Pooled elution fractions rebuffered to PBS.
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3.6. His6-BCL9 (243 – 469) production
The cDNA for BCL9 was purchased from biocat (Gene ID 607) in a pCR-BluntII-TOPO vector. 
PCR:
The Gene region of interest was amplified with BamHI and HindII restriction sites by PCR using 
complementary primer pairs (for conditions see table 8.4 and 8.5) 
(GTAGTGGATCCAACCAGGACCAGAATTCTTC and ATACGAAGCTTTTAC TGCTCGGGAGTCATATGGT) for 
cloning into the pET28a vector. Two PCRs were done in parallel. 
Reaction mix of PCR:
ddH2O 13.6 µl
Phu HF buffer (5x) (Thermo scientific, USA) 4 µl
template DNA (1 ng/µl) 1 µl
fwd primer mix (10 µM) 0.4 µl
rev primer mix (10 µM) 0.4 µl
dNTP mix (10 mM each) (Thermo scientific, USA) 0.4 µl
Phusion polymerase (Thermo scientific, USA) 0.2 µl
Cycle steps in mutagenesis PCR:
step cycles temp.[°C] time 
initial denaturation 1 98 30’’
denaturation 98 10’’
annealing 58 30’’
extension
30
72 3’
final extension 1 72 10’
hold 4 ∞
Digestion with restriction endonucleases
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The PCR product as well as the target vector pET28a was digested with the restriction endonucleases 
BamHI and HindII for 70 minutes at 37°C. To the vector digestion, 1 µL of FastAP Themosensitive 
Alkaline Phosphatase (1 U/µl) was added and again incubated at 37°C for 15 minutes.
Reaction mix of restriction digestion:
PCR product vector
DNA 2 x 20 µl 16 µl (1 µg)
FastDigestTM buffer (10x) 5 µl 2
BamHI enzyme (10 U/µl) 1 µl 1
HindII enzyme (10U/µl) 1 µl 1
ddH2O 3 µl -
DNA purification
DNA fragments were purified by agarose gel electrophoresis (1% agarose in TAE buffer) at 120 V in 1x 
TAE buffer for 20 minutes. The samples were mixed with MidoriGreen Direct before loading, for 
visualization purposes. GeneRuler 1kb Plus DNA Ladder was used as size marker. The target DNA bands 
were excised from the agarose gel with a clean scalpel and purified with a GeneJETTM Gel Extraction 
Kit according to the manufacturer’s protocol, but was eluted with 20µl ddH2O contrary to the included 
elution buffer. 
DNA ligation
The Ligation between vector and PCR product was done with T4 DNA ligase (Thermo Scientific USA) 
and the T4 Buffer (Thermo Scientific USA). The vector to insert ration was either 1:5 or 1:10 and was 
calculated according to length of both DNA parts and their respective concentration. The reation 
mixture was incubated at 16 °C for 16 hours and directly transformed into competent DH5α cells. 
Reaction mix of Ligation: 
vector DNA 50 – 100 ng
insert DNA variable
T4 buffer (10x) (Thermo scientific, USA) 2 µl
T4 DNA ligase (Thermo scientific USA) 1 µl
ddH2O adjust to 20 µl
Clones were picked and cultured over night in LBKana at 37°C; 180 rpm and DNA was isolated with a 
GeneJET Plasmid Miniprep Kit (Thermo Scientific, USA) according to manufacturer’s protocol, but again 
elution was done in 30 µl ddH2O. DNA concentration was determined by Nanodrop and send to 
sequencing. DNA was stored at -20°C.
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Protein expression and purification
Finally His-BCL9 (243 – 469) was expressed in E.coli BL21 (DE3) with LB medium including 100 µg/ml 
kanamycin. Cells were grown at 37°C at 180 rpm until OD600 reached 0.7 followed by induction with 
0.5 mM IPTG and expression at 18°C at 180 rpm for 16 hours.
The cells were harvested by centrifugation at 4000 g for 15 minutes at 4°C. Cell lysis was carried out in 
Dulbecco’s PBS with a sonicator at 30% for six minutes. Finally debris was centrifugation at 27000 g for 
20 minutes. His-BCL9 (243 – 469) purified via 5 ml HisTrapTM FF column on a BioRad NGC system. 
Elution was performed in PBS with 500 mM Imidazole. Elution fractions containing the wanted protein 
were combined and further purified by size exclusion chromatography using a Superdex 75 10/300 GL 
column on a ÄKTA FPLC system. The product fractions were combined and concentrated with a 
Vivaspin 20 filter unit (MWCO 10 kDa) then shock frozen and stored at -80°C. a) Purification of BCL9-
His6 via Ni-NTA beads. b) Further purification via SEC. D) MALDI-TOF spectra of pooled fractions.
3.7. Homogeneous Time Resolved Fluorescence (HTRF) energy transfer assay
Beta-catenin-GST (7,5 nM) was first mixed with peptides at different peptide concentrations in PBS 
with 0.05% Tween 20, in reaction volumes of 5 µl in 384-well microtiter plates (ProxyPlate, 
PerkinElmer), followed by addition of BCL9-His (125nM), Anti-GST-Terbium (CisBio; 1:100) and Anti-
His-XL665 (CisBio; 1:100) in PBS with 0.05% Tween 20 at final reaction volumes of 10 µl. Final assay 
concentrations were 3,75 nM for beta-catenin, 62,5 nM for BCL-9 and contained 1:200 dilutions for 
each antibody in PBS with 0,05% Tween-20. After mixing on a plate shaker for 15 seconds at 1500 rpm 
the plate was incubated for one hour at room temperature. The plate was read in an Envision plate 
reader using excitation at 320 nm and emission reading at 620/665 nm wavelengths using the prism 
software for data plotting. Positive control wells represent a mixture of both proteins and both 
antibodies. Negative control wells did not contain beta-catenin.
3.8. Cellular uptake experiments 
All cell uptake experiments were carried out with HeLa (ATCC CCL-2) cells cultured in Dulbecco’s MEM 
medium supplemented with 10% FBS and 1% Penicillin Streptomycin. 70 000 cells were seeded in an 
uncoated glass bottom 8-well µ-slide (Ibidi) 24 hours prior to treatment. 
The cellular uptake with FAM labeled peptides was carried out by gently washing cells three times 
with DMEM without FBS. The FAM labeled peptides which were solved in DMSO (1 mM stock solution), 
were added to the medium after the final wash. The cells were incubated for at 37°C in a 5% CO2 
atmosphere for two hours. Then the cells were gently washed with 25 mM HEPES in Dulbecco’s MEM 
supplemented with 10% FKS and cells were rested for 30 minutes at 37°C. The cell nucleus was stained 
with Hoechst 33342 and cells imaged with a Zeiss 710 confocal microscope. 
The cellular uptake of cR10-eGFP was carried out by gently washing cells three times with HEPES buffer 
pH 7.5 (5 mM HEPES, 140 mM NaCl, 2.5 mM KCl, 5 mM glycine). The peptide-protein conjugate 
buffered in the same HEPES buffer was added to the cells in 200 µl at respective concentration and 
incubated for at 37°C in a 5% CO2 atmosphere. After one hour cells were gently washed with 25 mM 
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HEPES in Dulbecco’s MEM supplemented with 10% FKS and cells were rested for 30 minutes at 37°C. 
The cell nucleus was stained with Hoechst 33342 and cells imaged with a Zeiss 710 confocal 
microscope. 
The percentage of cells that took up the GFP conjugate was determined by counting all cells showing 
nucleolar GFP relative to the total number of cells (all Hoechst stained nuclei). Each uptake experiment 
was repeated at least three times. 
4. Organic and peptide synthesis
4.1. Diethyl vinylphosphonite borane (1a)
P
OEtEtO
Cl
P
OEtEtOTHF, -78°C
to rt, 2h
MgBr1.5 eq. 1.0 eq. BH3
THF, 0 °C, 1h
P
OEtEtO
BH3
A 25-ml Schlenk flask was charged with 2.14 ml vinylmagnesium bromide (0.7 M in THF, 1.50 mmol, 
1.5 eq.) under an argon atmosphere, cooled to -78 °C and  140 µl diethyl chlorophosphite (1.00 mmol, 
1.0 eq.) were added drop wise. The yellowish solution was allowed to warm to 0 °C, stirred for another 
two hours and 1.00 ml of Borane (1.0 M in THF, 1.00 mmol, 1.0 eq.) were added and stirred for one 
more hour at 0°C. The organic solvents were removed under reduced pressure and the crude product 
was purified by flash column chromatography on silica gel (Hexane/EtOAc, 9:1) to yield the desired 
compound as colourless oil. (60 mg, 0.37 mmol, 37.0%) 
1H NMR (300 MHz, Chloroform-d) δ = 6.36 – 6.03 (m, 3H), 4.19 – 3.96 (m, 4H), 1.33 (t, J=7.1, 6H), 0.55 
(ddd, J=190.3, 94.1, 16.6, 3H). 13C NMR (75 MHz, Chloroform-d) δ = 134.62 (d, J=8.7), 130.12 (d, J=75.0), 
63.16 (d, J=4.8), 16.59 (d, J=5.6). 31P NMR (122 MHz, Chloroform-d) δ = 129.58 (dd, J=167.1, 82.6).
NMR data is in accordance with those reported in the literature.4 
4.2. General procedure 1 for the synthesis of borane protected vinylphosphonites from 
phosphorous trichloride (route I)
PCl3 P R
O
R
O
Cl
2.2 eq. R-OH
2.2 eq. Pyridine
Toluene/Et2O,
-78°C to rt, 0.5 h
P R
O
R
OTHF, -78°C
to rt, 2h
MgBr1.1 eq. 1.5 eq. BH3
THF, 0 °C, 1h
P
OO
RR
BH3
A flame-dried Schlenkflask was charged with 1.00 mmol (1.0 eq.) of phosphorous trichloride in 15 ml 
of dry toluene and cooled to -78 °C. 2.2 mmol of pyridine (2.2 eq.) and a solution of 2.2 mmol of the 
alcohol (2.2 eq.) in 3 ml Et2O were added drop wise. The resulting suspension was allowed to warm to 
room temperature, stirred for another 30 min and cooled again to -78 °C. 1.10 mmol (1.1eq.) of vinyl 
magnesiumbromide (1.0 M in THF) was added and the reaction was stirred at room temperature for 
two hours. Finally, 1.50 mmol (1.5 eq.) of borane (1.0 M in THF) were added at 0 °C and the suspension 
was stirred for another hour. The crude product was dry packed on a silica column for purification.
It should be noted, that mass analysis of borane protected phosphonites failed for all of the tested 
compounds, possibly due to decomposition under ESI-conditions.
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4.3. Di(2-nitrobenzyl) vinylphosphonite borane (1b)
P
O
NO2
O
O2N
BH3
The compound was synthesized according to the general procedure 1 from 260 µl PCl3 (3.00 mmol). 
The crude borane protected phosphonite was purified by flash column chromatography 
(Hexane/EtOAc, 4:1) and obtained as a yellowish solid. (555 mg, 1.48 mmol, 49.2%)
1H NMR (300 MHz, Chloroform-d) δ = 8.10 (d, J=8.2, 2H), 7.77 – 7.63 (m, 4H), 7.57 – 7.44 (m, 2H), 6.51 
– 6.18 (m, 3H), 5.45 (qd, J=14.8, 7.5, 4H), 1.42 – -0.02 (m, 3H). 13C NMR (75 MHz, Chloroform-d) δ = 
146.80, 136.84 (d, J=10.2), 132.52 (d, J=6.8), 129.10, 129.05, 128.67, 128.61 (d, J=74.3), 125.09, 65.56 
(d, J=3.6). 31P NMR (122 MHz, Chloroform-d) δ = 136.23 (dd, J=151.3, 56.0).
4.4. Diphenyl vinylphosphonite borane (1c)
P
OO
BH3
The compound was synthesized according to the general procedure 1 from 393 µl PCl3 (4.50 mmol). 
The crude borane protected phosphonite was purified by flash column chromatography 
(Hexane/EtOAc, 4:1) and obtained as a colourless oil. (700 mg, 2.71 mmol, 60.3%)
1H NMR (300 MHz, Chloroform-d) δ = 7.39 (td, J=7.7, 5.5, 4H), 7.30 – 7.17 (m, 6H), 6.67 – 6.18 (m, 3H), 
1.48 – 0.01 (m, 3H). 13C NMR (75 MHz, Chloroform-d) δ = 151.27 (d, J=8.7), 137.01 (d, J=12.5), 129.70 
(d, J=1.0), 129.05 (d, J=71.1), 125.35 (d, J=1.3), 120.90 (d, J=4.2). 31P NMR (122 MHz, Chloroform-d) δ 
= 134.08 – 130.87 (m). 
4.5. Bis(2,2,2-trifluoroethyl) vinylphosphonite borane (1d) (route II)
P
O O CF3F3C
BH3
P
Cl
N N
P
N N MeCN/THF,
rt, 16h
THF, -78°C
to rt, 30 min
MgBr1.1 eq.
2.2 eq.
2.2 eq. Pyridine
P
OO
1.5 eq. BH3
THF, 0 °C, 1h
F3C OH
F3C CF3
A flame-dried Schlenkflask was charged with 266 mg Bis(diisopropylamino)-chlorophosphine 
(1.0 mmol, 1.0 eq.), dissolved in 200 µl of dry THF and cooled to -78 °C. 1.1 ml of vinyl 
magnesiumbromide (1.0 M in THF, 1.10 mmol, 1.1eq.) were added and the reaction was stirred at 
room temperature for 30 minutes. A solution of 160 µl 2,2,2-Trifluoroethanol (2.20 mmol, 2.2 eq.) in 
1 ml of MeCN and 4.9 ml tetrazole (0.45 M in MeCN, 2.20 mmol, 2.2 eq.) were added subsequently. 
The resulting suspension was stirred at room temperature overnight. Finally, 1.50 ml of borane (1.0 M 
in THF, 1.50 mmol, 1.5 eq.) were added at 0 °C and stirred for another hour. The crude product was 
dry packed on a silica column for purification (Hexane/CH2Cl2, 9:1 to 4:1) and obtained as a colourless 
liquid. (87 mg, 0.32 mmol, 32.2%)
1H NMR (300 MHz, Chloroform-d) δ = 6.52 – 6.11 (m, 3H), 4.36 (p, J=8.1, 4H), 0.62 (ddd, J=203.0, 103.5, 
15.0, 3H).13C NMR (75 MHz, Chloroform-d) δ = 137.57, 127.48 (d, J=79.1), 122.37 (qd, J=276.0, 7.5), 
63.60 (qd, J=37.7, 2.5). 19F NMR (282 MHz, Chloroform-d) δ = 2.13. 31P NMR (122 MHz, Chloroform-d) 
δ = 145.49 (dd, J=135.6, 65.1).
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4.6. General procedure 2 for the synthesis of vinylphosphonamidates from diethyl 
chlorophosphite (route III) 
MgBr
Cl P
OEt
OEt
P
OEt
OEt
THF, 0.7 M
-78 °C - 0 °C, 2h
1.2 eq. I) 1.0 eq R-N3II) H2O.
THF, 0.2 M
0 °C - rt, 16 h
P
OEt
NH
R
O
A 25-ml Schlenk flask was charged with 1.71 ml vinylmagnesium bromide (0.7 M in THF, 1.20 mmol, 
1.2 eq.) under an argon atmosphere, cooled to -78 °C and  140 µl diethyl chlorophosphite (1.00 mmol, 
1.0 eq.) were added drop wise. The yellowish solution was allowed to warm to 0 °C, stirred for another 
two hours and 1.00 mmol of azide (1.0 eq.) dissolved in 3.2 ml of THF was added and stirred over night 
at room temperature. 5 ml of water were added and stirred for another 24 h. The solvents were 
removed under reduced pressure and the crude product was purified by flash column chromatography 
on silica gel. 
4.7. Ethyl-N-phenyl-P-vinylphosphonamidate (4a)
P
O
OEt
NH
The compound was synthesized according to the general procedure 2 from 1.15 ml diethyl 
chlorophosphite (8 mmol). The crude phosphonamidate was purified by flash column chromatography 
(EtOAc) and obtained as a white solid. (675 mg, 3.20 mmol, 40.0%) 
1H NMR (600 MHz, Chloroform-d) δ = 7.24 (dd, J=8.5, 7.3, 2H), 7.05 – 7.01 (m, 2H), 6.99 (d, J=5.8, 1H), 
6.94 (tt, J=7.3, 1.1, 1H), 6.33 – 6.23 (m, 2H), 6.10 (ddd, J=50.3, 9.6, 5.1, 1H), 4.29 – 4.04 (m, 2H), 1.35 
(t, J=7.1, 3H). 13C NMR (151 MHz, Chloroform-d) δ = 140.43, 134.44, 129.28, 127.51 (d, J=172.7), 
121.26, 117.31 (d, J=6.6), 60.44 (d, J=6.2), 16.22 (d, J=7.0). 31P NMR (122 MHz, Chloroform-d) δ = 15.68. 
HRMS for C10H15NO2P+ [M+H]+ calcd.: 212.0835, found: 212.0839.
4.8. Ethyl-N-(3-phenyl-propyl)-P-vinyl-phosphonamidate (5a)
P
O
OEt
NH
The compound was synthesized according to the general the general procedure 2 from 290 µl diethyl 
chlorophosphite (2 mmol). The crude phosphonamidate was purified by flash column chromatography 
(EtOAc) and obtained as a colourless oil. (165 mg, 0.65 mmol, 32.5%)
1H NMR (300 MHz, Chloroform-d) δ = 7.28 (dd, J=8.1, 6.2, 2H), 7.23 – 7.11 (m, 3H), 6.28 – 5.89 (m, 3H), 
4.04 (qt, J=10.2, 7.2, 2H), 2.92 (dq, J=9.1, 7.0, 2H), 2.84 – 2.70 (m, 1H), 2.70 – 2.60 (m, 2H), 1.82 (p, 
J=7.3, 2H), 1.31 (t, J=7.1, 3H). 13C NMR (75 MHz, Chloroform-d) δ = 141.28, 132.98 (d, J=1.5), 128.42 (d, 
J=169.0), 128.34, 128.24, 125.88, 59.95 (d, J=5.7), 40.23, 33.53 (d, J=5.6), 32.86, 16.32 (d, J=6.7). 31P 
NMR (122 MHz, Chloroform-d) δ = 20.82. HRMS for C13H21NO2P+ calcd.: 254.1304, found: 254.1312.
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4.9. General procedure 3 for the synthesis of vinylphosphonamidates from borane protected 
vinylphosphonites (route IV)
1.5 eq. DABCO
toluene (0.5 M),
50 °C, 2h
THF (0.2 M), rt, 16 h
P
OO
R1R1
BH3
P
OO
R1R1
I) 1.1 eq R2-N3
II) H2O
P
H
N
O
R2R1
O
A flame-dried Schlenkflask was charged with 1.0 mmol (1.0 eq.) of the borane protected phosphonite 
under an argon atmosphere and dissolved in 2 ml of dry toluene. In an argon stream, DABCO (1.50 
mmol, 1.5 eq.) was added and the solution was heated to 50 °C for 2 hours. The mixture was allowed 
to cool to room temperature and a solution of 1.1 mmol of the azide (1.1 eq.) in 3 ml dry THF or dry 
DMF was added. The resulting solution was stirred at room temperature overnight. Finally 1 ml of 
water was added and stirred for another two hours. The crude product was purified by column 
chromatographie.
4.10. 2-Nitrobenzyl-N-phenyl-P-vinyl-phosphonamidate (4b)
P
H
NO
O
NO2
The compound was synthesized according to the general procedure 3 from 100 mg Di(2-nitrobenzyl) 
vinylphosphonite borane (1b)  (0.266 mmol). The crude phosphonamidate was purified by flash 
column chromatography (30% hexane in EtOAc) and obtained as a colourless solid. (38 mg, 
0.119 mmol, 44.7%)
1H NMR (300 MHz, Chloroform-d) δ 8.12 (dd, J = 8.2, 1.3 Hz, 1H), 7.83 (dd, J = 7.9, 1.3 Hz, 1H), 7.68 (td, 
J = 7.6, 1.3 Hz, 1H), 7.50 (ddd, J = 8.1, 7.4, 1.5 Hz, 1H), 7.21 (dd, J = 8.5, 7.2 Hz, 2H), 7.09 – 6.82 (m, 3H), 
6.61 – 6.00 (m, 4H), 5.57 (ddd, J = 67.1, 14.9, 7.6 Hz, 2H). 13C NMR (75 MHz, Chloroform-d) δ 146.89, 
139.47, 135.77, 135.75, 134.02, 132.72 (d, J = 7.6 Hz), 129.44, 128.80 (d, J = 3.3 Hz), 126.71 (d, J = 172.1 
Hz), 125.01, 121.96, 117.63 (d, J = 6.5 Hz), 62.75 (d, J = 4.8 Hz). 31P NMR (122 MHz, CDCl3) δ 16.83. 
HRMS for C15H16N2O4P+ [M+H]+ calcd.: 319.0842, found: 319.0825.
4.11. 2-Nitrobenzyl-N-(3-phenyl-propyl)-P-vinyl-phosphonamidate (5b)
P
H
NO
O
NO2
The compound was synthesized according to the general procedure 3 from 100 mg Di(2-nitrobenzyl) 
vinylphosphonite borane (1b) (0.266 mmol). The crude phosphonamidate was purified by flash column 
chromatography (20% hexane in EtOAc) and obtained as a yellowish solid. (55 mg, 0.153 mmol, 57.5%)
1H NMR (300 MHz, Chloroform-d) δ 8.12 (d, J = 8.2 Hz, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.73 – 7.60 (m, 1H), 
7.56 – 7.43 (m, 1H), 7.27 (t, J = 7.2 Hz, 2H), 7.23 – 7.10 (m, 3H), 6.55 – 5.88 (m, 3H), 5.43 (h, J = 7.4 Hz, 
2H), 2.98 (dd, J = 9.4, 5.1 Hz, 3H), 2.65 (t, J = 7.7 Hz, 2H), 1.84 (p, J = 7.1 Hz, 2H). 13C NMR (75 MHz, 
Chloroform-d) δ 141.14, 133.98 (d, J = 1.5 Hz), 133.88, 133.21 (d, J = 7.7 Hz), 128.75, 128.60, 128.53, 
128.36, 128.24, 126.50, 125.91, 124.84, 62.30 (d, J = 4.4 Hz), 40.27, 33.45 (d, J = 5.5 Hz), 32.83. 31P NMR 
(122 MHz, CDCl3) δ 21.87. HRMS for C18H22N2O4P+ [M+H]+ calcd.: 361.1312, found: 361.1304.
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4.12. Phenyl-N-phenyl-P-vinyl-phosphonamidate (4c)
P
H
NO
O
The compound was synthesized according to the general procedure 3 from 134 mg Diphenyl 
vinylphosphonite borane (1c)  (0.519 mmol). The crude phosphonamidate was purified by flash column 
chromatography (50% hexane in EtOAc) and obtained as a yellowish oil. (34 mg, 0.131 mmol, 25.3%)
1H NMR (600 MHz, Chloroform-d) δ 7.32 – 7.25 (m, 5H), 7.24 – 7.20 (m, 2H), 7.16 (t, J = 7.3 Hz, 1H), 
7.10 – 6.96 (m, 3H), 6.56 – 6.12 (m, 3H), 5.64 (d, J = 5.7 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 
149.87 (d, J = 8.1 Hz), 139.26, 135.98, 129.71, 129.41, 126.99 (d, J = 173.3 Hz), 125.08, 122.19, 120.72 
(d, J = 4.6 Hz), 118.06 (d, J = 6.5 Hz). 31P NMR (243 MHz, CDCl3) δ 12.74. HRMS for C14H15NO2P+ [M+H]+ 
calcd.: 260.0835, found: 260.0836.
4.13. Phenyl-N-(3-phenyl-propyl)-P-vinyl-phosphonamidate (5c)
P
H
NO
O
The compound was synthesized according to the general procedure 3 from 150 mg Diphenyl 
vinylphosphonite borane (1c) (0.581 mmol). The crude phosphonamidate was purified by flash column 
chromatography (30% EtOAc in hexane) and obtained as a white solid. (100 mg, 0.332 mmol, 57.1%)
1H NMR (600 MHz, Chloroform-d) δ 7.35 – 7.28 (m, 4H), 7.26 – 7.19 (m, 3H), 7.19 – 7.13 (m, 3H), 6.41 
– 6.01 (m, 3H), 3.20 – 2.92 (m, 3H), 2.63 (t, J = 7.7 Hz, 2H), 1.80 (pd, J = 7.1, 1.6 Hz, 2H). 13C NMR (151 
MHz, Chloroform-d) δ 150.63 (d, J = 7.9 Hz), 141.30, 134.03, 129.64, 128.43, 128.35, 127.98 (d, J = 
172.0 Hz), 125.99, 124.55, 120.58 (d, J = 4.9 Hz), 40.48, 33.38 (d, J = 5.6 Hz), 32.87. 31P NMR (243 MHz, 
CDCl3) δ 18.79. HRMS for C17H21NO2P+ [M+H]+ calcd.: 302.1304, found: 302.1315.
4.14. 2,2,2-trifluoroethyl-N-phenyl-P-vinyl-phosphonamidate (4d)
O
P
H
NO
F3C
The compound was synthesized according to the general procedure 3 from 90 mg Bis(2,2,2-
trifluoroethyl) vinylphosphonite borane (1d) (0.333 mmol). The crude phosphonamidate was purified 
by flash column chromatography (60 to 70% EtOAc in hexane) and obtained as a white solid. (27 mg, 
0.102 mmol, 30.6%)
1H NMR (300 MHz, Chloroform-d) δ 7.27 (dd, J = 9.3, 6.3 Hz, 2H), 7.13 – 6.86 (m, 3H), 6.65 (d, J = 6.2 
Hz, 1H), 6.53 – 6.01 (m, 3H), 4.70 – 4.06 (m, 2H). 13C NMR (75 MHz, Chloroform-d) δ 138.93, 136.50 (d, 
J = 1.7 Hz), 129.43, 125.70 (d, J = 172.5 Hz), 122.23, 117.68 (d, J = 6.7 Hz), 60.42 (qd, J = 37.7, 5.1 Hz), 
51.28. 31P NMR (122 MHz, CDCl3) δ 17.93. 19F NMR (282 MHz, CDCl3) δ 2.69. HRMS for C10H12F3NO2P+ 
[M+H]+ calcd.: 266.0552, found: 266.0552.
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4.15. 2,2,2-trifluoroethyl-N-(3-phenyl-propyl)-phenyl-P-vinyl-phosphonamidate (5d)
P
H
NO
OF3C
The compound was synthesized according to the general procedure 3 from 80 mg Bis(2,2,2-
trifluoroethyl) vinylphosphonite borane (1d) (0.296 mmol). The crude phosphonamidate was purified 
by flash column chromatography (70 to 80% EtOAc in hexane) and obtained as a colourless oil. (18 mg, 
0.059 mmol, 19.8%)
1H NMR (300 MHz, Chloroform-d) δ 7.36 – 7.12 (m, 6H), 6.54 – 5.94 (m, 3H), 4.29 (dqt, J = 12.2, 8.4, 4.1 
Hz, 2H), 2.96 (dt, J = 9.6, 7.1 Hz, 2H), 2.82 (d, J = 8.4 Hz, 1H), 2.66 (t, J = 7.7 Hz, 2H), 1.85 (p, J = 7.3 Hz, 
2H). 13C NMR (75 MHz, Chloroform-d) δ 141.00, 135.06 (d, J = 1.5 Hz), 128.41, 128.22, 126.69 (d, J = 
170.2 Hz), 126.00, 60.48 (qd, J = 37.2, 4.6 Hz), 40.08, 33.40, 33.32, 32.79. 31P NMR (122 MHz, CDCl3) δ 
22.94. 19F NMR (282 MHz, CDCl3) δ 2.40. HRMS for C13H18F3NO2P+ [M+H]+ calcd.: 308.1022, found: 
308.1017.
4.16. Ethyl-N-phenyl-P-(2-(glutathionyl-thio)ethyl)-phosphonamidate
PO OEt
HN
HOOC
NH2
N
H
O
S
H
N
O
COOH
A 5-ml round-bottom-flask was charged with 12.2 mg Ethyl-N-phenyl-P-vinyl-phosphonamidate (4a) 
(0.058 mmol, 1.00 eq.) and 150 µl DMF. A solution containing 21.4 mg glutathione (0.070 mmol, 
1.20 eq.) in 150 µl H2O was adjusted to with potassium carbonate to pH 9.0 and added to the reaction 
mixture, which was stirred for 24h at room temperature. All volatiles were removed under reduced 
pressure and the crude product was purified by preparative HPLC and obtained as a colourless solid 
after lyophilization as a mixture of diastereoisomers (18 mg, 0.035 mmol, 60.3%).
1H NMR (600 MHz, Deuterium Oxide) δ 7.53 – 7.22 (m, 2H), 7.15 – 6.89 (m, 3H), 4.44 (tt, J = 9.1, 4.5 Hz, 
1H), 4.26 – 3.96 (m, 2H), 3.89 – 3.51 (m, 3H), 3.04 – 2.90 (m, 1H), 2.86 – 2.63 (m, 3H), 2.54 – 2.39 (m, 
2H), 2.37 – 2.19 (m, 2H), 2.19 – 2.03 (m, 2H), 1.37 – 1.23 (m, 3H). 13C NMR (151 MHz, Deuterium Oxide) 
δ 176.03, 174.84, 173.90, 171.74 (d, J = 3.7 Hz), 139.43, 129.79, 122.48, 118.34 (d, J = 6.1 Hz), 62.27 (d, 
J = 6.9 Hz), 54.15, 52.80 (d, J = 14.3 Hz), 43.33, 32.82 (d, J = 12.9 Hz), 31.45, 26.22, 26.08 (d, J = 124.0 
Hz), 24.10 (d, J = 10.6 Hz), 15.54 (d, J = 6.4 Hz). 31P NMR (243 MHz, D2O) δ 31.68. HRMS for 
C20H32N4O8PS+ [M+H]+ calcd.: 519.1673, found: 519.1675.
4.17. 2,2,2-trifluoroethyl-N-phenyl-P-(2-(glutathionyl-thio)ethyl)-phosphonamidate
PO O
HN
HOOC
NH2
N
H
O
S
H
N
O
COOH
F
F
F
A 5-ml round-bottom-flask was charged with 17.2 mg 2,2,2-trifluoroethyl-N-phenyl-P-vinyl-
phosphonamidate (4d) (0.065 mmol, 1.00 eq.) and 150 µl DMF. A solution containing 21.85 mg 
glutathione (0.072 mmol, 1.10 eq.) in 150 µl H2O was adjusted to with potassium carbonate to pH 9.0 
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and added to the reaction mixture, which was stirred for 24h at room temperature. All volatiles were 
removed under reduced pressure and the crude product was purified by preparative HPLC and 
obtained as a colourless solid after lyophilization as a mixture of diastereoisomers (33 mg, 0.058 mmol, 
89.0%).
1H NMR (600 MHz, Deuterium Oxide) δ 7.27 (dd, J = 8.5, 7.3 Hz, 2H), 7.05 – 7.00 (m, 3H), 4.54 – 4.36 
(m, 3H), 4.00 (td, J = 6.6, 3.4 Hz, 1H), 2.89 (dd, J = 14.1, 5.4 Hz, 1H), 2.80 – 2.66 (m, 3H), 2.49 (ddt, J = 
9.7, 7.4, 3.1 Hz, 2H), 2.40 – 2.25 (m, 2H), 2.22 – 2.06 (m, 2H). 13C NMR (151 MHz, Deuterium Oxide) δ 
174.15, 172.76, 172.51 – 172.47 (m), 171.42, 138.58, 129.78, 123.02, 118.82 (d, J = 5.1 Hz), 60.93 (qd, 
J = 37.6, 5.1 Hz), 52.76 (d, J = 9.6 Hz), 52.17, 41.04, 32.70 (d, J = 6.8 Hz), 30.87, 26.41, 25.59, 25.41, 
23.94. 31P NMR (243 MHz, D2O) δ 33.70. 19F NMR (282 MHz, D2O) δ 2.60, 1.91. HRMS for 
C20H29F3N4O8PS+ [M+H]+ calcd.: 573.1390, found: 573.1391.
4.18. Trifluorethyl-N-(4-(2,5-dioxo-1-pyrrolidinyl)oxy-carbonyl-phenyl)-P-vinylphosphonamidate
N3
O
O N
O
O
HN
OO
N OO
P
O
O
CF3
P
Cl
N N
P
N N MeCN/THF,
rt, 16h
THF, 0°C to
rt, 30 min
MgBr1.1 eq.
2.2 eq.
2.2 eq. Pyridine
P
OO DMF, 0 °C, 16h
F3C OH
F3C CF3
1.0 eq.
A flame-dried Schlenkflask was charged with 266 mg Bis(diisopropylamino)-chlorophosphine 
(1.0 mmol, 1.0 eq.), dissolved in 200 µl of dry THF and cooled to 0 °C. 1.1 ml of vinyl 
magnesiumbromide (1.0 M in THF, 1.10 mmol, 1.1eq.) were added and the reaction was stirred at 
room temperature for 30 minutes. A solution of 160 µl 2,2,2-Trifluoroethanol (2.20 mmol, 2.2 eq.) in 
1 ml of MeCN and 4.9 ml tetrazole (0.45 M in MeCN, 2.20 mmol, 2.2 eq.) were added subsequently. 
The resulting suspension was stirred at room temperature overnight. Afterwards, 260 mg 4-
azidobenzoic-acid-N-hydroxysuccinimide ester (1.0 mmol, 1.0 eq.), dissolved in 1 ml of dry DMF was 
added and the suspension was stirred overnight. All volatiles were removed under reduced pressure 
and the crude product was purified by silica column (EtOAc/n-hexane, 4:1) and obtained as a colourless 
solid. (223 mg, 0.55 mmol, 55.0%)
1H NMR (300 MHz, Chloroform-d) δ 7.93 (d, J = 8.8 Hz, 3H), 7.06 (d, J = 8.8 Hz, 2H), 6.54 – 5.96 (m, 3H), 
4.58 – 4.15 (m, 2H), 2.84 (s, 4H). 13C NMR (75 MHz, Chloroform-d) δ 169.79, 161.35, 146.14, 137.44, 
132.37, 126.35, 124.07, 117.83, 117.24 (d, J = 7.1 Hz), 60.76 (qd, J = 37.8, 5.1 Hz), 25.63. 31P NMR (122 
MHz, CDCl3) δ 17.53. 19F NMR (282 MHz, CDCl3) δ 2.88. HRMS for C15H15F3N2O6P+ [M+H]+ calcd.: 
407.0614, found: 407.0614.
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4.19. 5-((2-(O-trifluorethyl-P-vinyll-phosphonamidato-N-benzoyl)ethyl)amino)naphthalene-1-sulfonic acid 
(6)
NH
O
ON
O
O
P
O
O
CF3
S
HN
O
O
O-
NH2
1.2 eq.
5.0 eq. DIPEA
Na+
P
O
N
H
O
O
S
H
N
O
O
OH
N
H
CF3
6
DMF, rt, 16h
A 10-ml round-bottom-flask was charged with 50 mg Trifluorethyl-N-(4-(2,5-dioxo-1-pyrrolidinyl)oxy-
carbonyl-phenyl)-P-vinylphosphonamidate (0.123 mmol, 1.0 eq.), 43 mg EDANS sodium salt 
(0.147 mmol, 1.2 eq.) and 1.2 ml DMF. 107 µl DIPEA (0.615 mmol, 5.0 eq.) were added and the solution 
was stirred overnight. The crude product was purified by preparative HPLC and obtained as a colourless 
solid after lyophilization (60.360,3 mg, 0.108 mmol, 88.0%). HRMS for C23H24F3N3O6P+ [M+H]+ calcd.: 
558.1070, found: 558.1071.
1H NMR (600 MHz, DMSO-d6) δ 8.55 (t, J = 8.7 Hz, 2H), 8.41 (s, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 
7.1 Hz, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.42 (dt, J = 29.4, 7.9 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.99 (s, 1H), 
6.44 – 6.16 (m, 3H), 4.76 – 4.46 (m, 2H), 3.61 (q, J = 6.3 Hz, 2H), 3.47 (t, J = 6.3 Hz, 2H). 13C NMR (151 
MHz, DMSO-d6) δ 166.99, 153.70, 144.71, 144.02, 136.66, 130.59, 128.98, 128.24, 127.34, 127.15, 
126.39, 125.19, 124.88, 124.78, 124.07 (d, J = 6.3 Hz), 123.10, 117.39, 117.34, 61.90 – 59.65 (m), 45.88, 
38.01. 31P NMR (243 MHz, DMSO) δ 17.26. 19F NMR (282 MHz, DMSO) δ 4.13.
4.20. 2-Nitrobenzyl-N-(4-biotinamido-phenyl)-P-vinyl phosphonamidate
NH
HN
S
O
N
H
O
HN
P O
O2N
O
H
H
N-(4-azidophenyl) biotinamide was synthesized as previously described.2 The above stated compound 
was synthesized according to the general procedure 3 from 302 mg Di(2-nitrobenzyl) vinylphosphonite 
borane (1b) (0.803 mmol, 1.50 eq.) in DMF. The crude phosphonamidate was purified by flash column 
chromatography (12-15% MeOH in CH2Cl2) and obtained as yellowish solid. (150 mg, 0.268 mmol, 
50.1%)
1H NMR (300 MHz, DMSO-d6) δ 9.76 (s, 1H), 8.13 (d, J = 8.1 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.85 – 7.73 
(m, 2H), 7.69 – 7.54 (m, 1H), 7.40 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 6.61 – 5.99 (m, 5H), 5.37 
(qd, J = 14.8, 7.4 Hz, 2H), 4.30 (dd, J = 7.8, 4.9 Hz, 1H), 4.22 – 4.00 (m, 1H), 3.15 – 3.01 (m, 1H), 2.82 
(dd, J = 12.4, 5.1 Hz, 1H), 2.58 (d, J = 12.4 Hz, 1H), 2.25 (t, J = 7.3 Hz, 2H), 1.75 – 1.26 (m, 6H). 13C NMR 
(75 MHz, DMSO-d6) δ 171.02, 163.10, 147.09, 136.39, 135.17, 134.63, 133.42, 133.00 (d, J = 7.7 Hz), 
129.84, 129.44, 128.97, 125.18, 120.54, 118.24 (d, J = 6.6 Hz), 62.45 (d, J = 4.1 Hz), 61.41, 59.56, 55.78, 
48.97, 45.79, 36.44, 28.54 (d, J = 12.6 Hz), 25.56. 31P NMR (122 MHz, DMSO) δ 16.30. HRMS for 
C25H31N5O6PS+ [M+H]+ calcd.: 560.1727, found: 560.1725.
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4.21. Synthesis of RCM-BCL9-Nle peptide 7
AcLSQEQLEHRERSL TLR IQRNMLFNH2
The RCM-BCL9 peptide was synthesized in a 0.05 mmol scale on a Rink Amide Resin with a loading of 
0.78 mmol/g. Until the first olefinic amino acid the synthesis was carried out on a PTI synthesizer with 
single couplings (5 eq. amino acid for 40 minutes). Olefinic amino acids (2 eq.) were coupled manually 
with HATU (2eq.) and DIPEA (4 eq.) for two hours and full conversion was checked by trial cleavage. 
The three amino acids in between the olefinic ones were coupled manually (5 eg. for 40 minutes) all 
amino acids following the olefinic ones were coupled in double coupling steps with five equivalents for 
40 minutes. After the second olefinic amino acids the synthesis was resumed by automated SPPS on 
the PTI synthesizer. The N-terminus was acetylated by treatment with a lutidine:acetic anhydride:DMF 
(5:6:89;v:v:v) for 10 minutes. To generate the hydrocarbon staple the resin was incubated with a 
10 mM solution of bis(tricyclohexylphosphine)-benzylidene ruthenium (IV) (1st generation Grubb’s 
catalyst) in 1,2-dichloroethane for one hour twice.
The final cleavage from resin was achieved by incubation with a mixture of TFA:TIS:H2O 
(95:2.5:2.5;v:v:v) for two hours followed by precipitation in cold diethylether. The crude peptide was 
purified by preparative reverse phase C18 HPLC and the product was gained as white powder (14 mg, 
3.9 µmol, 7.8% yield).
HRMS: m/z: 1019.5471 [M+3H]3+ (calc. 1019.5881 m/z).
4.22. Synthesis of FAM RCM-BCL9-Nle peptide 7-CF
LSQEQLEHRERSL TLR IQRNMLFNH2
O
N
H
O
OO OH
HOOC
The FAM-RCM-BCL9 peptide was synthesized in a 0.05 mmol scale on a Rink Amide Resin with a loading 
of 0.78 mmol/g. Until the first olefinic amino acid the synthesis was carried out on a PTI synthesizer 
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with single couplings (5 eq. amino acid for 40 minutes). Olefinic amino acids (2 eq.) were coupled 
manually with HATU (2eq.) and DIPEA (4 eq.) for two hours and full conversion was checked by trial 
cleavage. The three amino acids in between the olefinic ones were coupled manually (5 eg. for 40 
minutes) all amino acids following the olefinic ones were coupled in double coupling steps with five 
equivalents for 40 minutes. After the second olefinic amino acids the synthesis was resumed by 
automated SPPS on the PTI synthesizer and Fmoc-β-Ala was coupled N-terminally. To generate the 
hydrocarbon staple the resin was incubated with a 10 mM solution of bis(tricyclohexylphosphine)-
benzylidene ruthenium (IV) (1st generation Grubb’s catalyst) in 1,2-dichloroethane for one hour twice. 
Finally the peptide was fluorescein labeled by coupling 5-(6)-carboxyfluorescein succinimidyl ester (2 
eq.) with DIPEA (3 eq.) as activating base for two hours.
The final cleavage from resin was achieved by incubation with a mixture of TFA:TIS:H2O 
(95:2.5:2.5;v:v:v) for two hours followed by precipitation in cold diethylether. The crude peptide was 
purified by preparative reverse phase C18 HPLC and the product was gained as yellow powder (16 mg, 
4.02 µmol, 8.0% yield).
HRMS: m/z: 1148.5795  [M+3H]3+ (calc. 1148.6129 m/z); 861.6882 [M+4H]4+ (calc. 861.7117 m/z).
4.23. General procedure 4 for synthesis of BCL9-peptides
The BCL9 peptide was synthesized in a 0.1 mmol scale on a Rink Amide Resin with a loading of 
0.78 mmol/g. The synthesis was carried out on a PTI synthesizer with a single coupling of each standard 
amino acid (5 eq. amino acid for 40 min). Fmoc-Azidohomoalanin (2 eq.) was coupled with HATU (2 
eq.) for four hours. Fmoc deprotection was accomplished by treating the peptide with 20% piperidine 
in DMF for 3 minutes two to three times according to UV read out. N-terminal acetylation was done 
by incubation with a mixture of lutidine:acetic acid:DMF (6%:5%:89%;v;v;v) for 10 minutes. Final 
cleavage from solid support was carried out by incubating the resin with 4 ml of a TFA:TIS:H2O 
(95:2.5:2.5) mixture for two hours and precipitated in cold diethylether. 
4.24. Synthesis of BCL9-Nle-Aha-LCys peptide 8a
AcLSQEQLEHRERSL TLR IQRNIeLFNH2
N3
SH
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The Peptide was synthesized according to general procedure 4. The crude peptide was purified by 
preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, 
water (0.1%TFA)/MeCN (0.1%TFA)). The product 8a was gained as white powder (35 mg as TFA-salt, 
9.7 µmol, 9.7 % yield). 
HRMS: m/z:  1012.5317 [M+3H]3+ (calc. 1012.5532 m/z).
4.25. Synthesis of BCL9-Nle-Aha-DCys 8b
AcLSQEQLEHRERSL TLR IQRNIeLFNH2
N3
SH
The Peptide was synthesized according to general procedure 4. The crude peptide was purified by 
preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, 
water (0.1%TFA)/MeCN (0.1%TFA)). The product was gained as white powder (50.5 mg as TFA-salt, 
14.0 µmol, 14 % yield). 
HRMS: m/z: 1012.5383 [M+3H]3+ (calc. 1012.5532 m/z).
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4.26. Synthesis of FAM-BCL9-Nle-Aha-DCys peptide (8b-CF)
LSQEQLEHRERSL TLR IQRNIeLFNH2
N3
SH
O
N
H
O
OO OH
HOOC
The Peptide was synthesized according to general procedure 4. After the final regular amino acid 
coupling and Fmoc-deprotection, Fmoc-β-Alanine (5 eq.) was coupled manually with HATU (5 eq.) and 
DIPEA (10 eq.) as activating base for one hour. After Fmoc-deprotection 5-(6)-carboxyfluorescein 
succinimidyl ester (2 eq.) was coupled with DIPEA (3 eq.) as activating base for four hours. Final 
cleavage from solid support was carried out by incubating the resin with 4 ml of a TFA:TIS:H2O 
(95:2.5:2.5) mixture for two hours and precipitated in cold diethylether. The crude peptide was purified 
by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 
10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product was gained as yellow powder (42.0 mg as TFA-
salt, 10.2 µmol, 10.2 % yield). 
HRMS: m/z:  1141.5472 [M+3H]3+ (calc. 1141.5780 m/z); 856.4244 [M+4H]4+ (calc. 856.4355 m/z).
4.27. General procedure 5 for the Staudinger induced peptide cyclization
Vinyl magnesium bromide in THF (1 M, 2 ml, 2 mmol, 1 eq.) was cooled to -78°C in a flame dried schlenk 
flask and diethylchlorophosphite (0.286 ml, 2 mmol, 1 eq.) was added. The solution was stirred for 10 
minutes at -78°C and let warm to room temperature and stirred for another 90 minutes. The full 
consumption of starting material was confirmed by 31P-NMR and used as crude in the following 
Staudinger reaction with an azido-peptide.
Purified azido-peptide was dissolved in DMSO at a 3 mM concentration and dried in a flame-dried flask 
for one hour prior to adding five equivalents of bisethoxyalkene-phosphonite (volume according to 
percentage of product determined by NMR). After the reaction mixture was stirred over night at room 
temperature and full conversion was observed by UPLC-UV/MS, water was added and the reaction 
mixture directly lyophilized. The crude product was purified by preparative HPLC. 
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4.28. Synthesis of cyclic-BCL9-Nle-Aha-LCys peptide 9a
AcLSQEQLEHRERSL TLR IQRNIeLFNH2
HN
P
O
OEt S
Peptide 8a (15 mg, 4.16 µmol, 1eq.) was reacted according to the general procedure 5. The crude 
peptide was purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 7a was gained as white 
powder (7 mg as TFA-salt, 1.89 µmol, 45.4 % yield). 
HRMS: m/z: 1043.1953 [M+3H]3+ (calc. 1043.2292 m/z).
4.29. Synthesis of Cyclic-BCL9-Nle-Aha-DCys peptide synthesis 9b
AcLSQEQLEHRERSL TLR IQRNIeLFNH2
HN
P
O
OEt S
Peptide 8b (34 mg, 9.43 µmol, 1eq.) was reacted according to the general procedure 5. The crude 
peptide was purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 8b was gained as white 
powder (15 mg as TFA-salt, 4.06 µmol, 43.1 % yield). 
HRMS: m/z: 1043.2085 [M+3H]3+ (calc. 1043.2292 m/z).
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4.30. FAM labeled cyclic-BCL9-Nle-Aha-DCys peptide synthesis (9b-CF)
LSQEQLEHRERSL TLR IQRNIeLFNH2
HN
P
O
OEt S
O
N
H
O
OO OH
HOOC
Peptide 8b-CF(21 mg, 5.1 µmol, 1eq.) was reacted according to the general procedure 5. The crude 
peptide was purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 8b-CF was gained as 
yellow powder (12 mg as TFA-salt, 2.9 µmol, 56.9 % yield). 
HRMS: m/z:  1172.1996 [M+3H]3+ (calc. 1172.2539 m/z); 879.4191 [M+4H]4+ (calc. 879.4424 m/z).
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4.31. Alkylated-BCL9-Nle-Aha-LCys peptide synthesis 10
AcLSQEQLEHRERSL TLR IQRNIeLFNH2
N3
S
O
NH2
Peptide 8a (43.2 mg, 12.0 µmol) was incubated with iodoacetamide (22.2 mg, 120 µmol, 10eq.) in a 
mixture of ammoniumbicarbonate buffer and acetonitrile (6:2) with a final pH of 8.5. After one hour 
the mixture was purified by preparative HPLC 0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 
min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product was gained as white powder (25 mg as 
TFA-salt, 6.8 µmol, 57 % yield). 
HRMS: m/z:  1031.5342 [M+3H]3+ (calc. 1031.5604 m/z).
4.32. Synthesis of cyclic-benzylphosphonamidate-BCL9-Nle-Aha-DCys peptide 13
AcLSQEQLEHRERSL TLR IQRNIeLFNH2
HN
P
O
OBn S
Bis(diisopropylamino) chlorophosphine (267 mg, 1 mmol, 1 eq.) was given into a flame dried schlenk 
flask and dried under vacuo for 30 minutes. Vinyl magnesium bromide in THF (1 M, 1.1 ml, 1.1 mmol, 
1.1 eq.) was added at -78°C and the reaction mixture was stirred for 10 minutes. Then the reaction was 
let to warm up to room temperature and stirred for another 30 minutes. First tetrazole in acetonitrile 
(0.45 M, 5.56 ml, 2.5 mmol, 2.5 eq.) was added to the reaction mixture followed by benzylalcohol (0.26 
ml, 2.5 mmol, 2.5 eq.). The reaction was stirred for 16 hours and used further as crude after 
confirmation of product formation via 31P-NMR (product at 164.2 ppm). Peptide 8b (15 mg, 4.04 µmol, 
1eq.) was solubilized in DMSO and reacted with the crude phosphonite (24.2 µmol, 6 eq.) in a final 
concentration of 10 mM. The reaction mixture was stirred for 16 hours at 40°C and the crude peptide 
was purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 
5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 13 was gained as white powder (5 
mg as TFA-salt, 1.33 µmol, 32.9 % yield). HRMS: m/z:  1063.8917 [M+3H]3+ (calc. 1063.9010 m/z).
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4.33. Synthesis of FAM labeled cyclic- benzylphosphonamidate-BCL9-Nle-Aha-DCys peptide (13-
CF)
LSQEQLEHRERSL TLR IQRNIeLFNH2
HN
P
O
OBn S
O
N
H
O
OO OH
HOOC
Bis(diisopropylamino) chlorophosphine (267 mg, 1 mmol, 1 eq.) was given into a flame dried schlenk 
flask and dried under vacuo for 30 minutes. Vinyl magnesium bromide in THF (1 M, 1.1 ml, 1.1 mmol, 
1.1 eq.) was added at -78°C and the reaction mixture was stirred for 10 minutes. Then the reaction was 
let to warm up to room temperature and stirred for another 30 minutes. First tetrazole in acetonitrile 
(0.45 M, 5.56 ml, 2.5 mmol, 2.5 eq.) was added to the reaction mixture followed by benzylalcohol (0.26 
ml, 2.5 mmol, 2.5 eq.). The reaction was stirred for 16 hours and used further as crude after 
confirmation of product formation via 31P-NMR (product at 164.2 ppm). Peptide 8b-CF (22 mg, 5.93 
µmol, 1eq.) was solubilized in DMSO and reacted with the crude phosphonite (35.6 µmol, 6 eq.) in a 
final concentration of 10 mM. The reaction mixture was stirred for 16 hours at 40°C and the crude 
peptide was purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 13-CF was gained as 
yellow powder (3.1 mg as TFA-salt, 0.75 µmol, 12.6 % yield). 
LRMS: m/z: 1193.11 [M+3H]3+ (calc. 1192.9258 m/z).
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4.34. Linear-(R10)-Aha-Cys 15
O
H
N
N3
HS
O
O
O
2
H
N
O
NH2
R10H2N
The cyclic-(R10)-azido peptide was synthesized in a 0.1 mmol scale on a Rink Amide Resin with a 
loading of 0.78 mmol/g. The synthesis was carried out on a PTI synthesizer with double couplings of 
each amino acid (5 eq. amino acid for 40 min) in DMF apart from Fmoc-azidohomoalanin, which (2eq.) 
was coupled with HATU (2 eq.) for four hours in presence of NMM (4 eq.) as activating base.  SPPS was 
ending with an Fmoc deprotection step to yield the free N-terminal amine. Final cleavage from resin 
was accomplished in two cleavage steps. First the peptide was cleaved from resin with a mixture of 
TFA:TIS:H2O (92:4:4;v:v:v) for 2.5 hours, followed by a second cleavage of not fully cleaved protecting 
groups with TFA:TIS:DTT:Thioanisole (88:2:2:8;v:v:v:v) for one hour. The crude peptide was purified by 
preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, 
water (0.1%TFA)/MeCN (0.1%TFA)). The product 15 was gained as white powder (78 mg as TFA-salt, 
24.1 µmol, 24.1 % yield). 
HRMS: m/z:  700.0462 [M+3H]3+ (calc. m/z: 700.0908).
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4.35. Cyclic-R10-Staudinger-Macrocycle 16
O
H
N
HN
S
O
O
O
H2N
2
P
O
OEt
H
N
O
NH2
R10
Peptide 15 was reacted according to general procedure 5 with the deviation that the reaction was 
carried out at 50°C instead of room temperature. The crude peptide was purified by preparative 
reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)). The product 16 was gained as white powder (10.7 mg as TFA-salt, 3.2 
µmol, 26.8 % yield). 
HRMS: m/z: 730.7141 [M+3H]3+ (calc. 730.7668 m/z).
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4.36. Alkyne-Cyclic-R10-Staudinger-Macrocycle 18
O
H
N
HN
S
O
O
O
N
H
2
O
NH
P
O
O
P
O
OEt
H
N
O
NH2
R10
O
H
N
HN
S
O
O
O
H2N
2
P
O
OEt
H
N
O
NH2
R10
O
NH
P
O
O
NHS
16
17
18
3.0 eq.
4.5 eq. DIPEA
DMF, rt, 1h
Peptide 16 (20 mg, 6 µmol, 1 eq.) solubilized in DMF (400 µl, c = 15 mM) was incubated with NHS-
phosphonamidate alkyne 17 (6.3 mg, 18.0 µmol, 3eq.) in presence of DIPEA (4.68 µl, 26.9 µmol, 4.5 
eq.) for one hour. After confirmation of product formation by LC-MS, the crude was diluted with water 
and purified by preparative HPLC. The product 18 was gained as white powder (9.8 mg as TFA salt, 2.8 
µmol, 46 %yield).
LRMS: m/z: 809.0552 [M+3H]3+ (calc. 809.1134 m/z).
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5. NMR spectra
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Diphenyl vinylphosphonite borane (1c)
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Bis(2,2,2-trifluoroethyl) vinylphosphonite borane (1d)
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Ethyl-N-phenyl-P-vinylphosphonamidate (4a) 
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Ethyl-N-(3-phenyl-propyl)-P-vinyl-phosphonamidate (5a)
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2-Nitrobenzyl-N-phenyl-P-vinylphosphonamidate (4b)
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2-Nitrobenzyl-N-(3-phenyl-propyl)-P-vinylphosphonamidate (5b)
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phenyl-N-phenyl-P-vinylphosphonamidate (4c)
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Phenyl-N-(3-phenyl-propyl)-P-vinylphosphonamidate (5c)
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2,2,2-trifluoroethyl-N-phenyl-P-vinylphosphonamidate (4d)
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2,2,2-trifluoroethyl-N-(3-phenyl-propyl)-phenyl-P-vinyl-phosphonamidate (5d)
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Ethyl-N-phenyl-P-(2-(glutathionyl-thio)ethyl)-phosphonamidate
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2,2,2-trifluoroethyl-N-phenyl-P-(2-(glutathionyl-thio)ethyl)-phosphonamidate
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31P NMR (243 MHz, D2O) δ33.70.
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19F NMR (282 MHz, D2O) δ2.60, 1.91.
Trifluorethyl-N-(4-(2,5-dioxo-1-pyrrolidinyl)oxy-carbonyl-phenyl)-P-vinylphosphonamidate
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31P NMR (122 MHz, CDCl3) δ17.53.
66
-170-150-130-110-90-70-50-30-101030507090110130150170
f1 (ppm)
-5000
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
55000
MAK-V-075.190409.12.fid
2.
88
19F NMR (282 MHz, CDCl3) δ2.88.
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13C NMR (151 MHz, DMSO-d6) δ166.99, 153.70, 14 .71, 144.02, 136.6 , 130.59, 128.98, 128.24,
127.34, 127.15, 126.39, 125.19, 124.88, 124.78, 124.07 (d), 123.10, 117.39, 117.34, 61.90 – 59.65 (m),
45.88, 38.01.
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31P NMR (243 MHz, DMSO)δ17.26.
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19F NMR (282 MHz, DMSO)δ4.13.
2-Nitrobenzyl-N-(4-biotinamido-phenyl)-P-vinyl phosphonamidate
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6.2.2. Scope of the SPhR with vinylphosphonites and further variation of the 
phosphonamidate ester residue  
In the previous chapter, only two small molecule azides without any functional groups attached have 
been used in the SPhR with vinylphosphonites. Furthermore, protein modification reactions were 
solely performed with cetuximab. To broaden the scope of vinylphosphonamidates in terms of 
applicability for protein modifications, the aim of this research project was to synthesize further 
vinylphosphonites and –phosphonamidates with increased complexity to facilitate thiol addition to 
various proteins with different functionalities attached to the O- and the N-substituent. 
6.2.2.1. Synthesis of various vinylphosphonamidates 
In addition to the two O-ethyl-vinylphosphonamidate derivatives that have been described in the 
previous chapter, more azides have been used in the one-pot synthesis protocol, starting from diethyl 
chlorophosphite 47 and vinylmagnesium bromide followed by azide addition and hydrolysis. The 
desired vinylphosphonamidates 48-51 were isolated in good to moderate overall yields (Scheme 54). 
It could be shown that carboxylic acids are tolerated in the reaction and electron-rich as well as 
electron-poor azides yield the desired vinylphosphonamidates. With compound 48, a 
vinylphosphonamidate with increased water solubility was synthesized that can be also further used 
as modular building block to attach the vinylphosphonamidate moiety to other functional amine 
containing molecules via amide coupling.  
  
Scheme 54: One-Pot-Procedure for the synthesis of vinylphosphonamidates via alkylation of diethyl chlorophosphite (47), followed by SPhR 
with different azides. Stated are isolated yields.*  
To further vary the phosphonamidate ester residue of vinylphosphonamidates, several 
vinylphosphonites, carrying different functional groups were synthesized. Since some alcohols are not 
compatible with subsequent addition of the highly reactive vinylmagnesium bromide reagent, the 
vinylphosphonites described in this chapter were synthesized, starting with vinylation of 
bis(diisopropylamino)chlorophosphine (2) followed by tetrazole mediated exchange of the 
diisopropylamine of 52 with the desired alcohol and borane protection, as described in the previous 
                                                          
* Compound 50 was synthesized and characterized by Jan Ole Kaufmann as part of his internship in the Hackenberger laboratory under the 
supervision of the author 
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chapter. Among others, it was possible to synthesize light cleavable vinylphosphonites carrying 
terminal alkynes with electron withdrawing 2-nitrobenzyl substituents (53 and 54). Other than that, it 
could be shown that electron-rich substituents such as 4-hydroxy phenyl in 55 as well as electron 
withdrawing substituents in 56 are well tolerated in the phosphonite synthesis (Scheme 55).  
  
Scheme 55: One-Pot-Procedure for the synthesis of various borane protected vinylphosphonites from 
bis(diisopropylamino)chlorophosphine. Stated are isolated yields.  
Next, the synthesized phosphonites were applied to SPhR with phenyl azide after borane deprotection 
with DABCO as described in the previous chapter. All of the tested phosphonites reacted smoothly 
under the tested conditions and could be isolated in decent to moderate yields. Electron withdrawing 
phosphonite-substituents were as well tolerated as electron donating groups.  
 
Scheme 56: SPhR with various phosphonites after borane deprotection with different phenyl azides. Reactions with phenyl azide were carried 
out, peptides were reacted in THF/DMF mixtures to ensure solubility. Stated are isolated yields 
Compound 61 was synthesized to generate a polar water-soluble vinylphosphonamidate diol after 
removal of the ketal. However, all attempts hydrolyze the acetonide under acidic conditions and with 
acidic cation exchange resins failed due to decomposition of the starting material. The functionality of 
the substituents of the compounds 59 and 60 will be further evaluated in the next chapter.  
6.2.2.2. Vinylphosphonamidates modification of proteins.  
Encouraged by the decent reactivity of vinylphosphonamidates towards glutathione in aqueous buffer 
and the successful modification of antibodies via reduction and alkylation protocols, described in 
chapter 6.1.1, the modification of cysteine residues on other proteins was evaluated in the next step. 
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At first, the aforementioned eGFP C70M S147C, carrying a single accessible cysteine residue was 
incubated at room temperature with the water-soluble phosphonamidate 48 in basic buffer. The 
reaction mixture was analyzed by MALDI-TOF/MS after overnight incubation, and an indicative shift of 
255 dalton with respect to the starting could be observed after 16 hours (Figure 21). However, in 
contrast to the experiments with ethynylphosphonamidates described in chapter 6.1.1 full conversion 
of the eGFP C70M S147C could not be achieved, even with prolonged reaction times and strong basic 
conditions of pH 9. This might be explained by slower reaction kinetics of O-ethyl-
vinylphosphonamidates in the reaction with cysteine, as described in chapter 6.2.1.  
 
 
Figure 21: Addition of the vinylphosphonamidate 48 to eGFP C70M S147C. MALDI-TOF/MS for the eGFP C70M S147C starting material (light 
blue) and the phosphonamidate adduct (cyan). Spectra are normalized. 
To overcome the issue of low conversions of cysteine residues on proteins, either the 
phosphonamidate equivalents with respect to the protein could be increased or the reactivity of the 
vinylphosphonamidates by attaching electron withdrawing O-substituent, as demonstrated in chapter 
6.2.1. To circumvent problems arising from limited solubility of the phosphonamidate at higher 
concentrations, all the following protein modification reactions were carried out using 
vinylphosphonamidates with electron-deficient O-substituents. 
For further labelling experiments of eGFP, a far-red-fluorescent Cy5-vinylphosphonamidate 63 that can 
be detected by in-gel fluorescence[336] and has been applied to cellular- and in-vivo imaging[337] was 
synthesized from Cy5-azide 45 and phosphonite 62 (Figure 22a). The desired 2-nitrobenzyl substituted 
Cy5 vinylphosphonamidate could be isolated by column chromatography and protein reactivity was 
probed with eGFP C70M S147C (Figure 22b). 
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Figure 22: Synthesis of an O-2-nitrobenzyl-Cy5-vinylphosphonamidate 63 and labelling of eGFP C70MS147C. a) Synthetic scheme for the 
synthesis of 63 via SPhR. b) Addition of 63 to two different eGFP mutants. Gel analysis with fluorescent readout; lane 1: Reaction with eGFP 
C70M (no addressable cysteine); lane 2: Reaction with eGFP C70M S147C; lane 3: eGFP C70M S147C starting material.  
In gel fluorescence with excitation at 635 nm revealed successful labelling of eGFP C70M S147C. To 
proof the chemoselectivity of the vinylphosphonamidate labelling for cysteine residues, the reaction 
was carried out with the eGFP mutant C70M that doesn’t carry any addressable cysteine.* Under the 
tested conditions at pH 9.0, an excellent selectivity for cysteine residues was observed, since no 
fluorescence signal was detected even after 16 hours of incubation (Figure 22c).  
6.2.2.3. Selectivity of vinylphosphonamidates for cysteine residues  
In chapter 6.2.1 it was shown that O-trifluoroethyl substituted vinylphosphonamidates can cross-react 
with lysine residues, when a large excess is used in the reaction. In order to elucidate the dependence 
of this phenomenon on the nature of the phosphonamidate ester substituent, modification of 
cetuximab with a large excess of 100 equivalents of the O-phenyl substituted phosphonamidate 64 
was performed, similar as described in chapter 6.2.1, employing the protocol of reducing and alkylating 
the interchain disulfide bonds.[70a] Cysteine selectivity was afterwards investigated by MS/MS analysis 
after trypsin digestion of the modified antibody with and without prior reduction with DTT.†  
                                                          
* eGFP C70M was designed and cloned by Dr. Dominik Schumacher as part of his PhD thesis. Expression was performed by Kristin Kemnitz-
Hassanin. 
† MS/MS analysis was performed by Martin Penkert as part of his PhD thesis and Dr. Michael Schümann. 
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Figure 23: Cetuximab modification with 64, followed by trypsin digestion and LC-MS/MS analysis. Shown are the results of the Mascot search 
on cetuximab’s heavy chain after incubation with 100 eq. of 64 with (top) and without (bottom) prior reduction of the disulfide bonds. 
Identified peptides are highlighted in grey. Amino acid residues modified with 64 are highlighted in red. Oxidation of methionine, alkylation 
of cysteine via iodoacetamide and the phosphonamidate on Y, S, T, C, K, H & R were searched as variable modifications. 
Two phosphonamidate modified sites on the heavy chain of cetuximab on Cys 146 and Cys 264 could 
be identified and confirmed via HCD-MS/MS. Those two cysteines were only modified after reduction 
and alkylation with 64 and no modification on any other nucleophilic amino acid was found without 
prior reduction (Figure 23). This observation suggests that the cross-reactivity of other nucleophilic 
side chains is lower for the O-phenyl-substituted vinylphosphonamidates when compared to the O-
trifluoroethyl substituent that modified several lysine sides when used in a large excess of 100 
equivalents. It should be noted that a comparison to the experiment described in chapter 6.2.1 is 
difficult since labelling was performed here at 4 °C and an antibody concentration of 1.5 mg/ml 
whereas the previous experiment was performed at room temperature and increased antibody 
concentration of 5 mg/ml. However, the experiments described here clearly show that a highly 
selective labelling of cysteine residues with O-phenyl-vinylphosphonamidates is possible under the 
conditions applied in this experiment.  
6.2.2.4. Vinylphosphonamidates for light cleavable triple conjugations  
The substituents of the phosphonites 53 and 54 allow for the attachment of an additional functionality 
to the terminal alkyne via CuAAC to the conjugated protein, similar as described in chapter 6.1.2.3. The 
2-nitrobenzyl substituent furthermore facilitates a triggered release of this substituent by light 
irradiation[338] and acts as an electron-withdrawing substituent that increases the reaction rate of the 
thiol addition. Release of the phosphonamidate ester residue to liberate a phosphonamidic acid has 
been shown to increase the lability of the P-N-bond.[322] This would cause a detachment of both 
functionalities, attached to the O- and the N-substituent of the phosphonamidate, from the protein. 
To overcome this limitation, a second substituent has been synthesized with an additional 
no reduction: Sequence coverage: 44% 
1   QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALT 
101 YYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY 
201 ICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 
301 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL 
401 DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
Reduction: Sequence coverage: 65% 
1   QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALT 
101 YYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY 
201 ICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 
301 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL 
401 DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
Results and Discussion 
 
 
248 
 
hydroquinone moiety between the 2-nitrobenzyl group and the phosphonamidate for applications 
were cleavage of both substituents is undesired (Scheme 57). Here, light mediated cleavage would 
yield a stable O-4-hydroxy-phenyl phosphonamidate similar to compound 58 that has been described 
in chapter 6.2.2.1.  
 
Scheme 57: 2-Nitrobenzyl Phosphonamidate ester substituents modified with terminal alkynes facilitate a light cleavable triple conjugation. 
Principle of the attachment and light mediated release. Direct attachment of the 2-nitrobenzyl group to the phosphonamidate facilitates a 
cleavage of both modifications from the protein whereas the hydroquinone spacer (red) releases only the alkyne handle.  
In order to test the possibility to incorporate the two different substituents into phosphonamidates 
with subsequent modification of a protein’s cysteine residue, a model peptide was reacted with the 
two phosphonites 53 and 54 after borane deprotection. The model peptide 65 was chosen due to its 
good water solubility and the ability to induce a gel-shift of a protein in a SDS-PAGE analysis. The two 
desired peptides could be isolated by preparative HPLC. Since the peptide contained unprotected 
alcohols, amines and carboxylic acids, this result underlines again a good functional group tolerance of 
the SPhR with vinylphosphonamidates. (Figure 24a). 
Next, the ability of the peptides to modify cysteine residues on proteins was evaluated. For this, a 
single cysteine containing ubiquitin mutant ubiquitin G75C was chosen as a model protein, which was 
incubated with 25 equivalents of the peptides in basic buffer at 4 °C overnight and the conjugation 
mixture was analyzed by SDS/PAGE (Figure 24b and c). A conversion of approximately 60% could be 
observed under these conditions for both of the peptides, estimated by the intensities of the two 
protein bands of starting material and product.  
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Figure 24: Synthesis of protein-peptide conjugates with alkyne modified 2-nitrobenzyl substituted phosphonamidate. a) Installation of the 
two different phosphonamidate moieties on an azide-containing model peptide. b) Synthetic scheme of the attachment of 66 and 67 to 
ubiquitin G75C. c) Western blot analysis of the reaction mixtures of ubiquitin G75C with 66 and 67. 
With the peptide-protein conjugate ubiquitin-66 in hands, CuAAC with a biotin azide was performed 
to attach a cleavable immobilization handle to the protein construct. Successful cycloaddition was 
confirmed by intact protein MS, which showed complete consumption of the starting material. Next, 
immobilization of the peptide-protein-biotin constructs on streptavidin beads followed by light 
irradiation was attempted (Figure 25). Incubation of the conjugation mixture that still contained 
unmodified protein with streptavidin beads and analysis of the supernatant demonstrated significantly 
reduced amount of conjugated ubiquitin, due to immobilization of the clicked peptide conjugate. This 
is further confirmed by the observation that a protein that is shifted to higher masses is released after 
washing and boiling of the beads. Next, the resin was irradiated for 20 minutes in PBS and the 
supernatant subjected to SDS/PAGE analysis. It was observed that this irradiation releases a protein 
with a gel shift close to the starting material, whereas the un-irradiated, boiled beads only showed a 
single band that is shifted towards higher masses.  
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Figure 25: Ubiquitin-66 can be modified with a biotin azide via CuAAC, immobilized on streptavidin beads and released by UV-irradiation. a) 
Scheme for the attachment of a biotin azide, immobilization and photorelease. b) SDS/PAGE analysis of the different fractions of the pull-
down experiment. All steps were performed in PBS.  
The fact that the protein is released from the beads by UV-irradiation suggests a cleavage of the biotin 
moiety and the gel shift points towards an additional loss of the peptide from the protein, most 
probably due to P-N-hydrolysis. This shift is not observed in the boiled beads fraction, suggesting that 
the peptide is still attached, which underlines the hypothesis of simultaneous P-O- and P-N-hydrolysis 
by UV-irradiation. These experiments demonstrate that the attachment of a peptide to a protein with 
an additional light cleavable CuAAC-handle at a vinylphosphonamidate is in principle possible. The 
observations on the behavior after light irradiation can be explained by the mechanism that is 
proposed in scheme 56. Further investigations with the hydroquinone spacer have to be undertaken 
to provide further evidence for this proposed principle.  
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6.3. Ethynylphosphonamidates for the cysteine-selective synthesis of Antibody-
Drug-Conjugates 
Requirements on linker technology for the attachment of cytotoxic drugs to antibodies to generate 
ADCs that effectively deliver the payload to the malignant cell are exceptionally high. The conjugation 
strategy determines factors such as linkage stability during blood circulation, overall hydrophobicity 
that is added to the antibody and homogeneity of the antibody conjugates that are important for the 
safety profile of the final product. As an alternative to conjugation methods that rely on elaborative 
antibody engineering, drug attachment to native antibodies via reduction of the interchain disulfide 
bonds and alkylation of the liberated cysteine residues is a very attractive strategy (see chapter 
4.3.1.3). Due to the remarkable linkage stability that has been described for cysteine conjugates in 
chapter 6.1 and 6.2, the aim of the work described in this chapter was to apply unsaturated 
phosphonamidates to the construction of ADCs. It was anticipated that phosphonamidates linkages 
facilitate an excellent linkage stability during blood circulation. Furthermore, the ability to vary the 
phosphonamidate’s O-substituent was exploited to improve linker properties in terms of 
hydrophilicity. Ethynylphosphonamidates were used, since they combine superior selectivity for 
cysteine with faster reaction kinetics when directly compared to their vinyl counterparts. The following 
main goals were defined to evaluate the ethynylphosphonamidate-cysteine conjugation reaction as a 
general tool for the synthesis of efficacious ADCs, starting from native unengineered antibodies: 
a) Synthetic attachment of the phosphonamidate moiety to cytotoxic drugs and incorporation of 
hydrophilic O-substituents to increase water solubility of the linker-drug constructs. 
b) Development of synthesis protocols for the construction of ADCs from native antibodies and 
ethynylphosphonamidates via disulfide reduction and alkylation strategies. 
c) Evaluation of the phosphonamidate-linked ADCs in terms of linkage stability during blood 
circulation, selective cytotoxic activity on antigen positive cell lines in vitro and efficacy in 
tumor xenograft mouse models in vivo. 
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6.3.1. Synthesis and biochemical in vitro and in vivo evaluation of phosphonamidate-
linked Antibody-Drug-Conjugates 
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Figure 26: Ethynylphosphonamidates facilitate straightforward synthesis of ADC via reduction and alkylation of the interchain disulfide bonds 
of native antibodies. Phosphonamidate-linked ADC are stable in rat serum, and efficacious in tumor xenograft mouse models.  
 
Abstract 
Requirements for novel bioconjugation reactions for the synthesis of Antibody-Drug-Conjugates 
(ADCs) are exceptionally high, since selectivity of the conjugation as well as stability and 
hydrophobicity of linkers and payloads drastically influence the performance and safety profile of the 
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final product. Herein we describe Cys-selective ethynylphosphonamidates as new reagents for the 
rapid generation of efficacious ADCs from native non-engineered monoclonal antibodies, applying a 
simple one-pot reduction and alkylation protocol. Ethynylphosphonamidates can be easily substituted 
with hydrophilic residues, giving rise to electrophilic labelling reagents with tunable solubility 
properties. We demonstrate that ethynylphosphonamidate-linked ADCs have excellent properties for 
next generation antibody therapeutics in terms of serum stability and in vivo antitumor activity. 
 Responsibility assignment 
Christian P. R. Hackenberger designed and conceived the project. Heinrich Leonhardt, Jonas Helma 
and Dominik Schumacher designed and conceived the in vitro and in vivo efficacy studies. The author 
designed the synthetic strategies for the attachment of phosphonamidates to the drug molecules and 
synthesized and characterized all phosphonites, phosphonamidates, drug-linker constructs and 
synthetic precursors thereof. The author furthermore developed the antibody-drug conjugation 
protocols, synthesized, purified and characterized all ADCs and conceived and performed the DAR 
analysis studies as well as the serum stability analyses. Andreas Stengl expressed and purified 
trastuzumab and performed all cellular imaging and cell-based proliferation assays. Philipp Ochtrop 
performed the solubility assay and synthesized drug-linker constructs. Marcus Gerlach performed cell 
viability assays and size-exclusion analyses of the ADCs and developed the ADC concentration 
determination. Tina Stoschek expressed and purified brentuximab. Martin Penkert and Eberhard 
Krause performed intact protein MS of the trastuzumab conjugates. The author wrote the manuscript 
supported by Christian P. R. Hackenberger, Dominik Schumacher, Philipp Ochtrop and Andreas Stengl. 
Summary of content  
Cysteine selective ethynylphosphonamidates have been applied to the synthesis and evaluation of 
ADCs via reduction and alkylation of the interchain disulfide bonds of native IgG antibodies. The Her2-
binding antibody trastuzumab was at first modified with the cytotoxic drug MMAF followed by 
evaluation of cell-viability on different Her2-positive and -negative cell lines. Here, the antibody 
concentrations leading to fifty percent of maximal growth inhibition (IC50) of trastuzumab could be 
improved by MMAF attachment by 81-fold for SKBR3 cells (Her2++), whereas an MDAMB468 cell line 
(Her2-) was mostly unaffected. Afterwards, a second antibody-drug pair was synthesized from the 
cytotoxic auristatin MMAE and the monoclonal antibody brentuximab, to synthesize an ADC that is 
structurally analogous to the FDA approved Adcetris® with the maleimide linkage exchanged by a 
phosphonamidate. Since MMAE is even more unpolar than the MMAF used in the first study, a small 
diethylene glycol chain was incorporated to the phosphonamidate’s O-substituent to increase water-
solubility of the drug-linker pair. Optimization of the subsequent antibody conjugation procedure lead 
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to the development of two ADC synthesis protocols that facilitate an average drug loading of 
approximately four drug molecules per antibody exactly like in Adcetris®, requiring only minimal excess 
of the drug molecules. One protocol is relying on complete reduction with an excess of DTT, followed 
by DTT removal and drug conjugation, whereas the other makes use of partial disulfide reduction with 
low amounts of TCEP in the presence of the phosphonamidate modified drug in a one-pot manner. 
With these protocols, a phosphonamidate linked brentuximab-MMAE with an average of four drug 
molecules was synthesized and directly compared to its structurally related Adcetris® in terms of 
linkage stability in serum, selective decrease of the viability in vitro and finally anti-tumor efficacy in 
vivo. It could be shown that the phosphonamidate is much more stable in the presence of rat serum, 
resulting in 90% intact linkage after seven days, whereas the maleimide decreased to 25% already after 
three days. Both ADCs showed a similar behavior on cell viability in vitro and an excellent efficacy in an 
in vivo tumor xenograft mouse model system, with tumor remission for all mice treated twice with 1 
mg/kg ADC already a few days after the treatments. In a final in vivo experiment, a reduced dosage of 
twice 0.5 mg/kg was administered in the same xenograft model. Here it could be shown that the 
median survival of the mice treated with Adcetris® increased from 21 to 48 days for the 
phosphonamidate linked ADC, which corresponds to a factor of 2.3. Correlating this increased efficacy 
at lower ADC doses with the superior linkage stability in serum of phosphonamidates when directly 
compared to maleimides in Adcetris®, one can speculate that the stable phosphonamidate linkage 
facilitates a prolonged drug delivery to the side of the tumor and therefore an increased antitumor 
activity.  
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Abstract: Requirements for novel bioconjugation reactions for
the synthesis of antibody–drug conjugates (ADCs) are excep-
tionally high, since conjugation selectivity as well as the
stability and hydrophobicity of linkers and payloads drastically
influence the performance and safety profile of the final
product. We report Cys-selective ethynylphosphonamidates as
new reagents for the rapid generation of efficacious ADCs
from native non-engineered monoclonal antibodies through
a simple one-pot reduction and alkylation. Ethynylphospho-
namidates can be easily substituted with hydrophilic residues,
giving rise to electrophilic labeling reagents with tunable
solubility properties. We demonstrate that ethynylphosphona-
midate-linked ADCs have excellent properties for next-gen-
eration antibody therapeutics in terms of serum stability and
in vivo antitumor activity.
Antibody conjugates consisting of a drug linked to a tumor-
selective antibody, so called antibody–drug conjugates
(ADCs), are an emerging class of targeted therapeutics.[1]
While most of the ADCs in clinical development contain
cytotoxic molecules, recent studies also include the treatment
of infectious diseases with antibody–antibiotic conjugates
(AACs).[2] ADCs are particular interesting for the treatment
of cancer, since they combine the high potency of cytotoxic
molecules with the tumor specificity of monoclonal anti-
bodies. ADCs thus have the potential to significantly broaden
the therapeutic window compared to standard chemother-
apy.[1, 3] Recent progress in clinical development include the
approval of inotuzumab ozogamicin (Besponsa)[4] and the re-
approval of gemtuzumab ozogamicin (Mylotarg).[5] Never-
theless, challenges remain, especially in improving the linkage
between drug and antibody.[6] Commonly used linker systems
face problems such as insufficient serum stability and
undesired aggregation behavior, which limits the number of
drug molecules linked to an antibody and leads to undesired
off-target toxicity.[7]
Maleimides have become the prime linker reagents for the
generation of ADCs, including two approved ADCs: trastu-
zumab emtansine (Kadcyla) and brentuximab vedotin
(Adcetris).[8] Maleimides can be applied to either modify
native IgG antibodies through interchain-disulfide reduction
and alkylation[9] or to engineered antibodies through addition
to an additionally incorporated cysteine (Thiomab technolo-
gy).[7a] Nevertheless, one of the biggest drawbacks of mal-
eimide linkages is their susceptibility towards retro-Michael
additions, which leads to premature drug cleavage during
circulation and reattachment to cysteine-containing proteins
like albumin.[7a, 10] Even though consequences arising from
such payload transfer are not yet fully understood, it is
anticipated that the anti-tumor efficacy might be lowered due
to decreased drug delivery to targeted cells. Furthermore
toxic side effects might occur.[11] Several compound classes
have been developed to overcome this issue, including self-
hydrolyzing maleimides[11] and structurally refined Michael-
type acceptors such as carbonyl acrylic derivatives[12] or
exocyclic maleimides.[13] All of these methods yield stable
sulfhydryl adducts; however, synthetic incorporation of these
electrophiles into functional molecules remains challeng-
ing.[14]
Undesired aggregation of ADCs is another challenge,
since many drugs used in the context of ADCs are hydro-
phobic.[15] The addition of organic co-solvents to the con-
jugation mixture is commonly employed to enable the
conjugation of hydrophobic drugs, which however may
affect the structural integrity of the antibody.[16] Additionally,
the hydrophobic nature of drugs increases the formation of
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high-molecular-weight species (HMWS) in the final prod-
uct.[17] Those aggregates impair the pharmacokinetic profile
and efficacy[18] of ADCs and often limit the drug-to-antibody
ratio (DAR) to a maximum of 4.[19] To overcome this issue,
hydrophilic polyethylene glycol (PEG) linkers have been
developed that compensate for the lipophilic nature of the
drug.[20] However, it has recently been shown that PEG can
negatively affect pharmacokinetics when incorporated as
a linear spacer between antibody and drug.[21] Increasing the
solvent exposure of the drug most likely facilitates unspecific
hydrophobic interactions. This unwanted effect has been
successfully mitigated by side-chain attachment of the solu-
bilizing polymer.[21]
Based on our recently reported phosphonamidite-based
labelling method,[22] we applied ethynylphosphonamidates as
a novel compound class for the generation of stable Cys-
linked ADCs. We initiated our studies by conjugating the
antimitotic agent Monomethyl auristatin F (MMAF)[23] to the
Her2-targeting antibody trastuzumab by using phosphonami-
date functionalized cathepsin B cleavable linker 4, which was
synthesized based on previously published procedures for
Fmoc-protected Val-Cit dipeptides[24] (Figure S1 in the Sup-
porting Information). In a first proof-of-concept study, we
conjugated 4 to trastuzumab following our previously estab-
lished method by applying 10 equiv labeling reagent per
Cys,[22] giving an average DAR of 4.6 (Figure 1a and Figure S2
in the Supporting Information). To validate the functionality
of trastuzumab–4, it was evaluated in a Her2-based prolifer-
ation assay with two Her2-overexpressing cell lines (BT474
and SKBR3) as well as a Her2-negative cell line as a control
(MDAMB468).[25] Since trastuzumab alone exhibits antipro-
liferative potency, cell viability was measured via a sensitive,
high-content assay to asses retained antibody functionality
after exposure to the conjugation procedure. The antibody
concentrations leading to half maximal growth inhibition
(IC50) decreased with trastuzumab–4 compared to trastuzu-
mab alone by 81-fold, from 900 to 11 pm, for SKBR3 cells
(Her2++) and by 42-fold, from 800 to 19 pm, for BT474 cells
(Her2+). An effect on the proliferation of the control cell
line MDAMB468 was only observed at very high ADC
concentrations (IC50> 100 nm). Notably, trastuzumab–4
inhibits the proliferation of close to 100% of cell population
for SKBR3 cells, while trastuzumab alone only inhibits up to
50%. As an additional control, trastuzumab was treated with
4 without prior disulfide reduction. Those constructs behaved
in a similar manner to the non-modified antibodies, thus
highlighting the high Cys-selectivity, efficient removal of
excessive toxin, and gentle reaction conditions of our method
(Figure 1b). We additionally validated our measured IC50
values in a standard cell viability assay and obtained similar
IC50 growth inhibition constants for trastuzumab–4 (Figure S3
in the Supporting Information). The mode of action of
MMAF is the destabilization of microtubules through inhib-
ition of tubulin polymerization.[26] Along these lines, we
observed by fluorescence microscopy a disturbance of tubulin
organization in BT474 cells upon treatment with 0.3 nm
trastuzumab–4 for 4 days in contrast to proper spindle
formation in untreated mitotic control cells (Figure 1c and
Figure S4 in the Supporting Information).
Figure 1. a) Synthetic scheme for the attachment of 4 to trastuzumab. b) Antiproliferative potency of trastuzumab–4 on two Her2-overexpressing
cell lines (SKBR3, BT474) and a control (MDAMB468). Plots depict the number of proliferating cells after 4 days of antibody treatment against
antibody concentration. Non-Red-trastuzumab treated with 4 without prior disulfide reduction. c) Effect of trastuzumab–4 treatment on mitotic
tubulin organization in BT474 (Her2+) cells. Shown are representative images of mitotic BT474 cells after 4 days of treatment with 0.3 nm
trastuzumab–4 compared to untreated cells.
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Furthermore, we anticipated that ethynylphosphonami-
dates bearing O-substituents with increased hydrophilicity
might serve as powerful building blocks to increase the
polarity of the whole linker system without increasing the
overall linker length. Since the Staudinger-phosphonite
reaction (SPhR) comprises a very convenient synthetic
route to incorporate the ethynylphosphonamidate moiety
into a given molecule, we focused on the synthesis of
a hydrophilic phosphonite. Following our previous methods,
we were able to synthesize the diethylene glycol substituted
phosphonite 5 in a one-pot procedure.[27] Subsequent SPhR
was performed with the NHS-modified azide 6 and yielded
the desired diethyleneglycol-phosphonamidate 7 in 31%
yield (Figure 2a).
To demonstrate the versatility of our method, we pro-
ceeded with the construction of a second antibody–drug pair.
Since we wanted to directly compare our linkage technology
with the maleimide linkage used in Adcetris, we continued
our studies with phosphonamidate-linked ADCs that are
structurally as close to Adcetris as possible. In addition to the
MMAF constructs used in the previous study, two ethynyl-
phosphonamidate MMAE derivatives were synthesized, one
with an ethyl substituent at the phosphorous (9) and one with
a diethylene glycol substituent (10 ; Figure 2b). RP-HPLC
analysis showed a reduced retention time for compound 10,
when compared to 9 or vedotin (Figure 2c). Solubility
measurements revealed that the aqueous solubility of the
conjugates is drastically increased by the diethylene glycol
substituent, from 95 mm (9) to 298 mm (10). The aqueous
solubility of 10 is also twice as high as vedotin (Figure 2d and
Figure S5 in the Supporting Information) Based on these
observations we decided to proceed with the hydrophilic
compound 10 for subsequent conjugation studies to anti-
bodies.
Next, we tried to optimize our conjugation method to
reduce the number of drug equivalents needed for sufficient
conjugation. Since Adcetris is modified with an average of
four vedotin molecules per antibody,[28] we started by screen-
ing different amounts of 10 to achieve similar modification
and analyzed the DAR by intact protein MS (Figure S6 in the
Supporting Information). We estimated that 16 equiv of 10
per antibody (2 equiv per Cys-residue) are needed to reach
a DAR of 4 at 1 mgmL@1 antibody concentration. We
attribute the required excess of phosphonamidate to slower
reaction kinetics of ethynylphosphonamidates compared to
maleimides.[22] To compensate for the slower kinetics, we
increased the antibody concentration in the conjugation
reaction to 5 mgmL@1, a concentration that was previously
also used for maleimide conjugations.[9] With this, we were
able to use as little as 4.5 equiv of 10 per antibody to achieve
a DAR of 4.0 (Figure S7 in the Supporting Information).
After this, upscaling of the conjugation reaction to 2.4 mg
brentuximab was performed at 1 or 5 mgmL@1 followed by
a preparative size-exclusion chromatography step to ensure
complete removal of the toxin prior to subsequent functional
evaluations, yielding 1.6 mg of the desired ADC brentuxi-
mab–10 with a DAR of 3.8–4.0. To furthermore simplify the
conjugation process, we applied partial reduction of the
interchain disulfide bonds with TCEP.[29] By screening TCEP
equivalents needed to modify brentuximab, we found out that
a partial reduction method with 3 equiv TCEP, 5 equiv 10, and
5 mgmL@1 brentuximab, applied in a one pot process,
produces an ADC with a DAR of 3.9 without the need for
removal of reducing agent prior payload conjugation (Fig-
ure S8 in the Supporting Information). This one-pot process
can be problematic with other cysteine-labelling reagents,
since it has been shown that maleimides and vinyl sulfones for
instance, irreversibly react with TCEP.[30]
Taking advantage of our ADC synthesis methods, we then
evaluated commercially available Adcetris in comparison to
our analogue brentuximab–10 (Figure 3a). We started with
a cell-based viability assay with a CD30-overexpressing cell
Figure 2. a) Synthesis of ethylene glycol substituted ethynylphosphonamidate building block 7 and structural comparison to the corresponding
ethyl-substituted 8.[22] b) Structure of vedotin and synthesis of ethyl (9) and diethylene glycol (10) phosphonamidate-based vedotin analogues.
c) RP-HPLC analysis of vedotin and analogues 9 and 10. d) Solubility in PBS with 5% DMSO of vedotin and analogues 9 and 10. Error bars
calculated from three independent measurements.
Angewandte
ChemieCommunications
11633Angew. Chem. Int. Ed. 2019, 58, 11631 –11636 T 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
line Karpas299 and a CD30-negative cell line HL60 as
a control. Both ADCs showed similar IC50 growth inhibition
constants in the range of 0.9 ngmL@1 in the antigen-positive
cell line. Whereas Adcetris slightly affected the antigen-
negative cell line at high ADC concentrations, we observed
no such effect for brentuximab–10. (Figure 3b).
As mentioned earlier, increased stability of the linkage
between drug and antibody in serum might improve the
properties of ADCs in terms of off-target toxicity and anti-
tumor efficacy.[11] In our experiment, we observed that 90% of
the phosphonamidate-linked MMAE was still connected to
brentuximab after 7 days of incubation in rat serum at 37 8C,
as measured by intact-protein MS after pulldown of the ADC
from serum. Under the same incubation conditions, Adcetris
lost more than 70% of its payload after three days. (Figure 3c
and Figure S9 in the supporting information). This data is in
accordance with previous observations that describe a drastic
DAR decrease of similar maleimide linked ADCs following
6 days of incubation in serum at 37 8C.[31] Although hydrolysis
of maleimides was shown to improve conjugate stability and
Figure 3. a) Structural comparison of Adcetris with brentuximab–10. b) Cell viability assays with a CD30-overexpressing cell line (Karpas299, top)
and a control (HL60, bottom) for brentuximab–10, Adcetris, and brentuximab alone. c) Linkage-stability studies in rat serum. ADCs were
incubated in rat serum for 0, 3, and 7 days at 37 8C and analyzed by MS after pulldown, deglycosylation, and reduction. Shown is the DAR relative
to the average DAR of day 0 for brentuximab–10 and Adcetris. d) Antitumor activity of brentuximab–10 and Adcetris and a PBS control in
a Karpas 299 tumor xenograft model in SCID mice. Treatment of 1 mgkg@1 was administered twice at day 7 and day 10 after tumor
transplantation. Tumor volumes of the four mice per group are shown separately. e) Kaplan–Meier survival analysis of the study shown in (d).
f) Treatment of 0.5 mgkg@1 at day 8 and day 12 after tumor transplantation. Tumor volumes of the eight mice per group are shown separately.
g) Kaplan–Meier survival analysis of the study shown in (f).
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generates ADCs with increased in vivo potency,[11,32] the
occurrence of incomplete hydrolysis of many maleimides may
limit this approach.[33] Taken together, the stability experi-
ments in serum clearly underlines our previously reported
data on the excellent stability of the phosphonamidate
linkage,[22] in particular when compared to maleimide-linked
ADCs. Additionally, we performed storage tests with bren-
tuximab–10 to analyze the formation of HMWS, as reported
previously.[34] Size-exclusion chromatography revealed less
than 9% HMWS formation with respect to the monomeric
species after storage at 40 8C over two weeks. No significant
increase in HMWSwas observed after two weeks of storage at
4 8C (Figure S10 in the Supporting Information).
Finally, brentuximab–10 was evaluated in vivo in
a Karpas 299 derived tumor xenograft model in immunode-
ficient female CB17-SCID mice in a similar manner as
previously reported.[35] In a first study, four mice were treated
twice, at day 7 and day 10, with 1 mg ADC per kg bodyweight
with brentuximab–10, Adcetris, or only PBS as a control. All 4
mice treated with brentuximab-10 or Adcetris showed an
excellent response to the treatment. Treated mice were in
tumor remission already a few days after ADC injection and
no relapse was observed over the whole observation period of
58 days, while the untreated control showed uncontrolled
tumor growth and had to be sacrificed within three weeks
after tumor transplantation (Figure 3d and Figure S11 in the
Supporting Information). It was previously reported that an
ADC with an average of four MMAEmolecules connected to
brentuximab via maleimides is significantly less efficacious in
a tumor xenograft model when the dosing is lowered from 1 to
0.5 mgkg@1.[35] From our serum stability studies (Figure 3c),
we anticipated that phosphonamidite-linked ADCs might still
be active at lower doses due to prolonged drug delivery in
circulation. Therefore, we initiated a second in vivo study,
with three groups of eight mice treated with either 0.5 mgkg@1
brentuximab–10 or Adcetris or only PBS twice at day 8 and
day 12. As expected, we observed decreased antitumor
activity for both constructs when compared to the first
study, leading to tumor remission in two mice for brentux-
imab–10 and only one for Adcetris. However, five out of eight
mice did not show any observable response to the treatment
with Adcetris, and the tumor growth was as fast as in the PBS-
treated control group. In contrast, this was only observed in
two mice treated with brentuximab–10 (Figure 3 f and Fig-
ure S11 in the Supporting Information). Hence, we were able
to show a drastic increase in median survival from 21 days for
commercial Adcetris to 48 days for brentuximab–10 (Fig-
ure 3g). This increase by a factor of 2.3 in comparison to
Adcetris indicates promising antitumor activity for our novel
phosphonamidate-linked ADCs. It should be noted that none
of the mice, treated with either construct, showed significant
changes in bodyweight over the observation period (Fig-
ure S11 in the Supporting Information).
In summary, we present ethynylphosphonamidates as
cysteine-reactive handles for the construction of next-gener-
ation cancer therapeutics. By making use of the SPhR, we
obtained a new modular diethyleneglycol-modified ethynyl-
phosphonamidate building block for the synthesis of hydro-
philic Cys-selective linker systems for the conjugation of
unpolar payloads. With this method, we synthesized an ADC
from brentuximab and MMAE, and demonstrated appropri-
ate linkage stability combined with beneficial in vivo anti-
tumor activity, resulting in an increased median survival from
21 days for Adcetris to 48 days for the phosphonamidate
linkage. The conjugation method is straightforward, using
only minimal drug excesses, and facilitates one-pot synthesis
of ADCs starting from native antibodies. Taken together, the
ethynylphosphonamidates described herein facilitate the
straightforward construction of ADCs for cancer therapeutics
and show great promise for other pharmacological targets.
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1. Supplementary Figures 
 
1.1. Figure S1  
Synthesis of a phosphonamidate modified, cathepsin B cleavable MMAF 4. Compound 1 was 
synthesized based on previously published procedures for Fmoc-protected Val-Cit 
dipeptides.[1] 1 was afterwards converted into the phosphonamidate 2 via Staudinger-
phosphonite reaction and activated as a carbonate (Scheme 1). The resulting compound 3 
constitutes a modular building block to install a cathepsin B cleavable phosphonamidate into 
any primary or secondary amine-containing payload. Here we used 3 for the synthesis of a 
phosphonamidate modified cleavable MMAF 4. 
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1.2. Figure S2 
Synthetic scheme for the attachment of 4 to trastuzumab. Deconvoluted spectrum of 
deglycosylated and reduced trastuzumab-4. LC: Light chain, HC: Heavy Chain. DAR: Drug to 
Antibody Ratio. 
 
1.3. Figure S3 
Increased cytotoxicity of MMAF linked trastuzumab on a Her2 overexpressing cell line 
(SKBR3) and a control (MDAMB468), demonstrated in a Resazurin assay. Plots depict cell 
viability after antibody treatment in dependency of the antibody concentration. Trastuzumab 
alone (pink) and trastuzumab-4 (green). (See chapter 3.4 for details) 
 
 
1.4. Figure S4 
Effect of trastuzumab-4 treatment on mitotic tubulin organization in BT474 (Her2+) cells. 
Shown are three representative images of mitotic BT474 cells after 4 days of treatment with 
0.3 nM trastuzumab-4 (a) and untreated (b). DAPI stain visualizes DNA condensation. Anti α-
tubulin immunostaining visualizes spindle organization in untreated mitotic cells. Cells treated 
with trastuzumab-4 show DNA condensation but a strongly altered and distorted α-tubulin 
pattern. 
 
1.5. Figure S5 
Solubility measurements of 9 (red), 10 (green) and vedotin (cyan) in PBS with 5% DMSO and 
Inosine as an internal standard. (See chapter 3.5 for details) a) Calibration curves of different 
analyte concentrations (5, 10, 50, 100 and 200 µM) were recorded by UPLC/UV by peak 
integration of the analyte in relation to Inosin as an internal standard. Shown are error bars 
from three independent measurements (black) and a linear fit. Values that were out of the 
concentration range and therefore not in the linear region were excluded from the fit (grey). b) 
Three independent measurements of saturated solutions and concentration calculation with 
the linear equation, estimated in a.  
 
1.6. Figure S6 
Modification of brentuximab at 1 mg/ml with varying equivalents of the vedotin analog 10 
delivers ADCs with different DARs. (See chapter 3.7 for details) a) SDS-PAGE of brentuximab, 
reduced with 1000 eq. DTT and alkylated with 10. Modification was carried out under the same 
conditions for every reaction: 1 mg/ml antibody, 50 mM tris-buffer, 1 mM EDTA pH 8.5 and 5% 
DMSO; reaction over-night at 14°C as described in chapter 3.6. b) Exemplary MS-spectrum 
and calculated DAR of sample in lane 5 (modification carried out with 10 eq. 10), as described 
in chapter 3.9. HC: heavy chain, LC: light chain. *deconvolution artefacts (half mass of HC 
species and double mass of LC species) c) Plot of phosphonamidate equivalents against the 
measured DAR. Shown are results of 20 independent experiments (dots) and an exponential 
fit (solid line, R2= 0.9540). Red line marks the theoretical equivalents (16 in this case) to reach 
a DAR of 4. 
 
 
1.7. Figure S7 
Increased conjugation efficiency can be observed at 5 mg/ml brentuximab. (See chapter 3.8 
for details) a) DAR-analysis of brentuximab, reduced with 200 eq. of DTT and alkylated with 
10. Modification was carried out under the same conditions for every reaction: 5 mg/ml 
antibody, 50 mM tris-buffer, 1 mM EDTA pH 8.5 and 5% DMSO; reaction over-night at 14°C 
as described in chapter 3.7. DAR-analysis was carried as described in chapter 3.9. b) 
Exemplary MS-spectrum and calculated DAR of sample in lane 2 (modification carried out with 
6 eq. 10). HC: heavy chain, LC: light chain. 
 
 
1.8. Figure S8 
Partial reduction of the interchain disulfides with small excess of TCEP yields ADCs with a high 
conjugation effiency in a one-step procedure. (See chapter 3.9 for details)  a) DAR-analysis of 
brentuximab, reduced and alkylated with 10. Modification was carried out under the same 
conditions for every reaction with varying equivalents of TCEP: 5 mg/ml antibody, 50 mM tris-
buffer, 100 mM NaCl, 1 mM EDTA pH 8.5, 167 µM 10 (5.0 eq.) and 5% DMSO; reaction over-
night at 14°C as described in chapter 3.8. DAR-analysis was carried as described in chapter 
3.9. b) Exemplary MS-spectrum and calculated DAR of sample in lane 3 (modification carried 
out with 3 eq. TCEP). HC: heavy chain, LC: light chain. 
 
 
1.9. Figure S9 
DAR analysis of brentuximab-10 (a, green) and Adcetris® (b, cyan) after incubation in rat 
serum for 0, 3 and 7 days as described in chapter 3.12. Shown are values from three 
independent measurements for each time point. We measured a DAR of 3.05 (mean of three 
measurements) for Adcetris at Day 0, even though, Adcetris is known to be modified with an 
average of 4 drug molecules.[2] We attribute this to a loss of modification during the analysis 
process of pulldown, deglycosylation, reduction and MS-analysis. Since this sample-
preparation was conducted in the same way for day 0, 3 and 7, this should not influence the 
relative values, given in the main manuscript. c) MS analysis of two Adcetris® measurements 
(day 0 top and day 3 bottom) indicating hydrolysis of the vedotin molecules that are still 
attached to the antibody. From this we concluded complete hydrolysis of maleimides to the 
open ring form at day 3, resulting in no further retro-Michael addition and associated payload 
loss until day 7 
 
 
1.10. Figure S10 
Size-exclusion HPLC analysis of Brentuximab-10 after storage at different temperatures in 
PBS. Chromatograms were recorded after 0, 7 and 14 days. Chromatograms are normalized 
to the maximal intensity. (See chapter 3.13 for details) 
 
1.11. Figure S11 
Changes in bodyweight (top) and tumorvolumes (bottom) of SCID mice with a Karpas 299 
tumor xenograft after treatment with PBS (magenta), Brentuximab-10 (blue) or PBS (green). 
Shown are tumor volumes of eight mice per group separately. a) 1. Study: Shown are tumor 
volumes of four mice per group separately treated at day 7 and 10 with 1 mg/kg ADC. b) 2. 
Study: Shown are tumor volumes of eight mice per group separately treated at day 8 and 11 
with 0.5 mg/kg ADC. (See chapter 3.14 for details) 
 
 
2. General Information 
2.1. Chemicals and solvents 
Chemicals and solvents were purchased from Merck (Merck group, Germany), TCI (Tokyo 
chemical industry CO., LTD., Japan) and Acros Organics (Thermo Fisher scientific, USA) and 
used without further purification. Dry solvents were purchased from Acros Organics (Thermo 
Fisher scientific, USA). Adcetris was obtained from Takeda. 
2.2. Flash- and thin layer chromatography  
Flash column chromatography was performed, using NORMASIL 60® silica gel 40-63 µm 
(VWR international, USA). Glass TLC plates, silica gel 60 W coated with fluorescent indicator 
F254s were purchased from Merck (Merck Group, Germany). Spots were visualized by 
fluorescence depletion with a 254 nm lamp or manganese staining (10 g K2CO3, 1.5 g KMnO4, 
0.1 g NaOH in 200 ml H2O), followed by heating. 
2.3. Preparative HPLC 
Preparative HPLC was performed on a Gilson PLC 2020 system (Gilson Inc, WI, Middleton, 
USA) using a VP 250/32 Macherey-Nagel Nucleodur C18 HTec Spum column (Macherey-
Nagel GmbH & Co. Kg, Germany). The following gradients were used: Method C: (A = H2O + 
0.1% TFA (trifluoroacetic acid), B = MeCN (acetonitrile) + 0.1% TFA, flow rate 30 ml/min, 5% 
B 0-5 min, 5-90% B 5-60 min, 90% B 60-65 min. Method D: (A = H2O + 0.1% TFA, B = MeCN 
+ +0.1% TFA), flow rate 30 ml/min, 5% B 0-5 min, 5-25% B 5-10 min, 25%-45% B 10-50 min, 
45-90% 50-60 min, 90% B 60-65 min. Method E: 0.1% TFA, flow rate 18 ml/min, 5% B 0-5 
min, 5-90% B 5-60 min, 90% B 60-65 min, using a VP 250/21 Macherey-Nagel Nucleodur C18 
HTec Spum column (Macherey-Nagel GmbH & Co. Kg, Germany) 
2.4. Semi-preparative HPLC 
Semi-preparative HPLC was performed on a Shimadzu prominence HPLC system (Shimadzu 
Corp., Japan) with a CBM20A communication bus module, a FRC-10A fraction collector, 2 
pumps LC-20AP, and a SPD-20A UV/VIS detector, using a VP250/10 Macherey-Nagel 
Nucleodur C18 HTec Spum column (Macherey-Nagel GmbH & Co. Kg, Germany). The 
following gradients were used: Method F: (A = H2O + 0.1% TFA, B = MeCN + +0.1% TFA), 
flow rate 5 ml/min, 30% B 0-5 min, 30-99% B 5-65 min, 99% B 65-75 min.   
2.5. NMR 
NMR spectra were recorded with a Bruker Ultrashield 300 MHz spectrometer and a Bruker 
Avance III 600 MHz spectrometer (Bruker Corp., USA) at ambient temperature. Chemical shifts 
δ are reported in ppm relative to residual solvent peak (CDCl3: 7.26 [ppm]; DMSO-d6: 2.50 
[ppm] for 1H-spectra and CDCl3: 77.16 [ppm]; DMSO-d6: 39.52 [ppm] for 13C-spectra . Coupling 
constants J are stated in Hz. Signal multiplicities are abbreviated as follows: s: singlet; d: 
doublet; t: triplet; q: quartet; m: multiplet.  
2.6. HR-MS 
High resolution ESI-MS spectra were recorded on a Waters H-class instrument equipped with 
a quaternary solvent manager, a Waters sample manager-FTN, a Waters PDA detector and a 
Waters column manager with an Acquity UPLC protein BEH C18 column (1.7 µm, 2.1 mm x 
50 mm). Samples were eluted with a flow rate of 0.3 mL/min. The following gradient was used: 
A: 0.01% FA in H2O; B: 0.01% FA in MeCN. 5% B: 0-1 min; 5 to 95% B: 1-7min; 95% B: 7 to 
8.5 min. Mass analysis was conducted with a Waters XEVO G2-XS QTof analyzer. 
2.7. UPLC-UV/MS 
UPLC-UV/MS traces were recorded on a Waters H-class instrument equipped with a 
quaternary solvent manager, a Waters autosampler, a Waters TUV detector and a Waters 
Acquity QDa detector with an Acquity UPLC BEH C18 1.7 μm, 2.1 x 50 mm RP column with a 
flow rate of 0.6 mL/min (Waters Corp., USA). The following gradient was used for purity 
analyses: A: 0.1% TFA in H2O; B: 0.1% TFA in MeCN. 5% B 0 - 1.5 min, 5-95% B 1.5-11 min, 
95% B 11-13 min, 5% B 13-15 min. The following gradient was used in the solubility assay: A: 
0.1% TFA in H2O; B: 0.1% TFA in MeCN. 5% B 0 - 0.5 min, 5-95% B 0.5-3 min, 95% B 3-3.9 
min, 5% B 3.9-5 min. 
2.8. Intact protein MS (trastuzumab conjugates only) 
Reduced antibody subunits were analyzed using a reversed-phase liquid chromatography 
system (Dionex Ultimate 3000 NCS-3500RS Nano, Thermo Scientific) connected to an 
Orbitrap Fusion mass spectrometer (Thermo Scientific). Chromatographic separation was 
performed with an Acquity UPLC protein BEH C4 column (300 Å, 1.7 µm, 2.1 mm x 50 mm). 
Component A of the mobile phase was 0.01% formic acid in water and component B consist 
of Acetonitrile with 0.01% formic acid. Separation was performed with a flow rate of 300 µL/min 
within 7.5 min linear gradient starting with 0% and ending with 40% of component B, followed 
by a flushing step until 80% of component B. Proteins were ionized in positive ion mode 
applying a spray voltage of 4.5 kV, using sheath gas (75 Arb), aux gas (12 Arb), sweep gas (1 
Arb) and a vaporizer temperature of 300°C. Ionized proteins were analyzed in intact protein 
mode with a resolution of 15000 (FWHM), 10 microscans and a scan range of m/z 500-3000. 
The maximum injection time was set to 100 ms to reach an AGC-Target value of 5e5. 
Raw data were analyzed with ProteinDeconvolut version 3.0 (Thermo Scientific), considering 
a m/z range of 800-3000 and charge states ranging from 10-100. 30000 was used as a 
targeted mass and the intact protein model was chosen. The output mass range was 10000-
70000. 
2.9. Intact protein MS (all brentuximab conjugates) 
Intact proteins were analyzed using a Waters H-class instrument equipped with a quaternary 
solvent manager, a Waters sample manager-FTN, a Waters PDA detector and a Waters 
column manager with an Acquity UPLC protein BEH C4 column (300 Å, 1.7 µm, 2.1 mm x 
50 mm). Proteins were eluted with a flow rate of 0.3 mL/min. The following gradient was used: 
A: 0.01% FA in H2O; B: 0.01% FA in MeCN. 5-95% B 0-6 min. Mass analysis was conducted 
with a Waters XEVO G2-XS QTof analyzer. Proteins were ionized in positive ion mode applying 
a cone voltage of 40 kV. Raw data was analyzed with MaxEnt 1. 
2.10. Preparative size-exclusion chromatography 
Protein purification by size-exclusion chromatography was conducted with an ÄKTA FPLC 
system (GE Healthcare, United States) equipped with a P-920 pump system, a UPC-900 
detector and a FRAC-950 fraction collector. 
2.11. Analytical size-exclusion chromatography 
Analytical size-exclusion chromatography (A-SEC) of the ADCs was conducted on a Vanquish 
Flex UHPLC System with a DAD detector, Split Sampler FT (4°C), Column Compartment H 
(25°C) and binary pump F (Thermo Fisher Scientific, USA) using a MAbPac SEC-1 300 Å, 4 x 
300 mm column (Thermo Fisher Scientific, USA) with a flow rate of 0.15 mL/min. Separation 
of different ADC/mAb populations have been achieved during a 30 minute isocratic gradient 
using a phosphate buffer at pH 7 (20 mM Na2HPO4/NaH2PO4, 300 mM NaCl, 5% v/v isopropyl 
alcohol as a mobile phase. 8 µg ADC/mAb where loaded onto the column for A-SEC analysis. 
UV chromatograms were recorded at 220 and 280 nm. Quantification of monomer and HMWS 
was achieved after integration of the peak area at 220 nm. 
 
3. Experimental procedures 
3.1. Trastuzumab production 
Trastuzumab expression and purification was executed as previously published with an 
additional final purification by gel filtration on a Superdex 200 Increase 10/300 from GE (GE 
life sciences, USA) with PBS and flow rate of 0.75 ml/min.[3]  
3.2. Synthesis and analysis of trastuzumab-MMAF conjugates 
Trastuzumab modification was carried out by incubating freshly expressed antibody (0.5 
mg/ml, 3.33 μM) with 1000 eq. of DTT in a buffer containing 50 mM sodium borate in PBS (pH 
8.0) with a total volume of 80 μl at 37 °C for 40 min. Excess DTT removal and buffer exchange 
to a solution containing 50 mM NH4HCO3 and 1mM EDTA (pH 8.5) was conducted afterwards 
using 0.5 mL Zeba™ Spin Desalting Columns with 7K MWCO (Thermo Fisher Scientific, USA). 
4 μl of O-Ethyl-P-ethynyl-phosphonamidate-VC-PAB-MMAF 4, dissolved in DMSO (5.33 mM) 
were added quickly to reach a final DMSO content of 5% and 80 eq. phoshonamidate with 
respect to the antibody. The mixture was shaken at 850 rpm and 14 °C for 16 hours. Excess 
reagent was again removed by buffer exchange to sterile PBS using 0.5 mL Zeba™ Spin 
Desalting Columns with 7K MWCO.  
For SDS-page-analysis, 2 μl of the crude reaction mixture were mixed with 10 μl of ultrapure 
water and 4 µl Laemmli sample buffer (Bio-Rad Laboratories, USA) containing 0.4 µl 2-
mercaptoethanol. Samples were heated to 95 °C for 15 minutes and completely loaded to the 
SDS-PAGE gel.  
 
For MS analysis: The modified antibody was rebuffered to 100 mM NH4HCO3 and 500 mM 
NaCl using 75 μL Zeba™ Spin Desalting Columns with 7K MWCO (Thermo Fisher Scientific, 
USA). 8 μl of this solution were treated with 1 μl RapiGest™ (Waters Corp., USA) solution (1% 
in H2O) and heated to 60 °C for 30 min. The solution was allowed to cool to room temperature, 
1 μl PNGase-F solution (Pomega, Germany, Recombinant, cloned from Elizabethkingia 
miricola 10 u/μl) was added and the solution was incubated at 37 °C over night. Remaining 
disulfide bridges were reduced by addition of 1 μl DTT solution (50 mM in H2O) and incubation 
at 37°C for 30 min. Samples were diluted with 1% HCl subjected to MS analysis with the 
Orbitrap Fusion system. (See chapter 2.8) 
MS spectrum shows the ion series, which was deconvoluted to obtain the spectrum in Figure 
1b.  
  
3.3. Cell based antiproliferation assays  
Antiproliferation assays were conducted as previously reported[3] with the following minor 
changes:  
- For MDAMB468 cells, a reduced amount of 2*103 cells were seeded in each well of a 96-well 
optical cell culture plate supplemented with 100 μL culture media.  
- Images were acquired with an Operetta High-Content Imaging system (PerkinElmer, 
Waltham, MA, USA) equipped with a 20× high NA objective.  
- Cell counts were calculated from duplicates  
3.4.  Resazurin assay 
HL60 and Karpas cell lines were cultured in RPMI-1640 supplemented with 10% FCS and 
0.5% Penicillin-Streptomycin. SKBR3 and MDAMB468 cell lines were cultured in DMEM/F12 
supplemented with 10% FCS and 0.5% Penicillin-Streptomycin. Cells were seeded at a density 
of 5*10^3 cells/well (SKBR3, HL60 and Karpas) or 1*10^3 cells/well (MDAMB468) in 96-well 
cell culture microplate. 1:4 serial dilutions of ADCs or antibodies were performed in cell culture 
medium starting at 3 µg/mL final concentration and transferred in duplicates to respective wells 
on the microplate. Plates were incubated for 96 h at 37°C 5 % CO2. Subsequently, resazurin 
was added to a final concentration of 50 µM followed by incubation for 3 – 4 h at 37°C, 5% 
CO2. Metabolic conversion of resazurin to resorufin is quantified by the fluorescent signal of 
resorufin (λEX = 560 nm and λEM = 590 nm) on a Tecan Infinite M1000 micro plate reader. Mean 
and standard deviation was calculated from duplicates, normalized to untreated control and 
plotted against antibody concentration. Data analysis was performed with MatLab R2016 
software. 
3.5. Solubility assay 
The aqueous solubility of compounds 9, 10 and vedotin was determined using a shake flask 
solubility assay. Saturated solutions of the compounds in 5% DMSO/PBS at pH 7.4 were 
prepared in triplicates by adding 2 µL of compound (40 mM in DMSO) to 38 µL PBS, pH 7.4 
containing 50 µM inosine as internal standard. The samples were incubated at 25°C for 2h and 
subsequently subjected to high-speed centrifugation (10 minutes, 16873 rcf). The supernatant 
was analyzed by UPLC/UV and the concentration was determined using a standard curve. For 
the standard curves, serial dilutions in 5% DMSO/PBS at pH 7.4 containing 50 µM Inosine 
were prepared in triplicates with final compound concentrations of 5 µM, 10 µM, 50 µM, 100 
µM and 200 µM. The samples were incubated at 25°C for 2 h and subsequently subjected to 
high-speed centrifugation (10 minutes, 16873 rcf). The supernatant was analyzed by UPLC/UV 
and the peak area of compound and internal standard were integrated. The normalized peak 
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areas (integrated area compound divided by integrated area standard) were plotted against 
the concentration and a linear fit was applied within the respective solubility range. 
3.6.  Brentuximab production 
Brentuximab expression and purification was executed in analogy to trastuzumab with final 
purification by gel filtration on a Superdex 200 Increase 10/300 from GE (GE life sciences, 
USA) with PBS and flow rate of 0.75 ml/min.  
3.7.  Procedure for the modification of brentuximab (1mg/ml) with different 
equivalents of 10 
35 μl of a 70 mM solution of DTT in 50 mM sodium borate in PBS (pH 8.0) was added to 350 μl 
of a brentuximab solution of 1.0 mg/ml in 50 mM sodium borate in PBS (pH 8.0) and the mixture 
was incubated at 37 °C for 40 min. Excess DTT removal and exchange to the conjugation 
buffer (50 mM Tris, 1 mM EDTA, 100 mM NaCl, pH 8.5 at 14°C) was conducted afterwards 
using 2 mL Zeba™ Spin Desalting Columns with 7K MWCO (Thermo Fisher Scientific, USA). 
50 μl of the reduced antibody solution (0.91 mg/ml, 6.07 μM antibody) were mixed quickly 
afterwards with the desired amount of O-2-(2-Hydroxyethoxy)ethyl-P-ethynyl-
phosphonamidate-VC-PAB-MMAE 10 dissolved in DMSO to give a final amount of 5% DMSO. 
The mixture was shaken at 850 rpm and 14 °C for 16 hours. For SDS-page-analysis, 2 μl of 
the crude reaction mixture were mixed with 10 μl of ultrapure water and 4 µl Laemmli sample 
buffer (Bio-Rad Laboratories, USA) containing 0.4 µl 2-mercaptoethanol. Samples were 
heated to 95 °C for 15 minutes and completely loaded to the SDS-PAGE gel.  
 
3.8. Procedure for the modification of brentuximab (5.0 mg/ml) with different 
equivalents of 10 
 
5 μl of a 70 mM solution of DTT in 50 mM sodium borate in PBS (pH 8.0) was added to 50 μl 
of a brentuximab solution of 5.0 mg/ml in 50 mM sodium borate in PBS (pH 8.0) and the mixture 
was incubated at 37 °C for 40 min. Excess DTT removal and exchange to the conjugation 
buffer (50 mM Tris, 1 mM EDTA, 100 mM NaCl, pH 8.5 at 14°C) was conducted afterwards 
using 0.5 mL Zeba™ Spin Desalting Columns with 7K MWCO (Thermo Fisher Scientific, USA). 
50 μl of the reduced antibody solution (4.55 mg/ml, 30.30 μM antibody) were mixed quickly 
afterwards with desired amount of O-2-(2-Hydroxyethoxy)ethyl-P-ethynyl-phosphonamidate-
VC-PAB-MMAE 10 dissolved in DMSO to give a final amount of 5% DMSO. The mixture was 
shaken at 850 rpm and 14 °C for 16 hours. 
 
3.9. Procedure for the partial reduction of brentuximabs interchain disulfide 
bonds with TCEP 
 
50 μl of a brentuximab solution of 5.0 mg/ml in conjugation buffer (50 mM Tris, 1 mM EDTA, 
100 mM NaCl, pH 8.5 at 14°C) were mixed with 5 µl of a TCEP solution in conjugation buffer 
containing the appropriate amount of TCEP. Directly afterwards, 2.75 µl of a 3.03 mM solution 
of O-2-(2-Hydroxyethoxy)ethyl-P-ethynyl-phosphonamidate-VC-PAB-MMAE 10 (5.0 eq. with 
respect to the antibody) dissolved in DMSO were added to give a final amount of 5% DMSO. 
The mixture was shaken at 850 rpm and 14 °C for 16 hours. 
 
 
3.10. Procedure for DAR determination of brentuximab conjugates by intact 
protein MS 
a) 
40 µl of the crude antibody modification mixture were purified by size-exclusion 
chromatography with a 5 ml HiTrap® desalting column and a flow of 1.5 ml/min eluting with 
100 mM NaHCO3 and 500 mM NaCl over two column volumes. An exemplary chromatogram 
is shown below. 
 
The antibody containing fractions were pooled and concentrated by spin-filtration to 40 µl 
(MWCO: 10 kDa, 0.5 ml, Sartorius, Germany).  
b) 
2 μl RapiGest™ solution (1% in H2O) (Waters Corp., USA) were added and the solution was 
heated to 60 °C for 30 min. The solution was allowed to cool to room temperature, 1 μl 
PNGase-F solution (Pomega, Germany, Recombinant, cloned from Elizabethkingia miricola 
10 u/μl) was added and the solution was incubated at 37 °C for at least 2 hours. Disulfide 
bridges were reduced by addition of 2 μl DTT solution (70 mM in H2O) and incubation at 37°C 
for 30 min. Samples were diluted with 120 µl 1% HCl and subjected to intact protein MS (see 
chapter 2.9), injecting 5 µl for each sample.  
c) For Adcetris pulldown samples from serum, 1 μl PNGase-F solution (Pomega, Germany, 
Recombinant, cloned from Elizabethkingia miricola 10 u/μl) was added to 20 µl of Adcetris in 
PBS and the solution was incubated at 37 °C for at least 2 hours. Disulfide bridges were 
reduced by addition of 2 μl DTT solution (70 mM in H2O) and incubation at 37°C for 30 min. 10 
µl of the samples were diluted with 190 µl of pure water and subjected to intact protein MS 
(see chapter 2.9), injecting 3 µl for each sample.  
After deconvolution of the crude spectra, the DAR was determined with the following formula, 
were I corresponds to the mass intensities of the respective species.  
 
3.11.  Synthesis and purification of an ADC from brentuximab and 10.  
240 μl of a 70 mM solution of DTT in 50 mM sodium borate in PBS (pH 8.0) were added to 2.4 
ml of a brentuximab solution of 1.0 mg/ml in 50 mM sodium borate in PBS (pH 8.0) and the 
mixture was incubated at 37 °C for 40 min. Excess DTT removal and exchange to the 
conjugation buffer was conducted afterwards using 10 mL Zeba™ Spin Desalting Columns 
with 7K MWCO (Thermo Fisher Scientific, USA). The reduced antibody solution (0.91 mg/ml, 
6.07 μM) was mixed quickly afterwards with 132 μl of a 1.94 mM solution of O-2-(2-
Hydroxyethoxy)ethyl-P-ethynyl-phosphonamidate-VC-PAB-MMAE 10 dissolved in DMSO to 
give a final amount of 5% DMSO and 16 eq. phosphonamidate. The solution was shaken at 
850 rpm and 14 °C for 16 hours. Afterwards, the mixture was concentrated to 900 μl by spin-
filtration (MWCO: 10 kDa, 0.5 ml, Sartorius, Germany) 
Alternatively, 48 μl of a 70 mM solution of DTT in 50 mM sodium borate in PBS (pH 8.0) was 
added to 480 µl of a brentuximab solution of 5.0 mg/ml in 50 mM sodium borate in PBS (pH 
8.0) and the mixture was incubated at 37 °C for 40 min. Excess DTT removal and exchange 
to the conjugation buffer was conducted afterwards using 2 mL Zeba™ Spin Desalting 
Columns with 7K MWCO (Thermo Fisher Scientific, USA). The reduced antibody solution (4.55 
mg/ml, 30.35 μM) was mixed quickly afterwards with 27.5 μl of a 2.73 mM solution of O-2-(2-
Hydroxyethoxy)ethyl-P-ethynyl-phosphonamidate-VC-PAB-MMAE 10 dissolved in DMSO to 
give a final amount of 5% DMSO and 4. eq. phosphonamidate. The solution was shaken at 
850 rpm and 14 °C for 16 hours. 
The reaction mixtures were purified in two portions by size-exclusion chromatography with a 
25 ml Superose™ 6 Increase 10/300GL (GE healthcare, United States) and a flow of 0.8 
ml/min eluting with sterile PBS (Merck, Germany). The antibody containing fractions were 
pooled and concentrated by spin-filtration (MWCO: 10 kDa, 6 ml, Sartorius, Germany). For 
DAR analysis, 10 μl of this sample were mixed with 30 μl of a buffer containing 500 mM NaCl 
and 100 mM NaHCO3and the sample was processed further as described under 3.9b. The 
final concentration was determined in a 96-well plate with a Pierce™ Rapid Gold BCA Protein 
Assay Kit (Thermo Fisher Scientific, USA) and a Bradford reagent B6916 (Merck, Germany) 
with pre-diluted protein assay standards of bovine gamma globulin (Thermo Fisher Scientific, 
USA). Results of both Assays were arithmetically averaged. 
The ADC was analyzed by analytical size exclusion chromatography (a) and intact protein MS 
(b) before subsequent experiments. HC: heavy chain, LC: light chain. *deconvolution artefacts 
(half mass of HC species and double mass of LC species). It should be noted that no species 
was detected in the MS that could be assigned to any form of unconjugated MMAE. 
 
3.12. Stability studies in rat serum: ADC incubation serum and analysis of the 
DAR after antibody pulldown 
In an Eppendorf-tube, 200 μl rat serum (Sigma Aldrich, United States) were mixed with 50 μl 
Brentuximab-10 (2.0 mg/ml) or Adcetris® for each sample individually to give a final solution 
of 0.4 mg/ml ADC in 80% rat serum. Samples were sterile filtered with UFC30GV0S centrifugal 
filter units (Merck, Germany) and incubated at 37°C for 3 and 7 days. Samples for day 0 were 
directly processed further.  
The supernatant of 50 l anti human igG (Fc-Specific) agarose slurry (Sigma Aldrich, United 
States) was removed by centrifugation and the remaining resin washed three times with 200 l 
PBS. The resin was incubated with 240 μl of the serum-ADC mix for 30 min at room 
temperature. Afterwards, the supernatant was removed and the resin washed 5 times with 
200 l PBS. Following by incubation for 5 minutes with 200 μl IgG elution buffer (Thermo-
Fisher, United States) at room temperature. Now the supernatant was transferred into a Spin 
filter (MWCO: 10 kDa, 0.5 ml, Sartorius, Germany), rebuffered to a buffer containing 500 mM 
NaCl and  100 mM NaHCO3, concentrated to 40 μl and processed further as described under 
3.9b for the Brentuximab-10 samples. Since we observed decomposition of the maleimide 
linkage in Adcetris® under our standard deglycosylation conditions, all Adcetris® samples 
were rebuffered to PBS, concentrated to 100 µl and processed further as described under 
3.9c. All measurements were performed in triplicates (n=3). MS Spectra that were obtained 
after 0, 3 and 7 days are shown below. HC: heavy chain, LC: light chain. 
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0 days of incubation of brentuximab-10 in rat serum at 37°C: 
 
3 days of incubation of brentuximab-10 in rat serum at 37°C: 
 
7 days of incubation of brentuximab-10 in rat serum at 37°C: 
 
 
0 days of incubation of Adcetris® in rat serum at 37°C: 
 
3 days of incubation of Adcetris® in rat serum at 37°C: 
 
7 days of incubation of Adcetris® in rat serum at 37°C: 
 
3.13. Stability assessment of ADCs with A-SEC 
Brentuximab-10 was adjusted to a protein concentration of 1 mg/mL in PBS (Dulbeccos 
Phospahte Bufferd Saline, Sigma-Aldrich Merck KGaA) and filtered sterile (Ultrafree-MC 
Centrifugal filter units, Merck Millipore). Samples were stored at 4-8°C, 37°C and 40°C for up 
to 14 days. For samples stored at elevated temperatures, it was ensured that no condensate 
was formed. Before analysis via A-SEC the samples where centrifuged at 4°C, 4000 x g for 4 
minutes.  
3.14. In vivo xenograft model 
 
The in vivo evaluations were performed at EPO GmbH. All animal experiments were conducted 
in accordance with German animal welfare law and approved by local authorities. In brief, 
1x107 Karpas 299 cells were subcutaneously injected to CB17-Scid mice at day 0. Treatment 
was initiated when tumors reached a mean tumor volume of 0.136±0.087 cm3 at day 7 (study 
1) and day 8 (study 2). Following randomization of mice into treatment and control groups, 1 
mg/kg of brentuximab-10 or Adcetris as well as vehicle (PBS) were administered as 
intravenous injection on days 7 and 10 for the first study and 0.5 mg/kg of brentuximab-10 or 
Adcetris as well as vehicle (PBS) on days 8 and 12 for the second study. Tumor volumes, body 
weights and general health conditions were recorded throughout the whole study. 
 
4. Organic synthesis 
4.1. N-(4-azidobenzoyl)-L-valine 
 
A 50-ml Schlenk-flask was charged with 1.00 g of 4-azidobenzoic acid (6.13 mmol, 1.00 eq.) 
and suspended in 8.5 ml of dry CH2Cl2 together with a drop of DMF under argon. 630 µl of 
oxalylchloride were added drop-wise at 0 °C and the reaction mixture was stirred at room 
temperature for 2 h until the solution became clear. All volatiles were removed under reduced 
pressure and the corresponding solid was redissolved in 4 ml of DMF. The corresponding 
solution was added drop-wise at 0 °C to a solution of 720 mg L-valin (6.13 mmol, 1.00 eq.) and 
612 mg sodium hydroxide (15.33 mmol, 2.50 eq.) in 8 ml water and stirred for 2 more hours. 
The solution was acidified with 1 N HCl and extracted three times with diethylether. The organic 
fractions were pooled, dried (MgSO4) and the solvents were removed under reduced pressure. 
Pure product was obtained by flash column chromatography on silicagel (30% EtOAc, 0.5% 
formic acid in n-hexane) as colourless fume. (954 mg, 4.96 mmol, 80.9%) 
1H NMR (600 MHz, Chloroform-d) δ = 10.12 (s, 1H), 7.79 (d, J=8.6, 2H), 7.05 (d, J=8.6, 2H), 
6.79 (d, J=8.5, 1H), 4.76 (dd, J=8.5, 4.9, 1H), 2.33 (pd, J=6.9, 4.9, 1H), 1.03 (d, J=6.9, 3H), 
1.01 (d, J=6.9, 3H). 13C NMR (151 MHz, CDCl3) δ = 175.82, 167.28, 144.03, 130.17, 129.13, 
119.20, 77.16, 57.79, 31.40, 19.16, 17.99. HR-MS for C12H15N4O3+ [M+H]+ calcd.: 263.1139, 
found 263.1151. 
4.2. N-(4-azidobenzoyl)-L-valine-anhydride 
 
In a 100-ml round-bottom flask, 954 mg N-(4-azidobenzoyl)-L-valine (3.64 mmol, 1.00 eq.), 
750 mg dicyclohexylcarbodiimide (3.64 mmol, 1.00 eq.), 418 mg N-hydroxysuccinimide 
(3.64 mmol, 1.00 eq.) and 9 mg 4-(dimethylamino)-pyridine (0.07 mmol, 0.02 eq.) were 
dissolved in 25 ml of THF and stirred over night at room temperature. The reaction mixture 
was filtered, the solids were washed several times with THF, the solvent was removed under 
reduced pressure and the crude product was purified by flash column chromatography on 
silicagel (20 to 40% EtOAc in n-hexane). The compound was isolated as white powder 
(513 mg, 1.01 mmol, 55.7%) 
1H NMR (600 MHz, Chloroform-d) δ = 8.01 (d, J=8.7, 2H), 7.13 (d, J=8.7, 2H), 4.29 (d, J=4.6, 
1H), 2.39 (heptd, J=6.9, 4.6, 1H), 1.16 (d, J=6.9, 3H), 1.03 (d, J=6.9, 3H). 13C NMR (151 MHz, 
CDCl3) δ = 177.52, 160.90, 144.51, 129.60, 122.43, 119.30, 70.68, 31.28, 18.76, 17.57. 
4.3. N-(4-azidobenzoyl)-L-valine-L-citrulline 
 
In a 50-ml round-bottom flask, 380 mg N-(4-azidobenzoyl)-L-valine-anhydride (0.75 mmol, 
1.00 eq.) were dissolved in 2 ml of 1,2-Dimethoxyethane and cooled to 0 °C. A solution of 
351 mg L-citrulline (1.50 mmol, 2.00 eq.) and 144 mg sodium hydrogencarbonate (2.25 mmol, 
3.00 eq.) in 4 ml H2O and 2 ml THF was added dropwise and stirred over night at room 
temperature. All volatiles were removed under reduced pressure and the crude product was 
purified by flash column chromatography on silicagel (10% MeOH, 0.5% formic acid in CH2Cl2). 
The compound was isolated as colourless oil (312 mg, 0.74 mmol, 99.0%). 
1H NMR (600 MHz, DMSO-d6) δ = 8.31 (d, J=8.8, 1H), 8.27 – 8.21 (m, 1H), 7.96 (d, J=8.6, 2H), 
7.20 (d, J=8.6, 2H), 6.05 (t, J=5.5, 1H), 5.47 (s, 2H), 4.37 (t, J=8.3, 1H), 4.18 (td, J=8.1, 5.1, 
1H), 2.98 (q, J=6.4, 2H), 2.15 (dq, J=13.6, 6.8, 1H), 1.78 – 1.68 (m, 1H), 1.68 – 1.56 (m, 1H), 
1.51 – 1.35 (m, 2H), 0.96 (d, J=6.8, 3H), 0.94 (d, J=6.8, 3H). 13C NMR (151 MHz, DMSO) δ = 
174.09, 171.54, 165.99, 159.40, 142.77, 131.36, 129.93, 119.23, 59.31, 52.57, 49.07, 30.77, 
29.01, 27.07, 19.75, 19.28. HR-MS for C18H26N7O5+ [M+H]+ calcd.: 420.1990, found 420.1990. 
4.4. N-(4-azidobenzoyl)-L-valine-L-citrulline-4-aminobenzyl alcohol (1) 
 
In a 50-ml round-bottom flask, 330 mg N-(4-azidobenzoyl)-L-vaine-L-citrulline (0.787 mmol, 
1.0 eq.) and 107 mg 4-aminobenzyl alcohol (0.866 mmol, 1.10 eq.) were dissolved in 8 ml 
CH2Cl2 and 4 ml MeOH under an argon atmosphere and cooled to 0 °C. 390 mg N-
Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (1.574 mmol, 2.00 eq.) were added portion-
wise and the resulting solution was allowed to warm to room temperature overnight. All 
volatiles were removed under reduced pressure and the crude product was isolated by flash 
column chromatography on silicagel (10% to 15% MeOH in CH2Cl2) and obtained as white 
solid (164 mg, 0.313 mmol, 39.8%). Enantiomeric pure compound was isolated by preparative 
HPLC (Method D) and obtained as a white solid after lyophilisation.  
1H NMR (600 MHz, DMSO-d6) δ = 9.93 (s, 1H), 8.32 (d, J=8.4, 1H), 8.21 (d, J=7.6, 1H), 7.96 
(d, J=8.6, 2H), 7.55 (d, J=8.6, 2H), 7.24 (d, J=8.6, 2H), 7.21 (d, J=8.6, 2H), 6.12 (bs, 2H), 4.44 
(s, 2H), 4.46 – 4.40 (m, 1H), 4.36 (t, J=8.1, 1H), 3.09 – 2.93 (m, 2H), 2.24 – 2.04 (m, J=6.7, 
1H), 1.84 – 1.58 (m, 2H), 1.55 – 1.34 (m, 2H), 0.95 (d, J=6.7, 3H), 0.94 (d, J=6.7, 3H). 13C 
NMR (151 MHz, DMSO) δ = 171.62, 170.79, 166.15, 159.46, 142.83, 137.95, 137.91, 131.29, 
129.96, 127.38, 119.34, 119.26, 63.07, 59.56, 53.64, 39.20, 30.61, 29.88, 27.16, 19.79, 19.37. 
HR-MS for C25H33N8O5+ [M+H]+ calcd.: 525.2568, found 525.2563. [α]ୈଶସ = ─49.6 (c = 0.81; 
MeOH) 
4.5. N-(4-(O-Ethyl-P-ethynyl-phosphonamidato-N-benzoyl)-L-valine-L-
citrulline-4-aminobenzyl-4-nitrophenyl carbonate (2) 
 
A 5-ml round-bottom flask was charged with 31 mg N-(4-(O-Ethyl-P-ethynyl-phosphonamidato-
N-benzoyl)-L-valine-L-citrulline-4-aminobenzyl alcohol (1) (0.050 mmol, 1.00 eq.) and 31 mg 
Bis(4-nitrophenyl) carbonate (0.101 mmol, 2.00 eq.). The solids were dissolved in 140 µl of 
DMF and 17.4 µl DIPEA (0.101 mmol, 2.00 eq.) were added. The yellow solution was stirred 
for 1 h at room temperature and the solution was added to 30 ml of ice-cold diethyl ether. The 
precipitate was collected by centrifugation, redissolved in DMF and again precipitated with 
ether. The procedure was conducted three times in total and finally the solid was dried under 
high vacuum conditions. The compound was isolated in quantitative yields and sufficiently pure 
for the next step. Analytical pure material was purified by preparative HPLC using method C.  
1H NMR (600 MHz, DMSO-d6) δ = 10.10 (s, 1H), 8.79 (d, J=8.5, 1H), 8.32 (d, J=9.1, 1H), 8.23 
(d, J=7.4, 1H), 8.07 (dd, J=8.5, 2.2, 1H), 7.81 (d, J=8.7, 2H), 7.66 (d, J=8.5, 2H), 7.57 (d, J=9.1, 
1H), 7.42 (d, J=8.5, 2H), 7.13 (d, J=8.7, 2H), 5.25 (s, 2H), 4.47 – 4.40 (m, 2H), 4.34 (t, J=8.0, 
1H), 4.20 – 4.05 (m, 2H), 3.01 (ddt, J=47.1, 13.4, 6.8, 2H), 2.20 – 2.09 (m, J=6.8, 1H), 1.80 – 
1.59 (m, 2H), 1.55 – 1.35 (m, 2H), 1.30 (t, J=7.0, 3H), 0.95 (d, J=6.7, 3H), 0.93 (d, J=6.7, 3H). 
13C NMR (151 MHz, DMSO-d6) δ = 171.79, 171.17, 166.58, 159.44, 155.75, 152.42, 145.63, 
143.50, 139.83, 129.95, 129.77, 129.30, 127.59, 125.86, 123.08, 119.51, 117.24 (d, J=7.8), 
91.67 (d, J=45.6), 77.26 (d, J=261.0), 70.71, 62.26 (d, J=5.0), 59.31, 53.68, 39.14, 30.71, 
29.76, 27.19, 19.80, 19.30, 16.41 (d, J=6.9). 31P NMR (243 MHz, DMSO) δ = -10.39, -10.44. 
HR-MS for C36H43N7O11P+ [M+H]+ calcd.: 780.2753, found 780.2744. 
4.6. N-(4-(O-Ethyl-P-ethynyl-phosphonamidato-N-benzoyl)-L-valine-L-
citrulline-4-aminobenzyl-4-nitrophenyl carbonate (3) 
 
A 5-ml round-bottom flask was charged with 31 mg N-(4-(O-Ethyl-P-ethynyl-phosphonamidato-
N-benzoyl)-L-valine-L-citrulline-4-aminobenzyl alcohol (2) (0.050 mmol, 1.00 eq.) and 31 mg 
Bis(4-nitrophenyl) carbonate (0.101 mmol, 2.00 eq.). The solids were dissolved in 140 µl of 
DMF and 17.4 µl DIPEA (0.101 mmol, 2.00 eq.) were added. The yellow solution was stirred 
for 1 h at room temperature and the solution was added to 30 ml of ice-cold diethyl ether. The 
precipitate was collected by centrifugation, redissolved in DMF and again precipitated with 
ether. The procedure was conducted three times in total and finally the solid was dried under 
high vacuum conditions. The compound was isolated in quantitative yields and sufficiently pure 
for the next step. Analytical pure material was purified by preparative HPLC using method C.  
1H NMR (600 MHz, DMSO-d6) δ = 10.10 (s, 1H), 8.79 (d, J=8.5, 1H), 8.32 (d, J=9.1, 1H), 8.23 
(d, J=7.4, 1H), 8.07 (dd, J=8.5, 2.2, 1H), 7.81 (d, J=8.7, 2H), 7.66 (d, J=8.5, 2H), 7.57 (d, J=9.1, 
1H), 7.42 (d, J=8.5, 2H), 7.13 (d, J=8.7, 2H), 5.25 (s, 2H), 4.47 – 4.40 (m, 2H), 4.34 (t, J=8.0, 
1H), 4.20 – 4.05 (m, 2H), 3.01 (ddt, J=47.1, 13.4, 6.8, 2H), 2.20 – 2.09 (m, J=6.8, 1H), 1.80 – 
1.59 (m, 2H), 1.55 – 1.35 (m, 2H), 1.30 (t, J=7.0, 3H), 0.95 (d, J=6.7, 3H), 0.93 (d, J=6.7, 3H). 
13C NMR (151 MHz, DMSO-d6) δ = 171.79, 171.17, 166.58, 159.44, 155.75, 152.42, 145.63, 
143.50, 139.83, 129.95, 129.77, 129.30, 127.59, 125.86, 123.08, 119.51, 117.24 (d, J=7.8), 
91.67 (d, J=45.6), 77.26 (d, J=261.0), 70.71, 62.26 (d, J=5.0), 59.31, 53.68, 39.14, 30.71, 
29.76, 27.19, 19.80, 19.30, 16.41 (d, J=6.9). 31P NMR (243 MHz, DMSO) δ = -10.39, -10.44. 
HR-MS for C36H43N7O11P+ [M+H]+ calcd.: 780.2753, found 780.2744. 
4.7. O-Ethyl-P-ethynyl-phosphonamidate-VC-PAB-MMAF 4 
 
A screw-cap vial was charged with 14.35 mg N-(4-(O-Ethyl-P-ethynyl-phosphonamidato-N-
benzoyl)-L-valine-L-citrulline-4-aminobenzyl-4-nitrophenyl carbonate (3) (0.0184 mmol, 1.00 
eq.), 0.50 mg 1-Hydroxybenzotriazol (0.0037 mmol, 0.20 eq.) and 13.15 mg MMAF 
(0.0184 mmol, 1.00 eq.). The solids were dissolved in 250 μl dry DMF and 25 μl pyridine and 
heated to 60 °C over-night. All volatiles were removed under reduced pressure, the crude 
product was purified by preparative HPLC using method E and the desired compound obtained 
as a white solid after lyophilization. (4.84 mg, 0.0035 mmol, 19.2 %). HR-MS for 
C69H104N11O16P2+ [M+2H]2+ calcd.: 686.8695, found 686.8694. 
 
4.8. Di-(2-(2-Hydroxyethoxy)ethyl) ethynylphosphonite (5) 
 
A 25-ml Schlenk flask was charged with 267 mg bis(diisopropylamino)chlorophosphine (1.00 
mmol, 1.00 eq.) under an argon atmosphere, cooled to 0 °C and 2.20 ml ethynylmagnesium 
bromide solution (0.5 M in THF, 1.10 mmol, 1.10 eq.) was added drop wise. The yellowish 
solution was allowed to warm to room temperature and stirred for further 30 minutes. 1.06 g 
diethylene glycol (10.00 mmol, 10.00 eq.), dissolved in 5.56 ml 1H-tetrazole solution (0.45 M 
in MeCN, 2.50 mmol, 2.50 eq.) were added and the white suspension was stirred over night at 
room temperature. The reaction mixture was directly placed on a silica gel flash column for 
purification (5% MeOH in CH2Cl2). The desired compound was obtained as a yellowish oil. 
(112 mg, 0.421 mmol, 42.1%). 
1H NMR (300 MHz, Chloroform-d) δ = 4.14 – 3.98 (m, 4H), 3.65 – 3.59 (m, 4H), 3.58 – 3.49 
(m, 8H), 3.15 (d, J=2.4, 1H) 13C NMR (75 MHz, Chloroform-d) δ = 92.51 (d, J=1.4), 84.30 (d, 
J=46.8), 72.60, 70.72 (d, J=4.0), 67.20 (d, J=6.0), 61.44. 31P NMR (122 MHz, CDCl3) δ = 
131.97. 
4.9. 2-(2-Hydroxyethoxy)ethyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-
P-ethynyl phosphonamidate (8) 
 
In a 5 ml round-bottom-flask, 93 mg Di-(2-(2-Hydroxyethoxy)ethyl) ethynylphosphonite (5) 
(0.192 mmol, 1.00 eq.) and 91 mg 4-azidobenzoic-acid-N-hydroxysuccinimide ester (6) 
(0.192 mmol, 1.00 eq.) were dissolved in 1 ml of DMF and the solution was stirred overnight. 
All volatiles were removed under reduced pressure and the residue purified by column 
chromatographie on silicagel (100% EtOAc). The compound was obtained as colourless oil. 
(45 mg, 0.109 mmol, 31.4%).  
1H NMR (300 MHz, Chloroform-d) δ 8.02 (d, J = 8.7 Hz, 2H), 7.79 (d, J = 7.6 Hz, 1H), 7.21 (d, 
J = 8.8 Hz, 2H), 4.30 (dp, J = 13.6, 4.5 Hz, 2H), 3.89 – 3.67 (m, 6H), 3.09 (d, J = 13.3 Hz, 1H), 
2.89 (s, 4H). 13C NMR (75 MHz, Chloroform-d) δ 169.67, 161.45, 145.78 (d, J = 1.6 Hz), 132.32, 
118.04, 117.66 (d, J = 8.1 Hz), 89.29 (d, J = 50.1 Hz), 75.34 (d, J = 294.4 Hz), 72.59, 69.44 
(d, J = 5.1 Hz), 66.19 (d, J = 5.9 Hz), 61.35, 25.68. 31P NMR (122 MHz, CDCl3) δ -9.66. HRMS 
for C17H20N2O8P+ [M+H]+ calcd.: 411.0952, found: 411.0951. 
4.10. O-ethyl-P-ethynyl-phosphonamidate-VC-PAB-MMAE 9 
 
In a screw-cap-vial equipped with a stirring bar, 5 mg of H2N-Val-Cit-PAB-MMAE 11 
(4.452 μmol, 1.00 eq.) and 3.12 mg 2-ethyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-
ethynyl phosphonamidate (7) (8.904  μmol, 2.00 eq.) were dissolved in 50 μl DMF. 3.1 μl 
DIPEA (17.808  μmol, 4.00 eq.) were added and the solution was stirred overnight at room 
temperature. The solution was diluted with 4 ml 30% MeCN in H2O and subjected to semi-
preparative HPLC purification using method F and the desired compound obtained as a white 
solid after lyophilization. (5.00 mg, 3.681 μmol, 82.7%). HR-MS for C69H105N11O15P+ [M+H]+ 
calcd.: 1358.7524, found 1358.7518. 
t [min]
25
4 
nm
 a
bs
or
ba
nc
e 
[m
Au
]
5 10 15
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
 
4.11. O-2-(2-Hydroxyethoxy)ethyl-P-ethynyl-phosphonamidate-VC-PAB-MMAE 
10 
 
In a screw-cap-vial equipped with a stirring bar, 5 mg of H2N-Val-Cit-PAB-MMAE 11 
(4.452 μmol, 1.00 eq.) and 3.65 mg 2-(2-Hydroxyethoxy)ethyl-N-(4-benzoic-acid-N-
hydroxysuccinimideester)-P-ethynyl phosphonamidate (8) (8.904  μmol, 2.00 eq.) were 
dissolved in 50 μl DMF. 3.1 μl DIPEA (17.808  μmol, 4.00 eq.) were added and the solution 
was stirred overnight at room temperature. The solution was diluted with 4 ml 30% MeCN in 
H2O and subjected to semi-preparative HPLC purification using method F and the desired 
compound obtained as a white solid after lyophilization. (2.73 mg, 1.589 μmol, 35.7%). HR-
MS for C71H109N11O17P+ [M+H]+ calcd.: 1418.7735, found 1418.7729. 
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5. NMR spectra 
N-(4-azidobenzoyl)-L-valine 
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N-(4-azidobenzoyl)-L-valine-L-citrulline 
 
 
N-(4-azidobenzoyl)-L-valine-L-citrulline-4-aminobenzyl alcohol (2) 
 
 
N-(4-(O-Ethyl-P-ethynyl-phosphonamidato-N-benzoyl)-L-valine-L-citrulline-4-aminobenzyl 
alcohol (2) 
 
 
  
 
N-(4-(O-Ethyl-P-ethynyl-phosphonamidato-N-benzoyl)-L-valine-L-citrulline-4-aminobenzyl-4-
nitrophenyl carbonate (3) 
 
  
 
Di-(2-(2-Hydroxyethoxy)ethyl) ethynylphosphonite (5) 
 
 
 
Di-(2-(2-Hydroxyethoxy)ethyl)-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-ethynyl 
phosphonamidate (8) 
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7. Summary and Outlook 
Within the present work, a novel cysteine selective protein- and antibody modification method based 
on electrophilic phosphonamidate reagents has been established. Additionally, it was demonstrated 
that the cysteine reactive vinyl- and ethynylphosphonamidates can be chemoselectively installed into 
a given azide modified molecule by means of the Staudinger-phosphonite reaction with vinyl- and 
ethynylphosphonites yielding electron-deficient phosphorus-(V) compounds. This chemoselective 
reaction chemically induces reactivity for the subsequent cysteine modification on proteins. The 
reaction sequence thereby constitutes an unprecedented modular strategy for the attachment of 
highly complex functional molecules to proteins. Furthermore, it was shown in several independent 
experiments, employing various model systems that the thiol adducts to the electrophilic 
phosphonamidate reagents are formed irreversibly under physiological conditions. Since linkage 
integrity is crucial for the safety and efficacy of functional drug conjugates that facilitate a selective 
delivery of a pharmacophore in the body towards the side of action, the phosphonamidate linker 
system has been applied to link cytotoxic payloads to monoclonal antibodies. The resulting ADCs were 
extensively evaluated in vitro and in vivo, which revealed a superior stability of the linker system paired 
with an increased antitumor efficacy in mice when directly compared to standard maleimide linkages 
in a FDA-approved ADC.  
7.1. Chemically induced cysteine modification of proteins and antibodies with 
ethynylphosphonamidates 
Previous research that dealt with the development of the SPhR for the chemoselective modification of 
azide containing proteins and for the modular conjugation of two azide containing building blocks using 
borane protected ethynylphosphonites has been continued within the present work. This lead to the 
establishment of a novel modular reaction sequence that employs the SPhR for the synthesis of 
ethynylphosphonamidates that subsequently undergo cysteine modification on proteins and 
antibodies. A synthetic procedure has been developed that facilitates the synthesis of 
ethynylphosphonamidates from various azide containing building blocks in the presence of several 
functional groups. Incorporation into a variety of different molecules has been performed in very good 
yields, including biotin derivatives, fluorescent dyes and unprotected peptides. Subsequent thiol 
addition studies revealed a second order rate constant of 0.62 M-1s-1 that is reasonably fast for cysteine 
modification on proteins. After method development, the technique was applied to the synthesis of 
various functional protein and antibody conjugates from fluorescent dyes, peptides and biotin 
derivatives (Figure 27), which generated the desired conjugates with an unprecedented selectivity for 
cysteine and good conjugation yields. Stability measurements revealed an excellent cysteine conjugate 
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stability under physiological conditions in the presence of large thiol excess, cellular lysate and human 
serum. In strong contrast to standard maleimide linkages, it was shown that antibodies modified with 
phosphonamidates do not transfer the attached payload to other cysteine containing proteins like 
albumin and phosphonamidate-cysteine linkages are generally less prone to retro-thiol addition once 
the conjugates are formed.  
 
Figure 27: Principle of the SPhR with ethynylphosphonites that induces thiol reactivity for the subsequent cysteine selective modification on 
proteins. Shown are chosen ethynylphosphonamidates that have been synthesized and proteins that have been modified within the present 
work.  
Furthermore, the synthetic incorporation of different O-substituents to the phosphonamidates has 
been performed within the current work. Several different phosphonites were prepared, carrying 
various functional handles and have been subsequently used in the SPhR with azides. Thereby it was 
possible to attach moieties to the O-substituent that expand the functionality of the final conjugate. It 
could be demonstrated that small ethylene glycol chains increase the water solubility of 
ethynylphosphonamidate modified hydrophobic payloads, which leads to a better cysteine 
conjugation efficiency to antibodies In addition to that, a terminal alkyne has been attached that allows 
for the attachment of a third functionality to the system via CuAAC. Finally, different tags have been 
synthetically attached to the phosphonamidate that allow a stimulated release of the O-substituent by 
light, esterase activity or reductive conditions to generate phosphonamidic acids with increased P-N-
lability (Figure 28). Here, intracellularly cleavable handles could facilitate a traceless release of a 
primary amine after cellular uptake, which makes those substituents in particular interesting for drug 
delivery applications.  
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Figure 28: Attachment of different handles to the phosphonamidate ester residue expands the functionality of the final conjugate. Shown 
are chosen substituents that have been synthetically incorporated and evaluated within this work. 
The current work described the synthesis of phosphonamidates with cleavable substituents and 
provides preliminary data that support the mechanistic principle of an intracellular release. Further 
investigations include intensive stability studies on the intact phosphonamidates and the released 
phosphonamidic acids intracellularly and during blood circulation to finally construct a drug-conjugate 
that is stably linked via a cleavable phosphonamidate and releases its payload only upon cellular 
uptake. The groundwork towards such a conceptually novel, phosphonamidate based cleavage side 
has been laid by the work described in this thesis.  
7.2. Variation of the O-substituent of vinylphosphonamidates facilitate reactivity 
tuning of the thiol-addition 
To further expand the scope of the methodology, the SPhR was also carried out with vinylphosphonites 
to synthesize electrophilic vinylphosphonamidates for subsequent cysteine modifications on proteins 
and antibodies. To overcome much slower reaction kinetics of vinylphosphonamidates when 
compared to their ethynyl counterparts, several vinylphosphonites with different electron-
withdrawing substituents have been synthesized, transformed into vinylphosphonamidates via SPhR 
and tested in the reactivity with glutathione. It could be shown that various electron-withdrawing 
phosphonamidate ester residues exert increasing effects on the kinetics of the thiol addition. With a 
second-order rate constant of 0.021 M-1s-1, the O-trifluoroethyl substituted reagent was the fastest 
vinylphosphonamidate tested (Figure 29). Even though this is one order of magnitude slower than the 
standard ethyl-substituted ethynylphosphonamidate, the reaction is still fast enough to modify 
cysteine residues on proteins, as exemplified by modification of the antibody cetuximab with an 
EDANS-fluorophore. Further functional cysteine reactive vinylphosphonamidates that have been 
synthesized within the current work include peptides, a biotin derivative and Cy5-fluorophore. 
Vinylphosphonamidates have been successfully conjugated to various proteins and antibodies, 
including eGFP, ubiquitin and cetuximab.  
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Figure 29: Principle of the SPhR with vinylphosphonites and subsequent cysteine addition. Variation of the O-substituent facilitates tuning of 
the vinylphosphonamidate’s reactivity for cysteine or enable a light-cleavable triple conjugation via CuAAC.  
Similar to ethynylphosphonamidates, the attachment of an additional terminal alkyne to the 
phosphonamidate ester residue that enables further CuAAC-modifications could also be accomplished 
for vinylphosphonamidates (Figure 29). The additional incorporation of a 2-nitrobenzyl substituent 
between the phosphonamidate and the alkyne handle facilitates both, increased thiol addition kinetics 
due to the electron-withdrawing nature and furthermore a controlled light-mediated release of the 
substituent after conjugation.  
The fine tuning of the cysteine reactivity by variation of the phosphonamidate ester residue is giving 
rise to novel cysteine reactive probes for applications where a narrow reactivity window is crucial, as 
in covalent enzyme inhibitors for active center cysteines, for instance. Other than that, future 
investigations include further application of the light mediated triple conjugation for example to 
protein catch and release strategies or defined light mediated release of a cargo from a protein in 
cellular imaging applications.  
7.3. Ethynylphosphonamidates facilitate a simple synthetic access to efficacious 
ADCs  
One important aspect in tumor directed drug delivery is linkage stability between the targeting unit 
and the drug to prevent premature release during blood circulation that can cause severe side effects. 
This is in particular important for drug delivery systems that are big in size such as ADCs due to long 
circulation times in the body. Since ethynylphosphonamidates exhibit excellent cysteine selectivity, 
good reaction kinetics and outstanding linkage stability, they were chosen in the present work to 
synthesize ADCs via interchain disulfide reduction and alkylation. It could be demonstrated in several 
in vitro experiments that phosphonamidate linked ADCs from two therapeutically relevant antibodies, 
brentuximab and trastuzumab linked to two cytotoxic payloads MMAF and MMAE efficiently reduce 
the viability of targeted cell lines. Incorporation of a diethylene glycol unit to the phosphonamidate 
ester residue significantly enhanced the water solubility of the less polar MMAE and thereby also the 
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conjugation efficiency to antibodies. It was shown that only 4.5 equivalents of the drug are needed to 
achieve an average antibody loading of 4. Further development of this already very efficient 
conjugation reaction resulted in a most simple one-pot reduction and alkylation protocol for the 
synthesis of efficacious ADCs from native antibodies in a single step.  
 
Figure 30: Phosphonamidate linked Brentuximab-MMAE that has been synthesized in a highly efficient one-pot protocol within this thesis. 
Phosphonamidate linkage has been shown to improve linkage stability of maleimide linked Adcetris® in rat serum (left) and lead to an 
increase in median survival in mice bearing a tumor xenograft by a factor of 2.3 (right). 
Having the synthetic protocols established, an ADC analogously to the FDA-approved Adcetris® was 
synthesized from brentuximab and cathepsin B cleavable MMAE with the only difference being a 
phosphonamidate- instead of a maleimide linkage. It was shown that the phosphonamidate linked ADC 
exhibits a superior linkage stability in serum with only 10% of payload loss after seven days over 
commercial Adcetris® that lost 75% of its payload already after three days. In addition to that, it was 
shown that a group of tumor bearing mice, treated twice with 0.5 mg/kg ADC showed an increase in 
median survival from 23 to 48 days, which corresponds to a factor of 2.3 for the phosphonamidate 
linked ADC when compared to commercially available Adcetris®. 
Next steps include further validation of the superior pharmacologic properties of the 
phosphonamidate linkage in the context of ADCs, conducting in vivo pharmacokinetic and in vivo 
linkage stability measurements and investigating the maximum tolerated dose in a direct comparison 
to maleimide linked ADCs. The final goal is the establishment of ethynylphosphonamidates as a new 
linker class for safer and more efficacious Antibody-Drug-Conjugates, to develop a new generation of 
cancer treatment.  
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8. Experimental part 
8.1. General information 
8.1.1. Chemicals and solvents 
Chemicals and solvents were purchased from Merck (Merck group, Germany), TCI (Tokyo chemical 
industry CO., LTD., Japan) and Acros Organics (Thermo Fisher scientific, USA) and used without further 
purification. Dry solvents were purchased from Acros Organics (Thermo Fisher scientific, USA). 
8.1.2. Flash- and thin layer chromatography  
Flash column chromatography was performed, using NORMASIL 60® silica gel 40-63 µm (VWR 
international, USA). Glass TLC plates, silica gel 60 W coated with fluorescent indicator F254s were 
purchased from Merck (Merck Group, Germany). Spots were visualized by fluorescence depletion with 
a 254 nm lamp or manganese staining (10 g K2CO3, 1.5 g KMnO4, 0.1 g NaOH in 200 ml H2O), followed 
by heating. 
8.1.3. Semi-preparative HPLC 
Semi-preparative HPLC was performed on a Shimadzu prominence HPLC system (Shimadzu Corp., 
Japan) with a CBM20A communication bus module, a FRC-10A fraction collector, 2 pumps LC-20AP, 
and a SPD-20A UV/VIS detector, using a VP250/21 Macherey-Nagel Nucleodur C18 HTec Spum column 
(Macherey-Nagel GmbH & Co. Kg, Germany) eluting with 10 ml/min. Compounds with a sample-size 
of less than 10 mg were purified using a VP250/21 Macherey-Nagel Nucleodur C18 HTec Spum column 
eluting with 5 ml/min. The following gradients were used: Method A: (Solvent A = H2O + 0.1% TFA, 
solvent B = MeCN + +0.1% TFA), 5% B 0-5 min, 5-99% B 5-65 min, 99% B 65-75 min. Method B: (Solvent 
A = H2O + 0.1% TFA, solvent B = MeCN + +0.1% TFA), 25% B 0-5 min, 25-99% B 5-65 min, 99% B 65-75 
min. 
8.1.4. NMR 
NMR spectra were recorded with a Bruker Ultrashield 300 MHz spectrometer and a Bruker Avance III 
600 MHz spectrometer (Bruker Corp., USA) at ambient temperature. Chemical shifts δ are reported in 
ppm relative to residual solvent peak (CDCl3: 7.26 [ppm]; DMSO-d6: 2.50 [ppm]; acetone-d6: 2.05 
[ppm]; CD3CN 1.94 [ppm]; 4.79 D2O [ppm] for 1H-spectra and CDCl3: 77.16 [ppm]; DMSO-d6: 39.52 
[ppm]; acetone-d6: 29.84 [ppm]; CD3CN 1.32 [ppm]; for 13C-spectra . Coupling constants J are stated 
in Hz. Signal multiplicities are abbreviated as follows: s: singlet; d: doublet; t: triplet; q: quartet; m: 
multiplet. 
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8.1.5. UPLC-UV/MS 
UPLC-UV/MS traces were recorded on a Waters H-class instrument equipped with a quaternary solvent 
manager, a Waters autosampler, a Waters TUV detector and a Waters Acquity QDa detector with an 
Acquity UPLC BEH C18 1.7 μm, 2.1 x 50 mm RP column with a flow rate of 0.6 mL/min (Waters Corp., 
USA). The following gradient was used: A: 0.1% TFA in H2O; B: 0.1% TFA in MeCN. 5% B 0 - 0.5 min, 5-
95% B 0.5-3 min, 95% B 3-3.9 min, 5% B 3.9-5 min. Analytical method: 5% B 0 – 1.5 min, 5-95% B 1.5-
13 min, 95% B 13-13.9 min, 5% B 13.91-15 min. 
8.1.6. HR-MS 
High resolution ESI-MS spectra were recorded on a Waters H-class instrument equipped with a 
quaternary solvent manager, a Waters sample manager-FTN, a Waters PDA detector and a Waters 
column manager with an Acquity UPLC protein BEH C18 column (1.7 µm, 2.1 mm x 50 mm). Samples 
were eluted with a flow rate of 0.3 mL/min. The following gradient was used: A: 0.01% FA in H2O; B: 
0.01% FA in MeCN. 5% B: 0-1 min; 5 to 95% B: 1-7min; 95% B: 7 to 8.5 min. Mass analysis was conducted 
with a Waters XEVO G2-XS QTof analyzer. 
8.1.7. Intact protein MS 
Intact proteins were analyzed using a Waters H-class instrument equipped with a quaternary solvent 
manager, a Waters sample manager-FTN, a Waters PDA detector and a Waters column manager with 
an Acquity UPLC protein BEH C4 column (300 Å, 1.7 µm, 2.1 mm x 50 mm) at a column temperature of 
80 °C. Proteins were eluted with a flow rate of 0.3 mL/min. The following gradient was used: A: 0.01% 
FA in H2O; B: 0.01% FA in MeCN. 5-95% B 0-6 min. Mass analysis was conducted with a Waters XEVO 
G2-XS QTof analyzer. Proteins were ionized in positive ion mode applying a cone voltage of 80 kV. Raw 
data was analyzed with MaxEnt 1. 
8.1.8. Preparative size-exclusion chromatography 
Protein purification by size-exclusion chromatography was conducted with an ÄKTA FPLC system (GE 
Healthcare, United States) equipped with a P-920 pump system, a UPC-900 detector and a FRAC-950 
fraction collector. 
8.1.9. MALDI-TOF MS 
MALDI-TOF MS of intact protein samples was conducted with a Bruker Microflex™ LT benchtop system 
(Bruker, United States). Using a matrix of saturated DHAP (2′,6′-Dihydroxyacetophenone) in 
acetonitrile. 
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8.2. Procedures and compound characterizations 
General procedure 1 for the synthesis of O-substituted ethynylphosphonites from 
bis(diisopropylamino)chlorophosphine 
 
A 25-ml Schlenk flask was charged with 267 mg bis(diisopropylamino)chlorophosphine (2) (1.00 mmol, 
1.00 eq.) under an argon atmosphere, cooled to 0 °C and 2.20 ml ethynylmagnesium bromide solution 
(0.5 M in THF, 1.10 mmol, 1.10 eq.) was added drop wise. The yellowish solution was allowed to warm 
to room temperature and stirred for further 30 minutes. The desired alcohol, dissolved in 5.56 ml 1H-
tetrazole solution (0.45 M in MeCN, 2.50 mmol, 2.50 eq.) was added and the white suspension was 
stirred overnight at room temperature. The reaction mixture was directly placed on a silica gel flash 
column for purification. It should be noted, that mass analysis of phosphonites failed for all of the 
tested compounds, possibly due to decomposition under ESI-conditions. 
2-Hydroxyethyl isopropyldisulfide 
 
A 250 ml-round bottom flask was charged with 2.00 ml isopropylthiol (21.53 mmol, 1.00 eq.), 1.52 ml 
2-mercaptoethanol (21.53 mmol, 1.00 eq.), 32 mg sodium iodide (0.21 mmol, 0.01 eq.) and 40 ml 
EtOAc and cooled to 0°C. The mixture was rapidly stirred and 10 mmol of a solution of 30% H2O2 in 
water was added drop-wise. 2.44 ml hydrogen peroxide solution (aqueous, 30%) (21.53 mmol, 1.00 
eq.) were added dropwise, the mixture was allowed to warm to room temperature and stirred for 1 h. 
All volatiles were removed under reduced pressure and the disulfide was isolated by column 
chromatography on silica (10% EtOAc in hexane) yielding 1.10 g of a colorless liquid (7.22 mmol, 
33.6%). 
1H NMR (300 MHz, Chloroform-d) δ = 3.88 (m, 2H), 3.02 (hept, J=6.7, 1H), 2.85 (t, J=5.9, 2H), 2.37 
(m, 1H), 1.32 (d, J=6.7, 6H). 13C NMR (75 MHz, CDCl3) δ = 60.48, 41.94, 41.14, 22.54. 
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Di-(2-isopropyl disulfido)ethyl) ethynylphosphonite (4) 
 
The compound was synthesized according to the general procedure 1 from 213 mg 
bis(diisopropylamino)chlorophosphine (2) (0.80 mmol, 1.00 eq.), 1.76 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 0.88 mmol, 1.10 eq.), 370 mg 2-Hydroxyethyl isopropyldisulfide (2.00 mmol, 
2.50 eq.), 4.44 ml 1H-tetrazole solution (0.45 M in MeCN, 2.00 mmol, 2.50 eq.) and purified by flash 
column chromatography on silica gel (10% EtOAc in hexane). The compound was obtained as yellowish 
oil. (183 mg, 0.51 mmol, 63.9%). 
1H NMR (300 MHz, Chloroform-d) δ = 4.21 (dt, J=8.0, 6.8, 4H), 3.15 (d, J=2.3, 1H), 3.04 (p, J=6.7, 2H), 
2.94 (t, J=6.8, 4H), 1.33 (d, J=6.7, 12H). 13C NMR (75 MHz, Chloroform-d) δ 92.47 (d, J = 1.0 Hz), 84.15 
(d, J = 47.9 Hz), 66.24 (d, J = 6.1 Hz), 41.18, 40.13 (d, J = 4.4 Hz), 22.58. 31P NMR (122 MHz, CDCl3) δ = 
130.40.  
Di-(2-tert-butyl disulfido)ethyl) ethynylphosphonite (5) 
 
The compound was synthesized according to the general procedure 1 from 167 mg 
bis(diisopropylamino)chlorophosphine (2) (0.63 mmol, 1.00 eq.), 1.38 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 0.69 mmol, 1.10 eq.), 260 mg 2-Hydroxyethyl tert-butyl disulfide (1.57 mmol, 
2.50 eq.), 3.48 ml 1H-tetrazole solution (0.45 M in MeCN, 1.57 mmol, 2.50 eq.) and purified by flash 
column chromatography on silica gel (10% EtOAc in hexane). The compound was obtained as yellowish 
oil. (190 mg, 0.49 mmol, 78.5%). 
1H NMR (300 MHz, Chloroform-d) δ = 4.20 (dt, J=7.9, 6.9, 4H), 3.14 (d, J=2.2, 1H), 2.95 (t, J=6.9, 4H), 
1.36 (s, 18H). 13C NMR (75 MHz, Chloroform-d) δ = 92.35 (d, J=1.0), 84.21 (d, J=47.8), 66.37 (d, J=6.1), 
47.98, 40.77 (d, J=4.3), 29.89. 31P NMR (122 MHz, CDCl3) δ = 130.28. 
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2-(3-Hydroxypropyl) isopropyl disulfide 
 
A 500-ml round-bottom flask was charged with 2.00 ml thiolactic acid (23.55 mmol, 1.00 eq.) and 
150 ml dry THF. At 0 °C, 1.60 g Lithium aluminum hydride (47.10, 2.0 eq.) were added portion-wise. 
The mixture was stirred at room temperature for 1 h, cooled again to 0 °C and quenched carefully with 
6 N HCl. The aqueous phase was extracted with twice with 100 ml EtOAc, the organic fractions pooled, 
dried (MgSO4) and all volatiles were removed under reduced pressure. The resulting colorless oil was 
redissolved in 20 ml EtOH and 2.18 ml isobutyl thiol (23.55 mmol, 1.00 eq.), 55 mg sodium iodide 
(0.24 mmol, 0.01 eq.) were added and the solution cooled to 0°C. 2.70 ml hydrogen peroxide solution 
(aqueous, 30%) (23.55 mmol, 1.00 eq.) were added and the yellowish solution was stirred for another 
hour at room temperature. Volatiles were removed under reduced pressure and the above stated 
disulfide isolated by column chromatography on silica (20% EtOAc in hexane) as colorless oil. Yield: 
1.15 g (6. 928 mmol, 29.4%) 
1H NMR (300 MHz, Chloroform-d) δ = 3.69 (dd, J=5.8, 3.2, 2H), 3.08 – 2.83 (m, 2H), 1.37 – 1.25 (m, 9H). 
13C NMR (75 MHz, CDCl3) δ = 65.49, 48.70, 41.66, 22.60, 22.51, 16.89. 
Di-((2-isopropyl disulfido)-3-propyl) ethynylphosphonite (6) 
 
The compound was synthesized according to the general procedure 1 from 267 mg 
bis(diisopropylamino)chlorophosphine (2) (1.00 mmol, 1.00 eq.), 2.20 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 1.10 mmol, 1.10 eq.), 415 mg 2-(3-Hydroxypropyl) isopropyl disulfide (2.50 
mmol, 2.50 eq.), 5.55 ml 1H-tetrazole solution (0.45 M in MeCN, 2.50 mmol, 2.50 eq.) and purified by 
flash column chromatography on silica gel (0-10% EtOAc in hexane). The compound was obtained as a 
diastereomeric mixture as a yellowish oil. (91 mg, 0.235 mmol, 23.5%). 
1H NMR (300 MHz, Chloroform-d) δ = 4.28 – 4.06 (m, 2H), 3.99 – 3.81 (m, 2H), 3.21 – 3.10 (m, 1H), 
3.07-2.95 (m, 4H), 1.37 – 1.28 (m, 18H). 13C NMR (75 MHz, Chloroform-d) δ = 92.39 (d, J=3.6), 84.32 (d, 
J=49.3), 71.18 (d, J=4.9), 48.18 – 44.79 (m), 41.65, 22.55 (d, J=6.5), 17.12. 31P NMR (122 MHz, CDCl3) δ 
= 130.56, 130.32, 130.10. 
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Di-(3-Butinyl) ethynylphosphonite (7) 
 
The compound was synthesized according to the general procedure 1 from 267 mg 
bis(diisopropylamino)chlorophosphine (2) (1.00 mmol, 1.00 eq.), 2.20 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 1.10 mmol, 1.10 eq.), 189 μl 3-Butyn-1-ol (2.50 mmol, 2.50 eq.), 5.56 ml 1H-
tetrazole solution (0.45 M in MeCN, 2.50 mmol) and purified by flash column chromatography on silica 
gel (10% EtOAc in n-hexane). The compound was obtained as a colorless oil. (152 mg, 0.774 mmol, 
77.4%). 
1H NMR (300 MHz, Chloroform-d) δ = 4.07 (dtd, J=8.1, 7.0, 1.5, 4H), 3.14 (d, J=2.3, 1H), 2.56 (tdd, J=7.0, 
2.7, 0.6, 4H), 2.03 (t, J=2.7, 2H). 13C NMR (75 MHz, Chloroform-d) δ = 92.42 (d, J=1.3), 83.92 (d, J=47.1), 
80.24, 70.02, 65.81 (d, J=6.5), 21.28 (d, J=4.7). 31P NMR (122 MHz, CDCl3) δ = 130.15. 
Di-(2-(2-Hydroxyethoxy)ethyl) ethynylphosphonite (8) 
 
The compound was synthesized according to the general procedure 1 from 267 mg 
bis(diisopropylamino)chlorophosphine (2) (1.00 mmol, 1.00 eq.), 2.20 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 1.10 mmol, 1.10 eq.), 1.06 g diethylene glycol (10.00 mmol, 10.00 eq.), 5.56 ml 
1H-tetrazole solution (0.45 M in MeCN, 2.50 mmol) and purified by flash column chromatography on 
silica gel (5% MeOH in CH2Cl2). The compound was obtained as a yellowish oil. (112 mg, 0.421 mmol, 
42.1%). 
1H NMR (300 MHz, Chloroform-d) δ = 4.14 – 3.98 (m, 4H), 3.65 – 3.59 (m, 4H), 3.58 – 3.49 (m, 8H), 3.15 
(d, J=2.4, 1H) 13C NMR (75 MHz, Chloroform-d) δ = 92.51 (d, J=1.4), 84.30 (d, J=46.8), 72.60, 70.72 (d, 
J=4.0), 67.20 (d, J=6.0), 61.44. 31P NMR (122 MHz, CDCl3) δ = 131.97. 
Di-(2-diethylamino benzyl) ethynylphosphonite (9) 
 
The compound was synthesized according to the general procedure 1 from 267 mg 
bis(diisopropylamino)chlorophosphine (2) (1.00 mmol, 1.00 eq.), 2.20 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 1.10 mmol, 1.10 eq.), 433 mg 2-diethylamino benzylalcoho (2.50 mmol, 2.50 
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eq.), 5.56 ml 1H-tetrazole solution (0.45 M in MeCN, 2.50 mmol) and purified by flash column 
chromatography on silica gel (20% EtOAc in hexane). The compound was obtained as a yellowish oil. 
(200 mg, 0.485 mmol, 48.5%). 
1H NMR (300 MHz, Chloroform-d) δ 7.34 – 7.16 (m, 2H), 6.74 – 6.62 (m, 6H), 5.08 – 4.86 (m, 4H), 3.39 
(q, J = 7.0 Hz, 8H), 3.18 (d, J = 2.4 Hz, 1H), 1.20 (t, J = 7.1 Hz, 12H). 13C NMR (75 MHz, Chloroform-d) δ 
147.98, 138.84 (d, J = 4.2 Hz), 129.41, 114.74, 111.44, 111.02, 92.07, 85.08 (d, J = 49.0 Hz), 70.65 (d, J 
= 6.3 Hz), 44.36, 12.63. 31P NMR (122 MHz, CDCl3) δ 129.82. 
Di-(4-acetoxy benzyl) ethynylphosphonite (10) 
 
The compound was synthesized according to the general procedure 1 from 267 mg 
bis(diisopropylamino)chlorophosphine (2) (1.00 mmol, 1.00 eq.), 2.20 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 1.10 mmol, 1.10 eq.), 415 mg 4-Acetoxybenzyl alcohol (2.50 mmol, 2.50 eq.), 
5.55 ml 1H-tetrazole solution (0.45 M in MeCN, 2.50 mmol, 2.50 eq.) and purified by flash column 
chromatography on silica gel (30% EtOAc in hexane). The compound was obtained as a as colorless oil. 
(118 mg, 0.306 mmol, 30.6%). 
1H NMR (300 MHz, Chloroform-d) δ = 7.34 (d, J=8.5, 4H), 7.08 (d, J=8.5, 4H), 4.95 (dd, J=8.4, 1.7, 4H), 
3.20 (d, J=2.3, 1H), 2.32 (s, 6H). 13C NMR (75 MHz, Chloroform-d) δ = 169.44, 150.37, 135.31 (d, J=4.3), 
128.89, 121.68, 92.68, 84.40 (d, J=47.6), 69.35 (d, J=6.8), 21.16. 31P NMR (122 MHz, CDCl3) δ = 131.09. 
Di (4-(diazophenyl)-benzyl) ethynylphosphonite (11) 
 
The compound was synthesized according to the general procedure 1 from 98 mg 
bis(diisopropylamino)chlorophosphine (2) (0.37 mmol, 1.00 eq.), 0.80 ml ethynylmagnesium bromide 
solution (0.5 M in THF, 0.4 mmol, 1.10 eq.), 195 mg 1-(4-(hydroxymethyl)phenyl)-2-phenyldiazene 
(0.93 mmol, 2.50 eq.), 2.00 ml 1H-tetrazole solution (0.45 M in MeCN, 0.93 mmol, 2.50 eq.) and 
purified by flash column chromatography on silica gel (0-10% EtOAc in hexane). The compound was 
obtained as orange solid. (82 mg, 0.171 mmol, 46.3%). 
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1H NMR (300 MHz, Chloroform-d) δ = 7.98 – 7.86 (m, 8H), 7.59 – 7.44 (m, 10H), 5.08 (d, J=8.5, 4H), 3.24 
(d, J=2.3, 1H). 13C NMR (75 MHz, Chloroform-d) δ = 152.60, 152.27, 140.55 (d, J=4.3), 131.07, 129.09, 
128.24, 123.03, 122.90, 92.89, 84.35 (d, J=47.2), 69.54 (d, J=6.9). 31P NMR (122 MHz, CDCl3) δ = 131.77. 
General procedure 2 for the synthesis of borane protected ethynylphosphonites from 
Bis(diisopropylamino)chlorophosphine 
 
A flame-dried Schlenk flask was charged with 1.0 mmol (1.0 eq.) Bis(diisopropylamino)-
chlorophosphine, dissolved in 200 µl of dry THF and cooled to 0 °C. 1.10 mmol (1.1eq.) of ethynyl 
magnesiumbromide (1.0 M in THF) was added and the reaction was stirred at room temperature for 
30 minutes. A solution of 2.5 mmol vacuum dried alcohol (2.5 eq.) in 1 ml of dry THF or MeCN and 
2.5 mmol (2.5 eq.) 1H-tetrazole (0.45 M in MeCN) was added. The resulting suspension was stirred at 
room temperature overnight. Finally 1.5 mmol (1.5 eq.) of borane (1.0 M in THF) were added at 0 °C 
and stirred for another hour. The crude product was dry packed on a silica column for purification. It 
should be noted, that mass analysis of phosphonites failed for all of the tested compounds, possibly 
due to decomposition under ESI-conditions. 
Diphenyl ethynylphosphonite borane (12) 
 
The compound was synthesized according to the general procedure 2 from 
Bis(diisopropylamino)chlorophosphine (267 mg, 1.00 mmol). The crude borane protected 
phosphonite was purified by flash column chromatography (30% CH2Cl2 in hexane) and obtained as a 
colorless oil. (90 mg, 0.351 mmol, 35.1%) 
1H NMR (300 MHz, Chloroform-d) δ 7.41 (dd, J = 8.7, 7.0 Hz, 4H), 7.34 – 7.20 (m, 6H), 3.28 (d, J = 7.5 
Hz, 1H), 1.77 – 0.20 (m, 3H). 13C NMR (75 MHz, Chloroform-d) δ 151.11 (d, J = 10.0 Hz), 129.88 (d, J = 
1.3 Hz), 125.98 (d, J = 1.5 Hz), 120.89 (d, J = 4.6 Hz), 95.75 (d, J = 24.7 Hz), 76.01 (d, J = 119.5 Hz). 31P 
NMR (122 MHz, Chloroform-d) δ 107.02 – 103.45 (m). 
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Di(2-nitrobenzyl) ethynylphosphonite borane (13) 
 
The compound was synthesized according to the general procedure 2 from 
Bis(diisopropylamino)chlorophosphine (534 mg, 2.00 mmol). The crude borane protected 
phosphonite was purified by flash column chromatography (20% EtOAc in hexane) and obtained as a 
colorless solid. (677 mg, 1.810 mmol, 90.5%) 
1H NMR (300 MHz, Chloroform-d) δ 8.36 – 8.12 (m, 2H), 7.87 – 7.67 (m, 4H), 7.62 – 7.45 (m, 2H), 5.76 
– 5.49 (m, 4H), 3.33 (d, J = 7.3 Hz, 1H), 1.78 – 0.18 (m, 3H). 13C NMR (75 MHz, Chloroform-d) δ 146.46, 
134.23, 131.83 (d, J = 7.5 Hz), 129.02, 128.36, 125.04, 94.63 (d, J = 24.6 Hz), 66.54 (d, J = 5.3 Hz), 62.49. 
31P NMR (122 MHz, Chloroform-d) δ 109.92 (dd, J = 152.1, 47.5 Hz). 
Bis(2,2,2-trifluoroethyl) ethynylphosphonite borane (14) 
 
The compound was synthesized according to the general procedure 2 from 
Bis(diisopropylamino)chlorophosphine (267 mg, 1.00 mmol). The crude borane protected 
phosphonite was purified by flash column chromatography (10% EtOAc in hexane) and obtained as a 
colorless oil. (158 mg, 0.590 mmol, 59.0%) 
1H NMR (300 MHz, Chloroform-d) δ 4.59 – 4.24 (m, 4H), 3.43 (d, J = 7.8 Hz, 1H), 1.54 – 0.03 (m, 3H). 13C 
NMR (75 MHz, Chloroform-d) δ 122.14 (d, J = 286.1 Hz), 95.97 (d, J = 28.2 Hz), 64.09 (qd, J = 38.4, 4.5 
Hz). 31P NMR (122 MHz, Chloroform-d) δ 121.41 – 114.01 (m). 19F NMR (282 MHz, CDCl3) δ 2.58. 
General procedure 3 for the synthesis of O-substituted ethynylphosphonamidates from 
unprotected ethynylphosphonites and 4-azidobenzoic acid NHS-ester 
 
1.00 mmol of an 4-azidobenzoic acid NHS-ester 15 (1.00 eq.) was stirred together with 1.00 mmol of 
an ethynylphosphonite (1.00 eq.) in 5 ml DMF overnight. The organic solvent was removed under 
reduced pressure and the residue purified by column chromatography on silica. 
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2-Isopropyl-disulfido-ethyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-
ethynylphosphonamidate (16) 
 
The compound was synthesized according to the general procedure 3 from 147 mg Di-(2-isopropyl 
disulfido)ethyl) ethynylphosphonite (4) (0.411 mmol, 1.00 eq.) and 106 mg 4-azidobenzoic-acid-N-
hydroxysuccinimide ester (15) (0.411 mmol, 1.00 eq.) and purified by flash column chromatography 
on silica gel (60% EtOAc in hexane). The compound was obtained as colorless oil. (80 mg, 0.175 mmol, 
42.6%).  
1H NMR (300 MHz, Chloroform-d) δ = 8.08 (d, J=8.7, 2H), 7.20 (d, J=8.8, 2H), 7.13 (d, J=7.5, 1H), 4.63 – 
4.18 (m, 2H), 3.23 – 2.76 (m, 8H), 1.31 (dd, J=6.7, 1.0, 6H). 13C NMR (75 MHz, Chloroform-d) δ 169.10 
(d, J = 55.1 Hz), 161.37, 145.27, 132.42, 118.41, 117.66 (d, J = 7.9 Hz), 89.15 (d, J = 50.2 Hz), 75.07 (d, J 
= 278.6 Hz), 64.26 (d, J = 5.2 Hz), 41.24, 38.75 (d, J = 7.5 Hz), 25.62 (d, J = 11.8 Hz), 22.51. 31P NMR (122 
MHz, CDCl3) δ = -10.16. HRMS for C18H21N2NaO6PS2+ [M+Na]+ calcd.: 479.0471, found: 479.0471. 
2-tert-butyl-disulfido-ethyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-
ethynylphosphonamidate (17) 
 
The compound was synthesized according to the general procedure 3 from 50 mg Di-(2- tert-butyl 
disulfido)ethyl) ethynylphosphonite (5) (0.129 mmol, 1.00 eq.) and 33 mg 4-azidobenzoic-acid-N-
hydroxysuccinimide ester (15) (0.129 mmol, 1.00 eq.) and purified by flash column chromatography 
on silica gel (70% EtOAc in hexane). The compound was obtained as colorless solid. (29 mg, 
0.0638 mmol, 47.4%).  
1H NMR (300 MHz, Chloroform-d) δ = 8.06 (d, J=8.7, 2H), 7.49 (d, J=7.5, 1H), 7.21 (d, J=8.7, 2H), 4.58 – 
4.26 (m, 2H), 3.09 – 2.81 (m, 7H), 1.33 (s, 9H). 13C NMR (75 MHz, Chloroform-d) δ 169.50, 161.40, 
145.32, 132.40, 118.34, 117.68 (d, J = 8.0 Hz), 89.19 (d, J = 50.2 Hz), 75.06 (d, J = 278.6 Hz), 64.38 (d, J 
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= 5.1 Hz), 48.28, 39.38 (d, J = 7.5 Hz), 29.83, 25.70. 31P NMR (122 MHz, CDCl3) δ = -9.98. HRMS for 
C19H22N2NaO6PS2+ [M+Na]+ calcd.: 493.0627, found: 493.0628. 
2-isopropyldisulfido-3-propyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-
ethynylphosphonamidate (18) 
 
The compound was synthesized according to the general procedure 3 from 61 mg Di-((2-isopropyl 
disulfido)-3-propyl) ethynylphosphonite (6) (0.158 mmol, 1.00 eq.) and 40 mg 4-azidobenzoic-acid-N-
hydroxysuccinimide ester (15) (0.158 mmol, 1.00 eq.) and purified by flash column chromatography 
on silica gel (70% EtOAc in hexane). The compound was obtained as mixture of diastereomers as 
colorless oil. (32 mg, 0.068 mmol, 43.0%).  
1H NMR (300 MHz, Chloroform-d) δ = 8.05 (d, J=8.7, 2H), 7.84 – 7.74 (m, 1H), 7.21 (d, J=8.8, 2H), 4.57 
– 4.27 (m, 2H), 3.20 – 2.66 (m, 7H), 1.46 – 1.21 (m, 9H). 31P NMR (122 MHz, CDCl3) δ = -9.87. 13C NMR 
(75 MHz, Chloroform-d) δ 169.46, 161.37, 145.30, 132.41, 118.40, 117.63 (d, J = 7.9 Hz), 89.17 (dd, J = 
50.1, 10.0 Hz), 72.01 – 66.52 (m), 45.32 (d, J = 8.1 Hz), 41.70 (d, J = 4.1 Hz), 25.70, 22.56, 22.45, 16.90 
(d, J = 1.3 Hz). HRMS for C19H22N2NaO6PS2+ [M+Na]+ calcd.: 493.0627, found: 493.0628. 
3-Butinyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-ethynylphosphonamidate (19) 
 
The compound was synthesized according to the general procedure 3 from 61 mg Di-(3-Butinyl) 
ethynylphosphonite (7) (0.192 mmol, 1.00 eq.) and 50 mg 4-azidobenzoic-acid-N-hydroxysuccinimide 
ester (15) (0.192 mmol, 1.00 eq.) and purified by flash column chromatography on silica gel (70% EtOAc 
in hexane). The compound was obtained as colorless oil. (55 mg, 0.147mmol, 76.6%).  
1H NMR (300 MHz, Chloroform-d) δ 8.02 (d, J = 6.9 Hz, 2H), 7.21 (d, J = 8.8 Hz, 2H), 4.42 – 4.04 (m, 2H), 
3.06 (d, J = 13.2 Hz, 1H), 2.89 (s, 4H), 2.65 (td, J = 6.7, 2.7 Hz, 2H), 2.07 (t, J = 2.6 Hz, 1H). 13C NMR (75 
MHz, Chloroform-d) δ 169.61, 145.52, 132.30, 118.19, 117.72 (d, J = 8.1 Hz), 89.38 (d, J = 50.0 Hz), 
Experimental part 
 
 
316 
 
75.22 (d, J = 315.3 Hz), 70.94, 63.92 (d, J = 5.0 Hz), 31.48, 25.69, 20.57 (d, J = 8.2 Hz). 31P NMR (122 
MHz, CDCl3) δ -9.74. HRMS for C17H16N2O6PS+ [M+H]+ calcd.: 375.0740, found: 375.0740. 
2-(2-Hydroxyethoxy)ethyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-
ethynylphosphonamidate (8) 
 
The compound was synthesized according to the general procedure 3 from 93 mg Di-(2-(2-
Hydroxyethoxy)ethyl) ethynylphosphonite (20) (0.192 mmol, 1.00 eq.) and 91 mg 4-azidobenzoic-acid-
N-hydroxysuccinimide ester (15) (0.192 mmol, 1.00 eq.) and purified by flash column chromatography 
on silica gel (100% EtOAc). The compound was obtained as colorless oil. (45 mg, 0.109 mmol, 31.4%).  
1H NMR (300 MHz, Chloroform-d) δ 8.02 (d, J = 8.7 Hz, 2H), 7.79 (d, J = 7.6 Hz, 1H), 7.21 (d, J = 8.8 Hz, 
2H), 4.30 (dp, J = 13.6, 4.5 Hz, 2H), 3.89 – 3.67 (m, 6H), 3.09 (d, J = 13.3 Hz, 1H), 2.89 (s, 4H). 13C NMR 
(75 MHz, Chloroform-d) δ 169.67, 161.45, 145.78 (d, J = 1.6 Hz), 132.32, 118.04, 117.66 (d, J = 8.1 Hz), 
89.29 (d, J = 50.1 Hz), 75.34 (d, J = 294.4 Hz), 72.59, 69.44 (d, J = 5.1 Hz), 66.19 (d, J = 5.9 Hz), 61.35, 
25.68. 31P NMR (122 MHz, CDCl3) δ -9.66. HRMS for C17H20N2O8P+ [M+H]+ calcd.: 411.0952, found: 
411.0951. 
4-acetoxy-benzyl-N-(4-benzoic-acid-N-hydroxysuccinimide ester)-P-
ethynylphosphonamidate (21) 
 
The compound was synthesized according to the general procedure 3 from 103 mg Di-(4-acetoxy 
benzyl) ethynylphosphonite (10) (0.267 mmol, 1.00 eq.) and 69 mg 4-azidobenzoic-acid-N-
hydroxysuccinimide ester (15) (0.267 mmol, 1.00 eq.) and purified by flash column chromatography 
on silica gel (70% EtOAc in hexane). The compound was obtained as colorless oil. (36 mg, 0.077 mmol, 
28.7%).  
1H NMR (300 MHz, Chloroform-d) δ = 7.53 – 7.34 (m, 2H), 7.20 – 6.99 (m, 7H), 5.14 (d, J=8.8, 2H), 3.01 
(d, J=13.3, 1H), 2.91 (s, 4H), 2.32 (s, 3H). 13C NMR (75 MHz, Chloroform-d) δ 169.52, 162.61, 161.39, 
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151.05, 145.42, 132.35, 129.69, 122.00, 119.31, 118.24, 117.58 (d, J = 8.0 Hz), 89.14 (d, J = 50.3 Hz), 
75.32 (d, J = 293.0 Hz), 67.27 (d, J = 4.8 Hz), 25.69, 21.12. 31P NMR (122 MHz, CDCl3) δ = -10.33. HRMS 
for C22H20N2O8P+ [M+H]+ calcd.: 471.0952, found: 471.0956. 
4-Diazophenyl-benzyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-
ethynylphosphonamidate (22) 
 
The compound was synthesized according to the general procedure 3 from 71 mg Di (4-(diazophenyl)-
benzyl) ethynylphosphonite (11) (0.148 mmol, 1.00 eq.) and 39 mg 4-azidobenzoic-acid-N-
hydroxysuccinimide ester (15) (0.148 mmol, 1.00 eq.) and purified by flash column chromatography 
on silica gel (50% EtOAc in hexane). The compound was obtained as orange solid. (58 mg, 0.112 mmol, 
75.8%).  
1H NMR (600 MHz, DMSO-d6) δ = 9.44 (d, J=8.6, 1H), 8.02 (d, J=8.8, 2H), 7.96 – 7.89 (m, 4H), 7.67 (d, 
J=8.5, 2H), 7.64 – 7.57 (m, 3H), 7.33 (d, J=8.8, 2H), 5.28 (ddd, J=45.1, 12.5, 8.7, 2H), 4.61 (d, J=13.0, 1H), 
2.88 (s, 4H). 13C NMR (151 MHz, DMSO-d6) δ = 170.90, 161.75, 152.36, 152.23, 147.36, 139.31 (d, J=7.6), 
132.33, 132.17, 129.97, 129.41, 123.14, 123.08, 118.17 (d, J=8.1), 117.25, 93.06 (d, J=46.9), 76.49 (d, 
J=265.4), 66.88, 25.98. 31P NMR (243 MHz, DMSO) δ = -10.42. HRMS for C26H22N4O6P+ [M+H]+ calcd.: 
517.1271, found: 517.1278. 
General procedure 4 for the amide bond formation between phosphonamidate-NHS esters 
and EDANS 
 
0.1 mmol NHS-phosphonamidate (1.00 eq.) and 0.12 mmol 5-((2-Aminoethyl)aminonaphthalene-1-
sulfonate (EDANS) sodium salt (1.20 eq.) were dissolved in 10 mL DMF. 0.40 mmol of DIPEA (4.0 eq.) 
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was added and the mixture stirred for 3 hours at room-temperature. All volatiles were removed under 
reduced pressure and the crude mixture was purified by semi preparative HPLC using Method A. 
5-((2-(O-(2-Isopropyl-disulfido-ethyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (23) 
 
The compound was synthesized according to the general procedure 4 from 72 mg 2-Isopropyl-
disulfido-ethyl-N-(4-benzoic-acid-N-hydroxysuccinimide ester)-P-ethynylphosphonamidate (16) 
(0.157 mmol, 1.00 eq.), 54 mg EDANS sodium salt (0.188 mmol, 1.20 eq.) and 109 μl DIPEA 
(0.628 mmol, 4.0 eq.) and purified by semi-preparative HPLC (method A). The compound was obtained 
as white solid. (62 mg, 0.102 mmol, 64.9%).  
1H NMR (600 MHz, DMSO-d6) δ = 8.90 (d, J=8.8, 1H), 8.61 (t, J=5.6, 1H), 8.56 (d, J=8.6, 1H), 8.13 (d, 
J=8.3, 1H), 8.04 (dd, J=7.2, 1.1, 1H), 7.82 (d, J=8.7, 2H), 7.60 – 7.31 (m, 2H), 7.17 (d, J=8.8, 2H), 4.51 (d, 
J=12.8, 1H), 4.37 – 4.17 (m, 2H), 3.65 (q, J=6.3, 2H), 3.52 (t, J=6.5, 2H), 3.07 (p, J=6.7, 1H), 3.03 (t, J=6.3, 
2H), 1.24 (dd, J=6.7, 2.8, 6H). 13C NMR (151 MHz, DMSO-d6) δ = 167.03, 144.53, 143.31, 130.53, 129.02, 
127.63, 126.33, 125.44, 125.15, 124.70, 123.21, 117.55, 117.50, 92.38 (d, J=45.7), 76.79 (d, J=262.5), 
63.85 (d, J=4.7), 46.85, 40.77, 39.01 (d, J=7.7), 37.65, 22.72. 31P NMR (243 MHz, DMSO) δ = -9.84. HRMS 
for C26H31N3O6PS3+ [M+H]+ calcd.: 608.1107, found: 608.1107. 
5-((2-(O-(2-tert-butyl-disulfido-ethyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (24) 
 
The compound was synthesized according to the general procedure 4 from 10 mg 2-tert-butyl-
disulfido-ethyl-N-(4-benzoic-acid-N-hydroxysuccinimide ester)-P-ethynylphosphonamidate (17) 
(0.021 mmol, 1.00 eq.), 7 mg EDANS sodium salt (0.025 mmol, 1.20 eq.) and 15 μl DIPEA (0.084 mmol, 
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4.0 eq.) and purified by semi-preparative HPLC (method A). The compound was obtained as white 
solid. (8 mg, 0.013 mmol, 62,3%).  
1H NMR (600 MHz, DMSO-d6) δ = 8.87 (d, J=8.7, 1H), 8.57 (t, J=5.8, 1H), 8.21 (d, J=8.6, 1H), 8.10 (d, 
J=8.5, 1H), 7.94 (dd, J=7.1, 1.2, 1H), 7.80 (d, J=8.7, 2H), 7.36 (dd, J=8.5, 7.1, 1H), 7.31 (dd, J=8.7, 7.5, 
1H), 7.14 (d, J=8.8, 2H), 6.74 (d, J=7.6, 1H), 4.49 (d, J=12.8, 1H), 4.37 – 4.11 (m, 2H), 3.60 (q, J=6.4, 2H), 
3.40 (t, J=6.5, 2H), 3.03 (t, J=6.5, 2H), 1.29 (s, 9H). 13C NMR (151 MHz, DMSO-d6) δ 166.87, 144.74, 
143.15, 130.64, 128.93, 127.87, 126.55, 124.89, 124.24, 123.20, 123.08, 117.52, 117.47, 92.34 (d, J = 
45.8 Hz), 76.82 (d, J = 261.9 Hz), 63.92, 48.31, 44.55, 38.50, 29.98. 31P NMR (243 MHz, DMSO) δ = -
9.87. HRMS for C27H33N3O6PS3+ [M+H]+ calcd.: 622.1264, found: 622.1265. 
5-((2-(O-2-isopropyl disulfido-3-propyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (25) 
 
The compound was synthesized according to the general procedure 4 from 29 mg 2-isopropyl disulfido-
3-propyl-N-(4-benzoic-acid-N-hydroxysuccinimide ester)-P-ethynylphosphonamidate (18) 
(0.061 mmol, 1.00 eq.), 21 mg EDANS sodium salt (0.073 mmol, 1.20 eq.) and 42 μl DIPEA 
(0.244 mmol, 4.0 eq.) and purified by semi-preparative HPLC (method A). The compound was obtained 
as a mixture of diastereomers as white solid. (15 mg, 0.024 mmol, 39.5%).  
1H NMR (600 MHz, DMSO-d6) δ = 8.88 (d, J=8.8, 1H), 8.58 (t, J=5.7, 1H), 8.35 (d, J=8.6, 1H), 8.10 (dt, 
J=8.6, 1.1, 1H), 7.98 (dd, J=7.1, 1.1, 1H), 7.81 (d, J=8.7, 2H), 7.39 (ddd, J=31.3, 8.6, 7.3, 2H), 7.15 (d, 
J=8.8, 2H), 6.91 (d, J=7.5, 1H), 4.51 (dd, J=12.9, 1.8, 1H), 4.25 – 4.13 (m, 1H), 4.13 – 3.98 (m, 1H), 3.61 
(q, J=6.4, 2H), 3.45 (t, J=6.6, 2H), 3.18 (dtd, J=10.6, 6.8, 5.2, 1H), 3.03 (h, J=6.7, 1H), 1.30 – 1.19 (m, 9H). 
13C NMR (151 MHz, DMSO-d6) δ = 166.92, 144.74, 143.21, 130.61, 128.96, 127.79, 126.43, 125.10, 
124.61, 123.82, 123.09, 117.50 (d, J=7.5), 92.58 (d, J=9.5), 92.28 (d, J=9.4), 76.76 (d, J=262.3), 68.10 (d, 
J=4.9), 45.48, 41.32 (d, J=8.6), 38.15, 22.74, 17.14 (d, J=4.1). 31P NMR (243 MHz, DMSO) δ = -9.76, -
9.79. HRMS for C27H33N3O6PS3+ [M+H]+ calcd.: 622.1264, found: 622.1264. 
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5-(3-Butinyl)-P-ethynylphosphonamidato-N-benzoyl)ethyl)amino)naphthalene-1-sulfonic 
acid (26) 
 
The compound was synthesized according to the general procedure 4 from 19.42 mg 3-Butinyl-N-(4-
benzoic-acid-N-hydroxysuccinimide ester)-P-ethynylphosphonamidate (19) (0.052 mmol, 1.00 eq.), 
18 mg EDANS sodium salt (0.062 mmol, 1.20 eq.) and 36 μl DIPEA (0.628 mmol, 4.0 eq.) and purified 
by semi-preparative HPLC (method A). The compound was obtained as white solid. (20 mg, 
0.039 mmol, 74.3%).  
1H NMR (300 MHz, DMSO-d6) δ 8.88 (d, J = 8.8 Hz, 1H), 8.58 (t, J = 5.7 Hz, 1H), 8.26 (d, J = 8.6 Hz, 1H), 
8.10 (d, J = 8.5 Hz, 1H), 7.95 (dd, J = 7.1, 1.0 Hz, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.36 (ddd, J = 17.3, 8.6, 7.4 
Hz, 2H), 7.15 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 7.6 Hz, 1H), 4.49 (d, J = 12.9 Hz, 1H), 4.22 – 3.93 (m, 2H), 
3.60 (q, J = 6.3 Hz, 2H), 3.42 (t, J = 6.5 Hz, 2H), 2.96 (t, J = 2.6 Hz, 1H), 2.61 (td, J = 6.3, 2.7 Hz, 2H). 13C 
NMR (75 MHz, DMSO-d6) δ 166.91, 144.66, 143.16, 130.59, 129.28, 128.95, 127.83, 126.55, 124.97, 
124.34, 123.43, 123.13, 117.53, 117.43, 92.30 (d, J = 45.9 Hz), 81.01, 76.76 (d, J = 262.2 Hz), 73.46, 
63.94 (d, J = 4.9 Hz), 44.81, 38.34, 20.39 (d, J = 8.2 Hz). 31P NMR (122 MHz, DMSO) δ -9.90. HRMS for 
C25H25N3O6PS+ [M+H]+ calcd.: 526.1196, found: 526.11968. 
5-(2-(2-Hydroxyethoxy)ethyl-)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (27) 
 
The compound was synthesized according to the general procedure 4 from 16.3 mg 2-(2-
Hydroxyethoxy)ethyl-N-(4-benzoic-acid-N-hydroxysuccinimideester)-P-ethynylphosphonamidate (20) 
(0.040 mmol, 1.00 eq.), 13.7 mg EDANS sodium salt (0.048 mmol, 1.20 eq.) and 27 μl DIPEA 
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(0.160 mmol, 4.0 eq.) and purified by semi-preparative HPLC (method A). The compound was obtained 
as white solid. (12.5 mg, 0.022 mmol, 56.0%).  
1H NMR (300 MHz, DMSO-d6) δ 8.84 (d, J = 8.7 Hz, 1H), 8.60 (t, J = 5.6 Hz, 1H), 8.40 (dd, J = 8.7, 2.6 Hz, 
1H), 8.12 (d, J = 8.5 Hz, 1H), 7.99 (dd, J = 7.2, 0.9 Hz, 1H), 7.80 (d, J = 8.7 Hz, 2H), 7.60 – 7.34 (m, 2H), 
7.16 (d, J = 8.7 Hz, 2H), 7.00 (dd, J = 7.8, 3.0 Hz, 1H), 4.47 (d, J = 12.8 Hz, 1H), 4.28 – 3.97 (m, 2H), 3.82 
– 3.56 (m, 4H), 3.57 – 3.37 (m, 6H). 13C NMR (75 MHz, DMSO-d6) δ 167.00, 144.63, 143.37, 143.36, 
130.56, 128.97, 127.64, 126.43, 125.21, 124.76, 124.74, 124.12, 124.09, 123.16, 117.43 (d, J = 7.9 Hz), 
92.09 (d, J = 45.6 Hz), 76.95 (d, J = 262.1 Hz), 72.72, 69.54 (d, J = 7.6 Hz), 65.20 (d, J = 5.3 Hz), 60.62. 31P 
NMR (122 MHz, DMSO) δ -9.71. HRMS for C25H29N3O8PS+ [M+H]+ calcd.: 562.1407, found: 562.1407. 
5-((2-(O-(4-acetoxybenzyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (28) 
 
The compound was synthesized according to the general procedure 4 from 36 mg 4-acetoxy-benzyl-N-
(4-benzoic-acid-N-hydroxysuccinimide ester)-P-ethynylphosphonamidate (21) (0.076 mmol, 1.00 eq.), 
22 mg EDANS sodium salt (0.095 mmol, 1.20 eq.) and 53 μl DIPEA (0.284 mmol, 4.0 eq.) and purified 
by semi-preparative HPLC (method A). The compound was obtained as white solid. (14 mg, 
0.023 mmol, 30.4%).  
1H NMR (600 MHz, DMSO-d6) δ = 8.92 (d, J=8.6, 1H), 8.56 (t, J=5.7, 1H), 8.32 (d, J=8.7, 1H), 8.10 (d, 
J=8.5, 1H), 8.03 – 7.92 (m, 1H), 7.80 (d, J=8.6, 2H), 7.47 (d, J=8.5, 2H), 7.41 (dd, J=8.5, 7.2, 1H), 7.36 (t, 
J=8.1, 1H), 7.17 (d, J=6.7, 2H), 7.15 (d, J=6.7, 2H), 6.88 (d, J=7.5, 1H), 5.25 – 5.05 (m, 2H), 4.49 (d, J=12.8, 
1H), 3.61 (q, J=6.3, 2H), 3.44 (t, J=6.6, 2H), 2.28 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ = 169.61, 
166.95, 150.96, 144.73, 143.29, 133.66 (d, J=7.7), 130.61, 129.81, 128.99, 127.82, 126.47, 125.06, 
124.53, 123.68, 123.10, 122.42, 117.44 (d, J=7.9), 92.28 (d, J=45.6), 77.01 (d, J=261.8), 66.59 (d, J=4.4), 
45.26, 38.24, 21.31. 31P NMR (243 MHz, DMSO) δ = -9.87. LC-MS for C30H29N3O8PS+ [M+H]+ calcd.: 
622.14, found: 622.15. 
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5-((2-(O-(4-Diazophenyl-benzyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (29) 
 
The compound was synthesized according to the general procedure 4 from 27 mg 4-Diazophenyl-
benzyl-N-(4-benzoic-acid-N-hydroxysuccinimide ester)-P-ethynylphosphonamidate (22) (0.053 mmol, 
1.00 eq.), 15 mg EDANS sodium salt (0.064 mmol, 1.20 eq.) and 37 μl DIPEA (0.212 mmol, 4.0 eq.) and 
purified by semi-preparative HPLC (method A). The compound was obtained as orange solid. (18 mg, 
0.027 mmol, 50.9%).  
1H NMR (600 MHz, DMSO-d6) δ = 8.98 (d, J=8.7, 1H), 8.57 (t, J=5.7, 1H), 8.36 (d, J=8.6, 1H), 8.11 (d, 
J=8.5, 1H), 7.98 (d, J=7.1, 1H), 7.97 – 7.88 (m, 4H), 7.81 (d, J=8.8, 2H), 7.66 (d, J=8.5, 2H), 7.64 – 7.52 
(m, 4H), 7.42 (dd, J=8.5, 7.1, 1H), 7.37 (t, J=8.1, 1H), 7.18 (d, J=8.7, 2H), 6.92 (d, J=7.5, 1H), 5.37 – 5.04 
(m, 2H), 4.53 (d, J=12.8, 1H), 3.61 (q, J=6.4, 2H), 3.45 (t, J=6.6, 2H). 13C NMR (151 MHz, DMSO-d6) δ = 
166.95, 152.36, 152.18, 144.75, 143.27, 139.56, 139.51, 132.15, 130.61, 129.97, 129.32, 129.01, 
127.84, 126.44, 125.11, 124.62, 123.83, 123.13, 123.07, 117.49 (d, J=8.0), 92.47 (d, J=45.9), 76.95 (d, 
J=262.7), 66.56 (d, J=4.4), 45.47, 38.15. 31P NMR (243 MHz, DMSO) δ = -9.68. HRMS for C34H31N5O6PS+ 
[M+H]+ calcd.: 668.1727, found: 668.1733. 
General procedure 5 for the synthesis of O-substituted ethynylphosphonamidates from 
borane protected ethynylphosphonites 
 
A flame-dried Schlenk flask was charged with 1.0 mmol (1.0 eq.) of the borane protected 
ethynylphosphonite under an argon atmosphere and dissolved in 2 ml of dry toluene. In an argon 
stream, DABCO (1.50 mmol, 1.5 eq.) was added and the solution was heated to 50 °C for 2 hours. The 
mixture was allowed to cool to room temperature and a solution of 1.1 mmol of the azide (1.1 eq.) in 
3 ml dry THF or dry DMF was added. The resulting solution was stirred at room temperature overnight. 
Finally 1 ml of water was added and stirred for another two hours. The crude product was purified by 
column chromatography. 
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Ethyl-N-phenyl-P-ethynylphosphonamidate  
 
The compound was synthesized according to the General procedure 5 from 85 mg Diethyl 
ethynylphosphonite borane (0.531 mmol, 1.00 eq.), 90 mg DABCO (0.797 mmol, 1.50 eq.) and 70 mg 
phenyl azide (0.584 mmol, 1.1 eq.). The compound was purified by flash column chromatography on 
silica gel (100% EtOAc) and obtained as colorless solid. (22 mg, 0.104 mmol, 19.5%) 
1H NMR (600 MHz, Chloroform-d) δ = 7.33 – 7.25 (m, 2H), 7.20 (d, J=7.6, 1H), 7.16 – 7.10 (m, 2H), 7.05 
– 6.94 (m, 1H), 4.35 – 4.10 (m, 2H), 2.91 (d, J=12.9, 1H), 1.39 (t, J=7.1, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ = 139.18, 129.28, 122.23, 118.16 (d, J=7.6), 87.77 (d, J=48.8), 76.39 (d, J=272.9), 62.13 
(d, J=5.1), 16.17 (d, J=7.4). 31P NMR (243 MHz, Chloroform-d) δ = -8.75. HR-MS for C10H13NO2P+ 
[M+H]+ calcd.: 210.0678, found 210.0680. 
Phenyl-N-phenyl-P-(2-phenyloxyvinyl)phosphonamidate (31) 
 
The compound was synthesized according to the General procedure 5 from 30 mg Diphenyl 
ethynylphosphonite borane (12) (0.117 mmol, 1.00 eq.), 20 mg DABCO (0.175 mmol, 1.50 eq.) and 15 
mg phenyl azide (0.128 mmol, 1.1 eq.). The compound was purified by flash column chromatography 
on silica gel (100% EtOAc) and obtained as colorless solid. (27 mg, 0.028 mmol, 24.3%) 
1H NMR (300 MHz, Chloroform-d) δ 7.51 (dd, J = 13.2, 11.0 Hz, 1H), 7.40 – 6.91 (m, 15H), 6.04 (d, J = 
6.4 Hz, 1H), 5.65 – 5.31 (t, J = 13.2, 1H). 13C NMR (75 MHz, Chloroform-d) δ 160.56, 160.26, 155.56, 
149.99 (d, J = 8.0 Hz), 139.54, 129.94, 129.71, 129.44, 125.02, 122.02, 120.84 (d, J = 4.7 Hz), 118.15, 
118.05 (d, J = 6.7 Hz), 95.74 (d, J = 189.7 Hz). 31P NMR (122 MHz, CDCl3) δ 15.62. HR-MS for 
C20H19NO3P+ [M+H]+ calcd.: 352.1097, found 352.1105. 
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General procedure 6 for the addition of a Cys-DABCYL peptide to different O-Substituted 
EDANS phosphonamidates 
 
Equal volumes of a 5 mM solution of the respective EDANS-phosphonamidate in DMF and a 5 mM 
solution of the above stated DABCYL-Modified Cys-peptide in 100 mM NH4HCO3-Buffer (pH 8.5) were 
freshly prepared, mixed and shaken at room temperature for 3 hours. All volatiles were removed under 
reduced pressure and the thiol adducts isolated by semi-preparative HPLC (method A). 
DABCYL-Cys peptide O-(2-Isopropyl-disulfido-ethyl)-phosphonamidate EDANS adduct (32) 
 
The above stated compound was synthesized according to the general procedure 6 from 452 µl of a 
5 mM solution of 5-((2-(O-(2-Isopropyl-disulfido-ethyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (23) in DMF and 452 µl of a 5 mM solution of the 
DABCYL-Cys peptide in 100 mM NH4HCO3-Buffer (pH 8.5). The peptide was obtained as a red solid (2.98 
mg, 39.4%). HR-MS for C74H96N15O20PS42+ [M+2H]2+ calcd.: 836.7783, found 836.7783. 
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DABCYL-Cys peptide O-(2-tert-butyl-disulfido-ethyl)-phosphonamidate EDANS adduct (33) 
 
The above stated compound was synthesized according to the general procedure 6 from 403 µl of a 
5 mM solution of 5-((2-(O-(2-tert-butyl-disulfido-ethyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (24) in DMF and 403 µl of a 5 mM solution of the 
DABCYL-Cys peptide in 100 mM NH4HCO3-Buffer (pH 8.5). The peptide was obtained as a red solid (3.04 
mg, 44.7%). HR-MS for C75H98N15O20PS42+ [M+2H]2+ calcd.: 843.7861, found 843.7863. 
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DABCYL-Cys peptide O-(2-isopropyl-disulfido-3-propyl)-phosphonamidate EDANS adduct 
(34) 
 
The above stated compound was synthesized according to the general procedure 6 from 1.04 ml of a 
5 mM solution of 5-((2-(O-(2-isopropyl-disulfido-3-propyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (25) in DMF and 1.04 ml of a 5 mM solution of the 
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DABCYL-Cys peptide in 100 mM NH4HCO3-Buffer (pH 8.5). The peptide was obtained as a red solid (2.16 
mg, 24.5%). HR-MS for C75H98N15O20PS42+ [M+2H]2+ calcd.: 843.7861, found 843.7858. 
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DABCYL-Cys peptide O-(4-acetoxybenzyl)-phosphonamidate EDANS adduct (35) 
 
The above stated compound was synthesized according to the general procedure 6 from 1.03 ml of a 
5 mM solution of 5-((2-(O-(4-acetoxybenzyl)-P-ethynylphosphonamidato-N-
benzoyl)ethyl)amino)naphthalene-1-sulfonic acid (26) in DMF and 1.03 ml of a 5 mM solution of the 
DABCYL-Cys peptide in 100 mM NH4HCO3-Buffer (pH 8.5). The peptide was obtained as a red solid (2.27 
mg, 26.1%). HR-MS for C78H92N15O222PS22+ [M+2H]2+ calcd.: 843.7933, found 843.7934. 
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DABCYL-Cys peptide O-ethyl-phosphonamidate EDANS adduct (36) 
 
The above stated compound was synthesized according to the general procedure 6 from 430 µl of a 
5mM solution of 5-((2-(O-ethyl-P-ethynylphosphonamidato-N-benzoyl)ethyl)amino)naphthalene-1-
sulfonic acid in DMF and 430 µl of a 5 mM solution of the DABCYL-Cys peptide in 100 mM NH4HCO3-
Buffer (pH 8.5). The peptide was obtained as a red solid (3.39 mg, 50.4%). HR-MS for C71H90N15O20PS22+ 
[M+2H]2+ calcd.: 783.7827, found 783.7804. 
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Procedure for the exposure of compounds 32-34 and 36 to TCEP 
 
 
10 μl of a 1 mM stock solution of the peptide (32-34 and 36) in PBS was premixed with 80 μl of PBS. 
10 μl of a 10 mM stock solution of TCEP in PBS was added and the solutions were shaken at 37°C for 
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two hours. Control reactions were shaken in PBS only. 15 μl samples were drawn afterwards, diluted 
with 15 μl of 2% TFA solution in water and subjected to UPLC-MS analysis.  
Procedure for the exposure of compounds 35 and 36 to HeLa cell lysate 
 
10 μl of a 1 mM stock solution of the peptide 35 and 36 in PBS was premixed with 90 μl of freshly 
prepared HeLa-lysate in PBS. HeLa-cell lysate was generated from approximately 3,9*107 cells, lysed 
in 2 mL PBS by sonification (final protein concentration: 1.7 mg/ml). Cells were grown on three 75 cm2 
cell culture plates, washed twice with PBS and harvested with a cell scraper. The solutions was shaken 
at 37°C for two hours. Control reactions were shaken in PBS only. A 15 μl sample was drawn afterwards, 
diluted with 15 μl of 2% TFA solution in water and subjected to UPLC-MS analysis.  
Fluorescence measurements of the DABCYL-EDANS adducts  
Stability studies were conducted in 96-well plate (Corning 3615, black with clear, flat bottom). 5 μl of 
a 200 μM Stock solution of compound 32 and 36 and 95 μl of 100 µM TCEP solution were added to a 
well. Fluorescence was measured on a Tecan Safire plate reader. Excitation: 360 nm, emission: 508 nm, 
bandwidth: 5nm at 20 °C. 
5-(3-Butinyl)-P-ethynylphosphonamidato-N-benzoyl)-cR10 (40) 
 
SPPS of cyclic R10-NH2 was carried out exactly as previously described.[167] An Eppendorf-tube was 
charged with 11.2 mg (3.324 mmol, 1.0 eq.) of cR10-NH2 39, 2.5 mg 3-Butinyl-N-(4-benzoic-acid-N-
hydroxysuccinimideester)-P-ethynylphosphonamidate (19) (6.648 mmol, 2.0 eq.), 2.3 µl DIPEA 
(13.296 mmol, 4.0 eq.) and 50 µl DMF. The yellowish mixture was shaken overnight at room 
temperature and the desired product isolated by semi-preparative HPLC (method A) as a white powder 
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after lyophilization (3.34 mg, 0.994 mmol, 29.9%). HR-MS for C96H175N47O22P3+ [M+3H]3+ calcd.: 
790.1258, found 790.1271. 
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Addition of eGFP C70M S147C to 40 
 
An Eppendorf-tube was charged with 500 µl eGFP in PBS (c=86 µM), 50 µl of a 86 mM solution of DTT 
in PBS were added and the solution was incubated at 37°C for 30 minutes. Excess DTT removal and 
buffer exchange to a solution containing 50 mM NH4HCO3 and 1mM EDTA (pH 8.5) was conducted 
afterwards using 2 mL Zeba™ spin Desalting Columns with 7K MWCO (Thermo Fisher Scientific, USA). 
Afterwards, 55 µl of a 8 mM solution of 40 in PBS were added and the solution was incubated at 14 °C 
overnight. Excess 40 removal and buffer exchange to PBS was conducted afterwards using 2 mL Zeba™ 
spin Desalting Columns with 7K MWCO (Thermo Fisher Scientific, USA). The product was analyzed by 
intact protein MS and SDS-PAGE. Raw spectra of the eGFP-starting material (left) and the product 
(right) that have been deconvoluted to produce the spectra in Figure 17e can be found below: 
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1-(2-azidoethyl)-3,3-Dimethyl-2-methyleneindoline (43) 
 
A 5-ml sealed microwave tube was charged with 500 µl 41 (3.140 mmol, 1.00 eq.), 2.7 ml 1,2-
Dibromoethane (31.40 mmol, 1.00 eq.) and a stirring bar and heated to a constant temperature of 
140 °C by microwave irradiation for 30 minutes. The mixture was cooled to room temperature and 
poured into ice-cold diethyl ether. The precipitate was collected by centrifugation, redissolved in 
methanol, precipitated with diethyl ether and collected by centrifugation again. 904 mg of a red solid 
were obtained after vacuum drying and used in the next step without further purification. A 50-ml 
round-bottom flask was charged with the residual substance, dissolved in 5 ml dry DMSO and 408 mg 
sodium azide (6.280 mmol, 2.0 eq.) were added. The red solution was stirred overnight, poured into 
100 ml saturated sodium bicarbonate solution and extracted three times with 50 ml EtOAc. The 
organic fractions were pooled, dried over MgSO4 and all volatiles were removed under reduced 
pressure. The crude mixture was purified by flash chromatography on silica (10% EtOAc in hexane) 
yielding 207 mg of a yellow oil (0.910 mmol, 29.0 %). 
1H NMR (300 MHz, Chloroform-d) δ 7.24 – 7.08 (m, 2H), 6.84 (td, J = 7.4, 0.8 Hz, 1H), 6.67 (d, J = 7.8 Hz, 
1H), 4.07 – 3.88 (m, 2H), 3.77 (t, J = 6.2 Hz, 2H), 3.54 (t, J = 6.1 Hz, 2H), 1.38 (s, 6H). 13C NMR (75 MHz, 
CDCl3) δ 161.11, 145.43, 137.43, 127.61, 122.09, 119.09, 105.18, 74.01, 47.71, 44.29, 42.26, 30.05. 
Cy5 azide 45 
 
Cy5 azide 45 was synthesized from 908 mg 1,3,3-trimethyl-2-((1E,3E)-4-(N-phenylacetamido)buta-1,3-
dien-1-yl)-3H-indolium iodide (44) (1.924 mmol, 1.08 eq.) and 405 mg 1-(2-azidoethyl)-3,3-Dimethyl-
2-methyleneindoline (43) (1.776 mmol, 1.00 eq.) by heating in a mixture of 15 ml acetic anhydride and 
15 ml pyridine for 2 hours under an argon atmosphere. All volatiles were removed under reduced 
pressure and the crude product was purified by flash chromatography on silica (0-5% MeOH in CH2Cl2) 
yielding 963 mg of a deep blue solid (1.705 mmol, 96.0 %). 
1H NMR (300 MHz, Chloroform-d) δ 8.08 (td, J = 13.0, 2.5 Hz, 2H), 7.37 (m, 4H), 7.30 – 7.11 (m, 4H), 
6.96 (t, J = 12.5 Hz, 1H), 6.60 (d, J = 13.4 Hz, 1H), 6.34 (d, J = 13.7 Hz, 1H), 4.43 (t, J = 5.4 Hz, 2H), 3.92 
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(t, J = 5.3 Hz, 2H), 3.69 (s, 3H), 1.75 (s, 6H), 1.73 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 173.87, 172.42, 
153.83, 153.42, 142.45, 142.22, 140.93, 140.62, 128.63, 128.49, 126.83, 125.42, 124.89, 122.14, 
122.09, 110.67, 110.62, 104.49, 104.05, 49.41, 49.24, 49.14, 44.10, 32.30, 28.17, 27.88, 20.90. HR-MS 
for C28H32N5+ [M]+ calcd.: 438.2652, found 438.2652. 
CuAAC of Cy5-N3 45 to eGFP, modified with 40 
 
A solution containing 78 µM eGFP-40, 0.8 mM Cy5-N3, 0.25 mM Copper(II) sulfate, 0.125 mM THPTA, 
5 mM amino guanidine and 5 mM sodium ascorbate in PBS with 10% DMSO was shaken for 3 hours at 
room temperature. The crude protein modification mixture was purified by size-exclusion 
chromatography with a 5 ml HiTrap® desalting column and a flow of 1.5 ml/min eluting with PBS over 
two column volumes. The protein containing fractions were pooled and concentrated by spin-filtration 
(MWCO: 10 kDa, 0.5 ml, Sartorius, Germany). The product was analyzed by intact protein MS and SDS-
PAGE. Raw spectrum of the product that has been deconvoluted to produce the spectra in Figure 18c 
can be found below: 
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Enantiomer separation of Ethyl-N-(4-(2,5-dioxo-1-pyrrolidinyl)oxy-carbonyl-phenyl)-P-
ethynylphosphonamidate (46) 
 
Enantiomers were separated by semi-preparative chiral HPLC eluting with 30% isopropanol in hexane 
with a Chiralpak® IA column (Chiral Technologies Europe, France) and analyzed with the same column 
type and isocratic gradient, eluting with 1 ml/min. 
Enantiomer A: [α]D
24 = ─30.1 (c = 0.76; CHCl3) 
 
Enantiomer B: [α]D
24 = +28.6 (c = 0.88; CHCl3) 
 
General procedure 7: One-pot protocol for the synthesis of vinylphosphonamidates from 
crude diethyl vinylphosphonites.  
 
A 25-ml Schlenk flask was charged with 1.71 ml vinylmagnesium bromide (0.7 M in THF, 1.20 mmol, 
1.2 eq.) under an argon atmosphere, cooled to -78 °C and 140 µl diethyl chlorophosphite (1.00 mmol, 
1.0 eq.) were added drop wise. The yellowish solution was allowed to warm to 0 °C, stirred for another 
two hours and 1.00 mmol of azide (1.0 eq.) dissolved in 3.2 ml of THF was added and stirred overnight 
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at room temperature. 5 ml of water were added and stirred for another 24 h. The solvents were 
removed under reduced pressure and the crude product was purified by flash column chromatography 
on silica gel.  
Ethyl-N-(4-carboxy-phenyl)-P-vinylphosphonamidate (48) 
 
The compound was synthesized according to the general procedure 7 from 288 µl diethyl 
chlorophosphite (2 mmol). The crude phosphonamidate was purified by flash column chromatography 
(10-20% MeOH in CH2Cl2) and obtained as a white solid. (173 mg, 0.68 mmol, 34.0%) 
1H NMR (600 MHz, DMSO-d6) δ = 8.37 (d, J=7.9, 1H), 7.80 (d, J=8.7, 2H), 7.12 (d, J=8.7, 2H), 6.42 – 6.04 
(m, 3H), 4.11 – 3.94 (m, 2H), 1.26 (t, J=7.0, 3H). 13C NMR (151 MHz, DMSO-d6) δ = 167.56, 146.36, 
135.00, 131.21, 129.04 (d, J=165.8), 123.06, 117.00 (d, J=6.9), 60.84 (d, J=5.7), 16.61 (d, J=6.3). 31P NMR 
(122 MHz, DMSO-d6) δ = 14.36. HRMS for C11H15NO4P+ [M+H]+ calcd.: 256.0733, found: 256.0723. 
Ethyl-N-benzyl-P-vinylphosphonamidate (49) 
 
The compound was synthesized according to the general general procedure 7 from 290 µl diethyl 
chlorophosphite (2 mmol). The crude phosphonamidate was purified by flash column chromatography 
(EtOAc) and obtained as a colorless oil. (155 mg, 0.69 mmol, 34.3%) 
1H NMR (300 MHz, Chloroform-d) δ = 7.36 – 7.21 (m, 5H), 6.33 – 5.88 (m, 3H), 4.16 – 3.90 (m, 4H), 3.21 
(d, J=8.5, 1H), 1.28 (t, J=7.1, 3H). 13C NMR (75 MHz, Chloroform-d) δ = 139.65 (d, J=5.9), 133.21 (d, 
J=1.5), 129.45, 128.46, 127.20, 127.17, 60.11 (d, J=5.7), 44.58, 16.27 (d, J=6.7). 31P NMR (122 MHz, 
Chloroform-d) δ = 20.52. HRMS for C11H17NO2P+ [M+H]+ calcd.: 226.0991, found: 226.1003. 
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Ethyl-N-(2-nitro-Benzyl)-P-vinylphosphonamidate (50) 
 
The Compound was synthesized according general procedure 7 from 120 µl diethyl chlorophosphite 
(0.83 mmol). The crude phosphonamidate was purified by flash column chromatography (2% MeOH in 
CH2Cl2) and obtained as a brown oil. (125 mg, 0.46 mmol, 55.4%) 
1H NMR (300 MHz, Chloroform-d) δ = 8.03 (d, J=8.1, 1H), 7.73 – 7.57 (m, 2H), 7.45 (t, J=7.6, 1H), 6.31 – 
5.83 (m, 3H), 4.39 (dd, J=11.2, 7.7, 2H), 4.12 – 3.85 (m, 2H), 3.65 (q, J=8.6, 1H), 1.26 (t, J=7.1, 3H). 13C 
NMR (75 MHz, Chloroform-d) δ = 148.09, 135.45 (d, J=4.2), 133.83, 133.52 (d, J=1.6), 131.10, 128.41, 
128.26 (d, J=169.7), 124.95, 60.35 (d, J=5.7), 42.42 (d, J=1.3), 16.22 (d, J=6.7). 31P NMR (122 MHz, 
Chloroform-d) δ = 20.63. HRMS for C11H16N2O4P+ [M+H]+ calcd.: 271.0842, found: 271.0851. 
Ethyl-N-cyclohexyl-P-vinylphosphonamidate (51) 
 
The compound was synthesized according to the general procedure 7 from 140 µl diethyl 
chlorophosphite (1 mmol). The crude phosphonamidate was purified by flash column chromatography 
(1.5% MeOH in CH2Cl2) and obtained as a colorless oil. (70 mg, 0.32 mmol, 32.2%) 
1H NMR (600 MHz, Chloroform-d) δ = 6.25 – 5.93 (m, 3H), 4.14 – 3.97 (m, 2H), 2.96 (dqd, J=13.8, 9.6, 
8.1, 4.2, 1H), 2.51 (t, J=9.6, 2H), 1.97 – 1.84 (m, 2H), 1.74 – 1.65 (m, 1H), 1.57 (dt, J=13.0, 3.9, 1H), 1.32 
(t, J=7.1, 3H), 1.30 – 1.09 (m, 5H). 13C NMR (75 MHz, Chloroform-d) δ = 132.56 (d, J=1.8), 129.30 (d, 
J=168.8), 59.80 (d, J=5.9), 49.71, 36.03, 25.24, 24.96, 16.32 (d, J=6.8). 31P NMR (122 MHz, Chloroform-
d) δ = 19.34. HRMS for C10H21NO2P+ [M+H]+ calcd.: 218.1304, found: 218.1302. 
General procedure 8 for the synthesis of vinylphosphonites from 
Bis(diisopropylamino)chlorophosphine 
 
A flame-dried Schlenk flask was charged with 1.0 mmol (1.0 eq.) Bis(diisopropylamino)-
chlorophosphine, dissolved in 200 µl of dry THF and cooled to -78 °C. 1.10 mmol (1.1eq.) of vinyl 
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magnesiumbromide (1.0 M in THF) was added and the reaction was stirred at room temperature for 
30 minutes. A solution of 2.2 mmol vacuum dried alcohol (2.2 eq.) in 1 ml of dry THF or MeCN and 
2.2 mmol (2.2 eq.) Tetrazole (0.45 M in MeCN) was added. The resulting suspension was stirred at 
room temperature overnight. Finally 1.50 mmol (1.5 eq.) of borane (1.0 M in THF) were added at 0 °C 
and stirred for another hour. The crude product was dry packed on a silica column for purification. It 
should be noted, that mass analysis of phosphonites failed for all of the tested compounds, possibly 
due to decomposition under ESI-conditions. 
4-(2-nitro-5-(oxypropargyl)benzyloxy)phenol  
 
A flame dried Schlenk-tube, 400 mg of 2-nitro-5-(oxypropargyl)benzyl alcohol (1.93 mmol, 1.0 eq.), 
together with 850 mg hydroquinone (7.72 mmol, 4.0 eq.) and 750 mg of triphenylphosphine 
(2.90 mmol, 1.5 eq.) were dissolved in 10 ml of dry THF. The solution was cooled to 0 °C and 1.33 ml 
of diethyl azodicarboxylate (40% solution in Toluene) (2.90 mmol, 1.5 eq.) were added dropwise and 
the reaction was allowed to warm to room temperature overnight. The crude product was dry packed 
on a silica column for purification, eluting with Hexane/EtOAc (7:3 to 3:2), yielding 505 mg of a yellow 
solid. (1.68 mmol, 87.5 %) 
1H NMR (300 MHz, Chloroform-d) δ = 8.26 (d, J=9.1, 1H), 7.51 (d, J=2.8, 1H), 7.00 (dd, J=9.2, 2.9, 1H), 
6.89 (d, J=9.0, 2H), 6.80 (d, J=9.0, 2H), 5.46 (s, 2H), 4.79 (d, J=2.4, 2H), 2.54 (t, J=2.4, 1H). 13C NMR (75 
MHz, Chloroform-d) δ = 161.86, 152.11, 150.03, 140.10, 137.71, 127.69, 116.11, 116.03, 113.88, 
113.69, 76.95, 76.68, 67.66, 56.20. HRMS for C16H14NO5+ [M+H]+ calcd.: 300.0866, found: 300.0871. 
Di(4-(2-nitro-5-(oxypropargyl)benzyloxy)phenyl) vinylphosphonite borane (53) 
 
The compound was synthesized according to the general procedure 8 from 
Bis(diisopropylamino)chlorophosphine (71 mg, 0.27 mmol). The crude borane protected phosphonite 
was purified by flash column chromatography (Hexane/ CH2Cl2, 1:1) and obtained as a yellowish solid. 
(75 mg, 0.11 mmol, 41.9%) 
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1H NMR (300 MHz, Chloroform-d) δ = 8.25 (d, J=9.1, 2H), 7.47 (d, J=2.8, 2H), 7.17 – 6.87 (m, 10H), 6.62 
– 6.14 (m, 3H), 5.48 (s, 4H), 4.78 (d, J=2.4, 4H), 2.55 (t, J=2.4, 2H), 1.51 - 0.24 (m, 3H). 13C NMR (75 MHz, 
Chloroform-d) δ = 161.89, 155.27 (d, J=1.3), 145.34 (d, J=8.4), 140.04, 137.08 (d, J=12.6), 136.97, 
129.06 (d, J=71.3), 127.77, 121.93 (d, J=4.0), 115.74 (d, J=1.1), 113.85, 113.79, 76.89, 76.89, 67.37, 
56.24. 31P NMR (122 MHz, Chloroform-d) δ = 136.36 – 131.69 (m).  
Di(2-nitro-5-(oxypropargyl)benzyl) vinylphosphonite borane (54) 
 
The compound was synthesized according to the general procedure 8 from 
Bis(diisopropylamino)chlorophosphine (513 mg, 1.92 mmol). The crude borane protected 
phosphonite was purified by flash column chromatography (Hexane/CH2Cl2, 4:1) and obtained as a 
yellowish solid. (704 mg, 1.45 mmol, 75.6%) 
1H NMR (300 MHz, Chloroform-d) δ = 8.19 (d, J=9.1, 2H), 7.31 (d, J=2.8, 2H), 7.00 (dd, J=9.2, 2.8, 2H), 
6.58 – 6.22 (m, 3H), 5.49 (qd, J=15.5, 7.4, 4H), 4.81 (d, J=2.4, 4H), 2.62 (t, J=2.4, 2H), 1.31 – 0.12 (m, 
3H). 13C NMR (75 MHz, Chloroform-d) δ = 161.86, 139.86, 136.92 (d, J=10.4), 135.78 (d, J=6.8), 128.43 
(d, J=73.2), 127.79, 114.10, 113.92, 76.95, 76.89, 65.54 (d, J=3.6), 56.31. 31P NMR (122 MHz, 
Chloroform-d) δ = 136.32 (d, J=107.0). 
Di-(4-Hydroxyphenyl) vinylphosphonite borane (55) 
 
The compound was synthesized according to the general procedure 8 from 
Bis(diisopropylamino)chlorophosphine (534 mg, 2.00 mmol) and hydroquinone (2.20 g, 10 eq.). The 
crude borane protected phosphonite was purified by flash column chromatography (Hexane/EtOAc, 
4:1 to 1:1) and obtained as a colorless solid. (280 mg, 0.96 mmol, 48.3%) 
1H NMR (300 MHz, DMSO-d6) δ = 9.49 (s, 2H), 6.96 (d, J=8.5, 4H), 6.74 (d, J=8.9, 4H), 6.63 – 6.22 (m, 
3H), 1.20 – -0.12 (m, 3H). 31P NMR (122 MHz, DMSO-d6) δ = 131.80.  
Di(4-nitrobenzyl) vinylphosphonite borane (56) 
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The compound was synthesized according to the general procedure 8 from 
Bis(diisopropylamino)chlorophosphine (533 mg, 2.00 mmol). The crude borane protected phosphonite 
was purified by flash column chromatography (Hexane/CH2Cl2, 9:1 to 4:1) and obtained as a white 
solid. (540 mg, 1.44 mmol, 71.8%) 
1H NMR (300 MHz, Chloroform-d) δ = 8.17 (d, J=8.6, 4H), 7.49 (d, J=8.5, 4H), 6.47 – 6.16 (m, 3H), 5.12 
(qd, J=13.2, 8.3, 4H), 1.40 - 0.00 (m, 3H). 13C NMR (75 MHz, Chloroform-d) δ = 147.66, 143.09 (d, J=6.1), 
136.50 (d, J=10.2), 128.80 (d, J=76.0), 127.78, 123.73, 67.30 (d, J=3.8). 31P NMR (122 MHz, Chloroform-
d) δ = 137.95 (d, J=95.6). 13C NMR (151 MHz, DMSO-d6) δ 155.22, 143.60 (d, J = 8.8 Hz), 137.79 (d, J = 
10.7 Hz), 129.63 (d, J = 69.9 Hz), 122.00 (d, J = 3.8 Hz), 116.43. 
Di(1,2-isopropylidene glyceryl) vinylphosphonite borane (57) 
 
The compound was synthesized according to the general procedure 8 from 
Bis(diisopropylamino)chlorophosphine (533 mg, 2.00 mmol). The crude borane protected phosphonite 
was purified by flash column chromatography (20% EtOAc in hexane) and obtained as a mixture of 
diastereomers as a colorless oil. (380 mg, 1.14 mmol, 57.9%) 
1H NMR (300 MHz, Chloroform-d) δ 6.45 – 6.05 (m, 3H), 4.30 (p, J = 5.7 Hz, 2H), 4.13 – 3.92 (m, 6H), 
3.79 (td, J = 8.6, 5.6 Hz, 2H), 1.42 (s, 6H), 1.35 (s, 6H). 1.20 – -0.34 (m, 3H) 13C NMR (75 MHz, Chloroform-
d) δ 135.62 (q, J = 10.4, 9.8 Hz), 129.11 (dt, J = 75.3, 9.5 Hz), 111.91 – 108.56 (m), 74.21 (dd, J = 8.2, 6.6 
Hz), 67.04 (ddd, J = 35.7, 4.9, 2.3 Hz), 66.45 – 65.34 (m), 27.87 – 26.18 (m), 25.18. 31P NMR (122 MHz, 
Chloroform-d) δ 137.23 – 132.50 (m). 
General procedure 9 for the synthesis of vinylphosphonamidates from borane protected 
phosphonites. 
 
A flame-dried Schlenk flask was charged with 1.0 mmol (1.0 eq.) of the borane protected phosphonite 
under an argon atmosphere and dissolved in 2 ml of dry toluene. In an argon stream, DABCO (1.50 
mmol, 1.5 eq.) was added and the solution was heated to 50 °C for 2 hours. The mixture was allowed 
to cool to room temperature and a solution of 1.1 mmol of the azide (1.1 eq.) in 3 ml dry THF or dry 
DMF was added. The resulting solution was stirred at room temperature overnight. Finally 1 ml of 
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water was added and stirred for another two hours. The crude product was purified by column 
chromatography. 
4-Hydroxyphenyl-N-phenyl-P-vinylphosphonamidate (58) 
 
The compound was synthesized according to the General procedure 9 from 55 mg Di-(4-
Hydroxyphenyl) vinylphosphonite borane (55) (0.189 mmol). The crude phosphonamidate was purified 
by flash column chromatography (50 to 100% EtOAc in hexane) and obtained as a white solid. (13 mg, 
0.047 mmol, 25.0%) 
1H NMR (600 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.16 (d, J = 8.2 Hz, 1H), 7.21 (dd, J = 8.5, 7.3 Hz, 2H), 7.14 
– 7.04 (m, 2H), 6.99 (dd, J = 8.9, 1.4 Hz, 2H), 6.93 – 6.82 (m, 1H), 6.70 (d, J = 8.9 Hz, 2H), 6.49 – 6.03 (m, 
3H). 13C NMR (151 MHz, DMSO-d6) δ 154.72, 142.58 (d, J = 7.9 Hz), 141.32, 135.49, 129.47, 129.04 (d, 
J = 166.3 Hz), 121.93 (d, J = 4.3 Hz), 121.31, 118.09 (d, J = 6.9 Hz), 116.23. 31P NMR (243 MHz, DMSO) δ 
13.07. HRMS for C14H15NO3P+ [M+H]+ calcd.: 276.0784, found: 276.0785. 
2-nitro-5-(oxypropargyl)benzyl-N-phenyl-P-vinylphosphonamidate (59) 
 
The compound was synthesized according to the general procedure 9 from 28 mg Di(2-nitro-5-
(oxypropargyl)benzyl) vinylphosphonite borane (54) (0.058 mmol). The crude phosphonamidate was 
purified by flash column chromatography (30% EtOAc in hexane) and obtained as a yellow solid. (10 
mg, 0.027 mmol, 46.7%) 
1H NMR (300 MHz, Chloroform-d) δ 8.20 (d, J = 9.1 Hz, 1H), 7.40 (d, J = 2.8 Hz, 1H), 7.22 (t, J = 7.8 Hz, 
2H), 7.08 – 6.89 (m, 4H), 6.55 – 5.97 (m, 4H), 5.58 (ddd, J = 62.8, 15.6, 7.4 Hz, 2H), 4.76 (d, J = 2.4 Hz, 
2H), 2.59 (t, J = 2.4 Hz, 1H). 13C NMR (75 MHz, Chloroform-d) δ 161.75, 140.10, 139.29, 136.07 (d, J = 
7.7 Hz), 135.74, 129.39, 127.77, 127.72, 125.49, 121.96, 117.63, 117.54, 114.13, 113.86, 62.90 (d, J = 
4.5 Hz), 56.21. 31P NMR (122 MHz, CDCl3) δ 16.43. HRMS for C18H18N2O5P+ [M+H]+ calcd.: 373.0981, 
found: 373.0979. 
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4-(2-nitro-5-(oxypropargyl)benzyloxy)phenyl-N-phenyl-P-vinylphosphonamidate (60) 
 
The compound was synthesized according to the general procedure 9 from 21 mg Di(4-(2-nitro-5-
(oxypropargyl)benzyloxy)phenyl) vinylphosphonite borane (53) (0.031 mmol). The crude 
phosphonamidate was purified by flash column chromatography (30% EtOAc in hexane) and obtained 
as a yellow solid. (5 mg, 0.011 mmol, 34.2%) 
1H NMR (300 MHz, Chloroform-d) δ 8.25 (d, J = 9.1 Hz, 1H), 7.42 (d, J = 2.8 Hz, 1H), 7.32 – 7.19 (m, 2H), 
7.12 (dd, J = 9.0, 1.5 Hz, 2H), 7.05 – 6.94 (m, 4H), 6.85 (d, J = 9.0 Hz, 2H), 6.54 – 6.00 (m, 3H), 5.82 (d, J 
= 5.7 Hz, 1H), 5.44 (s, 2H), 4.77 (d, J = 2.4 Hz, 2H), 2.54 (t, J = 2.4 Hz, 1H). 13C NMR (75 MHz, Chloroform-
d) δ 161.85, 155.07, 143.74, 143.62, 140.03, 139.21, 137.14, 135.98, 129.35, 127.73, 126.74 (d, J = 
173.4 Hz), 122.03, 121.80, 121.75, 117.79 (d, J = 6.5 Hz), 115.73, 113.96, 113.59, 67.31, 56.16. 31P NMR 
(122 MHz, CDCl3) δ 13.18. HRMS for C24H22N2O6P+ [M+H]+ calcd.: 465.1210, found: 465.1227. 
Procedure for Cys-modification of eGFP (C70M or C70M S147C) with 
vinylphosphonamidates  
 
The storage buffer of eGFP (PBS) was exchanged to 100 mM NH4HCO3, pH 8.5 using Amicon spin filters 
with a 10 kDa MWCO (Sartorius, Germany). The protein was filtered three times with the reaction 
buffer at 14000 rpm for 5 minutes to give a typical concentration of 50 µM. 2.5µl of a 100 mM solution 
of the vinylphosphonamidate (100 eq.) in MeCN, DMSO or DMF, depending on the solubility, were 
added to 50 µl of the protein. The reaction mixture was shaken at 25 °C and 850 rpm overnight. The 
excess phosphonamidate was removed by spin filtration using Amicon spin filters with a 10 kDa MWCO 
(Sartorius, Germany) and analyzed by MALDI-MS or SDS-PAGE.  
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Cy5-O-2-nitrobenzyl-P-vinylphosphonamidate 63 
 
The compound was synthesized according to the general procedure 9 from 37 mg Di(2-nitrobenzyl) 
vinylphosphonite borane (62) (0.097 mmol, 1.10 eq.) in DMF. The crude phosphonamidate was 
purified by flash column chromatography (0-5% MeOH in CH2Cl2) and obtained as deep blue solid. 
(10 mg, 0.013 mmol, 14.8%) 
1H NMR (600 MHz, Chloroform-d) δ 8.08 (dd, J = 8.2, 1.3 Hz, 1H), 7.99 – 7.90 (m, 2H), 7.84 – 7.71 (m, 
2H), 7.51 – 7.31 (m, 7H), 7.25 (t, J = 7.5 Hz, 1H), 7.20 (t, J = 7.4 Hz, 2H), 7.11 – 6.99 (m, 2H), 6.44 – 5.91 
(m, 3H), 5.48 – 5.39 (m, 2H), 5.36 (dt, J = 14.5, 7.7 Hz, 1H), 4.60 (dt, J = 14.5, 7.4 Hz, 1H), 4.41 (m, 1H), 
3.68 – 3.57 (m, 1H), 3.52 (s, 3H), 3.50 – 3.43 (m, 1H), 1.74 (s, 3H), 1.72 (s, 3H), 1.70 (s, 6H). 13C NMR 
(151 MHz, Chloroform-d) δ 174.93, 171.18, 154.32, 151.65, 146.35, 142.94, 141.94, 141.03, 140.41, 
134.54, 133.87, 129.20, 129.15, 128.87, 128.57, 128.08, 128.04, 126.81, 125.79, 124.58, 124.41, 
122.06, 121.94, 112.01, 109.64, 106.75, 102.53, 70.45 (d, J = 92.1 Hz), 62.56 (d, J = 4.2 Hz), 50.71, 49.68, 
48.62, 46.46, 37.81, 28.16, 28.11, 27.98, 27.96. 31P NMR (243 MHz, CDCl3) δ 23.21. HRMS for 
C37H42N4O4P+ [M]+ calcd.: 637.2938, found: 637.2940. 
Modification of cetuximab’s interchain disulfide bonds with 64 and MS/MS analysis 
 
Cetuximab modification was carried out by incubating the antibody (typical concentration 
c = 1.5 mg/ml, 10 µM) in a buffer containing 50 mM sodium borate and 4 mM DTT in PBS (pH 8.0) with 
a total volume of 80 μl at 37 °C for 30 min. Excess DTT removal and buffer exchange to a solution 
containing 50 mM NH4HCO3 and 1mM EDTA (pH 8.5) was conducted afterwards using 0.5 mL Zeba™ 
spin Desalting Columns with 7K MWCO (Thermo Fisher Scientific, USA). 1 μl of a solution containing 
50 mM N-phenyl-P-vinylphosphonamidate (64) in DMSO were added quickly to 50 μl of the reduced 
antibody solution. The mixture was shaken at 800 rpm and 4 °C for 16 hours. Excess reagent was again 
removed by buffer exchange to sterile PBS using 0.5 mL Zeba™ spin Desalting Columns with 7K MWCO. 
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Afterwards, 10 µl of the antibody solution were mixed with 10 µl of a 10 mM DTT solution and 
incubated at 55 °C for 30 minutes. After cooling to room temperature, 10 µl of a 55 mM iodoacetamide 
solution was added and the mixture was incubated for further 30 minutes in the dark. Finally, 10 µl of 
a solution of 0.1 mg/ml trypsin in 1 mM HCl was added, the mixture was incubated at 37°C overnight 
and subjected to MS/MS-analysis. 
Shown below are the results of the Mascot search on cetuximab’s heavy- and light chain after 
incubation with 100 eq. of 64 with prior reduction of the disulfide bonds. Matched Peptides are 
highlighted in grey. Amino acid residues modified with 64 are highlighted in red. Oxidation of 
methionine, alkylation of cysteine via iodoacetamide and the phosphonamidate on Y, S, T, C, K, H & R 
were searched as variable modifications. 
Next, the MS spectrum of the phosphonamidate-modified peptide 136-149, highlighted above in 
yellow is shown.  
Next, the MS/MS spectrum with HCD fragmentation of the phosphonamidate-modified peptide 136-
149, highlighted above in yellow is shown. The signal series 778.28-1335.85 show the y5-y12-
fragments, carrying the modification. y3 was detected as a small signal at 359.26, demonstrating 
modification at Cys146. 
MP09_HS640_117_1 #19025-19068 RT: 56.24-56.32 AV: 10 NL: 7.06E4
F: FTMS + p NSI Full ms [197.0777-1500.0000]
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reduction:  
light chain sequence coverage: 69% 
1  DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGA  
101 GTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG 
201 LSSPVTKSFNRGEC 
heavy chain sequence coverage: 65% 
1  QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALT 
101 YYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY 
201 ICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 
301 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL 
401 DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
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Shown below are the results of the Mascot search on cetuximab’s heavy- and light chain after 
incubation with 100 eq. of 64 without prior reduction of the disulfide bonds. Matched Peptides are 
highlighted in grey. Amino acid residues modified with 64 are highlighted in red. 
Synthesis of the O-2-nitro-5-(oxypropargyl)benzyl-P-vinyl modified peptide 66 
A 5-ml round-bottom-flask was charged with 4 mg Di(2-nitro-5-(oxypropargyl)benzyl) 
vinylphosphonite borane (53) (8.264 µmol, 1.5 eq.) and 1.8 mg DABCO (16.528 µmol, 3.0 eq.) dissolved 
in 400 µl dry THF under an argon atmosphere. The solution was heated to 50 °C for three hours, cooled 
to room temperature and 5.7 mg of the azido modified peptide 65 (5.510 µmol, 1.0 eq.), dissolved in 
200 µl of dry DMF was added. The solution was stirred overnight at room temperature, 200 µl of water 
were added and the mixture purified by semi-preparative HPLC. The desired product was obtained as 
white powder after lyophilization (1.7 mg, 1.322 µmol, 24.0%). HR-MS for C58H79N12O20P2+ [M+2H]2+ 
calcd.: 647.2630, found 647.2644. 
MP09_HS640_117_1 #19068 RT: 56.33 AV: 1 NL: 3.34E2
T: ITMS + c NSI r d Full ms2 762.3701@hcd32.00 [110.0000-1535.0000]
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no reduction:  
light chain sequence coverage: 71% 
1  DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGA  
101 ASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV 
201 DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
heavy chain sequence coverage: 44% 
1  QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALT 
101 YYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY 
201 ICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS 
301 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL 
401 DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
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Synthesis of the O-(2-nitro-5-(oxypropargyl)benzyloxy)phenyl-P-vinyl modified peptide 67 
 
A 5-ml round-bottom-flask was charged with 5.5 mg Di(4-(2-nitro-5-(oxypropargyl)benzyloxy)phenyl) 
vinylphosphonite borane (54) (8.233 µmol, 1.5 eq.) and 1.8 mg DABCO (16.466 µmol, 3.0 eq.) dissolved 
in 400 µl dry THF under an argon atmosphere. The solution was heated to 50 °C for three hours, cooled 
to room temperature and 5.7 mg of the azido modified peptide 65 (5.489 µmol, 1.0 eq.), dissolved in 
200 µl of dry DMF was added. The solution was stirred overnight at room temperature, 200 µl of water 
were added and the mixture purified by semi-preparative HPLC. The desired product was obtained as 
white powder after lyophilization (0.5 mg, 0.357 µmol, 6.5%). HR-MS for C64H83N12O21P2+ [M+2H]2+ 
calcd.: 693.2761, found 693.2773. 
Ubiquitin G75C conjugation to peptides 66 and 67 
 
A 32 µM solution of Ubiquitin G75C and 0.8 mM 66 or 67 in a buffer containing 50 mM NH4HCO3 and 
1 mM EDTA at pH 9.0 was shaken at 4 °C overnight. The solution was rebuffered to PBS by spin 
filtration using Amicon spin filters with a 3 kDa MWCO (Sartorius, Germany).  
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Biotin-azide conjugation via CuAAC to Ubiquitin-66 
 
CuAAC was performed based on a previously published protocol with slight variations.[339] 4.2 µl of 
5 mM solution of CuSO4 was premixed with 4.2 µl of a 25 mM solution of THPTA, 4.2 µl amino 
guanidine and 3 µl PBS. The mixture was added to a 70 µl solution of ubiquitin-66 in PBS and 4.2 µl of 
a 50 mM solution of biotin azide in DMSO were added. Finally, 4.2 µl of a 100 mM solution of sodium 
ascorbate were added to start the reaction. The mixture was incubated overnight at 37 °C. Reagent 
excesses were removed by spin filtration to PBS using Amicon spin filters with a 3 kDa MWCO 
(Sartorius, Germany).  
Ubiquitin-66-biotin pulldown experiment 
25 µl of a suspension of streptavidin immobilized on agarose (Solulink N-1000-005, Trilink, United 
States) was washed five times with 100 µl PBS and incubated for 2 hours at room temperature with 
11 µl of a 100 µM solution of ubiquitin-66-biotin. 10 µl of the supernatant were subjected to SDS-PAGE 
analysis. Beads were washed with PBS three times and 10 µl of the last wash fraction were subjected 
to SDS-PAGE analysis. Half of the beads were subjected to SDS-PAGE analysis and the other half was 
resuspended in 200 µl of PBS and UV-irradiated for 15 minutes at room temperature. The supernatant 
was concentrated by vacuum centrifugation and subjected to SDS-PAGE analysis. 
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10.1. NMR spectra 
2-Hydroxyethyl isopropyldisulfide 
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Di-(2-isopropyl disulfido)ethyl) ethynylphosphonite (4) 
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Di-(2-tert-butyl disulfido)ethyl) ethynylphosphonite (5) 
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2-(3-Hydroxypropyl) isopropyl disulfide
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Di-(3-Butinyl) ethynylphosphonite (7) 
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Di-(2-diethylamino benzyl) ethynylphosphonite (9) 
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